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Positron Emission Tomography 
 
 
Positron emission tomography (PET) is a highly sensitive imaging technique, suited for 
non-invasive in vivo detection, characterization and monitoring of diseases. It is also often 
used to investigate the efficacy of drugs during drug development studies. Compared to 
computed tomography (CT) or magnetic resonance imaging (MRI) techniques, a PET 
scanner provides an image only after intra venous (i.v.) injection of a radiopharmaceutical, 
a biologically active molecule tagged with a positron emitting nuclide. After positioning a 
patient in a PET camera, the coincident emission of the pair of photons of 511 keV emitted 
in opposite directions (~180 ⁰) is detected, resulting from the annihilation of the 
radionuclide. This unique process allows further data reconstruction and calculation of the 
location of this event and consequently distinct position of the radiopharmaceutical in the 
body at that certain moment, as shown in Figure 1.[1–3] 
 
Figures 1: Schematic illustration of the PET imaging principle: a positron emitted from the 
nucleus of a radionuclide annihilates with an electron from the tissue, releasing two 
gamma photons of 511 keV in opposite direction. The detectors surrounding the patient 
register these photons and the data is used for image reconstruction, resulting in a PET 
image with a precise location of the investigated disease (e.g. tumor lesion). 
Commonly employed radionuclides for PET imaging are listed in Table 1. They are 
generated directly by a particle accelerator, a so called cyclotron, via bombardment of a 
target material with either high energy protons or deuterons. Advantageously, some 
nuclides can be obtained from a generator, where the parent radionuclide is loaded on a 
stationary phase and the daughter isotope can be washed off the generator (e.g. gallium-
68), resulting in a solution of the desired nuclide, ready for radiolabeling reactions. The 
choice of radionuclide depends on its physical and chemical characteristics, availability, 
the timescale and location of the study, and ease of chemical incorporation in the 
molecule. Radiochemist should also bear in mind that radionuclide should match the 
biological half-life of a target compound and possible modifications radiolabeling reaction 
may impose (Figure 2).[1–5]  
 General Introduction and Thesis Outline   
9 
 
Fluorine-18 remains the most used isotope due to convenient half-life, well-suitable 
for shipment of the tracer, and low positron energy, which also contributed to the 
success of oncology tracer 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG). Even thought, 
the fluorine atom closely mimics the hydrogen atom in size and is quite common in 
drug molecules increasing the metabolic stability and affinity to the desired 
receptor, it is generally not part of the natural molecules. The same applies for 
radiometals, like zirconium-89 or gallium-68, mostly used for labeling of biologicals, 
such as monoclonal antibodies (mAb) and peptides, respectively. Although mAb 
labelings with 89Zr will most likely not change the behavior of the mAb the 68Ga 
isotopic effect on the peptide will be significant (Figure 2). Among the available 
positron emitting radionuclides exemplified in Table 1, only oxygen-15, nitrogen-13 
and carbon-11 are isotopes of natural elements present in most biochemicals and 
registered drugs. However, their short half-life poses special usability challenges, 
therefore, carbon-11 has become the most utilized. Its half-life is sufficiently long 
for multi-step synthesis and clinical application. Next to that, the relative short half-
life allows repeated injection with either the same or different radiotracer in one 
day, all desirable for longitudinal therapy monitoring, though an on-site cyclotron is 
required. For these obvious reasons, carbon-11 with complete β+-decay may be 
more appropriate choice for probes with rapid pharmacokinetics leading to lower 
radiation burden for the patient.[6,8–10] 
Table 1: Common radionuclides used for PET tracer production.[5–7] 
Radionuclide Half-life 
Emax (β
+) 
[keV] 
β
+-decay 
[%] 
Nuclear 
Reaction 
Chemistry 
Oxygen-15 2.0 min 1732 100 15N(d,n)15O On-line gas phase 
Nitrogen-13 10.0 min 1190 100 16O(p,α)13N Organic 
Carbon-11 20.4 min 961 100 14N(p,α)11C Organic 
Gallium-68 67.6 min 1899 89 69Ga(p,2n)68Ge Chelation 
Fluorine-18 109.7 min 634 97 18O(p,n) 18F Organic 
Copper-64 12.7 h 656 19 64Ni(p,n)64Cu Chelation 
Zirconium-89 3.3 d 897 23 89Y(p,n)89Zr Chelation 
 
Carbon is one of the main constituents in biologically organic molecules. Hence, the 
isotopologue labeling will results in an indistinguishable radiolabeled compound from its 
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non-labeled analogue, especially important when it is crucial to preserve the structure of 
the lead-compound. This makes carbon-11 an attractive radionuclide for PET tracers, 
regardless of its short half-life. Carbon-11 can theoretically be incorporated in all 
molecules of biological interest, however the limited availability of carbon-11 
reagents, losses because of radioactive decay and challenging automation restrain its 
wide spread application. Moreover, new methods to access the so far unattainable 
radiolabeled compounds are needed in addition to flexible and multi-step radiochemistry 
procedures.[3,5,6,11–13]  
 
Figure 2: The choice of radionuclide compromises between the availability and possible 
changes in in vivo behavior after introducing a radionuclide. 
With radiopharmaceutical chemistry techniques, the obtained radionuclide is 
incorporated in a molecule, resulting in a reactive radiolabeled reagent that can be used 
for a radiolabeling reaction with the so-called precursor, to obtain the 
radiopharmaceutical which is subsequently purified and formulated in a ready for 
injection solution. In contrast to organic chemistry, radiopharmaceutical chemistry makes 
use of nanomolar amounts of the radiolabeled reagent, reacting with the precursor under 
disturbed stoichiometric conditions with an excess of non-radiolabeled reagents, resulting 
in pseudo-first order reaction kinetics. This enables rapid reaction times in minutes or 
even seconds, highly desired when working with short-lived isotopes. However, the 
variety of reactions that can be applied in radiopharmaceutical chemistry is much smaller 
compared to organic chemistry, mainly because of the above-mentioned reason, but also 
because of practical reasons that make radiopharmaceutical chemistry less easy to apply. 
Main challenge that radiochemists are facing when working with short-lived radionuclides 
is the speed of the process required in order not to exceed a period of approximately 3 
half-lives. As a consequence, a relatively high amount of the radionuclide is used and 
safety aspects are highly important. Therefore, these procedures are executed in a special 
lead shielded ventilated box, so-called “hot-cell”, with dedicated synthesis equipment, to 
reduce the radiation exposure as much as possible. This requires fully automated, 
reproducible and efficient reactions with minimal mass of the radiolabeled reagent, in 
order to achieve a high molar activity (GBq·μmol-1), an important parameter that 
applies to most radiopharmaceuticals.[1–6,12,14] 
 
 General Introduction and Thesis Outline   
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Asymmetric Catalysis  
 
The presence of multiple stereogenic centers in bioactive compounds and their absolute 
and relative configurations is often crucial for their biological and/or pharmacological 
properties. These depend on the interactions between the molecule of interest and the 
chiral environment provided by the enzyme or receptor.[15] Over the last several decades, 
asymmetric catalysis, in which a chiral catalyst directs the formation of a chiral compound 
towards one particular favored stereoisomer, has enjoyed tremendous growth (Figure 3). 
It has been mostly driven by the demands of pharmaceutical industry, as almost two-
thirds of prescription drugs are chiral molecules, as well as material science or agricultural 
chemistry.[16] 
 
Figure 3: Simplified catalytic asymmetric synthesis of amino acids. 
Historically, the classic approaches to access enantiomerically enriched compounds 
involved chemical transformation of an enantiomerically enriched precursor or chiral 
resolution of a racemic mixture of two enantiomers, mostly by enzymes. Both of these 
methods possess several drawbacks, the former requires stoichiometric amounts of a 
precursor, and the later time-consuming procedure and yields only up to 50% of the 
desired enantiomer. While enzymes present exquisite chemical selectivity offering 
attractive alternatives to coventional chemistry, that can be also achieved in shorter 
reaction time[17],  their use is limited towards naturally occuring L-enantiomer. [16]  
Catalytic asymmetric synthesis has a significant potential benefits over the obsolete 
procedures as can generate many enantiomerically pure molecules with enantiomeric 
excess approaching 100%. It has reached its major breakthrough in 1970’s when Knowles 
and his colleagues at Monsato Company, St Louis, USA, demonstrated that a rhodium 
complex can produce a chiral catalyst that is able to transfer chirality to a non-chiral 
substrate achieving a chiral product. This can be exemplified by the first industrial catalytic 
asymmetric synthesis of L-DOPA, presented in Figure 4. Since then, it has escalated sharply 
and resulted in a Nobel Prize in Chemistry 2001, awarded to three scientists William S. 
Knowles, USA, Ryoji Noyori, Japan and K. Barry Sharpless, USA.[18]  
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Figure 4: Industrial synthesis of L-DOPA developed by Knowles and co-workers providing 
97.5% of L-DOPA after the chiral hydrogenation acid hydrolysis. 
This pioneering work has inspired many research groups to generate other methods to 
amongst which, asymmetric phase-transfer catalyzed carbon-carbon bond formations 
using chiral catalysts are the most important ones. Its foundations were already laid down 
in 1960s by Starks, however only recent efforts have shown the full advantage of these 
structurally and stereochemically well-defined catalysts, inducing high levels of 
enantioselectivity in alkylation, Michael, Aldol, Mannich and Darzens reactions, next to 
epoxidations and aziridations.[19–24] 
In general, stereoselectivity can be achieved either by varying the reaction conditions, like 
base, solvent, reaction temperature, substrate concentration or stirring, or catalysts.[15,19] 
Various quaternary ammonium salts, the largest and most well studied class of chiral 
phase-transfer catalysts, have provided excellent yields and high enantiomeric excess.[19–
21] The examination of the effectiveness of stereoselective Cα-Cβ bond formation has 
further opened meticulous studies of catalysts structure/activity and their selectivity 
relationship, identifying highly selective N-spiro C2-symmetric quaternary ammonium 
bromide catalyst for N-terminal alkylations of small peptides.[25–32] 
 
Asymmetric Synthesis in Carbon-11 Radiochemistry  
 
The importance of the enantiopurity plays pivotal role also in radiopharmaceuticals. 
Considering the lower patient radiation burden when administering a single enantiomer 
clinical radiopharmaceutical, but far more importantly, providing an optimal selectivity 
and specificity for the target since only the biologically preferred enantiomer is applied. 
Nonetheless, limited interest has been shown towards asymmetric carbon-11 reactions, 
since radiochemists would had typically considered separation of enantiomers over the 
impending syntheses.[33,34] 
Restricted to the two major carbon-11 precursors, [11C]CO2 and [
11C]CH4, and 
further their more reactive secondary precursor [11C]CH3I, the most common method 
of introducing carbon-11 remains 11C-methylation. Despite the single strategy, 11C-
methylation can access a great range of O-, N-, S- and 11C-C metal cross-coupling reactions, 
like Stille, Suzuki or Negishi, with great enantiopurity of final radiopharmaceutical. It 
should be emphasized that these particular reactions cannot be called stereoselective, as 
pre-existing chirality has been already built onto a precursor molecule prior to the 11C-
 General Introduction and Thesis Outline   
13 
 
labeling. Even though the carbon atoms are often centers of chirality, mostly racemic 
mixtures were obtained after 11C-methylation reaction of small-molecules.[6,10,35] An 
example of this is the synthesis of 11C-labeled 2-arylpropionic acids and their methyl 
esters, shown in Figure 5.[36,37] 
 
Figure 5: Synthesis of 11C-labeled 2-arylpropionic acids and their methyl esters. 
 
Carbon-11 Labeled Amino Acids 
 
Variety of natural amino acids as well as their non-natural analogues have proved as 
useful tracers, highlighted by the topmost used carbon-11 amino acid tracer applied to 
visualize tumor metabolism L-[11C]methionine. Stereoselective reactions have played a 
major issue for radiolabeled amino acids, as chirality influences the rates and selectivity of 
amino acid transport, preferred for L-enantiomers in mammalian cells.[38] As can be 
observed from the amino acid structure, in general two positions can be considered for 
carbon-11 labeling, firstly the carboxyl position and secondly the β-carbon (Scheme 1). In 
the past decades, most of enantiomerically pure 11C-amino acids have been prepared via 
highly stereoselective enzymatic approaches, providing only L-enantiomers. Early 
synthetic routes, like 11C-carboxylations, various 11C-alkylations and labeling using 
[11C]cyanide (Scheme 1), let to  enantiomeric excess up to 82% and often proved as non-
reliable, low yielding and time consuming, even requiring further enzymatic or chiral 
separation. Nowadays enantiomeric excess up to 95% can be achieved, while limited to 
only L-amino acids and hampered by non-commercial starting material (e.g. precursor for 
radiolabeling).[39–42]  
Stereochemistry influence in amino acid backbone can be illustrated by L- and D-
[11C]phenylalanine, synthesized using enzymatic separation in 1981, where the L-
enantiomer of [11C]phenylalanine showed better pancreas-to-liver ratios in rats.[43] 
Moderate tumor uptake in rats of racemic [11C]phenylalanine[44], was further 
confirmed by the better imaging properties of L-18F-labeled fluoroalkyl phenylalanine 
analogues, all demonstrating high uptake in tumor compared to surrounding tissues.[45,46] 
These studies, not mentioning the gold standards L-[11C]methionine or L-[18F]fluoroethyl 
tyrosine, thus emphasize the need for methods to synthesize enantiomerically pure amino 
acids as PET tracers.  
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labeling. Even though the carbon atoms are often centers of chirality, mostly racemic 
mixtures were obtained after 11C-methylation reaction of small-molecules.[6,10,35] An 
example of this is the synthesis of 11C-labeled 2-arylpropionic acids and their methyl 
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Figure 5: Synthesis of 11C-labeled 2-arylpropionic acids and their methyl esters. 
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Scheme 1: General synthetic routes to 11C-amino acids using most common carbon-11 
reagents. First step, presented above, is usually followed by deprotection of protective 
groups or hydrolysis to the desired 11C-amino acid. 
 
Radiolabeled Peptides in PET Imaging  
 
Radiolabeled peptides are powerful biological tools for diagnostic imaging of various 
diseases using PET.[3,6,47] Short peptides, mainly consisting of <20 amino acids, possess 
many favorable properties for molecular imaging, such as rapid clearance from circulation 
and high affinity and specificity to the target. Over the years, radiolabeled peptides have 
attracted considerable attention in variety of fields, especially tumor imaging due to the 
over-expression of specific peptide receptors on tumor cells leading to high uptake and 
target-to-background ratios.[47–52]  
A significant number of short peptides have been labeled using various well-established 
approaches in radiochemistry. Currently addition of a radionuclide can be achieved in four 
general ways via pendant, integrated, or direct labeling, and prosthetic group 
incorporation, as depicted in Figure 6. The most common, the pendant labeling requires 
bifunctional metal chelator attached via an aliphatic spacer to the peptide while 
coordinating a radiometal, with high in vivo stability. Unfortunately, this additional linkage 
drastically increases the molecular weight of the peptide, which can be illustrated by 
octreotide with a mass of 1000 Da where addition of the most frequently used DOTA 
chelate adds approximately another 500 Da. On the other hand, integrated labeling aims 
to incorporate a radiometal within the targeted peptide making it a key structural 
component of the peptide. Third method, ideal for radionuclides with lower atomic mass, 
is the prosthetic group labeling often requiring several purification and deprotection steps 
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detrimental to the overall radiochemical yield of the final pure product. A wide variety of 
different prosthetic groups, including click chemistry methodology, have been developed 
allowing rapid labeling with fluorine-18.[52,53]   
Contemporary radiolabeling techniques introducing chelating or prosthetic groups on the 
peptide are convenient, however result in sufficiently distinct alterations changing the 
pharmacokinetics and/or impaired receptor affinity. Ideally, a radionuclide would be 
added into a native peptide structure without changing its biological behavior. Direct 
labeling of small peptides, where a radionuclide is placed on a modified amino acid side 
chain, has become increasingly popular, however regio- and stereospecific labeling 
without disrupting key target interactions remains a challenge. More specifically, 
extraction and clearance kinetics of radiolabeled peptides are not only dependent on the 
amino acids sequence of the peptide, but also by the radiolabeling chemistry. 
Radioiodination and fluorination usually lead to an increase in peptide lipophilicity and 
thus increased hepatobiliary clearance. Also for “classical” radiometals, like 111In, 68Ga and 
64Cu, there is a certain influence of the chelation chemistry, especially for radiometallated 
octreotide analogs.[50] It should be mentioned that radiometallation bearing chelators is 
usually performed using kit-like procedures leading to unwanted “carrier added” 
radiopharmaceuticals and consequently low specific activity.[3,50] By the way of 
illustration, administration of the [111In]-DTPA-octreotide contains more than 90% of the 
unlabeled peptide determined by mass[50], where this percentage might be even higher 
with carbon-11.  
 
Figure 6: Current peptide radiolabelings. 
Radionuclide preference is another important aspect that should be considered. Selection 
of a beta emitter is determined by the availability, ease of attachment, next to the half-
life, energy of emission and % of positron decay.[53] More recently, ease of synthesis and 
generator availability increased the use of radiometals to label peptides, while their, in 
general, longer physical half-life does not always match with in vivo pharmacokinetics of 
the peptide.[7,54] Regardless of the short half-life, several peptide derivatives have been 
synthesized with carbon-11, mainly demonstrating novel 11C-radiochemistry towards 
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peptide application. Primarly these studies have not focused on evaluation in animal 
subjects, or even further clinical translation, however opened a niche for the use of 11C-
labled peptides as receptor binding PET-tracers.[55–57]  
In other words, the current methodology of introducing the radionuclide might hamper 
the translation from in vitro to in vivo evaluation of new peptide radiopharmaceuticals, 
critical threshold for further development and ultimately clinical applications. To 
accelerate the translation of peptides based tools for tumor diagnosis, preferably, the 
native structure of peptide should remain preserved after direct radiolabeling. By carbon-
11 labeling this could be ultimately achieved, while also reducing the dose exposure, 
facilitating repeated investigations and simplify translation into clinic by reducing 
extensive pharmacology and toxicology testing. Advantageously, due to the short half-life, 
an impact of the radionuclide on imaging characteristics using the same ligand scaffold 
could be probed in the same individual animal on the same day, reducing the 
interindividual bias, demonstrated for 11C-labeled antibody molecule in 2012[57].  
  
Somatostatin Analogues in Molecular Imaging 
 
Radiolabeled somatostatin peptide analogues have become indispensable tools for in vivo 
localization of tumors, their treatment and real-time monitoring of therapeutic response. 
The peptide hormone somatostatin (SST) is a naturally occurring cyclic peptide, existing in 
two biologically active forms with either 14 and 28 amino acids, which binds with 
nanomolar activity to all five known SST sub-type receptors (SSTr) highly expressed on 
neuroendocrine tumors (NETs), such as carcinoids, insulinomas and gastrinomas.[47,49,58,59] 
Systematic truncation of SST-14, owing its short plasma t1/2 of 2–3 min, identified the 
tetrapeptide unit Phe-D-Trp-Lys-Thr as the essential pharmacophore and further 
conformational constraining strategy led to the development of metabolically stabilized 
cyclic Veber-Hirschmann hexapepetide and cyclic octapeptide agonist - Octreotide (t1/2 = 2 
h), shown in Figure 7.[59–65]  
The potential of octreotide was recognized also as a radiolabeled analogue to non-
invasively diagnose and treat NETs, and also small-cell lung cancer, breast cancer and 
malignant lymphoma.[59]  Since the pioneering work in SSTr imaging using 123I-labeled SST 
analogue in human with endocrine-related tumors performed in 1989[66], octreotide 
reached its success by US Food and Drug Administration’s (FDA) approval of 111In-labeled 
DTPA-octreotide (111In-OctreoScan; Figure 8A) as the first registered peptide imaging 
agent in 1994.[55,67] The thriving advent of this SPECT agent, which has become the gold 
standard for diagnosis and staging of well-differentiated NETs, raised interest in its further 
modifications and labeling thereof with various radiometals, such as 99mTc, 64Cu, and 68Ga, 
as well as two widespread short-lived isotopes, 18F and 11C, for in vivo imaging, besides β-
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emitting isotopes, like 177Lu and 90Y, for receptor-mediated radionuclide therapy (Figure 
8).[47,52,58,59,68–72] Its advance in 2016 emerged a FDA approval for [68Ga]DOTATATE 
injection, a PET agent to locate tumors in patients with NETs.[73]  
 
Figure 7: Somatostatin-14 and its reduced size analogues.  
Overall, radiolabeled peptides targeting SSTr have been extensively used for more than 20 
years and contributed significantly to patient care, diagnostically and 
therapeutically.[56,74,75] Taking the benefit of this success, the octreotide would serve as a 
best possible comparison between current labeling strategies and in this thesis proposed 
direct native and stereoselective carbon-11 labeling, where the final optically pure 
product is structurally identical to the endogenous peptide, to serve as an important 
proof-of-concept for carbon-11 radiochemistry. 
 
Figure 8: Current octreotide labelings (native octreotide structure in blue): A) Complexing 
a radiometal 111In in a linear DTPA chelator coupled; B) Complexing a radiometal 68Ga in a 
cyclic DOTA chelator; C) 18F-labeled prosthetic groups or; D) 11C-labeled prosthetic groups 
linked via a spacer to a carbohydrated octreotide.  
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Peptidomimetics 
 
Peptides have shown their great potential as therapeutic drugs as well as molecular 
imaging agents, despite their high sensitivity to protease degradation, fast clearance and 
challenging multi-step synthesis. Considerable progress has been made to improve the 
pharmacokinetic properties of peptides, resulting in low molecular weight ligands for 
peptide receptors, so-called peptidomimetics. These small compounds whose essential 
elements mimic a natural peptide or protein in 3D space retain the ability to interact with 
the biological target, produce the same biological effect and conveniently exhibit better 
pharmacological properties.[69,76,77]   
 
Radiolabeled Substance P 
 
The neuropeptide Substance P (SP; H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) 
is produced in high levels within the central nervous system (CNS) and mediates a diverse 
range of physiological and pathological processes, such as activating a immunological 
response, generating a pain signal alarm or having a direct antibacetrial and antifungal 
properties, making it an attractive target for therapy.[78–81] Its selective receptor, the G-
protein coupled neurokinin 1 receptro (NK-1R), is abundantly expressed on neurons, 
including glial cells like microglia and astocytes, therefore this well-known 
neurotransmitter and neuromodulator has attracted remarkable attention in pain 
transmission.[56,78,82] Available results on SP and its metabolites show seemingly opposite 
effects, either nociceptive or antinociceptive, revealing their multifunctional role.[79]  
Selective radiolabeled SP antagonists have been labeled with the carbon-11 and fluorine-
18 and intensively studied as an in vivo tracers for visualization of NK-1R.[83–88] Showing the 
overexpression of NK-1R on glioma cells and tumor vessels provided a rationale to use α-
particle emitting radionuclides as ligands for targethed theraphy for selective irradiation 
of malignant gliomas, minimazing irradiation to adjacent tissue.[56] SP analog (DOTATAGA-
SP) has been radiolabeled with lutetium-177, bismuth-213, indium-111 and yttrium-90 
and applied to clinical studies.[56,89] 
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Figure 9: Substance P and its SP1-7 metabolites leading to peptidomimetics targeting the 
SP1-7 binding site.
[90] 
Contrary to SP, its N-terminal major bioactive fragment SP1-7 (H-Arg-Pro-Lys-Pro-Gln-Gln-
Phe-OH) effects through binding to specific sites apart from any known neurokinin or 
opioid receptor.[91] As shown in Figure 9, the absence of the amino acid sequence (i.e. 
Gly9-Leu10-Met11-NH2) on the C-terminus results in a peptide that does not bind to the NK-
1R anymore.[92] The presence of SP1-7 has been demonstrated in various CNS areas and 
spinal cord, confirming the heptapeptide is related to pain and reward processing when 
produced in the CNS by endopeptidases.[93,94] Despite to the poor understanding of SP1-7 
mechanism of action at the molecular level, its binding sites in rodents have been 
identified.[93,95] The heptapeptide SP1-7 and its amidated analogue, further their 
peptidomimetics (Figure 9; right part), have been recently studied in experimental pain 
models relieving neurophatic pain after administration.[91–97] Accordingly, these small SP1–7 
analogs in the low-nanomolar range, exemplified in Figure 9, could serve as interesting 
compounds to label for a proof-of-concept study to radiolabeled peptidomimetics with 
carbon-11. 
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Aims and Thesis Outline  
 
In general, radiolabeled amino acids, their analogues and peptides have proven to be 
valuable tools in molecular imaging. The progress in peptide radiochemistry let to several 
achievements, however distinct structural alterations during radiolabeling are inevitable. 
This thesis focuses on the development of novel carbon-11 regio- and stereoselective 
labeling methodology for native amino acids and peptides radiolabeling. Further it 
describes the implementation of carbon-11 peptidomimetics as novel PET tracers for the 
molecular imaging.  
Carbon-11 remains poorly explored in peptide labeling mainly due to the challenging 
radiolabeling procedures. To date, only a few peptides were successfully labeled with 
carbon-11, albeit with changing the molecular structure of the original peptide. Chapter 2 
provides a literature review of carbon-11 amino acids, their analogues and peptide tracer 
synthesis, including their applications.[98]  
On the basis of the contemporary procedures, the direct introduction of a side chain into a 
peptide backbone would serve as an excellent approach for the preparation of native 
carbon-11 labeled small peptides. The synthesis optimization of uncommon carbon-11 
labeling reagent [11C]benzyl iodide, prepared by an efficient automated procedure from 
[11C]CO2, is described in Chapter 3.
[99] Taking advantage of this carbon-11 labeled 
reagent and commercially available phase-transfer catalysts (PTC) we developed highly 
stereoselective syntheses of D- and L-[11C]phenylalanine, discussed in Chapter 4.[100]  
We investigated the labeling of dipeptides with carbon-11 using the same methodology in 
order to evaluate the influence of chiral PTC and the adjacent amino acid in the peptidic 
backbone. Chapter 5 described successive and high yielding N-terminal 11C-benzylations 
towards variety of H-[11C]Phe-XXX-OH dipeptides in moderate to high 
diastereoselectivity.[101]   
The binding motif of somatostatin, the tetrapeptide Phe-Trp-Lys-Thr, was selected to 
radiolabel with carbon-11 in a proof of concept study of the enenatioselective labeling of 
short peptides with carbon-11. By combining highly asymmetric phase-transfer alkylation 
of peptides with [11C]benzyl iodide in a multi-step procedure, the first native 11C-
tetrapeptides are described in Chapter 6.[102]  
Within the context of evaluation of carbon-11 labeled peptidomimetics as PET tracers, in 
Chapter 7 the effects of enantioselectivity of the amino acid within the Substance P1-7 
derived 11C-carbamate peptidomimetic on brain uptake and metabolic stability was 
investigated in healthy male rats.  
Finally, reflection and future perspectives of the work in this thesis are discussed in 
Chapter 8 and all the results described are summarized in Chapter 9.   
 General Introduction and Thesis Outline   
21 
 
References 
[1] S. M. Ametamey, M. Honer, P. A. Schubiger, Chem. Rev. 2008, 108, 1501–1516. 
[2] G. B. Saha, Basics of PET Imaging, 2005. 
[3] W. Wadsak, M. Mitterhauser, Eur. J. Radiol. 2010, 73, 461–469. 
[4] G. B. Saha, Basics of PET Imaging Basics of PET Imaging, 2005. 
[5] Z. Li, P. S. Conti, Adv. Drug Deliv. Rev. 2010, 62, 1031–1051. 
[6] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chemie Int. Ed. 2008, 47, 8998–9033. 
[7] C. S. Cutler, H. M. Hennkens, N. Sisay, S. Huclier-Markai, S. S. Jurisson, Chem. Rev. 2013, 
113, 858–883. 
[8] S. Vallabhajosula, L. Solnes, B. Vallabhajosula, Semin. Nucl. Med. 2011, 41, 246–264. 
[9] G. Antoni, J. Label. Compd. Radiopharm. 2015, 58, 65–72. 
[10] K. Dahl, C. Halldin, M. Schou, Clin. Transl. Imaging 2017, 5, 275–289. 
[11] S. H. Liang, N. Vasdev, Aust. J. Chem. 2015, 68, 1319–1328. 
[12] G. Antoni, J. Label. Compd. Radiopharm. 2015, 45, 65–72. 
[13] M. Bergström, A. Grahnén, B. Långström, Eur. J. Clin. Pharmacol. 2003, 59, 357–366. 
[14] J. S. Fowler, A. P. Wolf, Synthesis of Carbon-11, Fluorine-18, and Nitrogen-13 Labeled 
Radiotracers for Biomedical Applications, The National Academies Press, 1982. 
[15] M. Bihani, J. C.-G. Zhao, Adv. Synth. Catal. 2017, 359, 534–575. 
[16] B. M. Trost, Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5347. 
[17] E. S. da Silva, V. Gómez-Vallejo, J. Llop, F. López-Gallego, Catal. Sci. Technol. 2015, 5, 2705–
2713. 
[18] B. S. William Knowles, Ryoji Noyori, NobelPrize.org 2001. 
[19] T. Ooi, K. Maruoka, Angew. Chemie - Int. Ed. 2007, 46, 4222–4266. 
[20] S. Shirakawa, K. Maruoka, Angew. Chemie Int. Ed. 2013, 52, 4312–4348. 
[21] K. Brak, E. N. Jacobsen, Angew. Chemie Int. Ed. 2013, 52, 534–561. 
[22] Martin J. O’Donnell, Aldrichimica Acta 2001, 34, 3–15. 
[23] H. Gröger, European J. Org. Chem. 2016, 2016, 4116–4123. 
[24] S. Jew, H. Park, Chem. Commun. 2009, 46, 7090–7103. 
[25] M. J. O’Donnell, T. Burkholder, V. Khau, R. Roesk, Z. Tian, Pol J Chem 1994, 68, 2477–2488. 
[26] M. J. O. Donnell, C. Zhou, W. L. Scott, J. Am. Chem. Soc 1996, 7863, 6070–6071. 
[27] M. J. O’Donnell, M. D. Drew, R. S. Pottorf, W. L. Scott, J. Comb. Chem. 2000, 2, 172–181. 
[28] T. Ooi, E. Tayama, K. Maruoka, Angew. Chemie - Int. Ed. 2003, 42, 579–582. 
[29] K. Maruoka, E. Tayama, T. Ooi, Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5824–5829. 
[30] M. J. O’Donnell, F. Delgado, R. S. Pottorf, Tetrahedron 1999, 55, 6347–6362. 
[31] T. Ooi, M. Kameda, K. Maruoka, J. Am. Chem. Soc. 2003, 125, 5139–5151. 
[32] T. Ooi, Y. Uematsu, K. Maruoka, J. Org. Chem. 2003, 68, 4576–4578. 
[33] F. Buckingham, V. Gouverneur, Chem. Sci. 2016, 7, 1645–1652. 
[34] Y. S. Ding, J. S. Fowler, Drug Dev. Res. 2003, 59, 227–239. 
[35] B. H. Rotstein, S. H. Liang, M. S. Placzek, J. M. Hooker, A. A. Wilson, N. Vasdev, Chem. Soc. 
Rev. 2016, 45, 4708–4726. 
[36] K. Kato, T. Kikuchi, N. Nengaki, T. Arai, M. R. Zhang, Tetrahedron Lett. 2010, 51, 5908–5911. 
[37] M. Takashima-Hirano, M. Shukuri, T. Takashima, M. Goto, Y. Wada, Y. Watanabe, H. Onoe, 
H. Doi, M. Suzuki, Chem. - A Eur. J. 2010, 16, 4250–4258. 
[38] J. McConathy, M. M. Goodman, Cancer Metastasis Rev. 2008, 27, 555–573. 
[39] A. Popkov, O. Itsenko, J. Radioanal. Nucl. Chem. 2015, 304, 455–458. 
[40] J. Ermert, H. H. Coenen, J. Labelled Comp. Radiopharm. 2013, 56, 225–36. 
[41] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chem. Int. Ed. Engl. 2008, 47, 8998–9033. 
[42] J. P. Holland, P. Cumming, N. Vasdev, Am J Nucl Med Mol Imaging 2013, 3, 194–216. 
[43] D. L. Casey, G. a Digenis, D. a Wesner, L. C. Washburn, J. E. Chaney, R. L. Hayes,  a P. 
Callahan, Int. J. Appl. Radiat. Isot. 1981, 32, 325–330. 
[44] K. Kubota, K. Yamada, H. Fukada, S. Endo, M. Ito, Y. Abe, T. Yamaguchi, T. Fujiwara, T. Sato, 
15299 - Pekosak_BNW.indd   20 16-02-18   16:21
Ch
ap
te
r 1
  Chapter 1 
20 
 
Aims and Thesis Outline  
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On the basis of the contemporary procedures, the direct introduction of a side chain into a 
peptide backbone would serve as an excellent approach for the preparation of native 
carbon-11 labeled small peptides. The synthesis optimization of uncommon carbon-11 
labeling reagent [11C]benzyl iodide, prepared by an efficient automated procedure from 
[11C]CO2, is described in Chapter 3.
[99] Taking advantage of this carbon-11 labeled 
reagent and commercially available phase-transfer catalysts (PTC) we developed highly 
stereoselective syntheses of D- and L-[11C]phenylalanine, discussed in Chapter 4.[100]  
We investigated the labeling of dipeptides with carbon-11 using the same methodology in 
order to evaluate the influence of chiral PTC and the adjacent amino acid in the peptidic 
backbone. Chapter 5 described successive and high yielding N-terminal 11C-benzylations 
towards variety of H-[11C]Phe-XXX-OH dipeptides in moderate to high 
diastereoselectivity.[101]   
The binding motif of somatostatin, the tetrapeptide Phe-Trp-Lys-Thr, was selected to 
radiolabel with carbon-11 in a proof of concept study of the enenatioselective labeling of 
short peptides with carbon-11. By combining highly asymmetric phase-transfer alkylation 
of peptides with [11C]benzyl iodide in a multi-step procedure, the first native 11C-
tetrapeptides are described in Chapter 6.[102]  
Within the context of evaluation of carbon-11 labeled peptidomimetics as PET tracers, in 
Chapter 7 the effects of enantioselectivity of the amino acid within the Substance P1-7 
derived 11C-carbamate peptidomimetic on brain uptake and metabolic stability was 
investigated in healthy male rats.  
Finally, reflection and future perspectives of the work in this thesis are discussed in 
Chapter 8 and all the results described are summarized in Chapter 9.   
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Abstract 
 
Radiolabeled amino acids, their derivatives and peptides have a broad scope of application 
and can be used as receptor ligands, as well as enzyme substrates for many different 
diseases as radiopharmaceutical tracers. Over the past few decades the application of 
molecular imaging techniques such as positron emission tomography (PET) has gained 
considerable importance and significance in diagnosis in today’s advanced health care. 
Next to that, the availability of cyclotrons and state-of-the-art radiochemistry facilities has 
progressed the production of imaging agents enabling the preparation of many versatile 
PET radiotracers. Due to many favorable characteristics of radiolabeled amino acids and 
peptides, they can be used for tumor staging and monitoring the progress of therapy 
success, while aromatic amino acids can be employed as PET-tracer to study neurological 
disorders. This review provides a comprehensive overview of radiosynthetic and 
enzymatic approaches towards carbon-11 amino acids, their analogues and peptides, with 
focus on stereoselective reactions, and reflects upon their clinical application.  
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General Introduction and Historical Overview 
 
Over the past few decades the application of molecular imaging techniques has become 
widely available for all fields of today’s health care. Especially molecular imaging 
techniques using tracers for single photon emission computed tomography (SPECT) and 
positron emission tomography (PET) have gained great attention for the study of disease 
biology in vivo due to their sensitivity and specificity. Next to that, the availability of 
cyclotrons, coupled with a great variety of radiolabeling methods and automated 
synthesis modules for the production of PET radiopharmaceuticals, has enabled the 
preparation of the most frequently used PET radiotracer 2-deoxy-2-[18F]fluoro-D-glucose 
([18F]FDG) as well as a large variety of other PET tracers like receptor ligands or enzyme 
substrates. Among all classes of PET tracers, radiolabeled amino acids (AAs), their 
derivatives and peptides have a broad scope of clinical applications. [1] 
Natural, L-AAs play a crucial role in virtually all biologic processes, e.g., protein synthesis, 
cell signaling, precursors for biomolecular transmission and as neurotransmitters. [2,3] 
Their constant and dynamic degradation and recirculation results in metabolic 
intermediates, such as ureas, fatty acids, or glucose. Furthermore, AAs are used as 
metabolic fuel or reused by other tissues or cells. It is known that AAs can diffuse into 
cells, however the main transport of AAs into cells occurs through specific membrane-
associated proteins, so called AA-transporters. [4] Due to the imperative role of generally 
existing or tissue-specific AA-transport systems and their consumption in many cellular 
processes, radiolabeled AAs have become an appealing class of compounds to be used as 
PET tracer to study cancer biology, considering that malignant tissue often relies on 
increased AA uptake. [2,5] Next to cancer imaging with radiolabeled AAs, aromatic AAs 
can be employed as PET tracer to study neurological disorders. Additionally, the use of 
AAs as PET tracers often result in high contrast images which are not distorted by tissue 
inflammation, as is known for glucose based PET tracer [18F]FDG. The brain, heart and 
inflamed areas use glucose as nutrient, therefore, these regions are difficult to distinguish 
from metastasis in [18F]FDG PET studies. [2,6,7] The radionuclides used for PET to label 
natural and unnatural AAs include C-11 (t1/2 20.4 min), N-13 (t1/2 10.0 min), F-18 (t1/2 1.8 
h) and I-124 (t1/2 4.2 d). 
[3] 
Peptides, typically consisting of less than 50 AAs, are another important class of 
compounds to be used as PET tracer, and have gained increasing importance as imaging 
agents. Furthermore, they generally have a high affinity and specificity for their cellular 
target, which often occur in nanomolar concentrations, in diseased tissue [8,9]. Due to 
many favorable properties for molecular imaging, such as advantageous pharmacokinetics 
and specific tumor targeting characteristics, including the overexpression of peptide 
receptors on the tumor cells, radiolabeled peptides have an important impact not only in 
PET imaging of cancer, but also in targeted radionuclide therapy. [10] Peptide-based 
radiopharmaceuticals have been successfully employed for imaging of somatostatin (SST) 
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and bombesin or cholecystokinin/gastrin receptor overexpressing tumors, all common 
human cancers. [10–14]  
Contemporary radiolabeling methods to label peptides with radiometals such as Ga-68 
(t1/2 1.1 h),
 Tc-99m (t1/2 6.0 h), Cu-64 (t1/2 12.7 h), In-111 (t1/2 67.2 h) and Lu-177 (t1/2 
160.8 h) require chemical modifications introducing a bulky bifunctional chelators on the 
peptide in order to incorporate a radiometal. For non-metal isotope F-18 (t1/2 1.8 h), as 
well as C-11 (t1/2 20.4 min), bifunctional prosthetic groups are installed on the peptide 
allowing conjugation to the biologically relevant peptide. [15–19] Present peptide 
radiolabeling techniques require structural modification of the lead structure, 
consequently influencing the pharmacokinetics, receptor affinity, and/or selectivity, 
usually in a negative manner. [12,16] Ideally, a radionuclide should be added directly into a 
lead peptide structure, preserving an unmodified, so called “native” peptide without 
changing its chemical structure and thus its biological behavior. Direct labeling of small 
peptides has become increasingly popular; however, site specific labeling without 
disrupting key target interactions remains a challenge.  
The presence of carbon in organic molecules makes the PET isotope C-11 (99 % β+, 0.96 
MeV) [20] an attractive and valuable radionuclide for PET tracer development and thus also 
for the labeling of AAs, their derivatives and peptides. Isotopologue labeling without 
structural modifications conveniently includes C-11 as a normal constituent in well-
characterized molecules of known biological properties. [6,21–23] Currently, there is a great 
toolbox available for labeling AAs with C-11, which includes viable methods using two 
major C-11 precursors produced directly by cyclotrons: [11C]carbon dioxide ([11C]CO2) and 
[11C]methane ([11C]CH4), and their transformed products, like [
11C]methyl iodide 
([11C]CH3I), [
11C]methyl triflate ([11C]CH3OTf), [
11C]cyanide or other 11C-alkylating agents 
[23]. The half-life of C-11 is, with the current radiolabeling techniques, long enough to 
perform multi-step synthesis and biological PET tracer analysis. [24] Nevertheless, carbon-
11 labeled radiotracers necessitate production at onsite radiochemistry facilities which 
includes a cyclotron. Besides synthetic challenges, the clinical advantage is predominant 
allowing multi-tracer administrations in patients in a single day. Moreover, C-11 labeled 
radiotracers often provide a better match of physical and in vivo peptide half-live 
compared to long-lived radiometals.  
The merits of radiosynthetic methods enabling to label a variety of [11C]AA and their 
derivatives, and their value as PET-tracer, is well-recognized, exemplified by L-
[11C]methionine ([11C]MET), which is studied extensively for tumor imaging. On the other 
hand, C-11 labeled small peptides have received less attention until recently, where 
multiple independent papers described different methods for C-11 labeling of peptides, 
though clinical translation has thus far been inadequately examined.[10,15,19] With current 
achievements, the scope of C-11 labeling of peptides ranges from small proteins that have 
been successfully labeled with C-11 and used for applications such as blood flow 
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permeability studies, as well as C-11 labeled peptides for inflammation and tumor 
imaging. [25–28]  
To the best of our knowledge, we describe all currently available synthesis strategies for 
the radiosynthesis of [11C]AAs, their most common derivatives and peptides, with an 
emphasis on stereoselective synthesis. Besides production options for these classes of 
radiopharmaceuticals, we will also discuss the clinical application and value of [11C]AA, and 
we will identify remaining challenges in radiosynthesis procedures for widespread 
adoption of these PET tracers. 
Carbon-11 Amino Acids Labeling 
As depicted in Figure 1, despite the fact that theoretically all AAs can be labeled with C-11, 
the numerous attempts to radiolabel these molecules have shown that there is not one 
preferred strategy. All described methodologies to obtain radiolabeled AAs share both 
advantages and disadvantages. Synthesis strategies to obtain C-11 labeled AAs have to 
consider the labeling position and chirality in the AA structure, as well as the metabolic 
stability for intended biological applications. All these have resulted in the development of 
distinct strategies to radiolabel [11C]AAs for imaging purposes.  
 
Figure 1: Short historical overview of general synthetic routes to yield carbon-11 labeled 
alanine and phenylalanine in two possible positions. 
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1. Carbon-11 Amino Acid Labeling of [1-11C]Carboxyl-Function  
2.1. Bucherer-Strecker Synthesis 
 
The Strecker reaction, and its modified Bucherer-Strecker hydantoin synthesis, is one of 
the earliest one-pot and atom economic multi-component reactions for AA synthesis in 
general. The simplicity of the synthesis, simple mixing of the reagents acetaldehyde, 
ammonia (or amines) and hydrogen cyanide resulting in an α-aminonitrile adduct and its 
subsequent hydrolysis,has attracted radiochemists to synthesize [11C]AAs using 
[11C]carbonyls or [11C]cyanide. The first approaches described the use of [11C]hydrogen 
cyanide ([11C]HCN) to yield the corresponding [11C]aminonitrile [29], whereas the second 
approach employed [11C]CO2 which reacted with α-lithiated precursor. 
[30] In both cases, 
subsequent hydrolysis affords the corresponding AA as exemplified by Hayes, et al. [1-
11C]Aminocyclopentanecarboxylic acid (ACPC) was first obtained by a two-step high 
temperature reaction of cylcopentanone with [11C]HCN via a [11C]hydantoin anionic salt. 
[29] Unfortunately, when this methodology was developed, most procedures to obtain C-11 
labeled AAs required addition of “carrier-added” cyanide to the reaction mixture which 
resulted in diminished molar activity (AM) of the final radiopharmaceutical. In the 
following years after the first publications, the Bucherer-Strecker radiolabeling method 
was further optimized providing successful radiosynthesis of [11C]valine [31], 
[11C]tryptophan [32], [11C]leucine [32] and α-[11C]methylvaline [32] within 1 h including 
hydrolysis, final tracer purification and formulation. Subsequently, advances in technology 
generated other modified routes, for example the “no-carrier-added” synthesis by Iwata, 
et al., furnishing good yields for [11C]phenylalanine, [11C]valine and [11C]leucine. Here the 
starting material amino sulfonate reacted with on-line produced [11C]HCN[33]. Due to the 
high amount of precursor, around 400 mg (~2 mmol) of amino sulfonate, the application 
of this method might not be preferred, however could be realized using aldehydes and 
unhindered ketones, but not sterically hindered ketones (e.g. for the synthesis of α-
[11C]methylphenylglycine). However, modifications by Studenov, et al. in 2003, dismissed 
“carrier-added” cyanide and high amounts of amino sulfonates (only 4 mg, 20 µmol, 
needed). The synthesis of [11C]phenylalanine and [11C]tyrosine was performed at a slightly 
elevated temperature and after acidic hydrolysis AAs were obtained molar activities as 
high as 74-111 GBq·µmol-1, as depicted in Figure 2a.[34]  
Due to the general increased knowledge on radiochemical methods, this strategy for C-11 
labeled AA synthesis gradually attracted more attention and finally resulted in an 
alternative radiosynthesis the so called Zelinski-Stadnikoff variation. Prenant, et al. 
described the unique labeling of an AA in the 2-position of the AA using the C-11 reagent 
[11C]acetone, obtained from [11C]CO2 after reaction with methyllitihium (CH3Li). 
[35] An 
advantage of the Zelinski-Stadnikoff compared to the Bucherer reaction is the one-pot 
procedure in aqueous media. Utilizing this method, the labeling of α-[2-
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11C]aminoisobutyric acid was described in a radiochemical yield (RCY) of 4% with AM of 16-
20 GBq·µmol-1 in approximately 50 min. Inconveniently, side reactions have occurred and 
two known by-products were reported: [11C]lactic acid for incomplete conversion and/or 
[11C]tert-butanol for an excessive concentration of CH3Li.    
  
Figure 2: Non-stereoselective (a) and stereoselective (b) modified Bucherer-Strecker 
synthesis. 
Recently, an automated synthesis of no-carrier added [11C]carbonyl-labeled AAs using a 
modified Strecker synthesis has been reported. To overcome stated limitations such as 
“carrier” cyanide, the need for intermediate purification and reactions conducted in 
sealed tubes (which are mostly incompatible for automation due to high temperature and 
pressures required), Xing, et al. implemented an alternative design to label the carbonyl 
moiety by forming an [11C]amino nitrile with [11C]NaCN. A fully automated synthesis for 
[11C]sarcosine has been achieved in a non-decay corrected (n.d.c.) 1% RCY, calculated from 
[11C]HCN, and radiochemical purity (RCP) of >90% with AM 55.5 GBq·mmol
-1 in 40 min, 
sufficient for preliminary imaging. Furthermore, application of this method towards other 
C-11 labeled AAs was achieved with variable success for methionine (5% RCY; n.d.c. based 
on [11C]HCN), glycine (14% RCY) and N-phenylglycine (4% radiochemical conversion (RCC)). 
[36]  
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Nonetheless, very recently Hienzsch, et al. have focused on developing a simple and 
efficient synthesis of enantiomerically pure [11C]AA using a microfluidics platform and 
extended the use of an asymmetric version of the Strecker synthesis. As depicted in Figure 
2b, [11C]HCN is bubbled through a sulfinylimine precursor (1-3 mg, 4-20 µmol) in 1,4-
dioxane/methanol in the HCN chamber of a microfluidic chip. Next, hydrolysis occurs in a 
separate chamber at elevated T, followed by a purification using a cation exchange 
cartridge and enzymatic enrichment by the D-α-amino acid oxidase (D-AAO) to exclusively 
obtain L-AA (enantiomeric excess (ee) of 100%). [37] 
In summary, all described variations of the Strecker synthesis lead to a racemic mixture of 
C-11 labeled AAs where further enzymatic resolution to obtain enantiopure product is 
necessary. Time-consuming and low-yielding chiral purification to obtain a single 
stereoisomer, has, to date, hampered the application of Bucherer-Strecker synthesis or its 
variations as usually only one enantiomer displays favorable biological activity.  
2.2. [1-11C]Carboxylations using [11C]Carbon Dioxide 
 
[11C]CO2, mostly the first C-11 labeled reagent formed in a cyclotron target, is also a highly 
convenient reagent used to form C-11 labeled AAs. A route affording the [1-11C]carboxyl-
labeled position, based on carboxylation of α-lithioisocyanides with [11C]CO2, was for the 
first time reported in 1976 by Vaalburg et al. [26] Application of the direct carboxylation 
requires the activation of the α-carbon, achieved by the introduction of the isocyanide 
functionality on the N-terminus. At the same time, abstraction of the proton on the α-
carbon with n-butyl lithium (n-BuLi) followed by hydrolysis leads to the desired amine. 
Using this route, as described in Figure 3a, a vast number of racemic [11C]AAs have been 
described in literature, namely phenylalanine [26], ornithine and lysine [38], tyrosine [28,30], 
proline [39] and phenylglycine [26], and achiral glycine [25,26]. The [1-11C]proline has been 
reported in 12–18% RCY with a RCP of >95% in total synthesis time of 45 min. [39]  
As mentioned, direct use of [11C]CO2 results in shortes synthesis time which improves the 
non-decay corrected RCY. This was achieved by using lower precursor quantities, 
performing the synthesis in a “no-carrier-added” manner, and use of stronger base (e.g., 
sec-butyl lithium) to lithiate the precursor. Furthermore, essential technical details, of 
such as stirring, temperature control and successive addition of chemicals, had to be fine-
tuned as well. By adjusting the conditions, Bolster, et al. successfully synthesiezed [1-
11C]tyrosine [40], 3,4-[11C]dihydroxyphenylalanine ([11C]DOPA) [27] and [1-11C]MET [41,42] with 
RCP >94% within 35 min, followed by chiral resolution to obtain the desired enantiomer as 
PET tracer in RCY of 10-15%. 
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2.3.  [1-11C]Carboxylation of N-(α-Lithioalkyl)Oxazolidinones 
 
There has been continuous interest in the refinement of the [11C]CO2-fixation method 
towards chiral syntheses in order to overcome the challenges of time consuming and low-
yielding chiral separation. Driven by the success of C-11 labeled methionine, firstly C-11 
carboxylation using the N-(α-lithioalkyl)oxazolidinone reagents have been thoroughly 
explored to obtain the L-enantiomer of [11C]MET. [43] This procedure successfully yielded L-
[11C]MET in excellent ee of 95% and RCY of 85%, with short synthesis times of 35-40 min 
[44], and is now used for PET imaging studies. Using this approach, the general starting 
material, N-(α-lithioalkyl)oxazolidinon, was transformed by a tin-lithium exchange to the 
corresponding N-(α-stannylalkyl)oxazolidinon, which equilibrated rapidly to one 
diastereomer. This intermediate was further carboxylated using [11C]CO2 to the desired 
and diastereopure (α-carboxyalkyl)oxazolidinon, presented in Figure 3b. Finally, the chiral 
auxiliary was removed by a Birch-type reduction to yield the unprotected and 
entantiomerically pure C-11 labeled AA, which was purified by ion exchange 
chromatography. In view of the good results, this method has been extended to C-11 
labeled L-leucine, L-alanine and L-homocysteine, accomplished with an overall yield of 13–
33% with 92–95% ee. [45] 
To conclude, oxazolidinone moiety precursors necessitate longer times for organic 
synthesis , but the radiosynthesis itself can be achieved in beneficial shorter time frames 
and more importantly in high stereoselective manner. The optimization for the routine 
preparation of labeled L-[11C]MET has been initiated, however to the best of our 
knowledge has not been published. [45]  
Figure 3: [1-11C]-Carboxylation reactions with activated precursors.  
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3. Racemic and Asymmetric Syntheses to Label AA in the Side Chain  
 
With variable success many [11C]AA isotopologues have been synthesized with the label in 
the carboxylic position. Alternatively, the carbon-11 label can also be positioned in the 
side chain of the AA, which might be beneficial to detect different metabolism of the 
investigated AA. Therefore, alternative synthetic approaches for labeling the 3-position, or 
β, have been developed. An early approach towards novel 11C-C bond formation in the 
backbone of the molecule, utilized SN2 alkylations of an activated methylene group, the 
glycine Schiff base, by alkylation with C-11 labeled aliphatic or aromatic alkyl halides. The 
starting Schiff base precursor, N-(diphenylmethylene) glycine tert-butyl ester, is rather 
straightforward to synthesize and is even commercially available, and the α-carbon can be 
deprotonated easily under basic conditions. The first encouraging reports on racemic 
labeled [11C]AA by research groups in Uppsala, Sweden [46], and St. Louis, USA [47] date back 
to the early 1990’s. These initial attempts made use of achiral approaches and the AAs 
formed required enantiomer separation, either by chromatographic or enzymatic 
methods resulting in longer synthesis times and low radiochemical yields. To circumvent 
this problem, asymmetric alkylation methodologies have attracted radiochemists aiming 
to prepare the desired enantiomer in a highly stereoselective manner and with good RCY. 
Reliable methods to synthesize enantiomerically pure [11C]AAs have been accomplished 
with a variety of available Schiff bases and C-11 alkylating agents, as discussed further on 
in this section. [6,48,49]  
3.1. Racemic and Asymmetric Synthesis with Schiff Base Precursor:                                
N-(Diphenylmethylene)Glycine tert-Butyl Ester   
 
The alkylation of the achiral Schiff base glycine precursor was first reported for the 
radiosynthesis of [11C]phenylalanine by Kilbourn, et al. [47] Thereafter this strategy was 
followed to radiolabel a wide range of other racemic [3-11C]AAs, namely alanine, 2-
aminobutyric acid, norvaline, norleucine and leucine. [46] All these reactions employed 
phase-transfer alkylation conditions using achiral catalyst tetrabutylammonium hydrogen 
sulfate and the achiral precursor, N-(diphenylmethylene) glycine tert-butyl ester, with 
different [11C]alkyl iodides. The racemic [11C]AAs of interest were obtained in a d.c. RCY of 
10-50% and RCP of 93-99%. The reaction times for the C-11 alkylation were between 5 and 
10 min and typical reaction temperature of 40-45 °C, though reaction conditions were 
always dependent on the reactivity of [11C]alkyl iodides. The final step to obtain the 
unprotected [11C]AA, removal of the protecting group of the alkylated intermediate, 
occurred in 5 min at 130 °C using strong acidic conditions (e.g. concentrated HCl). An 
inconvenience with this methodology, when first reported, was its non-stereoselectivity. 
Therefore, special attention was devoted to treatment of [3-11C]alanine and [3-
11C]phenylalanine with the enzyme D-AAO to obtain enantiopure (99% ee) product. [46] 
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Though very successful, this enzymatic resolution was time-consuming and challenging to 
perform. 
Overall, these studies have identified phase-transfer alkylation is reliable and practical 
synthetic pathway to label [11C]AAs in the side-chain. [46] The formidable challenge in this 
methodology still lies in performing a stereoselective alkylation on the α-carbon starting 
from an achiral precursor. Important parameters that apply to all radiopharmaceuticals 
are the convenience and reliability of the radiolabeling process, however limited by 
synthesis time and AM. To overcome these challenges, especially the RYCs for these 
particular C-11 alkylations, more reactive alkylating reagents have been explored. 
Employing the highly reactive [11C]CH3OTf on the same precursor, N-(diphenylmethylene) 
glycine tert-butyl ester, resulted in very rapid and efficient C-11 methylation in only 1 min 
at 60 °C. Acidic deprotection over 5 min at 170 ºC finally yielded [1-11C]alanine where the 
RCY was increased to 70–90% within 25-30 min. [50]  
Considering the utility of obtaining one enantiomer of [11C]AAs, this attractive alkylation 
approach has been brought to the next level by taking inspiration from the wealth of 
literature surrounding asymmetric phase-transfer catalysis. [51,52] Recently, Windhorst, et 
al. achieved rapid and highly enantioselective 11C-C bond formation of L- and D-[11C]alanine 
[53] and L- and D-[11C]phenylalanine[54], as illustrated in Figure 4a. The commercially 
available glycine Schiff base was utilized, in the presence of quaternary ammonium salts 
as chiral phase-transfer catalysts (PTCs; Figure 4b) to yield specifically L- or D-[11C]AAs. 
Reactions were performed in near quantitative RCC of the alkylation reactions, resulting in 
L-[11C]alanine and L-[11C]phenylalanine in excellent ee of >90%, desirable AM of >50 and 85-
135 GBq·µmol-1, and sufficient d.c. RCY of 20% and RCP >95%, respectively. [53,54] 
Furthermore, Windhorst, et al. aimed to extend the catalyst controlled asymmetric 
induction to 1,4-Michael addition reactions with [11C]tert-butylacrylate and [11C]N-
tritylacrylamide to yield [11C]glutamate and [11C]glutamine, respectively. [55] Despite the 
versatility of C-11 synthons, so far the enantioselective addition reaction has been only 
moderately successful, which might be attributed to the Pd-ligand complex utilized in 
carbonylation reaction with [11C]CO.  
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Figure 4: Asymmetric phase-transfer alkylation reaction (a) with chiral phase-transfer 
catalysts (b). 
3.2. Asymmetric Synthesis with Schiff Base Precursor:  [(+)-2-
Hydroxypinanyl-3-Idene]Glycine Ester  
 
Alternative strategies to perform asymmetric alkylation reactions date back to 1979, 
where Långström and Stridsberg recognized the purification issues and this consequently 
led to the development of chiral starting materials. First attempts employed a chiral 
precursor 8-phenylmethyl-2-isocyanoacetate and alkylation reagent [11C]CH3I furnishing 
partially resolved [3-11C]alanine obtained in an ee of 48% with an excess of L-alanine in 50-
60 min. [56] In due course a similar chiral Schiff base precursor, [(+)-2-hydroxypinanyl-3-
idene]glycine tert-butyl ester, afforded under anhydrous conditions the first chiral 
synthesis of L-[3-11C]alanine in a high ee of 89%, determined by enantiomeric analysis 
using gas chromatography (GC), in 30-45 min (Figure 5a). As a final step, a two-step 
hydrolysis of the protecting groups, the imine and tert-butyl ester group, was performed 
without racemization. [57] Encouraged by the benefits of a single enantiomer, especially 
the L-form, asymmetric C-11 labeling of AAs was further extended using different [11C]alkyl 
iodides towards L-2-amino-[3-11C]butyric acid, L-[3-11C]norvaline and L-[3-11C]valine with a 
synthesis time of 50-55 min [58]. In addition to the previously employed Schiff base 
precursor, an additional chiral handle on the C-terminus (Figure 5a, lower part) was 
feasible, but unfortunately resulted in lower asymmetric induction affording ee ranging 
from 36 to 80%, d.c. RCY of 40% and excellent RCP (>98%) in 20-25 min. [59] 
Nevertheless, these examples highlight the potential for asymmetric C-11 alkylation with 
chiral Schiff base precursors. However, a general observation was that larger [11C]alkyl 
iodides proceed slowly, compared to the aforementioned [11C]alanine synthesis. An 
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acceleration of the reaction and considerable increase in radiochemical conversion (up to 
90%) was observed as a function of the addition of more the polar solvent 1,3-Dimethyl-
3,4,5,6-tetrahydro-2(1H)-pyrimidinone and its concentration, next to the addition of a 
strong base (BuLi) and increase of temperature. Nonetheless, the synthetic approach by 
Antoni, et al. [58] afforded previously mentioned [11C]AAs with decent RCY and excellent 
enantiomeric purities (>98%) which, however, has been discontinued due to occasional 
precipitations of lithiated precursor, inaccuracy in the ee determinations, and lastly, more 
approachable strategies.  
3.3. Asymmetric Synthesis with Schiff Base Precursor: (-)-8-Phenylmenthan-
3-Yl N-(Diphenylmethylene)Glycinate  
 
Comparable to the procedure described in the previous paragraph, herein the C-terminal 
chiral auxiliary (Figure 5b), appeared as a simple method with high reproducibility and 
minimized technical handling. The starting material (-)-8-Phenylmenthan-3-yl N-
(diphenylmethylene)glycinate was subjected to the achiral phase-transfer catalyst tetra-
butyl ammonium hydroxide and [11C]CH3I or [
11C]CH2PhI to furnish L-[3-
11C]alanine and L-
[3-11C]phenylalanine, respectively. Similarly to the previous approach, both [11C]AAs had 
reasonable RCY, 40 and 15%, respectively, and excellent RCP >98%, however 
enantioselectivity was lower. [60] 
3.4. Asymmetric Synthesis with the Oppolzer Chiral Sultam-Derived Glycine  
 
During the years, Schiff base precursors have been the spotlight of research in which their 
C- and N-terminal sides have been modified, aiming to improve the RCY and, more 
importantly, the ee of the desired [11C]AA product. A very successful chiral precursor 
proved to be the sultam-derived glycine synthon, developed by Oppolzer, et al. [61] 
Advantageously, Nagren, et al. adopted and improved this methodology by reacting the 
precursor with n-BuLi at low temperature for 30 min, followed by [11C]CH3I, trapping at 
the same temperature, enabling a quantitative alkylation within 5 min, while the reaction 
temperature slowly reached room temperature. Subsequently, the alkylated intermediate 
was subjected to two-step hydrolysis yielding L-[3-11C]alanine in d.c. RCY 40-50%, counted 
from [11C]CH3I, and 94% ee in a total synthesis time of 50 min (Figure 5c). [6,49] Since 
these very encouraging results, even the precursor has become commercially available 
which maintained great interest for chiral alkylation reactions to obtain [11C]AAs.  
3.5. Asymmetric Synthesis of α-[11C]Methyl Tryptophan with [11C]Methyl 
Iodide 
 
Considerable potential in the use of Schiff base precursors has also been displayed by the 
radiosynthesis of the unnatural α-[11C]methyl tryptophan. Here, the natural amino acid, 
15299 - Pekosak_BNW.indd   36 16-02-18   16:21
Ch
ap
te
r 2
Chapter 2 
36 
 
Figure 4: Asymmetric phase-transfer alkylation reaction (a) with chiral phase-transfer 
catalysts (b). 
3.2. Asymmetric Synthesis with Schiff Base Precursor:  [(+)-2-
Hydroxypinanyl-3-Idene]Glycine Ester  
 
Alternative strategies to perform asymmetric alkylation reactions date back to 1979, 
where Långström and Stridsberg recognized the purification issues and this consequently 
led to the development of chiral starting materials. First attempts employed a chiral 
precursor 8-phenylmethyl-2-isocyanoacetate and alkylation reagent [11C]CH3I furnishing 
partially resolved [3-11C]alanine obtained in an ee of 48% with an excess of L-alanine in 50-
60 min. [56] In due course a similar chiral Schiff base precursor, [(+)-2-hydroxypinanyl-3-
idene]glycine tert-butyl ester, afforded under anhydrous conditions the first chiral 
synthesis of L-[3-11C]alanine in a high ee of 89%, determined by enantiomeric analysis 
using gas chromatography (GC), in 30-45 min (Figure 5a). As a final step, a two-step 
hydrolysis of the protecting groups, the imine and tert-butyl ester group, was performed 
without racemization. [57] Encouraged by the benefits of a single enantiomer, especially 
the L-form, asymmetric C-11 labeling of AAs was further extended using different [11C]alkyl 
iodides towards L-2-amino-[3-11C]butyric acid, L-[3-11C]norvaline and L-[3-11C]valine with a 
synthesis time of 50-55 min [58]. In addition to the previously employed Schiff base 
precursor, an additional chiral handle on the C-terminus (Figure 5a, lower part) was 
feasible, but unfortunately resulted in lower asymmetric induction affording ee ranging 
from 36 to 80%, d.c. RCY of 40% and excellent RCP (>98%) in 20-25 min. [59] 
Nevertheless, these examples highlight the potential for asymmetric C-11 alkylation with 
chiral Schiff base precursors. However, a general observation was that larger [11C]alkyl 
iodides proceed slowly, compared to the aforementioned [11C]alanine synthesis. An 
Carbon-11 Labeled Amino Acids and Peptides  
37 
 
acceleration of the reaction and considerable increase in radiochemical conversion (up to 
90%) was observed as a function of the addition of more the polar solvent 1,3-Dimethyl-
3,4,5,6-tetrahydro-2(1H)-pyrimidinone and its concentration, next to the addition of a 
strong base (BuLi) and increase of temperature. Nonetheless, the synthetic approach by 
Antoni, et al. [58] afforded previously mentioned [11C]AAs with decent RCY and excellent 
enantiomeric purities (>98%) which, however, has been discontinued due to occasional 
precipitations of lithiated precursor, inaccuracy in the ee determinations, and lastly, more 
approachable strategies.  
3.3. Asymmetric Synthesis with Schiff Base Precursor: (-)-8-Phenylmenthan-
3-Yl N-(Diphenylmethylene)Glycinate  
 
Comparable to the procedure described in the previous paragraph, herein the C-terminal 
chiral auxiliary (Figure 5b), appeared as a simple method with high reproducibility and 
minimized technical handling. The starting material (-)-8-Phenylmenthan-3-yl N-
(diphenylmethylene)glycinate was subjected to the achiral phase-transfer catalyst tetra-
butyl ammonium hydroxide and [11C]CH3I or [
11C]CH2PhI to furnish L-[3-
11C]alanine and L-
[3-11C]phenylalanine, respectively. Similarly to the previous approach, both [11C]AAs had 
reasonable RCY, 40 and 15%, respectively, and excellent RCP >98%, however 
enantioselectivity was lower. [60] 
3.4. Asymmetric Synthesis with the Oppolzer Chiral Sultam-Derived Glycine  
 
During the years, Schiff base precursors have been the spotlight of research in which their 
C- and N-terminal sides have been modified, aiming to improve the RCY and, more 
importantly, the ee of the desired [11C]AA product. A very successful chiral precursor 
proved to be the sultam-derived glycine synthon, developed by Oppolzer, et al. [61] 
Advantageously, Nagren, et al. adopted and improved this methodology by reacting the 
precursor with n-BuLi at low temperature for 30 min, followed by [11C]CH3I, trapping at 
the same temperature, enabling a quantitative alkylation within 5 min, while the reaction 
temperature slowly reached room temperature. Subsequently, the alkylated intermediate 
was subjected to two-step hydrolysis yielding L-[3-11C]alanine in d.c. RCY 40-50%, counted 
from [11C]CH3I, and 94% ee in a total synthesis time of 50 min (Figure 5c). [6,49] Since 
these very encouraging results, even the precursor has become commercially available 
which maintained great interest for chiral alkylation reactions to obtain [11C]AAs.  
3.5. Asymmetric Synthesis of α-[11C]Methyl Tryptophan with [11C]Methyl 
Iodide 
 
Considerable potential in the use of Schiff base precursors has also been displayed by the 
radiosynthesis of the unnatural α-[11C]methyl tryptophan. Here, the natural amino acid, 
15299 - Pekosak_BNW.indd   37 16-02-18   16:21
Chapter 2 
38 
 
transformed into a Schiff base, is used as a precursor which is on its turn was alkylated at 
the -carbon. The scope and potential of these precursor has, however, only been 
explored to a limited extent. Previous successful syntheses of [1-11C]tryptophan were not 
desirable, as the radiolabel would be lost during metabolism. To circumvent this, Chaly, et 
al. developed the tryptophan imine moiety precursor, allowing stereospecific “no-carrier 
added” C-11 methylation to obtain the alternative tracer of [11C]tryptophan. The 
stereospecific alkylation with [11C]CH3I, was achieved in 30 min and resulted in a 20-25% 
n.d.c. RCY and AM of 74 GBq·µmol
-1 (Figure 5d). Intriguing, the authors proposed that the 
intermediate is “locked” in the position existing in the original AA, in this case L-
tryptophan, resulting in product of the same chiral configuration as starting precursor, 
with no D-stereoisomer present. [62]  
3.6. Asymmetric Synthesis with Chiral Nickel Complexes 
 
With respect to the alkylations of Schiff bases, the scope of avaliable methods for PET-
labeling has been broadened by the chemistry of metallo-complex AA synthons for the 
asymmetric preparation of α-AA. The methodology has been introduced in organic and 
organometallic chemistry by Belokon in 1985. [63] These chiral Nickel complexes proved to 
be highly versatile and allowed a very high level of stereocontrolled C-11 alkylation 
reactions due to high acidity of the α-hydrogen. Also F-18 analogues have been obtained 
via this route, though these will not be further discussed here. [7,64] Consequently, the 
condensation of Ni(ІІ) with (S)-N-(2-benzoylphenyl)-1-benzylpyrrolidine-2-carboxamide 
(BPB) and glycine has become popular due to commercial availability of BPB, the chiral 
scaffold required for the stereoselective alkylation reaction and its reusage potential. The 
first radiosynthetic approach to obtain [11C]AAs was evaluated by Fasth et al. [65] 
Accordingly, [11C]alanine (de of 80%; RCY of 60%) and [11C]phenyalanine (de of 90%; RCY of 
40%) were synthesized, as well as [11C]tyrosine with an excellent de of 90% and RCY of 
12% (Figure 5e).  
Furthermore, by adapting the metallocomplex of Ni(ІІ) with BPB, with either tyrosine or 
dopamine (green part in Figure 5e), Popkov, et al. was also able to synthesize unnatural α-
[11C]methyl-tyrosine and α-[11C]methyl-DOPA with [11C]CH3I,giving slight excess of the LD-
stereoselectivity with RCY 7% and 9%, respectively. [7,66] Demonstrating the general 
applicability of this methodology, chiral Ni(II)-complexes were also explored with 
[11C]formaldehyde as alkylating reagent by Popkov, et al. [67] While the successful and 
reliable synthesis D-[11C]serine resulted in 50% d.c. RCY, the diastereoselectivity achieved 
was only 80%, indicating improvements in the high performance liquid chromatrography 
(HPLC) separation of intermediate diastereomers are needed. [67]  
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Figure 5: Asymmetric syntheses of various amino acids with different chiral starting 
material. 
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 Specific Carbon-11 Labeling in the Side Chain of Amino Acid 4.
 
4.1. Condensation Reaction with 2-Aryl-5-Oxazolones  
 
The merits of C-11 alkylation, in particular the C-11 methylation, as a choice for 
radiotracer production have been well-recognized. Schiff bases have been acknowledged 
as valuable precursors for stereoselective synthesis of various [11C]AAs by the formation of 
new 11C-C-bond through alkylation. However, multiple attempts have been reported to 
apply other precursors as well, aiming to obtain a C-11 labeled AA under similar alkylation 
reactions. [49] For example, α-[11C]methyl-L-tryptophan, also described by Chaly, et al. [61] 
in the chapter 3.5, was reported by Plenevaux, et al. [68], where the N-terminal amine 
functionality was covalently attached to the indole precursor’s side chain to induce 
activation at the -carbon as well as to protect the amine-functionality. The precursor was 
deprotonated with the base lithium diisopropylamide at low temperature to activate the 
α-carbon, followed by alkylation with [11C]CH3I in 5 min (Figure 6a). Subsequently, 
deprotection of the labeled precursor was achieved by acidic hydrolysis to yield the 
alkylated product in 36% d.c. RCY in 22 min with an exceptional ee >97%. [68] When the 
results of Plenevaux, et al. are compared to the method described by Chaly, et al. (chapter 
3.5), this approach yields the product slightly faster in a higher RCY, however the 
precursor synthesis for the Plenevaux’s approach is more demanding. 
4.2. Asymmetric Synthesis of the 2-tert-Butyl-3-Methyl-1,3-Imidazolidin-4-
on with  [11C]Alkyl Iodides 
 
Another promising method that provides [11C]AAs in an almost enantiomerically pure form 
is the alkylation of imidazolidinone derivatives. These precursors form a highly 
stereoselective 11C-C bond with [11C]alkyl iodides on stabilized carbanions, as depicted in 
Figure 6b. The imidazolidinone derivatives, (R)- or (S)-Boc-2-tert-butyl-3-methyl-1,3-
imidazolidin-4-one (BMI), is treated with lithium 2,2,6,6-tetramethylpiperidide in 
tetrahydrofuran at low temperature to initiate deprotonation on the α-carbon, followed 
by an C-11 alkylation and subsequent acidic hydrolisation to furnish the desired [11C]AAs. 
Via this route, D- and L-[3-11C]alanine and D- and L-[3-11C]phenylalanine have been 
obtained within 50 min. Using this approach, the [11C]alanine synthesis was achieved in 
d.c. RCY of 75% with an ee of exceptional 98%. On the other hand, [11C]phenylalanine 
could only be obtained in a RCY of 30%. This lower RCY might be explained by the lower 
electrophilicity of [11C]CH2PhI as reagent. Nevertheless, the ee of the product was 96%, 
which is highly satisfactory. Additionally, this methodology has also been used to obtain 
[6-11C]lysine with (S)-Boc-BMI as precursor that was radiolabeled with [11C]4-
iodobutyronitrile achieving an ee of 96%, though these were only preliminary findings. In 
the same paper attempts to obtain [1-11C]valine with 2-[11C]isopropyl iodide were 
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described, but proved to be unsuccessful. Unfortunately, the application of this 
methodology is hampered by the commercially available (R)- or (S)-Boc-BMI precursors as 
their enantiomeric purities can vary a few percent dependent on the batch, as revealed by 
Fasth and Låndström [65,69], which may influence the enantioselective synthesis of [11C]AAs. 
4.3. S-Methylations on Homocysteine with [11C]Methyl Iodide 
 
Among alkylations to form a new 11C-C bond, C-11 methylations on homocysteine residue 
are important as well, especially considering their versatility in peptide radiolabeling, 
discussed later. As early as 1976, Comar, et al. recognized C-11 as a beneficial radioisotope 
for 11C-methyl-methionine labeling of DL-homocysteine or L-homocysteine thiolactone 
with [11C]CH3I. 
[70] Continuous research strived to improve and simplify methods to obtain 
latest PET tracer resulting in a “no-carrier added” and rapid S-alkylation of L-homocysteine 
adsorbed on solid-supported Al2O3/KF with [
11C]CH3I (Figure 6c). The acidic S-H proton of 
the homocystein is easily removed by the strong base.  Therefore, the final purification 
was simplified, as 90% of the precursor remained adsorbed on the solid support and was 
eliminated by a simple filtration, providing a superb d.c. RCY of 94% with no required 
preparative HPLC. Hence, this methodology provides important simplification enabling 
fast production of L-[11C-methyl]methionine ready for injection within 10 min in excellent 
RCP of 99% and acceptable AM of 37 ± 6 GBq·μmol
-1. [71]  
4.1. Palladium-Mediated Coupling with Organo-Boron Precursor and 
[11C]Methyl Iodide 
 
Another research advance which should enable easier access to [11C]AAs is the Pd-
catalyzed coupling reaction between a boronic ester precursor and [11C]CH3I. In this 
reaction a Suzuki coupling is employed between an unsaturated AA precursor subjected to 
cross-coupling reactions. The newly formed 11C-C bond can then be reduced to obtain a 
saturated alkyl side chain of the AA. The organo-boron precursor reacted within 5 min 
with [11C]CH3I in the presence of tris(dibenzylideneacetone)dipalladium(0), tri(o-
tolyl)phosphine and base at elevated temperature, followed by mild hydrogenation and 
deprotection to furnish L-[1-11C]leucine. Ozaki’s radiosynthesis is illustrated in Figure 6d. 
[72] By a similar method unnatural S-α-[11C]methyl leucine was also synthesized showing 
the suitability for syntheses of various 11C-methyl-labeled branched alkanes. [72] 
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eliminated by a simple filtration, providing a superb d.c. RCY of 94% with no required 
preparative HPLC. Hence, this methodology provides important simplification enabling 
fast production of L-[11C-methyl]methionine ready for injection within 10 min in excellent 
RCP of 99% and acceptable AM of 37 ± 6 GBq·μmol
-1. [71]  
4.1. Palladium-Mediated Coupling with Organo-Boron Precursor and 
[11C]Methyl Iodide 
 
Another research advance which should enable easier access to [11C]AAs is the Pd-
catalyzed coupling reaction between a boronic ester precursor and [11C]CH3I. In this 
reaction a Suzuki coupling is employed between an unsaturated AA precursor subjected to 
cross-coupling reactions. The newly formed 11C-C bond can then be reduced to obtain a 
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deprotection to furnish L-[1-11C]leucine. Ozaki’s radiosynthesis is illustrated in Figure 6d. 
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Figure 6: Miscellaneous 11C-alkylations with various starting material.  
4.5. [11C]Cyanide Nucleophilic Reactions 
 
Alternatively to the Bucherer-Strecker synthesis, described earlier in the chapter 2.1, the 
highly polarized soft base [11C]cyanide has been further explored to radiosynthesize 
[11C]AAs. This methodology was more recently published by Qu, et al., where the 
nucleophilic substitution reaction with aliphatic halides furnished the enantiopure 
radiosynthesis of L-[5-11C]glutamine. [71] The radiosynthesis depicted in Figure 7a was 
achieved by a reaction of [11C]KCN with protected enantiopure precursor 4-iodo-2-amino-
butanoic ester in a three step synthesis, and successive deprotection and hydrolysis 
yielding L-[5-11C]glutamine in RCY of 25% with high purity, but unfortunately rather low AM 
of 1.85 GBq·µmol-1.  
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Figure 7: Nucleophilic reactions with [11C]Cyanide. 
4.6. Aziridine Ring-Opening Reactions 
 
The versatility of the [11C]cyanide reagent allows the facile functionalization and 
derivatization of many precursors where aziridines can serve as alternative electrophiles 
for development of different [11C]carbonyl AAs. Aziridine ring-opening reactions have 
been reported by Gillings, et al. as a novel and fast methodology for the synthesis of the  
following [11C]AAs: [4-11C]aspartic acid, [4-11C]asparagine and 2,3-diamino-[4-11C]butyric 
acid, all obtained in a d.c. RCY of 30–40% within 30 min. [73] Racemic N-activated aziridine-
2-carboxylates were synthesized in four steps, where in particular N-(tert-
butoxycarbonyl)aziridine-2-isopropyl carboxylate underwent nucleophilic ring-opening 
reactions with [11C]tetra-butylammoniumcyanide by heating in dimethylformamide (DMF), 
shown in Figure 7b. The use of [11C]tetra-butylammoniumcyanide with the tetra-
butylammonium counter ion was crucial since half of the radioactivity remained unreacted 
when [11C]HCN in DMF was used. The low reactivity of [11C]HCN in DMF was attributed to 
insolubility of the reagent in the solvent. To establish a stereoselective synthesis using this 
methodology, the racemic starting material was resolved by chiral HPLC; however, 
racemization occurred mainly during the ring opening reaction due to the acidity of the β-
hydrogen. Up till now, despite several attempts, no successful chiral syntheses have been 
reported using this methodology. [73]  
5. Enzyme-Catalyzed Synthesis of Carbon-11 Amino Acids  
 
The relative short half-life of C-11 urges fast and efficient synthetic methods for PET tracer 
production and therefore biocatalysis offers attractive solutions, such as stereoselective 
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reactions or the possibility to omit protecting groups in the precursor. To date, enzymes 
have been used in a number of radiosyntheses to obtain C-11 labeled AAs and this 
approach resulted in exquisite selectivity and high turnover numbers, enabling rapid high 
yielding reactions to obtain pure products under mild conditions. Despite the general 
challenge of enzymatic reaction kinetics and the speed of radiolabel incorporation to the 
molecule, the application of low enzyme concentrations in C-11 labeled radiotracers 
preparation has proven to be a rewarding strategy for 12 carbon-11 labeled AAs. [49]  
Thus far, two different types of enzymatic transformations can be distinguished, firstly the 
11C-C bond formation and secondly the functional group transfer, exemplified by 
transaminiations or oxidations of amino groups to ketones. [49]   
The first example of a pioneering, well-performed enzyme application, where an enzyme 
served as a resolving agent, was the preparation of L-[3-11C]phenylalanine and L-[3-
11C]alanine, exemplified in Figure 8. Treatment of the corresponding racemic mixture by 
D-AAO (EC 1.4.3.3) in 10-20 min resulted in enantiomerically pure [11C]AAs, where ee of 
the product was determined by GC (N-trifluoroacetylalanine methyl ester) or LC ([3-
11C]phenylalanine as free acid). [46] Advantageously, this method uses immobilized 
enzymes which improved the previous challenges regarding the product purification and 
reduced the risk of product contamination. Next to that, immobilization allowed effortless 
recovery of the enzyme and enabled the possibility to perform several syntheses with the 
same enzyme. [49] 
Nowadays, the most described methodology remains the multi-step enzymatic [11C]AA 
synthesis, where initially a radiochemical reaction is combined with one or more 
enzymatic reactions. Employing this approach the syntheses of four aromatic AAs were 
described: 3,4-dihydroxy-L-[11C]phenylalanine, known as [11C]DOPA, L-[11C]tyrosine, L-
[11C]tryptophan and [5-11C]hydroxytryptophan, as well as L-[11C]alanine achieved using 
[11C]CH3I or [
11C]CN-. As illustrated in Figure 8, the synthesis of all these [11C]AAs starts 
from [11C]alanine, labeled at the carboxylic acid position (in red) or the β-carbon position 
(in blue). After initial labeling, [11C]alanine is resolved using D-AAO/catalase and further 
converted to 11C-pyruvic acid by glutamic-pyruvic transaminase (GPT). Accordingly, 
subsequent one-pot 11C-C bond forming reaction between the aromatic precursor (indole 
or phenol) and 11C-pyruvate by β-tyrosinase (tyrosine phenol-lyase; EC 4.1.99.2) or 
tryptophanase (tryptophan indole-lyase; EC 4.1.99.1) yielded products in more than 99% 
ee. After the addition of HCl, the enzymes precipitated and final crude AA was purified by 
prep HPLC. Synthesis of L-[11C]DOPA required also addition of ascorbic acid, in order to 
prevent possible oxidation. [48,74] 
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Figure 8: Enzymatic synthesis of aromatic L-enriched 11C-AAs (carboxylic- (in red) or the 
methyl- (in blue) position).  
Next to the aromatic [11C]AAs, laudable achievements have been also made towards C-11 
aliphatic AAs by a variety of combined 11C-C bond-forming chemo-enzymatic reactions 
published in the last three decades. As a first example, the synthesis of L-[4-11C]aspartic 
acid [75] and L-[4-11C]glutamic acid [76] by O-acetyl-L-serinase and O-Acetyl-L-homoserine 
was published in early 1980 [77], where further meticulous improvements by Antoni et al. 
in 2001 enabled their synthesis in 45-55 min. [77] Satisfactory d.c. RCY of 50-60% and 60-
70%, respectively, and RCP >95% and an overall AM of 30 GBq·µmol
-1 starting from 
[11C]HCN were obtained. Additional success was the high enantiomeric purity, determined 
by derivatization with Marfay’s reagent, of 98% ee for both aliphatic [11C]AAs.  
Finally, chemo-enzymatic synthesis advances were achieved for L-[11C]methionine 
([11C]MET) via 11C-S bond formation. Based on a wide spectrum for substrate specificity of 
O-acetyl-L-homoserine and its success in the synthesis of γ-[11C]cyano-α-amino-L-butyric 
acid by Antoni, et al. [77], Kaneko et al. later published the synthesis of [11C]MET from O-
acetyl-L-homoserine and the [11C]methanethiol precursor obtained from [11C]CH3I. 
[78] As S-
H compounds are very reactive, its C-11 isotopologue rapidly reacted with immobilized α-
γ-cyano-α-aminobutyric acid synthase and the radioactivity eluted from the column was 
only [11C]MET. The tracer was obtained within 15 min after EOB with an enantiomeric 
purity of >99% and d.c. RCY of 70% (based on [11C]CH3I). 
[78] Other [11C]MET analogues, like 
[11C]ethionine and [11C]propionine could also be prepared from the corresponding 
[11C]alkanethiols.  
Finally, we should also mention that a series of coupled enzymatic reactions have been 
reported to radiosynthesize L-[3-11C]serine from [11C]methanol ([11C]MeOH), starting from 
[11C]CO2. The immobilized enzymes alcoholoxidase (EC 1.1.13.13) combined with catalase 
(EC 1.11.1.16) selectively oxidized [11C]MeOH to [11C]formaldehyde, which condensed with 
tetrahydrofolate and was subsequently treated with immobilized serine 
hydroxymethyltransferase. Accordingly, only the L-[3-11C]serine enantiomer was detected 
by LC-analysis and obtained in 1-2% d.c. RCY (from [11C]CO2) after a synthesis time of 50-
65 min with AM of 1.1-1.9 GBq·µmol
-1. [79]  
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In general it can be concluded that enzyme transformation reactions can indeed be highly 
stereoselective towards the naturally occurring L-enantiomer. On the other hand, 
obtaining the D-product still remains a special challenge. A disadvantage that may arise is 
the long reaction time and loss of the radioactivity, resulting in a low RCY when enzymes 
function as a resolving agent. Nevertheless, the specificity remains their main asset, even 
after several reuses of these specialized immobilized enzymes. 
6. Synthesis Strategies for Carbon-11 Small Peptides 
 
Next to the use of C-11 labeled AAs as PET tracers, there has been tremendous interest in 
using C-11 labeled peptidic radiopharmaceuticals, as peptides offer a maximum degree of 
freedom and flexibility. [9] Only a few peptides have been successfully labeled with C-11 
and applied in tumor and other imaging studies. The earliest reports from the 1980s were 
conducted on several biologically active peptides by attaching an isotopologue methyl 
group using [11C]CH3I or [
11C]formaldehyde. [80–82]  
Inspired by the prosperity of formaldehyde labeling, Straatman, et al. labeled proteins 
with [11C]formaldehyde in a borate buffer at different pH and subsequently treated the 
reaction mixture with various concentrations of NaBH4 at room temperature. Using this 
methodology, the proteins human serum albumin (66.5 kDa), fibrinogen (340 kDa) and 
luteinizing hormone (LH, 42 kDa) have been labeled succesfully, all using similar reaction 
conditions. Albumin required slightly basic pH, and after the optimization it was concluded 
that higher amounts of protein in the reaction gave higher RCYs with a mean of 39% 
(representive structure in Figure 9a). On the other hand, [11C]fibrinogen was obtained in 
33% RCY and exhibited still similar biological behaviour as the unlabeled fibrinogen. [81] 
Finally, methylated glycoprotein LH obtained via the reductive alkylation with on-line 
produced [11C]formaldehyde, retained its biological potency; however, the AM of 7.2 
GBq·µmol-1 hampered pre-clinical application. [80] Evidently, the successful synthesis route 
illustrated in Figure 9a preserved the biological activity of protein despite its lack of 
specificity considering the location of the radioactive label and the amount nuclide per 
molecule. Consequently for C-11 LH, high AM is hardly achievable especially as high 
amounts of starting protein are needed to achieve a successful radiolabeling. 
Carbon-11 labeled proteins provided an insight into their mechanism of action in the early 
development of PET in routine diagnostic use (early 2000s) and proved their value and 
biological importance. Confirmation of their safety and already acknowledged specificity 
of small peptides expanded the development of C-11 radiolabeling strategies to obtain 
peptidic radiotracers via fast and efficient routes.  
Other early examples of C-11 peptide labeling is the carboxylation of α-lithioisocyanides to 
obtain dipeptides with a radiolabeled carboxylic acid functionality. [25] Initially, [11C]glycine 
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was produced from methylisocyanide via C-11 carboxylation, as discussed in chapter 2.1, 
which is subequently reacted with a cyclic AA anhydride to obtain L-phenylalanyl[1-
11C]glycine and L-leucyl[1-11C]glycine. Bolster, et al. achieved  the dipeptides in a isolated 
RCY of 3-6% in a total synthesis time of 50 min, as illustrated in Figure 9b. [25] In theory, 
many anhydrides, also more complex cyclic ones, could react with [11C]glycine providing 
longer peptidic structures where  the chiral center is preserved, generating a single 
enantiomer. 
Figure 9: Early beginnings of simplified strategies for carbon-11 labeled peptides.  
Carbon-11 methylation was also described as a strategy for peptide radiolabeling, mainly 
for the alkylation of the thiol functionality of homocysteine in the peptide. The complete 
deprotection of benzyl-homocysteine followed by side-specific methylation performed in 
one-step in liquid ammonia. Initial studies applying this approach have been described by 
Långström, et al., where a tripeptide with the sequence Z-Gly-L-Homocysteine(Bzl)-Gly-O-
Bzl was methylated to obtain H-Gly-[11C]Met-Gly-OH with more than 90% RCY in less than 
25 min. [83] Since C-11 methylation of homocysteine residues proved to be successful, this 
methodology has been used to obtain radiolabeled Substance P, enabling its thorough 
investigation in biological studies. Its undecapeptide and octapeptide were labeled using a 
homocysteine precursor in satisfactory 35% RCY within 1 h production time, including 
purification. Even though, deprotection problems of other protecting side groups and 
partial cleavage involving proline nitrogens arose, a high RCC could be obtained [84,85]. 
Furthermore, neuropeptide MET-enkephalin, a 5-mer peptide, and its two metabolic 
fragments thereof, Gly-Phe-MET and Phe-MET, were labeled using the C-11 methylation 
strategy by Nagren, et al. S-[11C]MET-enkephalin and corresponding C-11 labeled 
fragments, were reported in a RCY of 50-80%, after LC purification, in 35-50 min with AM 
ranging 0.4-7.2 GBq·µmol-1, depending on the AM of [
11C]CH3I. 
[86] Though this method of 
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peptide radiolabeling proved to be highly reliable and high yielding, it should be noted 
that radiolabeling can only be conducted if a methionine residue is present in the peptidic 
structure. Though being an interesting approach, further optimization of this procedure, 
especially with the respect of deprotection and generation of the sulfide anion for the 
reaction, has not been published. 
More recently, analogous to the methodology developed by Långström, et al., advantage 
was obtained by making use of the more reactive and volatile [11C]MeOTf for the 
methylation of three peptides. Here, a thiol nucleophile from a cysteine residue was 
alkylated and thereby a high single-step regioselective C-11 methylation of cysteine 
residues was demonstrated. [15] [11C]MeOTf as an alkylating reagent for peptides has been 
further explored to label more complex peptides as well, such as C-11 labeled glutathione 
(GSH) by using excess of NaOH in dimethylsulfoxide, furnishing successful methylation in 
less than 1 min (Figure 10a). Additionally, a decapeptide has been labeled and was 
obtained in a 59–65% incorporation yield. The strategy was also possible with the 
challenging cyclic somatostatin analogue [11C]Cys(Me)-[Tyr3-octreotate], as described in 
the next section. [15,87] 
Recently the use of C-11 labeled peptides has attracted considerable attention with three 
promising novel methodologies to label small peptides containing 2 to 10 amino acids. 
One approach utilizes direct incorporation of C-11 label via stereoselective alkylation, 
published as “native” peptide labeling. This methodology is comparable to the one 
described in paragraph 3.1, where an N-terminal Schiff base peptide precursor was 
alkylated at the -carbon, potentially in a stereoselective manner. Pekošak, et al. 
described the first C-11 labeled peptides  and afforded multiple tetrapeptides [88] 
employing chiral phase-transfer catalysts in a reliable RCC and high diastereoselectiviy, as 
depicted in Figure 10b and discussed in more detail in the next chapter. Follow-up studies 
of Filp, et al. investigated the influence of the substrate peptidic backbone precursor and 
phase-transfer catalyst (see the Figure 4b) induction on stereoselectivity for various 
natural dipeptides labeled with either [11C]CH3I or [
11C]CH2PhI. 
[89] Overall, excellent 
conversion rates of >85% and diasteremomeric excess up to 94% were uniformly observed 
in only 5 or 7 min (Figure 10b), thereby showing the procedure can be extended to various 
N-terminal peptides using other [11C]alkyl halides and used for rapid preclinical 
assessment of the peptidic-lead structure.  
A second recent methodology to obtain C-11 labeled peptides depends on the use of 
palladium-mediated amino-carboxylation using [11C]CO. Figure 10c shows the production 
of N-[11C]acetylated peptides on terminal amine or lysine residues was reported by 
Andersen, et al. The strength of this paper is that several N-acetylated peptides have been 
described, such as [11C]LULU-Phol (RCC: 43%; d.c. RCY: 33 %), [11C]acetyl-cRGDfK (RCC: 
63%; d.c. RCY: 37%), [11C]lacosamide (RCC: 63%; d.c RCY: 46%) in in excellent RCP of 99% 
within 30 min, and also a larger peptide the [11C]SPF-5506-A4 (RCC: 15-21%; d.c. RCY: 2%). 
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The C-11 acetylation provided the labeled peptides with high AM ([
11C]LULU-Phol: 281 
GBq·µmol-1) and proved to be N-terminal selective, however has a competing reaction on 
cysteine residues, namely the S-acetylation, might serve as an additional challenge for 
future applications. [90]  
A more recent paper by Zhao, et al., reported a direct [11C]cyanide labeling of cysteine-
containing unprotected peptides via palladium-mediated sequential cross-coupling 
reaction. This method enables “nucleophilic-nucleophilic” coupling of a peptide with 
[11C]HCN, as [11C]cyanide source via Pd-complex dihaloarene oxidative addition. In this 
manner a cysteine residue is chemoselectively labeled in the presence of other potentially 
nucleophilic functional side groups. Outstandingly, low amounts of peptide precursor (20 
nmol) are needed for this reaction which can be of added value. The potential of the 
methodology was shown on the RGD peptides ligands for the αVβ3 integrin receptor 
yielding 10% n.d.c. RCY with AM 37 GBq·µmol
-1 within only 15 min (Figure 10d) confirming 
the applicability of the method. [91] 
In recent years, the development in biotechnology and its applications has lead us towards 
combined and improved mechanistic possibilities of peptidic radiopharmaceutical as 
molecular imaging agents. An early research example of using a biotechnological method 
for the synthesis of radiolabeled peptides was exemplified by Harada, et al. [92] A cell-free 
system, so called PURESYSTEM, was combined with [11C]MET to obtain interleukin-8 (IL-8). 
IL-8 is involved in neutrophils activation, and already showed potential in inflammation 
imaging with Tc-99m and I-131. [93,94] Briefly, PURESYSTEM is a novel reconstituted protein 
synthesis kit consisting of necessary enzymes for in vitro transcription, translation and 
energy recycling. The in vitro biochemical reaction proceeded well in a RCY of 63% with 
RCP of >95%. [11C]IL-8 was obtained in n.d.c. RCY of 13% in 20 min, sufficient for a small 
animal imaging study. It is important to bear in mind that protein synthesis will stop when 
[11C]MET is exhausted, therefore high molar activity can be reached.    
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Figure 10: Most recent novel carbon-11 radiolabeling strategies for small peptides.  
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6.1. Carbon-11 Labeled Somatostatin or Octreotate Analogues   
 
In the emerging field of molecular imaging, radiolabeled somatostatin analogues have 
become indispensable tools for in vivo localization of tumors and real-time monitoring of 
therapeutic response. Many somatostain analogues have been developed and analyzed, 
whereas the radiolabeled analogue of the most well-known cyclic octapeptide – 
Octreotide has become the gold standard for neuroendocrine tumors. Driven by the 
success of Octreotide and the significant potential of a large number of C-11 PET 
radiopharmaceuticals in clinical application, several C-11 somatostatin/octreotide 
analogues have been developed. [1,88,95] 
A chemoselective labeling strategy of carbohydrate analogue of Tyr3-octreotate based on 
the formation of oximes reacting with labeled prosthetic group has been proposed by 
Henriksen, et al. [19] Accordingly, 4-[11C]methoxy-benzaldehyde, derived from [11C]CH3I, 
reacted with aminooxy-functionalized peptide precursors of D-Phe1-Tyr3-Thr8-octreotide 
and a two-step synthesis yielded Cel-Dpr-[11C]MBOS-TOCA (Figure 11a) in a d.c. RCY of 
21% within 60 min with a AM of 22–28 GBq·μmol
-1, starting from [11C]CO2. 
[19] Another 
well-known example is a one-step regioselective [11C]methylation of cysteine residue with 
[11C]MeOTf towards [11C]Cys(Me)-[Tyr3-octreotate] (Figure 11b), resulting in n.d.c. RCY of 
11% and AM of 96 MBq·μmol
-1, after purification within 30 min [15]. Very recently, the C-11 
labeled “unmodified” peptide was described by asymmetric phase-transfer catalyzed 
alkylation with [11C]CH2PhI (Figure 11c). As shown in Figure 11c, the H-D-[
11C]Phe-D-Trp-
Lys-Thr-OH, the essential pharmacophore for somatostatin receptors, was labeled in a 
highly stereoselective manner using catalyst 8 (Figure 4b) with a diastereomeric excess of 
94% with d.c. RCY of 9-10 % and AM of 15-35 GBq·μmol
-1 in less than 60 min. [88]  
Obviously, the advantage of the last strategy is to obtain a non-modified peptide as highly 
enriched diastereomer, where further biological studies are not hampered comparing the 
radiolabeled compound to the natural peptide. 
 
Figure 11: Carbon-11 labeled analogues of Octreotate. 
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7. Reflections on the Preclinical and Clinical Applications of Applied 11C-
Labeled Amino Acids  
 
Besides the radiosynthetic development, radiolabeled AAs and peptides have gained an 
increased interest for preclinical and clinical studies on the nature of various diseases. As 
diverse naturally occurring compounds accountable for many biological functions, [11C]AAs 
and peptides can be considered as attractive radiopharmaceutical tracers. These targeting 
vectors labeled with C-11 possess no structural changes whereas, with F-18 or radiometal 
labeled tracers, structural differences arise. Notwithstanding, the radiosynthesis of F-18 
labeled AAs and peptides is well developed and a comprehensive overview is given by 
Ermert, et al. [96] and Richter, et al. [96,97] Radiometals, such as gallium-68, require a 
corresponding bifunctional metal chelator, and due to the size of the chelation, these 
must be separated with the linker not to interfere the peptide binding region. [11]  
Table 1:  Important 11C-AAs and derivatives in (pre)clinic. 
Amino Acid 
Synthetic Approach 
Applicability Highlights Reference 
Methionine 
 
Brain tumor imaging 
Urinary, gynecological 
and lung cancer 
AM: NA# 
RCY: 40-90% 
RCP: >98% 
ee: >99% 
t: 20-30 min 
[98–100] 
DOPA 
 
Neurological disorders 
(e.g. Parkinson’s 
disease, Schizophrenia) 
Brain kinetics 
AM: 0.4-2.0 GBq∙μmol-1 
RCY: 45-60% 
RCP: >98% 
ee: >99% 
t: 45 min 
[48,101] 
Glutamine 
 
Glutaminolysis 
metabolism: tumor 
trapping (only  
preclincal) 
AM: 1.85 ± 0.74 
GBq∙μmol-1 
RCY: (EOB) 5% 
RCP: >95% 
ee: >98% 
t: 60 min 
[102] 
Valine 
 
Small scale patient 
study: pancreatic 
diseases 
AM: 0.56-1.30 GBq∙mg-1 
RCY: 70% 
RCP: >95% 
ee: racemic 
t: 45 min 
[31] 
Tyrosine 
 
Brain tumor imaging 
(prolactinomas) 
AM: NA 
RCY: (EOB) 16% 
RCP: >NA 
ee: >98% 
t: 40 min 
[30,103] 
#If AM cannot be determined to release [
11C]MET for patient PET scan, radiochemical and 
enantiomeric purity are important. 
Carbon-11 Labeled Amino Acids and Peptides  
53 
 
The advantages of C-11 labeled “native” compounds are: 1) structurally preserved 
molecule, 2) equivalent biological properties, 3) favorable radionuclide characteristics, 4) 
low radiation burden for patient, and 5) feasible multiple tracer injections per day.  
Regardless of the half-life and restricted use by PET centers with cyclotrons, the 
development towards C-11 “native” AAs and peptides has been strongly enhanced. 
Promising imaging studies are presented in the next paragraphs, starting with the top-
most used PET AA radiotracer: [11C]MET. The in vivo evaluation of other [11C]AAs is limited 
and has been mostly performed with only small animals, where some studies even date 
back to the 1980’s. Over the years, indeed some have progressed to small scale human 
studies; however, no substantial trails have been conducted recently. 
7.1. [11C]Methionine  
 
[11C]MET has been used extensively to visualize tumor metabolism. Nowadays, many 
different tumors are imaged using [11C]MET by increased fluxes into metabolic pathways 
and cellular proliferation, next to its involvement in the synthesis of phospholipids [99,100]. 
The transport of [11C]MET into the brain is highly enhanced in tumor tissue (e.g. gliomas) 
across the reversible sodium-independent transport system L (LAT 1). 
In 1985, the first report was published on the application of [11C]MET as a PET-tracer  in 
patients with supratentorial gliomas. It was proven that the uptake of [11C]MET is not only 
caused by passive diffusion and leakage in the blood-brain barrier (BBB), but should also 
be attributed to active AA-transport into the cell. [98] Since then, various follow up studies 
compared the use of [11C]MET with [18F]FDG in glioma, meningioma, non-small lung cancer 
and non-Hodgkin’s lymphoma patients to evaluate metabolism, as well as to detect and 
delineate tumors. [104–108] Both [11C]MET and [18F]FDG as PET-tracers have been used 
complimentary, however the advantage of [11C]MET was clear. Especially for brain tumor 
imaging better tumor-to-background ratios can be achieved in addition to tumor staging 
and determination of tumor margins. Overall, the conclusion of the various studies is that 
[11C]MET is better suited for low and intermediate grade brain tumors compared to 
[18F]FDG. [109] Another breakthrough in the use of [11C]MET was a study in young children 
and adults with confirmed brain tumors, conducted by O’Tuama, et al. The consumption 
of administered [11C]MET was declined with patient age in the tumor, proposing that AA 
consumption deteriorates. [110] In a follow up study, Harris, et al. showed that the pancreas 
and liver are the organs with the highest uptake of [11C]MET also for pediatric patients. 
[111] All this suggests that the main metabolic pathway of [11C]MET is protein incorporation, 
as the high uptake might be related to the need of MET for protein synthesis, for example 
plasma proteins in the liver. [99,112] 
In recent years, the clinical value of [11C]MET has been thoroughly investigated for brain 
tumors by Glaudemans, et al. as well as in a meta-analysis by Zhao, et al. Both studies 
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showed an excellent diagnostic performance of [11C]MET in brain tumor differentiation 
where the threshold for determination of brain tumors, relying on tumor-to-background 
ratio, was determined to be acceptable between 1.5 and 1.9. [113,114] Furthermore, 
[11C]MET uptake in the normal brain in comparison to glioma patients offered significant 
advantages, also for white matter changes, which are normally missed in standard analysis 
methods. [115] 
With respect to imaging of other tumor types, [11C]MET has been extensively studied in 
urinary and gynecological cancers, as well as in lung cancer patients, however in 
mentioned tumors it is of critical importance to identify the exact metabolic mechanism 
and its use has limitations (e.g. influence of AA-transport and protein synthesis, 
alternative metabolic pathways). [99,116,117] The development of [11C]MET has been 
summarized by Coope, et al. They concluded that the future of quantitative analysis of 
[11C]MET uptake needs sophisticated computer programs and standardization of tumor-
to-background cut-off values. [115] Moreover, contemporary PET/MRI imaging might 
significantly improve the diagnosis with more precise reference regions maps compared to 
CT. [113]  
7.2 [11C]Tyrosine 
The application of a racemic [11C]tyrosine was assessed in preliminary studies in tumor-
bearing rats by Vaalburg, et al. in 1984 [29] and later Daemen, et al. [102] Both 
enantiomers of [11C]tyrosine showed tumor uptake, which was even slightly in favor of the 
D-enantiomer. With respect to the metabolism, [11C]CO2 appeared as the major 
breakdown product, meaning that [11C]tyrosine is firstly metabolized via decarboxylation. 
Advantageously, the metabolite [11C]CO2 can be rapidly cleared through the lungs, not 
disturbing PET measurements and potentially even increasing the signal to noise ratio. 
[118,119] 
A small scale study investigated the potential reduction on tumor growth after 
radiotherapy in rats and patients with prolactinomas, benign tumors in the brain 
overproducing the hormone prolactin and bromocriptine. L-[11C]Tyrosine proved superior 
to [18F]FDG for the visualization of this particular brain tumor after radiotherapy. [105,120] 
Regardless of the successes achieved the use of [11C]tyrosine has been limited. 
7.3. [11C]Valine 
 
[11C]Valine has been described as a potential pancreas-imaging agent in 1978 by 
Washburn, et al. performing an extensive biodistribution study in rats and other small 
animals. [31] Tissue distribution of [11C]valine in all animals showed high uptake and fast 
clearance, although [11C]valine was also exposed to rapid decarboxylation. Nevertheless, 
studies performed in patients with pancreatic disease, showed uptake in the diseased 
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tissue of racemic [11C]valine and [11C]tryptophan. [121] Both AAs showed steady pancreatic 
uptake, however they also found a high concentration in the kidneys, making the scan 
interpretation difficult. At that time, in 1979, injecting a racemic mixture of PET tracer has 
not been recognized as problematic as it was assumed that D-AAs are simply not 
metabolized and remain in the blood flow. By contrast, L-AAs are either taken up by tumor 
or metabolized earlier. Therefore, with the lack for the sufficient model for quantitative 
analysis, strong conclusions could not be made. 
7.4. [11C]DOPA 
 
Though most C-11 labeled AAs are applied for tumor imaging, advances have also been 
made for imaging of neurological diseases with L-[11C]DOPA The development of this PET 
tracer proved challenging and the first successful synthesis was reported in 1973 by 
Fowler, et al. [122] Later Hartvig, et al. reported the initial biological evaluation and clinical 
use of L-[11C]DOPA [101,123], consequently showing its importance for various neurological 
disorders such as Parkinson’s disease and schizophrenia, next to its well-known analogue 
[18F]fluoro-3,4-dihydroxyphenyl-l-alanine (FDOPA). [124]  The best position for incorpation 
of the C-11 label in [11C]DOPA molecule was evaluated by the metabolism study in an 
enzyme-activity study, by decarboxylation of [11C]DOPA to [11C]Dopamine in endocrine 
pancreatic tumors[125]. The biological evaluation revealed that the C-11 position is 
important, and the radiolabel is not metabolized in the β-position. L-[11C]DOPA is stored 
mainly in one type of secretory granula. However, in active tumors it is constantly released 
thereby diminishing the content of radioactivity. Its metabolism was reported to be slow 
with in vivo half-life of roughly 2 h. Furthermore, metabolites of DOPA play an insignificant 
role, since these are stored in vesicles in areas with high density of dopaminergic 
pathways in the brain (e.g. the striatal region). 
7.5. [11C]Glutamine 
 
In recent preclinical studies it was demonstrated that glutamine metabolism is a vital 
process for tumor development and progression. With the better understanding of tumor 
metabolism and the fact that glutamine, a non-essential AA available in high 
concentrations in blood, is a very important nutrient for diseases in the so-called 
glutaminolysis pathway [102], the interest in glutamine as a PET-tracer have grown. Further, 
in vivo PET imaging in tumor-bearing rats suggested a rapid tumor uptake and trapping. 
This led to the proposal to utilize [11C]glutamine in addition to negative [18F]FDG tumor 
studies to discriminate a tumor’s reliance on different nutrients for growth. Interestingly, 
this tracer utilizes a different mechanism of action in tumors and its uptake is 
complementing glucose metabolism. Cells are able to employ alternative energy sources, 
compared to all other available AAs tracer so far, which are mostly dependent on elevated 
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levels of AA-transporters on the cell membrane. [126] All this suggest, there is still a great 
interest in glutamine or its derivatives as PET-tracer. 
Taken together, these findings enhanced the understanding of AA metabolism, transport 
mechanism in cells, biological behavior of radiolabeled compounds, and applicability in 
diagnosis of tumors as well as for neurological disorders. The main weakness of 
[11C]tyrosine, [11C]valine and [11C]dopamine studies conducted more than 20 years ago is 
their obsolence and lack of more recent re-evaluation with state of the art PET analysis 
techniques. Reasons for the reluctant use of these labeled compounds in general might be 
the underdeveloped radiosynthesis methods and obviously need of proximity to 
radiochemistry facilities with cyclotrons. Also, F-18 labeled tracers are in some cases 
preferred (e.g. L-6-[18F]fluoro-DOPA), especially as they can be distributed to other 
hospitals. On the other hand, as new C-11 synthetic radiolabeling strategies advance, the 
accessibility can be broadened and consequently open doors for new imaging agents. That 
can be especially interesting for biological evaluation of peptides where no additional 
toxicological studies have to be performed before (pre)clinical studies.  
8. Application of Carbon-11 Labeled Peptides as Imaging Agents 
 
Although peptides and AAs are alike in many ways, such as AAs scaffold and consequently 
position for radiolabeling or short in vivo half-life, it should be emphasized that the use of 
C-11 labeled peptides is, up to date, far more challenging. Their translation into PET 
imaging agents has been supported with specialized radiolabeling reactions in very recent 
years. [12] However, the application of C-11 labeled peptides remains largely unexplored. A 
challenge for the application might be associated with slow distribution for in vivo studies 
due to rapid metabolism.  
The very first example of in vivo study using a C-11 labeled peptide/protein was human 
serum albumin microspheres. Turton, et al. evaluated [11C]albumin in dogs and 
demonstrated ideal properties of labeled microspheres to study blood flow for 
investigation of pulmonary and BBB permeability. [127] In 2004, Henriksen, et al. reported a 
convenient synthetic procedure to obtain a functionalized sugar-containing derivative of 
octreotate and assessed the product in vivo as well. [19] With a AM of 22-28 GBq·µmol
-1, 
biodistribution and PET-imaging studies in pancreatic carcinoma-bearing mice showed 
good results recommending its further use.  
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9. Conclusion and Future Perspective 
 
In conclusion, advances in radiopharmaceutical chemistry have enabled the establishment 
of efficient and reliable syntheses of many C-11 labeled AAs and peptides. Starting with 
[11C]CO2, [
11C]HCN or [11C]CH3I, a multitude of AAs and their derivatives have been 
obtained as PET-tracers. Next to that, based on these synthesis strategies, C-11 labeled 
peptides can be successfully achieved. The main challenge of all these radiolabeling 
methods remains their stereocontrol, which might diminish the yield. With the upcoming 
advances in asymmetric synthesis and the commercial availability of chiral phase-transfer 
catalysts, the radiosynthesis has progressed as far as having natural enantiopure AAs and 
even small peptides in hand, with reasonable synthesis steps and reaction times.  
Ensuring appropriate systems at hospitals, C-11 labeled biologically active compounds 
have versatile functions in physiology and are thereof ideal for PET research. To improve 
diagnosis, C-11 labeled AAs could be used complimentary to other tracers such as 
[11C]MET and [18F]FDG. A combination of two PET scans in one day, firstly with a short-
lived [11C]AAs followed by a [18F]FDG scan, could serve as an additional tool for primary 
and metastatic brain tumors, peripheral tumors such as lymphoma, lung or breast tumors 
[128] or inflammation, as confirmed by [11C]MET. This suggests that [11C]AAs tracers could 
be used complimentary since they are potentially more suitable than [18F]FDG for 
differentiation of tumors and inflammation. However, use of [11C]AAs tracers are limited 
to the PET centers with an in-house facility and cyclotron due to the short half-life of C-11. 
Flourine-18 labeled AAs might be more appropriate for distant shipment or longer 
scanning times. This can be seen in various developments in the field where [18F]AAs are 
developed and successfully applied as well. A concern in general when using F-18 is 
defluorination that has also been reported for the [18F]AAs. [129,130]  
With respect to imaging with C-11 labeled peptides, further in-depth research is required. 
Nevertheless, in recent years, development in biotechnology and its applications has lead 
towards combined and improved mechanistic possibilities in peptide-based 
radiopharmaceutical as molecular imaging agents. Even more, the recent achievements 
furnished various methodologies to label peptides with C-11 which are now ready to be 
applied to biologically relevant peptides. This will only boost future application of peptides 
in imaging. It should be noted that a handful of radiosynthetic options have been 
developed, but the preclinical and clinical applications are running behind. Furthermore, 
despite the significant advances in the field of radiosynthesis there is a continuous need 
for discovery of unprecedented molecular targets, such as peptide receptors 
overexpressed on common human cancers, and development of their appropriate imaging 
agents.  
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Abstract 
 
Positron emission tomography has increased the demand for new carbon-11 radiolabeled 
tracers and building blocks. A promising radiolabeling synthon would be [11C]benzyl iodide 
([11C]BnI), since the benzyl group is a widely present functionality in biologically active 
compounds. Unfortunately, synthesis of [11C]BnI has received little attention, resulting in 
limited application. Therefore, we investigated the synthesis in order to significantly 
improve, automate and to apply it for labeling of the dopamine D2 antagonist 
[11C]clebopride as a proof of concept. [11C]BnI was synthesized from [11C]CO2 via a 
Grignard reaction and purified prior the reaction with desbenzyl clebopride. According to 
a one-pot procedure [11C]BnI was synthesized in 11 min from [11C]CO2 with high yield, 
purity and molar activity, 52±3%, 95±3% and 123±17 GBq·μmol-1, respectively. Changes in 
the [11C]BnI synthesis are reduced amounts of reagents, a lower temperature in the 
Grignard reaction and the introduction of a solid-phase intermediate purification. 
[11C]Clebopride was synthesized within 28 min total synthesis time (82±11% (n=10)) 
incorporation of [11C]benzyl) in an isolated decay-corrected yield of 11±3% (n=3), 
calculated from [11C]CO2, with a purity of >98% and AM of 54±4 GBq·μmol
-1 (n=3). The 
reliable synthesis of [11C]BnI allows the broad application of this synthon in PET 
radiopharmaceutical development. 
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Introduction 
 
Positron emission tomography (PET) allows functional non-invasive three-dimensional 
imaging of fundamental biochemical and physiological processes in living organisms using 
targeted radiopharmaceuticals.[1] The use of PET in medical physics, clinical imaging[2] and 
drug discovery[3] is of great value to unveil in vivo metabolic information or cellular 
receptor expression. With the increased understanding of systems biology, there is also a 
continuous need to develop imaging techniques and chemical approaches for the 
synthesis of PET-labeled molecules, which also includes the development novel building 
blocks.[4]  
Over the last decades a large number of radiopharmaceuticals has been labeled with 
carbon-11 and demonstrated significant potential utility and application in three major 
areas of clinical application: oncology, cardiology and neurology.[1,2] Especially for 
neurological imaging purposes, carbon-11 radiopharmaceuticals remain essential for the 
development of new radiotracers[5,6], despite the fact that fluor-18 (β+, t1/2 = 110 min) 
labeled tracers seem desirable due to its longer half-life.[5]   
The presence of carbon in all organic compounds makes the PET isotope carbon-11 (β+, 
t1/2 = 20 min) an attractive and valuable radionuclide since carbon-11 can be included as a 
normal constituent in molecules of biological interest without chemical modification on 
the molecule.[4] Nevertheless, also for carbon-11 PET-tracer synthesis, chemical structures 
of the compounds of interest are changed as well to simplify PET-tracer synthesis. 
Therefore, the main challenge in the synthesis of carbon-11 labeled PET radiotracers still 
lies in the complicated multi-step synthesis of the desired product. Nonetheless, from 
cyclotron produced [11C]CO2 and [
11C]CH4 many useful labeling reagents can be obtained, 
such as [11C]methyl iodide for methylation reactions or [11C]CO for carbonylation 
reactions.[4] 
A promising labeling synthon, [11C]benzyl iodide, can be prepared from [11C]CO2 via a 
Grignard reaction and has been used in radiolabeling. Unfortunately, little attention has 
been devoted to its relatively long synthesis time (from 20 - 30 min)[7-10], low 
radiochemical yield (10 - 30%)[8] and complex application (liquid-liquid extraction 
procedure[7,9-12], high radiation exposure to the radiochemist[7]) (Table 1). All this resulted 
in surprisingly limited application of [11C]benzyl iodide in radiotracer synthesis over the 
years. In addition, no results have been presented about the molar activity of [11C]benzyl 
iodide, an important parameter in the application of radiotracers.[2] 
The aim of the present work extends on the use of [11C]benzyl iodide, prepared from 
[11C]CO2
[7] and thoroughly investigates reaction parameters. Furthermore, the application 
of [11C]benzyl iodide will be demonstrated in N-alkylation reactions. This resulted in 
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successful radiolabeling of [11C]clebopride, a selective D2-antagonist as a potential PET-
tracer for the dopamine D2 receptor.
[13,14] 
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successful radiolabeling of [11C]clebopride, a selective D2-antagonist as a potential PET-
tracer for the dopamine D2 receptor.
[13,14] 
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Results and Discussion 
 
Preparation of [11C]benzyl iodide  
The overall synthesis of [11C]benzyl iodide is shown in Scheme 1. The synthesis involved 4 
steps: Grignard reagent carboxylation, reduction, iodination and purification.  
 
Scheme 1: Radiosynthesis of [11C]benzyl iodide. 
The preparation of [11C]benzyl iodide was achieved without the isolation of the synthetic 
intermediates in a one-pot reaction to establish an efficient procedure for the desired 
product (Table 3). In order to optimize this procedure, the following parameters have 
been thoroughly investigated: temperature, solvent, reaction time, Helium flow, amount 
of reagents, purification procedure and solvent for purification. These parameters were 
changed one by one per experiment. 
Temperature played the most important role in the synthesis described. For the first and 
second reaction, a temperature of 35 °C was crucial to give the highest conversion 
(determined by HPLC) and the least side-products. Secondly, efficient heating to 130 °C 
after addition lithium aluminum hydride was important for proper evaporation of 
tetrahydrofuran (THF) and also promoted the conversion of [11C]benzoic acid into 
[11C]benzyl alcohol. Thirdly, for the iodination reaction, the reaction vessel needed to be 
cooled to 0 °C before the addition of the HI and immediately after that heated to 120 °C. 
Insufficient heating at this point resulted in low conversion (determined by HPLC) and 
consequently low total yield. Cooling the vessel from 130 °C before addition of the HI was 
previously indicated by Guillouet in 1996[15], while the exact temperature was not 
reported. It should be mentioned that Fasth[9] also reported cooling the vessel before 
addition of the HI to -72 °C, however this will be time-consuming and consequently 
undesired due to the short half-life of carbon-11. Moreover, no difference was observed 
when the vessel was cooled to 0 °C compared to -10 or -20 °C.  
Tetrahydrofuran[7-9,11,15] and diethyl ether (Et2O)
[10] were investigated as solvents during 
optimization of the synthesize procedure of [11C]benzyl iodide, as they were both 
described as a successful solvents for Grignard reaction. We have shown THF to be 
superior over Et2O, with higher radiochemical yields under the same reaction conditions. 
Furthermore, when the Grignard reagent was dissolved in Et2O two radioactive side 
products were formed during the carboxylation reaction.  
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The amounts of reagents used in the production of [11C]benzyl iodide were investigated as 
well. The most effective amount of Grignard reagent in THF was 0.1 mmol. A higher 
amount, 0.2 mmol of Grignard in THF, did not show any increase in yield and would 
potentially lower specific activity of the final [11C]benzyl iodide.[7,16] For the reduction, 
significant difference in using 1 or 2 equivalents of LiAlH4 compared to the Grignard 
reagent was not observed, in contrast to previous reports.[7-10,16] As a consequence 0.1 
mmol of LiAlH4 (100 μL of 1 M solution in THF) was used, leading to smaller THF volumes, 
which have to be evaporated after reduction, the decrease of the total synthesis time for 
at least 1 min and potential increase of specific activity. 
Table 2: Yields of intermediates and final product for synthesis of [11C]benzyl iodide. 
Time (min) Product Radiochemical yield [%]a 
0 [
11C]CO2 100 
2 Ph[11C]COOH 89 ± 2 (n=3) 
5 Ph[11C]CH2OH 78 ± 4 (n=4) 
9 Ph[11C]CH2I 68 ± 12 (n=2) 
11 Purified Ph[
11C]CH2I 52 ± 3 (n=5) 
aDecay corrected overall radiochemical yield. 
 
The final step in the production of [11C]benzyl iodide and major improvement was its 
purification. All previously described and common used purification procedures, from 
distillation, Sep-Pak® cartridge[7,8,15,16], extraction[7,9-12] and various filled columns[7,9,15], 
have been investigated. We found that a column filled with Na2S2O3/MgSO4 or 
K2CO2/MgSO4 proved to be most efficient. To that end, the reaction mixture was diluted 
with dichloromethane, toluene or acetone and passed through a filled column into a 
second reaction vial. The combination of K2CO3/MgSO4 resulted in higher radiochemical 
purity compared to Na2S2O3/MgSO4. A purification column filled with K2CO3/MgSO4 and 
dissolving the reaction mixture in 3 mL of CH2Cl2 gave the best result, [
11C]benzyl iodide 
was obtained in a radiochemical purity of 95 ± 3% (n=13). Purification using 3 mL of 
toluene or 2 mL of acetone resulted only in 87 ± 4% (n=3) or 76 ± 7% (n=3) radiochemical 
purity, respectively.  
The rapid and mild automated preparation and work-up procedure enabled efficient 
synthesis of [11C]benzyl iodide in a decay-corrected and isolated radiochemical yield of 52 
± 3% (n=5) calculated from starting [11C]CO2 with a radiochemical purity 95 ± 3% (n=13), a 
molar activity of 123 ± 17 GBq·μmol-1 (n=5) and an overall synthesis time of 11 min (Table 
2).  
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Table 3: Incorporation according to HPLC of intermediates and [11C]benzyl iodide. 
Reagent 
Temperature 
[°C] 
Product 
Conversion according to 
HPLC [%] 
100 μmol PhMgBr 35 Ph[11C]COOH 96 ± 4 (n=4) 
100 μmol LiAlH4 130 Ph[
11C]CH2OH 98 ± 2 (n=4) 
100 μL 57% HI 120 Ph[11C]CH2I 84 ± 7 (n=6) 
 
Preparation of [11C]tribenzyl amine 
To determine the chemical reactivity of [11C]benzyl iodide, a model alkylation study of 
amines was performed (Scheme 2). Reaction of [11C]benzyl iodide with secondary amine, 
dibenzylamine, occurred rapidly under mild conditions (1.5 eq K2CO3 for 5 min at 50 °C) to 
give the corresponding [11C]tribenzyl amine in high conversion 87 ± 3% (n=2; determined 
as percentage of the total activity of the crude reaction mixture observed on analytical 
HPLC),  without any radioactive side product. N-alkylation was examined in the presence 
of 1.5 equivalent of potassium carbonate and cesium carbonate[18], approximately 700 µL 
of acetone at at 50 °C for 5 min. There has been a slight difference between the bases in 
favor of K2CO3, moreover 10 min synthesis did not result in higher yield. This suggests that 
[11C]benzyl iodide can be an sufficient competitor of [18F]4-fluorobenzyl iodide[13] to yield 
secondary amines labeled with radionuclides with a short half-life. 
 
Scheme 2: Radiosynthesis of [11C]tribenzyl amine.  
Synthesis 
Reference compound clebopride was synthesized according to Mach et al.[13] The 
synthesis route towards precursor, 4-(4-amino-5-chloro-2-methoxybenzamido)piperidin-1-
ium chloride, (shown in Scheme 3) was adapted from this procedure. The synthesis of tert-
butyl carbamate-protected piperidine was started with reaction 4-amino-5-chloro-2-
methoxybenzoic acid with ethylchloroformate in CH2Cl2 in the presence of triethylamine 
and tert-butyl 4-aminopiperidine-1-carboxylate resulting in tert-butyl 4-(4-amino-5-chloro-
2-methoxybenzamido)piperidine-1-carboxylate in 53% yield. This intermediate was 
deprotected under acidic conditions, by treatment with hydrochloric acid in 1,4-
Synthesis and Application of [11C]Benzyl Iodide  
71 
 
dioxane[17], to obtain 4-(4-amino-5-chloro-2-methoxybenzamido)piperidin-1-ium chloride 
quantitatively.  
 
Scheme 3: Synthesis route towards precursor. 
Synthesis of [11C]clebopride 
In order to obtain [11C]clebopride, the piperidine amine group of precursor was subjected 
to an alkylation reaction with [11C]benzyl iodide in the presence of a base (Scheme 4). As 
concluded in the model N-alkylation reaction of [11C]tribenzyl amine, [11C]clebopride was 
also synthesized at 50 °C for 5 min in the presence of potassium carbonate. Radiolabeling 
was performed using dimethylformamide (DMF) and CH2Cl2 or CH3CN as a solvent. On 
average the conversion of [11C]benzyl iodide in CH2Cl2 to [
11C]clebopride was 82 ± 11% 
(n=10), which is determined as percentage of the total activity of the crude reaction 
mixture observed on analytical HPLC. Contrary to CH2Cl2, conversion of [
11C]benzyl iodide 
in CH3CN, under the same conditions, did not result in such a successful labeling (48 ± 8% 
(n=4)). Purification of [11C]clebopride was achieved using C18 reverse phase semi-
preparative HPLC as shown in Figure 1. [11C]Clebopride was obtained in 28 min from the 
release of [11C]CO2 in a excellent radiochemical purity of > 98% and satisfactory molar 
activity 54 ± 4 GBq·μmol-1 (n=3) and is therefore able to be evaluated in vivo.   
 
Scheme 4: Radiosynthesis of [11C]clebopride. 
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2-methoxybenzamido)piperidine-1-carboxylate in 53% yield. This intermediate was 
deprotected under acidic conditions, by treatment with hydrochloric acid in 1,4-
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dioxane[17], to obtain 4-(4-amino-5-chloro-2-methoxybenzamido)piperidin-1-ium chloride 
quantitatively.  
 
Scheme 3: Synthesis route towards precursor. 
Synthesis of [11C]clebopride 
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(n=4)). Purification of [11C]clebopride was achieved using C18 reverse phase semi-
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Scheme 4: Radiosynthesis of [11C]clebopride. 
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Figure 1: Representative chromatogram of isolated [11C]clebopride. 
 
Summary 
 
Successful radiosynthesis of [11C]clebopride enabled us to compare synthesis parameters, 
like reaction time, [11C]benzyl iodide reactivity and specific activity, described in this paper 
with previous radiolabeling of clebopride using [11C]methyl iodide.[14] Firstly, this paper 
demonstrates that [11C]benzyl iodide is a versatile synthon, like [11C]methyl iodide, for 
radiolabeling molecules that contain a methyl or benzyl group. The here described 
procedure resulted in short alkylation time of 5 min at 50 °C, indicating that [11C]benzyl 
iodide is highly reactive under mild conditions. Furthermore, in this paper high specific 
activity is reported, especially important for receptor studies, where in general AM > 18.5 
GBq·μmol-1 is required. This leads us to the conclusion that [11C]benzyl iodide can be used 
as an additional labeling method for carbon-11 labeled clebopride in a high yield, specific 
activity and radiochemical purity, that results a more stable PET-tracer for in vivo studies.  
 
Conclusions 
 
[11C]Benzyl iodide can be used as a versatile carbon-11 synthon for many other types of 
reactions, like alkylations reactions of amines, alcohols and carboxylic esters as well as 
cross-couplings like Stille and Suzuki reactions, amongst others. 
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Experimental 
 
General 
Chemicals were obtained commercially from Sigma-Aldrich (Zwijndrecht, the Netherlands) 
and Fluorochem (Derbyshire, United Kingdom) and used without further purification. 
Solvents were purchased from Biosolve (Valkenswaard, the Netherlands) and used as 
received unless stated otherwise. Reactions were performed at ambient temperature 
unless stated otherwise. Reactions were monitored by thin layer chromatography on pre-
coated silica 60 F254 aluminum plates (Merck, Darmstadt, Germany). Spots were 
visualized by UV light, bromocresol green and ninhydrine. Solvents were evaporated 
under reduced pressure using a rotary evaporator (Rotavapor® R II, Flawil, Switzerland). 
Flash column chromatography was performed manually on Silica gel 60 Å (Merck, 
Darmstadt, Germany) or on a Büchi (Flawil, Switzerland) Sepacore system (comprising a C-
620 control unit, a C-660 fraction collector, two C-601 gradient pumps and a C-640 UV 
detector) equipped with Büchi Sepacore pre-packed flash columns. NMR spectroscopy 
was performed on a Bruker (Billerica, MA, USA) Avance 250 (250.13 MHz for 1H) or a 
Bruker Avance 500 (500.23 MHz for 1H and 125.78 MHz for 13C) with chemical shifts (δ) 
reported in parts per million (ppm) relative to the solvent (CDCl3, 
1H 7.26 ppm, 13C 77.16 
ppm; D2O, 
1H 4.79 ppm; (CD3)2SO, 
13C 39.52 ppm). Electrospray ionization-high resolution 
mass spectrometry (ESI-HRMS) was carried out using Bruker microTOF-Q instrument in a 
positive ion mode (capillary potential of 4500 V). Analytical HPLC was performed on a 
Jasco (Easton, MD, USA) PU-2089 Plus station with a Alltima C18 5 μm (250 x 4.6 mm) 
column (Grace, Breda, The Netherlands) (A) or Fermentation Monitoring Column 9 μm 
(150 x 7.8 mm) (Bio-Rad, Veenendaal, the Netherlands) (B) with Jasco UV-2075 Plus UV 
detector (254 nm) and NaI radioactivity detector (Raytest, Straubenhardt, Germany) at 
ambient temperature. Acetonitrile (CH3CN) (C), methanol (MeOH) (D), water (E), buffer 1 
(4 mM sodium formate and 4 % dimethylformamide) (F), buffer 2 (0.1 M ammonium 
formate and 1 % dimethylformamide, pH=4.1) (G), solution 1 (0.1 M ammonium formate) 
(H) and solution 2 (0.005 M sulfuric acid) (I) were used as mobile phases. Chromatograms 
were acquired with Raytest GINA Star software (version 5.8). Semi-preparative isocratic 
HPLC was performed on Jasco UV-2087 Plus station with a Alltima C18 5 μm (250 x 10 mm) 
column (Grace, Breda, The Netherlands) (J) using MeOH/buffer 2 (65/35, v/v) as a eluent, 
flow rate 4 mL·min-1 (method A), a Jasco UV-2075 Plus UV detector (254 nm), a 
homemade radioactivity detector and Jasco ChromNAV CFR software (version 1.14.01).  
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Synthesis  
Clebopride (4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide)[13] 
Triethylamine (0.85 eq, 906 μmol, 125 μL) was added to 4-amino-5-chloro-2-
methoxybenzoic acid (1 eq, 215 mg, 1.07 mmol) and dichloromethane (CH2Cl2) (10 mL) to 
give a white suspension. The mixture was cooled to 0°C and ethylchloroformate (1 eq, 102 
μL, 1.07 mmol) was added and stirred at 0 °C for 4 h.  A solution of 4-amino-1-
benzylpiperidine (1 eq, 217 μL, 1.07 mmol) in dichloromethane (10 mL) and triethylamine 
(0.85 eq, 906 μmol, 125 μL) was added at ambient temperature. The reaction mixture was 
left to stir overnight at ambient temperature. The reaction was quenched with aqueous 
sodium hydroxide (3 M, 10 mL) and the organic layer was collected, dried with MgSO4 and 
concentrated in vacuo.  Flash column chromatography was performed (ethyl 
acetate/hexane = 70/30 + 0.1 % triethylamine) to obtain Clebopride in 75.5 % yield (302 
mg, 0.808 mmol) and > 98 % purity, determined by HPLC (column A, solvents C/F, 70/30, 
v/v, wavelength 254 nm, column temperature – ambient, flow 1 mL·min-1, Rt 6.3 min). 
Rf value, 0.30 (ethyl acetate/hexane=70/30 + 0.1% triethylamine); 
1H NMR (250.13 MHz, 
CDCl3) δ 7.99 (s, 1H, CHbenzamide), 7.58 (d, 1H, J=7.5 Hz, -NH-CO-), 7.21 (m, 5H, CHAr), 6.20 (s, 
1H, CHbenzamide), 4.32 (s, 2H, -CH2-), 3.77 (s, 3H, CH3), 2.77 (m, 2H, CH2piperidine), 2.21 (m, 2H, 
CH2piperidine), 1.90 (m, 2H, CH2piperidine), 1.55 (m, 2H, CH2piperidine); 
13C NMR (125.78 MHz, 
CDCl3) 163.70 (C=O), 157.41 (CArOCH3), 146.57 (CArNH2), 133.09 (CHAr), 129.51 (CHAr), 
128.37 (CHAr), 127.43 (CHAr), 112.59 (CArCl), 111.65 (CArC=O), 97.85 (CHAr), 62.99 (-CH2-), 
56.10 (O-CH3), 52.06 (CHpiperidineNH), 45.92 (CH2piperidine), 29.72 (CH2piperidine); ESI-HRMS: 
calculated for C20H24ClN3O2: 373.88, found 374.16 [M + H]
+.  
tert-butyl 4-(4-amino-5-chloro-2-methoxybenzamido)piperidine-1-carboxylate 
Triethylamine (1 eq, 690 μL, 496 μmol) was added to 4-amino-5-chloro-2-methoxybenzoic 
acid (1 eq, 100 mg, 496 μmol) and dichloromethane (10 ml) to give a white suspension. 
The mixture was cooled to 0°C and ethylchloroformate (1 eq, 480 μL, 496 μmol) was 
added and stirred at 0 °C for 10 h. A solution of tert-butyl 4-aminopiperidine-1-carboxylate 
(1 eq, 970 mg, 496 μmol) in dichloromethane (10 mL) and triethylamine (1 eq, 690 μL, 496 
μmol) was added at ambient temperature and the mixture was stirred for 6 h. The solvent 
was dried with MgSO4 and concentrated in vacuo. The crude compound was purified using 
flash column chromatography (ethyl acetate/hexane=50/50) to obtain tert-butyl 4-(4-
amino-5-chloro-2-methoxybenzamido)piperidine-1-carboxylate in 52.6% yield (100 mg, 
261 μmol).  
Rf value, 0.45 (ethyl acetate/hexane=50/50); 
1H NMR (250.13 MHz, CDCl3) δ 8.02 (s, 1H, 
CHbenzamide), 7.58 (d, 1H, J=7.5 Hz -NH-CO-), 6.29 (s, 1H, CHbenzamide), 3.95 (m, 2H, 
CH2piperidine), 3.82 (s, 3H, CH3), 2.93 (m 2H, CH2piperidine), 1.92 (m, 2H, CH2piperidine), 1.40 (s, 9H, 
(CH3)3), 1.18 (m 2H, CH2piperidine); 
13C NMR (125.78 MHz, CDCl3) 163.69 (C=O), 157.39 
(CArOCH3), 154.77 (C=O-O-), 146.66 (CArNH2), 133.10 (CHAr), 112.43 (CArCl), 111.68 (CArC=O), 
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97.82 (CHAr), 79.61 (-C(CH3)3), 56.14 (O-CH3), 52.15 (CHpiperidineNH), 46.40 (CH2piperidine), 
31.98 (CH2piperidine), 28.46 ((CH3)3); ESI-HRMS: calculated for C18H26ClN3O4: 383.87, found 
384.17 [M + H]+. 
Precursor (4-(4-amino-5-chloro-2-methoxybenzamido)piperidin-1-ium chloride) 
Tert-butyl 4-(4-amino-5-chloro-2-methoxybenzamido)piperidine-1-carboxylate (1 eq, 95 
mg, 0.25 mmol) was dissolved in 1,4-dioxane (5.5 mL) and HCl (4 M in 1,4-dioxane, 3.5 ml) 
was added at 0 °C. The mixture was allowed to stir at room temperature for 30 minutes 
followed by drying with MgSO4 and concentration in vacuo. The residue was washed 2 
times with diethyl ether (20 mL) and collected by filtration. The precipitate was dried in a 
vacuum oven for 24 h at 40 °C to obtain precursor in 99% yield (78 mg, 0.24 mmol) and > 
98% purity, determined by HPLC (column A, solvents D/H, 55/45, v/v, wavelength 254 nm, 
column temperature – ambient, flow 1 mL·min-1, Rt 4.5 min).  
Rf value, 0.0 (ethyl acetate/hexane=70/30 + 0.1% triethylamine); 
1H NMR (250.13 MHz, 
D2O) δ 7.53 (s, 1H, CHbenzamide), 6.47 (s, 1H, CHbenzamide), 4.00 (m, 1H, CHpiperidine), 3.73 (s, 3H, 
CH3), 3.37 (q, J1=5 Hz, J2=17.5 Hz, 2H, CH2piperidine), 3.04 (m 2H, CH2piperidine), 2.09 (q, J1=2.5 
Hz, J2=15 Hz, 2H, CH2piperidine), 1.69 (m 2H, CH2piperidine); 
13C NMR (125.78 MHz, (CD3)2SO) δ 
163.82 (C=O), 157.72 (CArOCH3), 148.95 (CArNH2), 131.74 (CHAr), 111.06 (CArCl), 109.27 
(CArC=O), 97.98 (CHAr), 56.42 (CH3), 44.45 (CHpiperidineNH), 42.28 (CH2piperidine), 28.66 
(CH2piperidine) ; ESI-HRMS: calculated for C13H18ClN3O2: 283.12, found 284.11 [M + H]
+ and 
calculated for C13H20N3O2
+: 250.16, found 251.15 [M + H]+.  
Radiosynthesis 
[11C]benzyl iodide ([11C]BnI) 
[11C]CO2 was produced by the 
14N(p,α)11C nuclear reaction performed in a 0.5 % O2/N2 gas 
mixture using IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium). After trapping of 
[11C]CO2 from the target in a stainless trap dispensed in liquid N2, [
11C]CO2 was transferred 
with a He flow of 10 mL·min-1 into 100 μL of 1 M phenylmagnesium bromide in 
tetrahydrofuran (THF) at 35 °C. After obtaining the maximum radioactivity in the vessel, 
the reaction mixture was stirred using He flow (10 mL·min-1) for 1 min and additional 1 
min at a He flow of 50 mL·min-1. 100 μL 1 M LiAlH4 in THF was added and immediately 
evaporated to dryness by heating the reaction vial to 130 °C under a He flow (50 mL·min-1) 
for 90 s. Subsequently, 100 μL of 57 % HI in water was added at 0°C and the mixture was 
left to react for 2 min at 120°C to yield [11C]benzyl iodide. The product was dissolved in 3 
mL dichloromethane and passed though 5x0.5 cm column filled with potassium carbonate 
and magnesium sulfate (approx. 8/2 by volume) into a second reaction vial, containing 
one KOH pellet (96 ± 9 mg (n=20)). [11C]benzyl iodide was obtained in a decay-corrected 
radiochemical yield of 52 ± 3% (n=5) from the release of [11C]CO2 with a radiochemical 
purity 95 ± 3% (n=13), an average molar activity (AM) of 123 ± 17 GBq·μmol
-1 (n=5) and an 
overall synthesis time of 11 min. The identity of the purified product was confirmed with 
15299 - Pekosak_BNW.indd   74 16-02-18   16:21
Ch
ap
te
r 3
Chapter 3 
74 
 
Synthesis  
Clebopride (4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide)[13] 
Triethylamine (0.85 eq, 906 μmol, 125 μL) was added to 4-amino-5-chloro-2-
methoxybenzoic acid (1 eq, 215 mg, 1.07 mmol) and dichloromethane (CH2Cl2) (10 mL) to 
give a white suspension. The mixture was cooled to 0°C and ethylchloroformate (1 eq, 102 
μL, 1.07 mmol) was added and stirred at 0 °C for 4 h.  A solution of 4-amino-1-
benzylpiperidine (1 eq, 217 μL, 1.07 mmol) in dichloromethane (10 mL) and triethylamine 
(0.85 eq, 906 μmol, 125 μL) was added at ambient temperature. The reaction mixture was 
left to stir overnight at ambient temperature. The reaction was quenched with aqueous 
sodium hydroxide (3 M, 10 mL) and the organic layer was collected, dried with MgSO4 and 
concentrated in vacuo.  Flash column chromatography was performed (ethyl 
acetate/hexane = 70/30 + 0.1 % triethylamine) to obtain Clebopride in 75.5 % yield (302 
mg, 0.808 mmol) and > 98 % purity, determined by HPLC (column A, solvents C/F, 70/30, 
v/v, wavelength 254 nm, column temperature – ambient, flow 1 mL·min-1, Rt 6.3 min). 
Rf value, 0.30 (ethyl acetate/hexane=70/30 + 0.1% triethylamine); 
1H NMR (250.13 MHz, 
CDCl3) δ 7.99 (s, 1H, CHbenzamide), 7.58 (d, 1H, J=7.5 Hz, -NH-CO-), 7.21 (m, 5H, CHAr), 6.20 (s, 
1H, CHbenzamide), 4.32 (s, 2H, -CH2-), 3.77 (s, 3H, CH3), 2.77 (m, 2H, CH2piperidine), 2.21 (m, 2H, 
CH2piperidine), 1.90 (m, 2H, CH2piperidine), 1.55 (m, 2H, CH2piperidine); 
13C NMR (125.78 MHz, 
CDCl3) 163.70 (C=O), 157.41 (CArOCH3), 146.57 (CArNH2), 133.09 (CHAr), 129.51 (CHAr), 
128.37 (CHAr), 127.43 (CHAr), 112.59 (CArCl), 111.65 (CArC=O), 97.85 (CHAr), 62.99 (-CH2-), 
56.10 (O-CH3), 52.06 (CHpiperidineNH), 45.92 (CH2piperidine), 29.72 (CH2piperidine); ESI-HRMS: 
calculated for C20H24ClN3O2: 373.88, found 374.16 [M + H]
+.  
tert-butyl 4-(4-amino-5-chloro-2-methoxybenzamido)piperidine-1-carboxylate 
Triethylamine (1 eq, 690 μL, 496 μmol) was added to 4-amino-5-chloro-2-methoxybenzoic 
acid (1 eq, 100 mg, 496 μmol) and dichloromethane (10 ml) to give a white suspension. 
The mixture was cooled to 0°C and ethylchloroformate (1 eq, 480 μL, 496 μmol) was 
added and stirred at 0 °C for 10 h. A solution of tert-butyl 4-aminopiperidine-1-carboxylate 
(1 eq, 970 mg, 496 μmol) in dichloromethane (10 mL) and triethylamine (1 eq, 690 μL, 496 
μmol) was added at ambient temperature and the mixture was stirred for 6 h. The solvent 
was dried with MgSO4 and concentrated in vacuo. The crude compound was purified using 
flash column chromatography (ethyl acetate/hexane=50/50) to obtain tert-butyl 4-(4-
amino-5-chloro-2-methoxybenzamido)piperidine-1-carboxylate in 52.6% yield (100 mg, 
261 μmol).  
Rf value, 0.45 (ethyl acetate/hexane=50/50); 
1H NMR (250.13 MHz, CDCl3) δ 8.02 (s, 1H, 
CHbenzamide), 7.58 (d, 1H, J=7.5 Hz -NH-CO-), 6.29 (s, 1H, CHbenzamide), 3.95 (m, 2H, 
CH2piperidine), 3.82 (s, 3H, CH3), 2.93 (m 2H, CH2piperidine), 1.92 (m, 2H, CH2piperidine), 1.40 (s, 9H, 
(CH3)3), 1.18 (m 2H, CH2piperidine); 
13C NMR (125.78 MHz, CDCl3) 163.69 (C=O), 157.39 
(CArOCH3), 154.77 (C=O-O-), 146.66 (CArNH2), 133.10 (CHAr), 112.43 (CArCl), 111.68 (CArC=O), 
Synthesis and Application of [11C]Benzyl Iodide  
75 
 
97.82 (CHAr), 79.61 (-C(CH3)3), 56.14 (O-CH3), 52.15 (CHpiperidineNH), 46.40 (CH2piperidine), 
31.98 (CH2piperidine), 28.46 ((CH3)3); ESI-HRMS: calculated for C18H26ClN3O4: 383.87, found 
384.17 [M + H]+. 
Precursor (4-(4-amino-5-chloro-2-methoxybenzamido)piperidin-1-ium chloride) 
Tert-butyl 4-(4-amino-5-chloro-2-methoxybenzamido)piperidine-1-carboxylate (1 eq, 95 
mg, 0.25 mmol) was dissolved in 1,4-dioxane (5.5 mL) and HCl (4 M in 1,4-dioxane, 3.5 ml) 
was added at 0 °C. The mixture was allowed to stir at room temperature for 30 minutes 
followed by drying with MgSO4 and concentration in vacuo. The residue was washed 2 
times with diethyl ether (20 mL) and collected by filtration. The precipitate was dried in a 
vacuum oven for 24 h at 40 °C to obtain precursor in 99% yield (78 mg, 0.24 mmol) and > 
98% purity, determined by HPLC (column A, solvents D/H, 55/45, v/v, wavelength 254 nm, 
column temperature – ambient, flow 1 mL·min-1, Rt 4.5 min).  
Rf value, 0.0 (ethyl acetate/hexane=70/30 + 0.1% triethylamine); 
1H NMR (250.13 MHz, 
D2O) δ 7.53 (s, 1H, CHbenzamide), 6.47 (s, 1H, CHbenzamide), 4.00 (m, 1H, CHpiperidine), 3.73 (s, 3H, 
CH3), 3.37 (q, J1=5 Hz, J2=17.5 Hz, 2H, CH2piperidine), 3.04 (m 2H, CH2piperidine), 2.09 (q, J1=2.5 
Hz, J2=15 Hz, 2H, CH2piperidine), 1.69 (m 2H, CH2piperidine); 
13C NMR (125.78 MHz, (CD3)2SO) δ 
163.82 (C=O), 157.72 (CArOCH3), 148.95 (CArNH2), 131.74 (CHAr), 111.06 (CArCl), 109.27 
(CArC=O), 97.98 (CHAr), 56.42 (CH3), 44.45 (CHpiperidineNH), 42.28 (CH2piperidine), 28.66 
(CH2piperidine) ; ESI-HRMS: calculated for C13H18ClN3O2: 283.12, found 284.11 [M + H]
+ and 
calculated for C13H20N3O2
+: 250.16, found 251.15 [M + H]+.  
Radiosynthesis 
[11C]benzyl iodide ([11C]BnI) 
[11C]CO2 was produced by the 
14N(p,α)11C nuclear reaction performed in a 0.5 % O2/N2 gas 
mixture using IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium). After trapping of 
[11C]CO2 from the target in a stainless trap dispensed in liquid N2, [
11C]CO2 was transferred 
with a He flow of 10 mL·min-1 into 100 μL of 1 M phenylmagnesium bromide in 
tetrahydrofuran (THF) at 35 °C. After obtaining the maximum radioactivity in the vessel, 
the reaction mixture was stirred using He flow (10 mL·min-1) for 1 min and additional 1 
min at a He flow of 50 mL·min-1. 100 μL 1 M LiAlH4 in THF was added and immediately 
evaporated to dryness by heating the reaction vial to 130 °C under a He flow (50 mL·min-1) 
for 90 s. Subsequently, 100 μL of 57 % HI in water was added at 0°C and the mixture was 
left to react for 2 min at 120°C to yield [11C]benzyl iodide. The product was dissolved in 3 
mL dichloromethane and passed though 5x0.5 cm column filled with potassium carbonate 
and magnesium sulfate (approx. 8/2 by volume) into a second reaction vial, containing 
one KOH pellet (96 ± 9 mg (n=20)). [11C]benzyl iodide was obtained in a decay-corrected 
radiochemical yield of 52 ± 3% (n=5) from the release of [11C]CO2 with a radiochemical 
purity 95 ± 3% (n=13), an average molar activity (AM) of 123 ± 17 GBq·μmol
-1 (n=5) and an 
overall synthesis time of 11 min. The identity of the purified product was confirmed with 
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analytical HPLC by co-injection of the product and non-labeled benzyl iodide (column A, 
solvents C/E, 60/40, v/v, wavelength 254 nm, column temperature – ambient, flow 1 
mL·min-1, Rt 6.1 min). In addition, synthetic intermediates were identified with analytical 
HPLC by co-injection of the corresponding intermediate and non-labeled benzoic acid or 
benzyl alcohol ([11C]benzoic acid: (column B, solvents I/C, 80/20, v/v, wavelength 254 nm, 
column temperature – ambient, flow 0.65 mL·min-1, Rt 8.5 min); ([11C]benzyl alcohol: 
(column A, solvents C/E, 50/50, v/v, wavelength 254 nm, column temperature – ambient, 
flow 1 mL·min-1, Rt 5.2 min)). 
[11C]tribenzylamine 
A mixture of dibenzylamine (1 eq, 1.9 mg, 9.6 μmol) and potassium carbonate (1.5 eq, 2.0 
mg, 14 mmol) or cesium carbonate (1.5 eq, 4.7 mg, 14 mmol) in acetone (0.20 mL) was 
added to a solution of [11C]benzyl iodide in acetone (0.50 mL)  and stirred at 50 °C for 5 
min. Conversion of [11C]benzyl group, determined by HPLC, into [11C]tribenzylamine was  
87 ± 3% (n=2)  in presence of  potassium carbonate or 74 ± 10% (n=2) when cesium 
carbonate was used. The identity of the product was confirmed with analytical HPLC by 
co-injection of the product and non-labeled tribenzylamine (column A, method B, solvents 
C/E, 70/30, v/v (mobile phase A), solvents C/E, 90/10, v/v (mobile phase B), wavelength 
254 nm, column temperature – ambient, flow 1.5 mL·min-1, Rt 15.2 min). 
Method B: 0 min (mobile phase A), 0-15 min 0-100% (mobile phase B), 15-20 min 100% 
(mobile phase B), 20-21 min 0-100% (mobile phase A) 
[11C]clebopride 
A mixture of 4-(4-amino-5-chloro-2-methoxybenzamido)piperidin-1-ium chloride (3.0 mg, 
9.4 μmol) and potassium carbonate (2 eq, 2.6 mg, 19 mmol) in dimethylformamide (0.20 
mL) was added to a solution of [11C]benzyl iodide in dichloromethane (1.5 mL)  and stirred 
at 50 °C for 5 min. The solution was diluted with 1.0 mL of HPLC eluent (MeOH/buffer 
2=65/35). The crude product was purified by semi-preparative HPLC (method A) to give 
[11C]clebopride in 11 ± 3% (n=3) yield, decay-corrected from the starting amount of 
[11C]CO2, with a radiochemical purity > 98% and molar activity 54 ± 4 GBq·μmol
-1 (n=3) in a 
synthesis time of 28 min. The identity of the purified product was confirmed with 
analytical HPLC by co-injection of the product and non-labeled clebopride (column A, 
method C, solvents D/H, 55/45, v/v (mobile phase C), solvent D, wavelength 254 nm, 
column temperature – ambient, flow 1 mL·min-1, Rt 9.2 min) (Figure 1). 
Method C: 0-3 min (mobile phase C), 3-14 min 0-90% (solvent D), 14-15 min 90-99% 
(solvent D), 15-18 min 1-100% (mobile phase C), 18-23 min 100% (mobile phase C) 
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Abstract 
 
A rapid method for the synthesis of carbon-11 radiolabeled phenyalanine was developed 
using a chiral phase-transfer catalyst and sub-nanomolar quantity of [11C]benzyl iodide as 
radio-precursor. Based upon a reported synthesis of [11C]benzyl iodide, a Schiff base 
precursor was evaluated for stereoselective [11C]benzylation. Extensive and interactive 
screening of precursor, catalyst, base, stirring and temperature was required to achieve 
high stereoinduction. The result is an efficient 5-step radiolabeling method to reliably 
synthesize L- or D-[11C]phenylalanine with an excellent enantiomeric excess of >90% and 
almost quantitative radiochemical conversion of >95% (n>5).   
Additionally, a phase-transfer catalyzed alkylation was utilized on the preparative scale 
using automated platform. The application resulted in high specific activity ranging from 85 
to 135 GBq·μmol−1 of the enantiomericaly pure [11C]phenylalanine, showing the process is 
robust and amenable to broad use in PET.  
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Introduction 
 
Positron emission tomography (PET) is a non-invasive imaging technique used for 
clinical diagnostic applications in oncology, neurology and cardiology, as well as drug 
development. The radionuclide carbon-11 (t1/2 = 20.4 min, 99% β+, 0.96 MeV) is 
commonly used in PET, since the ubiquity of carbon atoms in all naturally occurring 
organic compounds makes it an attractive isotope for radiolabeling.[1–4] The notable 
information PET can provide strongly depends on the development and availability 
of PET-tracers. Current tracer development remains challenging and still relies on 
the application of a very small number of radiochemistry methods, consequently 
limiting facile synthesis of novel radiopharmaceuticals.[3,5]  
An important class of chiral PET radiopharmaceuticals are radiolabeled amino acids 
(AAs) used to image e.g. up-regulated AA metabolism that is described for cancer 
cells.[6,7] With variable successes, and often in an asymmetric manner, many carbon-
11 AAs isotopologues have been accomplished, where carbon-12 is substituted with 
radioactive carbon-11. The formidable challenge in the synthesis of 11C-labeled AAs 
still lies in the stereoselective reaction on the α-carbon avoiding time consuming 
chiral separation via HPLC to ontain enantimoerically pure form[8], next to 
convenience and reliability of the radiolabeling process, limited by synthesis time 
and molar activity (AM) (GBq·μmol
-1), all important parameters that apply to 
radiopharmaceuticals.[1,5,9–11]  
Our approach to synthesize chiral α-AAs utilizes the alkylation of an activated 
methylene group, the glycine Schiff base, in the presence of quaternary ammonium 
salts as chiral phase-transfer catalysts (PTCs).[12–15] To the extent of our knowledge, 
the use of chiral alkylation reactions in the presence of PTCs have not been 
described for the enantioselective radiolabeling of phenyalanine with carbon-11, as 
depicted in Figure 1.[9,16–20] Accordingly, asymmetric alkylation would be a powerful 
approach to overcome the mentioned limitations in 11C-chemistry preserving the 
known properties, like target affinity, selectivity and specificity.  
The importance of enantiopurity of radiopharmaceuticals is paramount for 
radiolabeled AAs where stereochemistry influences the rate and selectivity of AA 
transport, preferential for L-enantiomers in mammalian cells.[21] Demonstrated by 
the application of L- and D-[11C]phenylalanine, synthesized using enzymatic 
separation, where the L-enantiomer of [11C]phenylalanine showed better pancreas-
to-liver ratios.[22] This was even further proven by the better imaging properties of L-
18F-labeled fluoroalkyl phenylalanine analogues, all demonstrating high uptake in 
tumor compared to surrounding tissues. These studies, not mentioning the gold 
standards L-[11C]methionine and L-[18F]-fluoroethyl tyrosine, thus emphasize the 
need for methods to synthesize enantiomerically pure AAs as PET-tracers.[23–25] 
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Figure 1: General synthetic routes to obtain [11C]phenylalanine.[8,9] 
In this communication we describe a new and generally applicable radiosynthetic 
method for the enantioselective synthesis of carbon-11 labeled L- and D-AAs by 
employing chiral PTC. This method is applied to synthesize L- and D-
[11C]phenylalanine, an essential aromatic AA used for tumor imaging, and its 
unnatural analogue phenylalanine amide.[26] The methodology described was 
translated from manual proof-of-concept radiosynthesis to a preparative scale on an 
automated platform in a GMP compliant laboratory. Furthermore, the here 
described rapid and robust radiolabeling might enable unprecedented native 11C-
labeling of peptides by alkylating a prochiral Schiff base-activated glycine residue. 
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Results and Discussion 
 
The enantioselective synthesis of L- and D-[11C]phenylalanine was achieved in 5 steps 
starting from cyclotron produced [11C]CO2, as depicted in Scheme 1. The first 3 steps 
involved a one-pot Grignard reaction to obtain [
11C]benzyl iodide ([11C]BnI),[26] as 
alkylating reagent followed by subsequent asymmetric 11C-benzylation on the 
commercially available Schiff base precursor P[15] with the aid of a commercially 
available chiral PTC. Acidic deprotection of the alkylated intermediate yielded 
enantiopure [11C]phenylalanine, the desired product.  
 
Scheme 1: Radiosynthesis of L-[11C]phenylalanine and DL-[11C]phenylalanine amide. 
A major challenge in translating the mild phase-transfer conditions from successful 
organic to carbon-11 radiochemistry is the reaction time and the distorted 
stoichiometric condition in radiochemistry. Where in organic chemistry, reactions 
are allowed for several hours, in carbon-11 radiochemistry only a few minutes are 
acceptable. In addition, one is limited in radiochemistry by the low amount of 
carbon-11 labelled reagent, typically between 50-100 nmoles, resulting in large 
excess of non-radiolabelled reagents which are typically in the mmol range, 
influencing the reaction kinetics dramatically. Furthermore, small contaminants 
present in the reaction mixture might destroy the low amounts of carbon-11 labeled 
reagent easily.  
We first engaged in the SN2 alkylation to obtain high radiochemical conversion (RCC) 
into the intermediate I by controlling the following parameters: order of addition, 
mixing of the reaction, amount of precursor Ph2C=N-Gly-O
tBu (P) and precursor 
concentration, reaction time, base, amount of base, solvent and temperature (T) 
(Table 2, Experimental Section). As a proof-of-principle, we initially investigated 
reaction conditions in presence of a strong base, tetra-n-butylammonium fluoride 
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(TBAF).[27] At this stage, we speculated that it was necessary to carefully examine the 
precursor concentration in order out-compete an undesired side effect during the 
radiolabeling, namely cleavage of the diphenylmethylene group on N-terminus[27] to 
benzophenone and glycine tert-butylester, crucial for activation of Ph2C=N-Gly-O
tBu, 
and provide a sufficinet amount of Ph2C=N-Gly-O
tBu for the [11C]benzylation. An 
increased amount of Ph2C=N-Gly-O
tBu (17 µmol per alkylation reaction), gave 
indeed high RCC and further experiments confirmed that precursor concentration 
can range 55-60 mM. The radio-HPLC analysis was very encouraging and proved 
85±6% RCC (of [11C]BnI to racemic Ph2C=N-[
11C]Phe-OtBu) after 10 min at 45 ⁰C in 
presence of DCM and DMSO as a solvent§§.  
Encouraged by the rapid and near quantitative [11C]benzylation, we turned our attention to 
five commercially available chiral PTCs and their influence on stereoinduction (Figure 2). 
Adapting the conditions from sucessful organic chemistry, we envisioned that high excess 
of hydroxide base CsOH·H2O, namely 150 eq compared to precursor Ph2C=N-Gly-O
tBu, 
toluene as solvent at 0 ⁰C provided us almost quantitative RCC with moderate 
stereoselectivity (enantiomeric excess (ee) of 46±2%) for L-[11C]phenylalanine in presence 
of 10 mol% Corey’s
[28] Cat 1 (Table 1, Entry 9). Large excess of base provided suficcient 
interfacial area between the two phases for this solid-liquid PTC. The ee was further 
increased to 75% by cooling the Ph2C=N-Gly-O
tBu solution to 0 ⁰C prior to the addition of 
[11C]BnI (Table 1, Entry 11). These series of experiments also revealed new optimized 
reaction conditions, 170 eq of CsOH·H2O for 7 min at 0 ⁰C, where precursor 
concentration could even range between 20-90 mM.  
 
Figure 2: Chiral PTC explored for the radiosynthesis of L- and D-[11C]phenylalanine and L- 
and D-[11C]phenylalanine amide.  
An enhanced enantioselective formation of L-[11C]phenylalanine was observed by 
employing Maruoka’s catalyst (R)-Cat 3 to ee of 91%, without having an effect on 
the RCC (Table 2). Unfortunately, the combination of toluene and dichloromethane 
as solvent mixture resulted in a decrease of enantioselectivity (ee of 78%). 
Employing a lower mol% of catalyst was fruitless as well (ee of 78%), contrary to 
Kitamura.[29] However, a high ee could also be obtained at lower temperature of -20 
⁰C (ee of 88%). 
 
 
Enantioselective C-11C Bond Formation of L-[11C]Phenylalanine  
  
85 
 
Table 1: Screening the [11C]alkylation conditions for Cat 1. 
Entry c of P 
[mM] 
Base 
Eq of 
basea 
Solvent T [⁰C] 
RCC [±SD; 
%]b 
ee  
[±SD; %]c 
1 55-60 KOH 10 PhMe+DCM -5 5 / 
2 55 KOH 20 PhMe+DCM -5 <1 / 
3 55 KOH 30 PhMe+DCM -5 4±2 / 
4 55-60 KOH 35 PhMe+DCM -5 4±0 / 
5 55 KOH 40 PhMe+DCM RT 10 / 
6 60 CsOH·H2O 10 PhMe+DCM -5 4 / 
7 60 CsOH·H2O 10 PhMe+DCM RT 2 / 
8 60 CsOH·HO 10 PhMe RT 6 / 
9 40 CsOH·H2O 150 PhMe -5 92±1 46±2 
10 20 CsOH·H2O 150 PhMe 0 83±8 / 
14 90 CsOH·H2O 170 PhMe 0* 91±1 75±2 
All reactions were conducted with 17 µmol P and 0.1 eq of Cat 1 in 10 min. PhMe stands for 
toluene and DCM for dichloromethane. aCompared to Ph2C=N-Gly-O
tBu. bRadiochemical 
conversions were determined by HPLC of the Ph2C=N[
11C]Phe-OtBu. cEnantiomeric excess 
was determined by chiral HPLC of final L-[11C]Phe. *Reaction was performed for 7 min. 
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9 Cat 2 (10) 170 0* 7 92±1 85.5 
10 Cat 2 (10) 170 -20* 7 56±7 57±1 
11 Cat 2 (10) 40 0* 7 54±13 76±6 
12 Cat 4 (10) 150 0* 10 90±1 66±10 
13 Cat 5 (10) 170 0* 7 91±3 77±0 
14 Cat 5 (5) 170 0* 7 91±1 68±1 
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All reactions were conducted with 17 µmol P and 400 µL of toluene in 10 min. a% of catalyst 
and eq of base are compared to P. bRadiochemical conversions were determined by HPLC of 
the Ph2C=N-[
11C]Phe-OtBu. cEnantiomeric excess was determined by chiral HPLC of final L- (or D-
)[11C]Phe.*Precooled [11C]BnI to desired T. dCombination of toluene and DCM (400 µL; 
v/v=1/1). 
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Catalyst-controlled asymmetric induction of the [11C]benzyl group was investigated 
when (S)-Cat 2 was used to yield specifically D-[11C]phenylalanine (Table 2). As 
depicted in Figure 2, Cat 2 and Cat 3 are enantiomers, therefore both chiral PTCs 
should yield comparable RCC and ee under the same reaction conditions, however 
with opposite enantiomers as product. Surprisingly, slightly lower enantioselectivity 
of ee up to 86%, relative to Cat 3 was observed (Experimental Section). In contrast, 
lower T of -20 ⁰C this time gave rather disappointing results, decrease of 
enantioselectivity to 57%, next to a lower RCC. The lower RCC is explained by the 
lower T and consequently slower reaction kinetics, as Ph2C=N-Gly-O
tBu was still 
observed on HPLC. 
Despite the success of N-spiro C2-symmetric chiral Cat 4
[14] in organic chemistry and 
also in the radiosynthesis of [18F]FDOPA[30], this catalyst did not demonstrate desired 
enantioselectivity in the 11C-benzylation reaction. Standard conditions, resulted in 
an excellent RCC of 90%, but undesired ee of only 66% for L-[11C]phenylalanine 
(Table 2, Entry 12).  
Lastly, the use of dimeric Cinchona-derived alkaloid Cat 5 was investigated. The use 
of Cat 5 resulted in a high RCC of the reaction, but unfortunately, a lower ee of the 
product of 79% towards L-[11C]phenylalanine was obtained (Table 2). Experiments 
with lower mol% of catalyst or lower T (-20 ⁰C) were meaningless, contrary to 
remarkable catalytic and chiral efficiency in organic chemistry.[31] Introduction of a 
naphthalene ligand in Cat 5, compared to 9-anthracenylmethyl in Cat 1, resulted in 
enhancement in enantioselectivity.  
Unexpectedly, as can be concluded from the results obtained, slight reaction rate 
retardation in the enantiofacial differentiation compared to benzylation in organic 
chemistry seems inevitable. The excellent RCCs obtained can be explained by the 
effective surface area of solid base and nanomolar and sub-stoichiometric amounts 
of [11C]BnI that react instantly. On the other hand, latest advantage might serve as a 
drawback for enantioselectivity, since the alkylating agent should be longer exposed 
to the PTC conditions employing lower Ts (-78 to -40 ⁰C), which are regularly used in 
organic chemistry, to result in extremely high enantioselectivities.[13–15] 
Extrapolation of these conditions to radiochemistry, especially with short-lived 
isotopes like carbon-11, is not feasible as the synthesis time must be kept as short as 
possible in radiochemistry.  
After screening all selected chiral PTCs, Cat 3 has been identified as a catalyst of 
choice for the preparation of L-[11C]phenylalanine (Graph 1). Further investigations 
therefore focused on decreasing the excess of base used, monitoring the effect on 
RCC and ee. With 40 eq of CsOH·H2O(s) high conversion and enantioselectivity (RCC: 
90±6%; ee: 83±5%) were still observed (Graph 2), and are consistent with results of 
other reports.[30–33] Recently Kano reported asymmetric solid-liquid phase-transfer 
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benzylation on the P in organic chemistry using the homogenizer in 5 min.[34] Aiming 
to adapt these conditions we achieved RCC of 93±0% and ee of 90±3% in only 40 s 
using vortex mixing. Though the superfast 11C-benzylation (from 7 min to 40s) 
provided slighly better results (Graph 2), the manual use of Vortex mixer is not 
justified due to the radioation dose radiochemist is exposed during the experiment. 
Base upon, it was clear that vigorous stirring enlarges the interfacial contact 
between the two phases and results in considerable rate enhacement. At this stage, 
we could speculate that even lower amounts of base would attain a sufficient 
raction rate on Vortex mixer.  
 
Graph 1: An overview of the screened PTC for the radiosynthesis of L- or D-
[11C]phenylalanine. All reactions were conducted with 17 µmol of Ph2C=N-Gly-OtBu, 
10% of catalyst, 170 eq of CsOH·H2O(s) and 400 µL of toluene for 7 min at 0 ⁰C.
 
 
 
Graph 2: Effect of CsOH·H2O on RCC [±SD; %] and ee [±SD; %] of Cat 3. 
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Having established an efficient enantioselective synthesis for L-[11C]phenylalanine, 
we extended the PTC use and application to the asymmetric synthesis of unnatural 
α-AAs as well, since nonproteinogenic AAs play a special role in peptidomimetics. In 
order to explore the applicability of the developed method, achiral glycinamide 
precursor Ph2C=N-[
11C]Gly-NH2 has been studied (Scheme 1), since amides tend to be 
more stable under PTC conditions and in vivo.[35–37] As anticipated from initial 
experiments with TBAF for LD-[11C]phenylalanine, this strong base appeared 
sufficient for 11C-benzylation towards Ph2C=N-[
11C]Phe-NH2 (RCC up to 70%), while 
Cs2CO3(s) or PTCs, like TBAB(s) and TBAHS(s), were ineffective (RCC of <5%). Aiming to 
achieve the enantioselective synthesis of unnatural L-[11C]phenylalanine amide, 
chiral PTC from Figure 2 demonstrated no stereocontrol, despite the superb 
incorporation (RCC up to 99%) of [11C]BnI and variations in the solvent and 
temperature (Table 3, ESI). Evidently, deprotonation of α-hydrogen of Ph2C=N-
[11C]Gly-NH2 does not generate the enolate to interact with the ammonium cation 
from chiral catalysts resulting in formation of lipophilic onium enolate, like P (Figure 
15, Experimental Section).[13,38,39]  
Final step, removal of protecting groups has been achieved at elevated 
temperatures (120 ⁰C for 2 min) and under acidic conditions by addition of 12M 
HCl(aq) (200 µL) resulting in a quantitative >96% conversion to product L-
[11C]phenylalanine or L-[11C]phenylalanine amide (Table 4, Experimental Section). 
Afterwards, the exact stereochemical outcome was determined using chiral 
radioHPLC (Experimental Section and Figure 3).  
In order to demonstrate the utility of the developed method in producing a novel 
PET-tracer, the total synthesis of L-[11C]phenylalanine was scaled-up and fully 
automated with starting amounts of approximately 50 GBq of [11C]CO2 according to 
GMP standards (Experimental Section). L-[11C]Phenylalanine was synthesized within 
24 minutes and yields were 5-7 GBq at the end of synthesis, corresponding to a decay-
corrected radiochemical yield of 27±7%, calculated from the end of the production 
of [11C]CO2. Analysis showed an ee of >90% (Figure 2) and a AM of 85-135 GBq·µmol
-1 
at the end of synthesis (EOS). 
 
Enantioselective C-11C Bond Formation of L-[11C]Phenylalanine  
  
89 
 
  
Figure 3: HPLC UV and radioactivity profile of the crude reaction mixture after automation 
procedure with co-injection of the cold standard L- and D-Phenylalanine: Separation of D- 
and L-[11C]phenylalanine on chiral column to determine ee %. 
 
Summary and Conclusions 
 
In summary, we successfully developed a novel, rapid and efficient multi-step 
synthesis to obtain enantiomerically pure L-[11C]phenylalanine by applying a chiral 
PTC, so far unexplored in carbon-11 radiochemistry. Moreover, this methodology 
enables enantiomerically pure D-[11C]phenylalanine, which cannot be obtained using 
well established enzyme-catalyzed synthesis. The overall process illustrates the 
challenges in determining optimal conditions for controling this 11C-benzylation that 
yielded an enantiopure [11C]phenylalanine. More specifically, an interactive 
systematic automation of all 5 steps revealed the procedure is reliable and 
reproducible, and employs commercially available precursor and Cat 3. Further 
research that is under investigation focuses on translating this powerful methodology 
towards carbon-11 labeling of peptides in an enantioselective manner.  
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Experimental Section 
General 
Chemicals were obtained commercially from Sigma-Aldrich (Zwijndrecht, the Netherlands), 
Fluorochem (Derbyshire, United Kingdom), Bachem (Bubendorf, Switzerland) and Wako 
Chemicals GmbH (Neuss, Germany) and used without further purification. Solvents were 
purchased from Biosolve (Valkenswaard, the Netherlands) and used as received unless 
stated otherwise. Reactions were performed at ambient temperature unless stated 
otherwise. Reactions were monitored by thin layer chromatography on pre-coated silica 60 
F254 aluminum plates (Merck, Darmstadt, Germany). Spots were visualized by UV light, 
ninhydrine and bromcrezol green. Solvents were evaporated under reduced pressure using 
a rotary evaporator (Rotavapor® R II, Flawil, Switzerland). Flash column chromatography 
was performed on a Büchi (Flawil, Switzerland) Sepacore system (comprising a C-620 
control unit, a C-660 fraction collector, two C-601 gradient pumps and a C-640 UV 
detector) equipped with Büchi Sepacore pre-packed flash columns.  
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker (Billerica, 
MA, USA) Avance 250 (250.13 MHz for 1H) or a Bruker Avance 500 (500.23 MHz for 1H and 
125.78 MHz for 13C) with chemical shifts (δ) reported in parts per million (ppm) relative to 
the solvent (CDCl3, 
1H 7.26 ppm, 13C 77.16 ppm). Splitting patterns are indicated as s: 
singlet, d: doublet, t: triplet, q: quartet, m: multiplet and br: broad peak, and J, coupling 
constant in Hz.  
Electrospray ionization-high resolution mass spectrometry (ESI-HRMS) was carried out 
using Bruker microTOF-Q instrument in a positive ion mode (capillary potential of 4500 V).  
Analytical isocratic high pressure liquid-chromatography (HPLC) was performed on a Jasco 
(Easton, MD, USA) PU-2089 Plus station with a Alltima C18 5 μm (250 x 4.6 mm) column 
(Grace, Breda, the Netherlands) (A), ReproSil 100 Chiral-AA 8 μm  (250 x 4.0 mm) column 
(Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) (B), and Chiralcel OJ 10 μm (250 x 4.6 
mm) (Chiral Tecnologies Europe, Illkirch, France) (C) with Jasco UV-2075 Plus UV detector 
(254 nm and 210 nm) and NaI radioactivity detector (Raytest, Straubenhardt, Germany) at 
ambient temperature. Acetonitrile (CH3CN) (D), methanol (MeOH) (E), water (F), n-Hexane 
(G), 2-propanol (H) and buffer 1 (4 mM sodium formate and 4 % dimethylformamide) (I) 
were used as mobile phases. Chromatograms were acquired with Raytest GINA Star 
software (version 5.8).  
Synthesis  
N-(diphenylmethylene)-L-phenylalanine tert-butyl ester (Ph2C=N-[
11C]Phe-OtBu) 
Reference compound was synthesized and characterized according to O'Donnell et al.1,2  
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Benzophenone imine (1 eq, 1.94 mmol, 354 mg), dissolved in 2 mL of dichloromethane 
(DCM), was added to (S)-phenylalanine tert-butyl ester (1 eq, 1.94 mmol, 499 mg), 
dissolved in 2 mL of DCM. The mixture was stirred for 48 h at RT, filtered and evaporated 
to dryness on a rotary evaporator. Ether (20 mL) was added to the residue and the 
resulting solution was washed with water (3 x 10 mL), dried over MgSO4 and concentrated 
in vacuo. The crude compound was purified using flash column chromatography to obtain 
pure product in 74.6% yield (557 mg, 1.45 mmol). 1H NMR (250.13 MHz, CDCl3, ambient T): 
δ 7.77 -7.67 (m, 2 H), 7.61 -7.55 (m, 2 H), 7.49 – 7.35 (m, 7 H), 7.22 - 7.19 (m, 2 H), 7.05 – 
7.02 (m, 2 H), 6.67 (s, 1H), 3.12 (d, J= 7.5 Hz, 1 H), 3.04 (d, J= 7.5 Hz, 1 H), 1.36 (s, 9 H) ppm. 
N-(diphenylmethylene)-glycine amide (Ph2C=N-[
11C]Gly-NH2) 
Reference compound was synthesized according to O'Donnell et al.1 and characterized 
according to O'Donnell et al.3  
Benzophenone imine (1 eq, 13.5 mmol, 2.50 g), dissolved in 10 mL of DCM, was added to 
glycine amide (1 eq, 13.5 mmol, 1.00 g), dissolved in 20 mL of DCM. The mixture was 
stirred for 16 h at RT, filtered and evaporated to dryness on a rotary evaporator. After 
addition of small amount of EtOAc and n-Hexane, precipitation occurred and white crystals 
were filtered to obtain Ph2C=N-[
11C]Gly-NH2 in 6.31% yield (203 mg, 851 µmol). No 
further isolation was performed with the remaining reaction mixture. 1H NMR (250.13 
MHz, CDCl3, ambient T): δ 7.61 -7.56 (m, 2 H), 7.44 – 7.30 (m, 6 H), 7.08 (m, 2 H), 5.63 (s, 1 
H), 3.91 (s, 2 H) ppm. 13C NMR (125.78 MHz, CDCl3, ambient T): δ 173.51, 170.34, 138.74, 
129.05, 128.90, 57.06 ppm. HRMS (m/z) calculated for C15H16N2O 239.12; found 239.1216 
[M+H+], calculated for C15H14N2NaO 261.10; found 261.1033 [M+Na]
+.  
N-(diphenylmethylene)-L-phenylalanine amide (Ph2C=N-[
11C]Phe-NH2) 
Reference compound was synthesized according to O'Donnell et al.1 and characterized 
according to Hyett et al.4  
Benzophenone imine (1 eq, 1.22 mmol, 221 mg), dissolved in 7 mL of DCM, was added to L-
phenylalanine amide (1 eq, 1.22 mmol, 200 mg), dissolved in 14 mL of DCM and 
triethylamine (1 eq, 1.22 mmol, 170 µL) at 40 ⁰C. The mixture was stirred for 16 h at RT,  
evaporated to dryness on a rotary evaporator and purified by flash chromatography to 
yield Ph2C=N-[
11C]Phe-NH2 in 13.0% yield (52.0 mg, 15.9 µmol).  
1H NMR (250.13 MHz, 
CDCl3, ambient T): δ 7.53 – 7.50 (m, 2 H), 7.38 – 7.10 (m, 11 H), 6.98 – 6.94 (m, 2 H), 6.36 
(d, J= 5.0 Hz, 2 H), 5.43 (s, 1 H), 4.12 – 4.04 (m, 1 H), 3.18 – 3.11 (m, 1 H), 3.03 – 2.94 (m, 1 
H) ppm. 13C NMR (125.78 MHz, CDCl3, ambient T): δ 175.56, 170.23, 139.05, 137.85, 
130.59, 128.61, 128.32, 127.34, 126.37, 67.63, 41.52 ppm. HR-MS (m/z) calculated for 
C22H21N2O 329.17; found 329.1670 [M+H
+], calculated for C22H20N2NaO 351.15; found 
351.1477 [M+Na]+.  
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Experimental Section 
General 
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ninhydrine and bromcrezol green. Solvents were evaporated under reduced pressure using 
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(Grace, Breda, the Netherlands) (A), ReproSil 100 Chiral-AA 8 μm  (250 x 4.0 mm) column 
(Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) (B), and Chiralcel OJ 10 μm (250 x 4.6 
mm) (Chiral Tecnologies Europe, Illkirch, France) (C) with Jasco UV-2075 Plus UV detector 
(254 nm and 210 nm) and NaI radioactivity detector (Raytest, Straubenhardt, Germany) at 
ambient temperature. Acetonitrile (CH3CN) (D), methanol (MeOH) (E), water (F), n-Hexane 
(G), 2-propanol (H) and buffer 1 (4 mM sodium formate and 4 % dimethylformamide) (I) 
were used as mobile phases. Chromatograms were acquired with Raytest GINA Star 
software (version 5.8).  
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Reference compound was synthesized and characterized according to O'Donnell et al.1,2  
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Benzophenone imine (1 eq, 1.94 mmol, 354 mg), dissolved in 2 mL of dichloromethane 
(DCM), was added to (S)-phenylalanine tert-butyl ester (1 eq, 1.94 mmol, 499 mg), 
dissolved in 2 mL of DCM. The mixture was stirred for 48 h at RT, filtered and evaporated 
to dryness on a rotary evaporator. Ether (20 mL) was added to the residue and the 
resulting solution was washed with water (3 x 10 mL), dried over MgSO4 and concentrated 
in vacuo. The crude compound was purified using flash column chromatography to obtain 
pure product in 74.6% yield (557 mg, 1.45 mmol). 1H NMR (250.13 MHz, CDCl3, ambient T): 
δ 7.77 -7.67 (m, 2 H), 7.61 -7.55 (m, 2 H), 7.49 – 7.35 (m, 7 H), 7.22 - 7.19 (m, 2 H), 7.05 – 
7.02 (m, 2 H), 6.67 (s, 1H), 3.12 (d, J= 7.5 Hz, 1 H), 3.04 (d, J= 7.5 Hz, 1 H), 1.36 (s, 9 H) ppm. 
N-(diphenylmethylene)-glycine amide (Ph2C=N-[
11C]Gly-NH2) 
Reference compound was synthesized according to O'Donnell et al.1 and characterized 
according to O'Donnell et al.3  
Benzophenone imine (1 eq, 13.5 mmol, 2.50 g), dissolved in 10 mL of DCM, was added to 
glycine amide (1 eq, 13.5 mmol, 1.00 g), dissolved in 20 mL of DCM. The mixture was 
stirred for 16 h at RT, filtered and evaporated to dryness on a rotary evaporator. After 
addition of small amount of EtOAc and n-Hexane, precipitation occurred and white crystals 
were filtered to obtain Ph2C=N-[
11C]Gly-NH2 in 6.31% yield (203 mg, 851 µmol). No 
further isolation was performed with the remaining reaction mixture. 1H NMR (250.13 
MHz, CDCl3, ambient T): δ 7.61 -7.56 (m, 2 H), 7.44 – 7.30 (m, 6 H), 7.08 (m, 2 H), 5.63 (s, 1 
H), 3.91 (s, 2 H) ppm. 13C NMR (125.78 MHz, CDCl3, ambient T): δ 173.51, 170.34, 138.74, 
129.05, 128.90, 57.06 ppm. HRMS (m/z) calculated for C15H16N2O 239.12; found 239.1216 
[M+H+], calculated for C15H14N2NaO 261.10; found 261.1033 [M+Na]
+.  
N-(diphenylmethylene)-L-phenylalanine amide (Ph2C=N-[
11C]Phe-NH2) 
Reference compound was synthesized according to O'Donnell et al.1 and characterized 
according to Hyett et al.4  
Benzophenone imine (1 eq, 1.22 mmol, 221 mg), dissolved in 7 mL of DCM, was added to L-
phenylalanine amide (1 eq, 1.22 mmol, 200 mg), dissolved in 14 mL of DCM and 
triethylamine (1 eq, 1.22 mmol, 170 µL) at 40 ⁰C. The mixture was stirred for 16 h at RT,  
evaporated to dryness on a rotary evaporator and purified by flash chromatography to 
yield Ph2C=N-[
11C]Phe-NH2 in 13.0% yield (52.0 mg, 15.9 µmol).  
1H NMR (250.13 MHz, 
CDCl3, ambient T): δ 7.53 – 7.50 (m, 2 H), 7.38 – 7.10 (m, 11 H), 6.98 – 6.94 (m, 2 H), 6.36 
(d, J= 5.0 Hz, 2 H), 5.43 (s, 1 H), 4.12 – 4.04 (m, 1 H), 3.18 – 3.11 (m, 1 H), 3.03 – 2.94 (m, 1 
H) ppm. 13C NMR (125.78 MHz, CDCl3, ambient T): δ 175.56, 170.23, 139.05, 137.85, 
130.59, 128.61, 128.32, 127.34, 126.37, 67.63, 41.52 ppm. HR-MS (m/z) calculated for 
C22H21N2O 329.17; found 329.1670 [M+H
+], calculated for C22H20N2NaO 351.15; found 
351.1477 [M+Na]+.  
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N-(diphenylmethylene)-D-phenylalanine amide (Ph2C=N-[
11C]-D-Phe-NH2) 
Reference compound Ph2C=N-[
11C]-D-Phe-NH2 was synthesized according to O'Donnell et 
al.1 and characterized according to Hyett et al.4 
Benzophenone imine (1 eq, 1.00 mmol, 181 mg), dissolved in 5 mL of DCM, was added to 
D-phenylalanine amide (1 eq, 1.00 mmol, 164 mg), dissolved in 5 mL of 2-propanol. The 
mixture was stirred for 16 h at RT, evaporated to dryness on a rotary evaporator and 
purified by flash chromatography to yield (Ph2C=N[
11C]-D-Phe-NH2 in 29.2 % yield (96.0 
mg, 29.2 µmol). 1H NMR (250.13 MHz, CDCl3, ambient T): δ 7.53 – 7.50 (m, 2 H), 7.38 – 7.10 
(m, 11 H), 6.98 – 6.94 (m, 2 H), 6.36 (d, J= 5.0 Hz, 2 H), 5.41 (s, 1 H), 4.12 – 4.04 (m, 1 H), 
3.18 – 3.11 (m, 1 H), 3.03 – 2.94 (m, 1 H) ppm. 13C NMR (125.78 MHz, CDCl3, ambient T): δ 
177.95, 171.13, 139.16, 137.77, 130.17, 128.61, 128.30, 128.15, 127.37, 126.44, 67.79, 
41.57 ppm. HR-MS (m/z) calculated for C22H21N2O 329.17; found 329.1634 [M+H
+], 
calculated for C22H20N2NaO 351.15; found 351.1460 [M+Na]
+.  
Radiosynthesis 
[11C]Benzyl iodide  
[11C]Benzyl iodide was synthesized according to the procedure in Chapter 3.  
Racemic [11C]Phenylalanine  
→ Reactions in presence of a strong base: tetra-n-butylammonium fluoride  
1 M Tetra-n-butylammonium floride (TBAF) in tetrahydrofuran (THF) (2 eq, 34 μL, 34 
μmol), dissolved in 200 μL of dimethyl sulfoxide (DMSO), was added in the reaction vessel 
containing precursor N-(diphenylmethylene)glycine tert-butyl ester (1 eq, 5.0 mg, 17 
μmol), dissolved in 100 μL of dichloromethane (DCM) and 100 μL of dimethyl sulfoxide 
(DMSO), 30 s prior addition of [11C]BnI. [11C]Benzyl iodide in DCM (300 μL) was slowly 
added to the reaction vessel and stirred for 10 min at 45 °C with He flow (10 mL·min-1).  
Afterwards 200 μL of 37 % HCl was added to the reaction vessel and heated to 120 °C for 2 
min. The reaction mixture was cooled down to ambient temperature and quenched with 
1.0 mL of 0.1 M solution of ammonium phosphate dibasic. The identity of the product was 
confirmed with analytical HPLC by co-injection of the product and authentic reference of 
D- or L-Phenylalanine (column B, solvents E/EF, 70/30, v/v, wavelength 210 nm, column 
temperature – ambient, flow 1 mL·min-1, Rt 5.0 min for L-phenylalanine and Rt 6.4 min for 
D-Phenylalanine). In addition, the identity of the synthetic intermediate Ph2C=N-[
11C]Phe-
OtBu was confirmed with analytical HPLC by co-injection of the corresponding racemic 
intermediate Ph2C=N-[
11C]Phe-OtBu and authentic reference of N-(diphenylmethylene)-L-
phenylalanine tert-butyl ester (column A, solvents D/I, 80/20, v/v, wavelength 254 nm, 
column temperature – ambient, flow 1 mL·min-1, Rt 12.5 min). 
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Figure 1: HPLC UV and radioactivity profile of the crude reaction mixture after 11C-
benzylation: Separation of [11C]benzyl iodide and racemic intermediate to determine RCC. 
Racemic [11C]Phenylalanine amide 
→ Reactions in presence of a strong base: tetra-n-butylammonium fluoride  
1 M Tetra-n-butylammonium floride (TBAF) in tetrahydrofuran (THF) (2 eq, 30 μL, 30 
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containing precursor N-(diphenylmethylene)glycine amide (1 eq, 3.5 mg, 15 μmol), 
dissolved in 100 μL of dichloromethane (DCM) and 100 μL of dimethyl sulfoxide (DMSO), 
30 s prior addition of N-(diphenylmethylene)glycine amide. [11C]Benzyl iodide in DCM (300 
μL) was slowly added to the reaction vessel and stirred for 10 min at 45 °C with He flow (10 
mL·min-1). The reaction mixture was cooled down to ambient temperature and quenched 
with 1.0 mL of mobile phase. The identity of the product was confirmed with analytical 
HPLC by co-injection of the product and authentic reference of Ph2C=L-Phe-NH2 (column A, 
solvents D/I, 70/30, v/v, wavelength 254 nm, column temperature – ambient, flow 1 
mL·min-1, Rt 15.3 min). 
 
Figure 2: HPLC UV and radioactivity profile of the crude reaction mixture with co-injection 
of the cold standards: Separation of D- and Ph2C=N-L-Phe-NH2 on chiral column.  
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N-(diphenylmethylene)-D-phenylalanine amide (Ph2C=N-[
11C]-D-Phe-NH2) 
Reference compound Ph2C=N-[
11C]-D-Phe-NH2 was synthesized according to O'Donnell et 
al.1 and characterized according to Hyett et al.4 
Benzophenone imine (1 eq, 1.00 mmol, 181 mg), dissolved in 5 mL of DCM, was added to 
D-phenylalanine amide (1 eq, 1.00 mmol, 164 mg), dissolved in 5 mL of 2-propanol. The 
mixture was stirred for 16 h at RT, evaporated to dryness on a rotary evaporator and 
purified by flash chromatography to yield (Ph2C=N[
11C]-D-Phe-NH2 in 29.2 % yield (96.0 
mg, 29.2 µmol). 1H NMR (250.13 MHz, CDCl3, ambient T): δ 7.53 – 7.50 (m, 2 H), 7.38 – 7.10 
(m, 11 H), 6.98 – 6.94 (m, 2 H), 6.36 (d, J= 5.0 Hz, 2 H), 5.41 (s, 1 H), 4.12 – 4.04 (m, 1 H), 
3.18 – 3.11 (m, 1 H), 3.03 – 2.94 (m, 1 H) ppm. 13C NMR (125.78 MHz, CDCl3, ambient T): δ 
177.95, 171.13, 139.16, 137.77, 130.17, 128.61, 128.30, 128.15, 127.37, 126.44, 67.79, 
41.57 ppm. HR-MS (m/z) calculated for C22H21N2O 329.17; found 329.1634 [M+H
+], 
calculated for C22H20N2NaO 351.15; found 351.1460 [M+Na]
+.  
Radiosynthesis 
[11C]Benzyl iodide  
[11C]Benzyl iodide was synthesized according to the procedure in Chapter 3.  
Racemic [11C]Phenylalanine  
→ Reactions in presence of a strong base: tetra-n-butylammonium fluoride  
1 M Tetra-n-butylammonium floride (TBAF) in tetrahydrofuran (THF) (2 eq, 34 μL, 34 
μmol), dissolved in 200 μL of dimethyl sulfoxide (DMSO), was added in the reaction vessel 
containing precursor N-(diphenylmethylene)glycine tert-butyl ester (1 eq, 5.0 mg, 17 
μmol), dissolved in 100 μL of dichloromethane (DCM) and 100 μL of dimethyl sulfoxide 
(DMSO), 30 s prior addition of [11C]BnI. [11C]Benzyl iodide in DCM (300 μL) was slowly 
added to the reaction vessel and stirred for 10 min at 45 °C with He flow (10 mL·min-1).  
Afterwards 200 μL of 37 % HCl was added to the reaction vessel and heated to 120 °C for 2 
min. The reaction mixture was cooled down to ambient temperature and quenched with 
1.0 mL of 0.1 M solution of ammonium phosphate dibasic. The identity of the product was 
confirmed with analytical HPLC by co-injection of the product and authentic reference of 
D- or L-Phenylalanine (column B, solvents E/EF, 70/30, v/v, wavelength 210 nm, column 
temperature – ambient, flow 1 mL·min-1, Rt 5.0 min for L-phenylalanine and Rt 6.4 min for 
D-Phenylalanine). In addition, the identity of the synthetic intermediate Ph2C=N-[
11C]Phe-
OtBu was confirmed with analytical HPLC by co-injection of the corresponding racemic 
intermediate Ph2C=N-[
11C]Phe-OtBu and authentic reference of N-(diphenylmethylene)-L-
phenylalanine tert-butyl ester (column A, solvents D/I, 80/20, v/v, wavelength 254 nm, 
column temperature – ambient, flow 1 mL·min-1, Rt 12.5 min). 
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D- or L-[11C]Phenylalanine  
→ Reactions in presence of the chiral phase-transfer catalyst: Cat 1-5  
[11C]Benzyl iodide in toluene (400 μL) was slowly transferred in the reaction vessel 
containing N-(diphenylmethylene)glycine tert-butyl ester (1 eq, 5.0 mg, 17 μmol), cesium 
hydroxide monohydrate (40 eq, 114 mg, 679 μmol) and Cat 2 or 3 (0.1 eq, 1.30 mg, 1.74 
μmol) and stirred for 7 min at 0 °C with He flow (25 mL·min-1). Afterwards 200 μL of 37 % 
HCl was added to the reaction vessel and heated to 120 °C for 2 min. The reaction mixture 
was cooled down to ambient temperature and quenched with 1.0 mL of 0.1 M solution of 
ammonium phosphate dibasic. The identity of the product was confirmed with analytical 
HPLC by co-injection of the product and authentic reference of D- or L-Phenylalanine 
(column B, solvents E/F, 90/10, v/v, wavelength 210 nm, column temperature – ambient, 
flow 1 mL·min-1, Rt 6.1 min for L-Phenylalanine and Rt 9.2 min for D-Phenylalanine). In 
addition, the identity of the synthetic 11C-intermediate was confirmed with analytical HPLC 
by co-injection of the corresponding intermediate and authentic reference of N-
(diphenylmethylene)-L-phenylalanine tert-butyl ester (column A, solvents D/I, 80/20, v/v, 
wavelength 254 nm, column temperature – ambient, flow 1 mL·min-1, Rt 12.9 min). 
 
Figure 3: HPLC radioactivity profile of the crude reaction mixture after 11C-benzylation: 
Separation of [11C]benzyl iodide and intermediate to determine RCC. 
 
Figure 4: HPLC UV and radioactivity profile of the crude reaction mixture with the aid of 
Cat 2 with co-injection of the cold standard L- and D-phenylalanine: Separation of L- and D-
[11C]phenylalanine on chiral column to determine ee.  
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Figure 5: HPLC UV and radioactivity profile of the crude reaction mixture with the aid of 
Cat 3 with co-injection of the cold standard L- and D-phenylalanine.  
→ Reaction performed on Vortex mixer in presence of the chiral phase-transfer 
catalyst: Cat 3  
[11C]Benzyl iodide in toluene (400 μL) was slowly transferred in the reaction vessel 
containing N-(diphenylmethylene)glycine tert-butyl ester (1 eq, 5.0 mg, 17 μmol), cesium 
hydroxide monohydrate (40 eq, 114 mg, 679 μmol), catalyst 3 (0.1 eq, 1.30 mg, 1.74 μmol) 
and magnetic stirrer, precooled for 20 min at 0 °C, and stirred for 40 s at ambient 
temperature using Vortex mixer. Afterwards 200 μL of 37 % HCl was added to the reaction 
vessel and heated to 120 °C for 2 min. The reaction mixture was cooled down to ambient 
temperature and quenched with 1.0 mL of 0.1 M solution of ammonium phosphate dibasic. 
The identity of the product was confirmed with analytical HPLC by co-injection of the 
product and authentic reference of D- or L-Phenylalanine (column B, solvents E/F, 90/10, 
v/v, wavelength 210 nm, column temperature – ambient, flow 1 mL·min-1, Rt 5.2 min for L-
Phenylalanine and Rt 8.3 min for D-Phenylalanine).  
In addition, the identity of the synthetic intermediate Ph2C=N-[
11C]Phe-OtBu was 
confirmed with analytical HPLC by co-injection of the corresponding intermediate and 
authentic reference of N-(diphenylmethylene)-L-phenylalanine tert-butyl ester (column A, 
solvents D/I, 80/20, v/v, wavelength 254 nm, column temperature – ambient, flow 1 
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→ Reactions in presence of the phase-transfer catalyst: Cat 1, 3 and 4  
[11C]Benzyl iodide in toluene or DCM (400 μL) was slowly transferred in the reaction vessel 
containing N-(diphenylmethylene)glycine amide (1 eq, 3.3 mg, 15 μmol), cesium hydroxide 
monohydrate (205 eq, 516 mg, 3.08 mmol) and catalyst 1, 3 or 4 (0.1 eq) and stirred for 10 
min at 0 °C with He flow (25 mL·min-1). The reaction mixture was cooled down to ambient 
temperature and quenched with 1.0 mL of mobile phase. The identity of the product was 
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D- or L-[11C]Phenylalanine  
→ Reactions in presence of the chiral phase-transfer catalyst: Cat 1-5  
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μmol) and stirred for 7 min at 0 °C with He flow (25 mL·min-1). Afterwards 200 μL of 37 % 
HCl was added to the reaction vessel and heated to 120 °C for 2 min. The reaction mixture 
was cooled down to ambient temperature and quenched with 1.0 mL of 0.1 M solution of 
ammonium phosphate dibasic. The identity of the product was confirmed with analytical 
HPLC by co-injection of the product and authentic reference of D- or L-Phenylalanine 
(column B, solvents E/F, 90/10, v/v, wavelength 210 nm, column temperature – ambient, 
flow 1 mL·min-1, Rt 6.1 min for L-Phenylalanine and Rt 9.2 min for D-Phenylalanine). In 
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by co-injection of the corresponding intermediate and authentic reference of N-
(diphenylmethylene)-L-phenylalanine tert-butyl ester (column A, solvents D/I, 80/20, v/v, 
wavelength 254 nm, column temperature – ambient, flow 1 mL·min-1, Rt 12.9 min). 
 
Figure 3: HPLC radioactivity profile of the crude reaction mixture after 11C-benzylation: 
Separation of [11C]benzyl iodide and intermediate to determine RCC. 
 
Figure 4: HPLC UV and radioactivity profile of the crude reaction mixture with the aid of 
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Figure 5: HPLC UV and radioactivity profile of the crude reaction mixture with the aid of 
Cat 3 with co-injection of the cold standard L- and D-phenylalanine.  
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confirmed with analytical HPLC by co-injection of the product and authentic reference of D- 
and Ph2C=L-Phe-NH2 (column C, solvents G/H, 97/3, v/v, wavelength 220 nm, column 
temperature – ambient, flow 1 mL·min-1, Rt 15.0 min for Ph2C=L-Phe-NH2 and Rt 19.2 min 
for Ph2C=D-Phe-NH2). In addition, the radiochemical conversion was determined by 
analytical HPLC by co-injection of the corresponding intermediate and authentic reference 
Ph2C=L-Phe-NH2 (column A, solvents D/I, 70/30, v/v, wavelength 254 nm, column 
temperature – ambient, flow 1 mL·min-1, Rt 15.3 min). 
Radiochemical Conversion Calculation 
Radiochemical conversion (RCC) was determined by HPLC analysis as the percentage of 
converted [11C]benzyl iodide to desired product (intermediate) in the crude reaction 
mixture using an analytical HPLC method described in the radiochemistry section under 
each procedure (see Figure 1). Before each RCC analysis, sample of [11C]benzyl iodide was 
injected on the analytical HPLC using the same method, to determine purity of the 11C-
alkylating agent and possible contaminants, which were not accounted for the RCC 
calculation. 
Radiochemical Yield Calculation 
Radiochemical yield (RCY) is the amount of radioactivity in the product expressed as the 
percent of related starting radioactivity used in the corresponding synthesis. RCY was 
calculated as the quotient of measured activity at the end of the synthesis (EOS) in the 
vessel (non-isolated) and the measured activity at the end of the cyclotron 
bombardment (EOB) in the vessel at the beginning of the synthesis. RCY has been 
corrected for decay from the end of the cyclotron bombardment (EOB). No 
corrections have been made for material losses (activity withdrawn for analysis, 
potentially volatile radioactive species, or residual activity in the vial, tubes and 
syringes). 
Enantiomeric Excess Calculation 
Enantiomeric excess (ee) of D- or L-[11C]phenylalanine was determined by HPLC analysis of 
the free amino acid in the crude reaction mixture using a chiral column (column B, solvents 
D/E, 90/10, v/v, wavelength 210 nm, column temperature – ambient, flow 1 mL·min-1, Rt 
6.1 min for L-Phenylalanine and Rt 9.2 min for D-Phenylalanine). For the calculations 
following formula has been used: ee (%) = ((D-L)/(D+L)*100 ; D+L=1 for preferential D-
[11C]alkylation and ee (%) = ((L-D)/(D+L)*100 ; D+L=1 for preferential L-11C-alkylation. 
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Molar Activity Calculation 
Molar activity (AM) of the radioactive products was determined by measurement of 
the UV absorbance of a known amount of radioactivity under identical analytical 
chiral HPLC conditions used to generate a calibration curve for the corresponding 
nonradioactive standard. 
 
Figure 6: Calibration curve of UV absorbance vs. injected amount of L-Phenylalanine 
(μmol). For raw data used to construct the curve, see supplementary Table 1. 
Table 1: Data for UV calibration of L-Phenylalanine. 
Entry L-Phenylalanine [μmol  injected] 
UV Absorbance at 210 nm 
[mV*s] 
1 1.85-02 5598.2 
2 1.478-02 4934.8 
3 7.39E-03 1946.8 
4 5.54E-03 1641.6 
5 3.70E-03 924.9 
6 3.69E-03 1130.4 
7 1.48E-03 382.3 
8 1.11E-03 442.2 
9 3.69E-04 60.9 
Full Optimization of Asymmetric Synthesis of L-[11C]Phenylalanine 
 
Scheme 1: Fully automated radiosynthesis of L-[11C]phenylalanine with Cat 3. 
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Molar Activity Calculation 
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chiral HPLC conditions used to generate a calibration curve for the corresponding 
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Keypoints: 
Excellent incorporation (85±6%) of [11C]benzyl iodide to intermediate has been 
achieved using 5 mg of precursor Ph2C=N-Gly-O
tBu, 2 eq of TBAF, compared to 6, 
100 µL of DCM and 300 µL of DMSO at 45 ⁰C for 10 min, as deducted from Table 2.  
Strong base such as TBAF, especially in combination with DMSO as solvent, 
deprotonated α-carbon of the Schiff base precursor Ph2C=N-Gly-O
tBu resulting in 
the corresponding enolate, observed as a yellow color in the reaction mixture.  
As a side effect, these conditions also promote cleavage of the diphenylmethylene 
group on N-terminus6, crucial for alkylation of the Schiff base. In order to reduce 
decomposition of Ph2C=N-[
11C]Phe-OtBu, we proposed that the base was added to 
Ph2C=N-Gly-O
tBu shortly before [11C]BnI.  
In addition to the right sequence, the optimal amount of glycine precursor has been 
increased from 5 to 17 µmol in the alkylation reactions.  
Solid-liquid PTC conditions resulted in accelerated and higher incorporation, but 
lower ee than reported by Corey and co-workers (23 h at -78 ⁰C; ee of 94%)7. 
Extrapolation of these conditions to radiochemistry, especially with short-lived 
isotope carbon-11, is not feasible as the synthesis time must be kept as short as 
possible.  
Table 2: Screening the 11C-alkylation conditions with TBAF. 
Entry Precursor [mM] 
Eq of 
basea Solvent 
T 
[⁰C] 
Time 
[min] Stirring
b RCC [±SD; %]c 
1 20 2 DCM 45 10 He flow <1 
2 45 2 DCM 45 10 He flow 4 
3 50 2 DCM 45 10 He flow 4 
4 60 2 DCM 45 10 He flow <1 
5 70 2 DCM 45 10 He flow 5 and 87 
6 70 3 DCM 45 10 He flow 4 
7 55 2 DCM 35 10 He flow 1 
8 55 2 DCM 25 10 He flow 3 
9 40 2 DCM+DMSO 45 10 He flow 21 
10 55 2 DCM+DMSO 45 10 He flow 85±6% 
11 60 2 DCM+DMSO 45 10 He flow 86±0% 
12 55 2 DCM+DMSO 45 5 He flow 30±2% 
13 55 2 DCM+DMSO 45 10 Stirrer 78±3% 
a1M TBAF solution in THF, compared to Ph2C=N-Gly-O
tBu. bHelium flow of 25 mL·min-1. 
cRadiochemical conversions were determined by HPLC.  
 
Between the different batches of commercially available PTC (Cat 2 and Cat 3) that 
were used during this study, different results with respect to the obtained ee of the 
product were observed. These different batches of the PTC used, were inevitably 
slightly different with respect to HPLC purity and optical rotation angle. 
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Nonetheless, even a minor difference in optical purity can change the ee for a few 
%, as ee is defined as an absolute difference between each enantiomer. Notable is 
also the difference in HPLC purity and specific rotation of Cat 2 and Cat 3, where the 
certified specific rotation is always higher for Cat 3. Therefore, the catalyst with 
higher optical purity should always give higher ee of the desired product.  
Our results with Cat 5 (Table 2; Results and Discussion) might be explained by the 
temperature influence, since Park achieved high enantioselectivitie of 99% (S) for 
Cat 5 at -40 ⁰C over 20 h.11 As argued for Cat 1, in radiochemical reactions with 
carbon-11 we proposed reactions at 0 ⁰C for smooth automation and the required 
shorter reaction times. 
Full Optimization of Asymmetric Synthesis of L-[11C]Phenylalanine Amide 
 
Scheme 2: Radiosynthesis of [11C]phenylalanine amide with the aid of chiral PTC.  
 
 
Figure 7: Tetrahedron selectivity model for Cat 1 and the proposed contact between 
enolate anion (A: glycine ester; B: glycinamide) and the ammonium cation. Three of the 
faces of this tetrahedron are blocked by the quinuclidine, quinoline, and anthracenyl 
group, while the remaining face is sufficiently open to allow the stabilizing R3N
+···-O-C=C 
hydrogen bonds.14 
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Table 3: Screening the solid-liquid PTC conditions for L-[11C]phenylalanine amide 
(n>3). 
Entry Base PTC T [°C] Solvent RCCb [±SD; %] Erb (S:R)c  [%] 
1 CsOH·H2O(s) Cat 1 25 Toluene 84±9 47:53 
2 CsOH·H2O(s) Cat 1 0 Toluene 74±10 59:41 
3 CsOH·H2O(s) Cat 3 25 DCM 93±4 46:54 
4 CsOH·H2O(s) Cat 3 0 DCM 94±4 54:46 
5 CsOH·H2O(s) Cat 4 0 DCM 99 54:45 
6 CsOH·H2O(s) /
a 0 DCM 99 46:54 
All reactions were conducted with 15 µmol of precursor, 205 eq of base, 400 µL of solvent 
and 10% of PTC. Eq of base and % of Cat is compared to precursor. aChiral catalyst has not 
been employed. bRadiochemical conversion and enantiomeric ratio (er) were determined 
by chiral HPLC. cConfiguration at α-position.  
Full Optimization of Deprotection of L-[11C]Phenylalanine and of L-[11C]Phenylalanine 
Amide 
Deprotection of tert-butyl ester and/or diphenylmethylene moiety was studied from 
the beginning of our experiments, since alkylated product had to be deprotected 
quantitatively to [11C]phenylalanine and [11C]phenylalanine amide to determine the 
exact stereochemical outcome of the alkylation reaction using chiral radioHPLC.  
Table 4: Screening the acidic deprotection conditions (n>3). 
Entry Alkylated Intermediate Acid T [°C] 
Time 
[min] RCC
b [±SD; %] 
1 Ph2C=N-[
11C]Phe-OtBu 6M HCl(aq) 120 2 25±5% 
2 Ph2C=N-[
11C]Phe-OtBu 12M HCl(aq) 120 2 >96% 
3 Ph2C=N-[
11C]Phe-NH2 12M HCl(aq) 120 2 >98% 
All reactions were conducted with 200 µL of HCl(aq). 
bRadiochemical conversion 
was determined by HPLC.  
Automated synthesis of L-[11C]Phenylalanine 
Previously described synthesis procedure was first performed manually (whole 5 step 
radiosynthetic procedure) in the research dedicated hot-cells and has been later on 
automated using adjustable home-build synthesis units and performed according to state-
of-the-art GMP standards. 
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Table 3: Screening the solid-liquid PTC conditions for L-[11C]phenylalanine amide 
(n>3). 
Entry Base PTC T [°C] Solvent RCCb [±SD; %] Erb (S:R)c  [%] 
1 CsOH·H2O(s) Cat 1 25 Toluene 84±9 47:53 
2 CsOH·H2O(s) Cat 1 0 Toluene 74±10 59:41 
3 CsOH·H2O(s) Cat 3 25 DCM 93±4 46:54 
4 CsOH·H2O(s) Cat 3 0 DCM 94±4 54:46 
5 CsOH·H2O(s) Cat 4 0 DCM 99 54:45 
6 CsOH·H2O(s) /
a 0 DCM 99 46:54 
All reactions were conducted with 15 µmol of precursor, 205 eq of base, 400 µL of solvent 
and 10% of PTC. Eq of base and % of Cat is compared to precursor. aChiral catalyst has not 
been employed. bRadiochemical conversion and enantiomeric ratio (er) were determined 
by chiral HPLC. cConfiguration at α-position.  
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Amide 
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b [±SD; %] 
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Automated synthesis of L-[11C]Phenylalanine 
Previously described synthesis procedure was first performed manually (whole 5 step 
radiosynthetic procedure) in the research dedicated hot-cells and has been later on 
automated using adjustable home-build synthesis units and performed according to state-
of-the-art GMP standards. 
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Abstract 
 
The use of various quaternary ammonium salts as chiral phase-transfer catalysts allows 
the effective and stereoselective radiochemical 11C-alkylation to obtain functionalized 
dipeptides. The here reported asymmetric 11C-alkylation of dipeptides allows a broadly 
applicable procedure to obtain labeled N-terminal peptides using different 11C-alkyl 
halides. Contended stereoselectivities of the reactions were observed using 11C-labeled 
alkyl halides, [11C]methyl iodide and [11C]benzyl iodide, achieving diastereomeric ratio with 
different specialized catalayst of 95:5 and 90:10, respectively. Accordingly, straightforward 
synthesis of enantioenriched compounds should play a vital role in peptide based 
radiopharmaceutical development and PET imaging.      
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Introduction 
 
Positron emission tomography[1] (PET) is a non-invasive imaging technique enabled by the 
administration of trace amounts of biochemically active compounds labeled with positron-
emitting radioisotope. In recent years, PET has proven itself in disease diagnosis, drug 
efficacy testing and treatment monitoring.[2,3] The presence of carbon in all biological and 
organic compounds makes positron emitting isotope carbon-11 (100 % β+, Emax=0.96 MeV, 
t1/2 = 20.4 min)
[4] an attractive radionuclide for PET tracer development. In theory, carbon-
11 can be incorporated in all molecules of biological interest without changing the lead 
structure. For native peptide-based PET-tracers however, carbon-11 remains almost 
unexplored compared to well established approaches like radiometal chelation (e.g. 
gallium-68) or the addition of a prosthetic group (e.g. 4-[18F]fluorobenzaldehyde). These 
strategies of peptide radiolabeling lead to molecular changes resulting in different 
physico-chemical properties compared to the lead peptide. As a result, clinical translation 
of these peptides requires additional research for the validation of the tracer, which 
delays the development of peptide based PET-tracers.[5–7]  
Recently, more progress has been made in the radiolabeling of peptides with carbon-11.[8–
10] In addition, the high molar activity, low radiation dose to the human subject and the 
option of doing multiple scans per day, offers unique possibilities of carbon-11 labeled 
peptides as PET-tracers. Nevertheless, carbon-11 has its challenges, mainly caused by its 
short half-live, meaning that reactions and work-up procedures must be fast (typically 
minutes) with a complete synthesis time of 60 minutes including purification and 
formulation. With respect to reaction kinetics, an advantage of the high molar activity is 
that the carbon-11 labeled reagent is typically present in low nanomolar amounts whereas 
other reagents are present in micromolar amounts. This distorted stoichiometry leads to 
fast reactions, since radiochemical yields are based only upon the carbon-11 labeled 
reagent.  
Asymmetric alkylation of Schiff base glycine derivatives, utilizing phase-transfer catalysts 
(PTC), is a highly efficient and generally applicable method to synthesize natural and 
unnatural amino acids under mild reaction conditions.[11] Nevertheless, a careful selection 
of reaction conditions and catalysts needs to be performed based upon the peptidic 
backbone.  
We previously reported on the successful asymmetric synthesis of [11C]alanine[12], 
[11C]phenylalanine[13], and two small 11C-peptides[10] applying this methodology. We 
postulate that the stereoselective synthesis of dipeptides will have implications in the 
development of asymmetric chemical transformations in the radiosynthesis of 
functionalized small peptides (Figure 1A) to be used as PET-tracers.[14] In this study the aim 
was to investigate the influence of the peptidic backbone and catalyst induction on 
stereoselectivity. To achieve this, mild PTC conditions were transferred towards various 
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dipeptides with two different alkylating agents, [11C]methyl iodide ([11C]MeI) and 
[11C]benzyl iodide[15] ([11C]BnI), to evaluate efficacy and chiral induction of direct 
alkylation. Generally applicable conditions were identified by screening and optimizing the 
reagent conditions with the amount of precursor and base, the catalyst, reaction time and 
temperature to obtain high diastereomeric ratios (dr) and radiochemical conversion 
yields. 
 
Results and Discussion 
 
We previously reported on the successful asymmetric synthesis of [11C]alanine[12], 
[11C]phenylalanine[13], and two small 11C-peptides[10] applying this methodology. We 
postulate that the stereoselective synthesis of dipeptides will have implications in the 
development of asymmetric chemical transformations in the radiosynthesis of 
functionalized small peptides (Figure 1A) to be used as PET-tracers.[14] In this study the aim 
was to investigate the influence of the peptidic backbone and catalyst induction on 
stereoselectivity. To achieve this, mild PTC conditions were transferred towards various 
dipeptides with two different alkylating agents, [11C]methyl iodide ([11C]MeI) and 
[11C]benzyl iodide[15] ([11C]BnI), to evaluate efficacy and chiral induction of direct 
alkylation. Generally applicable conditions were identified by screening and optimizing the 
reagent conditions with the amount of precursor and base, the catalyst, reaction time and 
temperature to obtain high diastereomeric ratios (dr) and radiochemical conversion 
yields.  
The first aim here was to optimize the concentration of the Schiff base precursor for 11C-
alkylation reactions. Due to higher reactivity of [11C]MeI only 30-40 mM of precursor were 
necessary, whereas for 11C-benzylation concentrations between 50-60 mM were required 
(Experimental Section). With the acquired knowledge, protected 11C-dipeptides as 
alkylated product were successfully obtained in high radiochemical yields, determined by 
analytical HPLC and expressed as radiochemical conversion (RCC). The results were also 
dependent upon the amount of base - CsOH·H2O, which was assessed to be optimal 
between 80-110 equivalents compared to precursor. This excess provides adequate 
effective surface area for phase-transfer alkylations. To attain sufficient exchange 
between solid-liquid system[16] efficient stirring was of paramount importance. The 
vigorous mixing of the reaction mixture was achieved with a helium flow of 20-50 mL·min-1 
which enlarges the interfacial area, as experiments without vigorous reagent mixing 
showed little to no product formation (Experimental Section). From experience, solvent 
toluene was optimal.[17] Next, the reaction has been set to 5 min with satisfactory RCC of > 
75% overall. Finally, Figure 1C illustrates that the optimized conditions yielded product for 
all mentioned dipeptides in excellent RCC, exemplified by a representative 
radiochromatogram in Figure 1B.  
Stereocontrolled 11C-Alkylation of Dipeptides 
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In general, [11C]methylation reactions that were performed at 10 °C had slightly higher 
outcome than 0 °C, while for the 11C-benzylation reactions 0 °C proved to be favorable.[10] 
We also observed that the adjacent amino acid (1 - 2 compared to 3 - 4) has no influence 
on the conversion to racemic 11C-dipeptides.  
 
 
Figure 1: (A) Radiochemical synthesis scheme by alkylation of precursor 1 - 8 with [11C]MeI 
or [11C]BnI; (B) HPLC profiles of the UV and radioactive signal of the crude alkylation 
mixture of [11C]9; (C) Radiochemical yield of the crude reaction mixture, determined by 
analytical HPLC and defined as radiochemicall conversion (RCC) of asymmetric alkylation to 
compound [11C]9-20. 
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Gratified by the excellent conversion rates, the stereoselectivity of the 11C-alkylations was 
examined. Table 1 presents the results of the analysis of alkylation reactions comparing 
the situation without catalyst and with an achiral catalyst TBAB (tetra-butyl ammonium 
bromide). The results are high-yielding and RCCs are comparable with results employing 
CsOH·H2O as deprotonating agent and base. Hereby, the application of a catalyst was 
confirmed not to influence the RCC. Remarkably, the influence of the second amino acid 
was larger in the reactions with [11C]MeI, resulting in a ratio of approx. 60:40 (Table 1, 
Entry 1-4), whereas in the reactions with [11C]BnI the outcome was 50:50 (Table 1, Entry 5-
8). Without catalyst, we assume the dipeptides are in a slightly bended position in the 
apolar organic medium, therefore favoring one diastereomer, whereas the bulkiness of 
phenyl group imparts a stronger effect resulting in a racemic mixture. The influence of 
TBAB is clearly shown in decreasing the ratio for [11C]MeI due to ion-stabilization of Schiff 
base enolate, while for [11C]BnI no influence on the dr is observed.  
The next challenge was to achieve high dr making use of commercially available chiral 
phase-transfer catalysts. The reaction mixtures of the protected dipeptides 9-10 and 15-16 
could not be separated efficiently on C18 reversed-phase or normal-phase HPLC. However, 
the separation with dipeptides 11-14 and 17-20 was successful on RP-C18 (see 
Experimental Section), thus our efforts focused on achieving the best dr for these 
dipeptides with the catalysts specified in Figure 2. In all likelihood, the diastereomeric 
separation is possible due to the configuration of the second amino acid, which enables 
stronger van der Waals bonds of the sterically more hindered dipeptide to the C18 column. 
Henceforth, we moved on with precursor 3 and counterpart 7, as well as 4 and 8, to be 
able to examine the backbone influence in particular.  
In organic asymmetric synthesis lower temperatures (-40 to 0 °C) are preferred to obtain 
better dr of the product, however considering the short half-life of carbon-11, ambient 
temperatures are preferable for reaction kinetics to accomplish higher conversion rates. 
Indeed, the temperature had significant influence on the dr as shown in Table 2 (Entry 3-
5), while maintaining slightly lower but acceptable conversion rates (Table 2, Entry 1-2 and 
3-5). Surprisingly, the lower temperature reduced the dr negatively presumably due to the 
enolate-catalyst complex not forming properly in distorted radiochemistry conditions and 
also due to less time to react. This unexpected result has also been observed in other 
organic chemistry experiments implementing a derivative of Cat 3.[18] Furthermore, the 
amount of catalyst (Table 2, Entry 6-8) used in the reactions hardly influenced the 
diastereoselectivity of the formed product. 
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Table 1: Diasteriomeric ratio of 11C-dipeptides without catalyst and with an achiral phase-
transfer catalyst TBAB. 
 
Table 2: Evaluation of catalyst amount and temperature influence with precursor 4. 
 
For the asymmetric alkylation reactions further on, the amount of catalyst used ranged 
from 0.5 to 1 eq, compared to the amount of Schiff base precursor. The first set of 
experiments was performed with Schiff base glycine-L/D-valine tert-butylester 3/7 yielding 
L/D-alanine-L/D-valine tert-butylester 11/13 and L/D-phenylalanine-L/D-valine tert-
butylester 17/19 with results summarized in Table 3. The use of Cinchona-based[19] 
pseudo-enantiomers Cat 1 and Cat 6, which were most promising for [11C]BnI (Table 3, 
Entry 3-4), showed less selective results for [11C]MeI. The yield and dr of the obtained 
product 15 was clearly dependent on the starting material and catalyst used, which can be 
called a match and mismatch situation for precursor and catalyst (Table 3, Entry 3-4). We 
have also observed a substantial improvement in stereochemical control with Cat 5 – 
Park’s two cinchona alkaloid unit catalyst[19] (Table 2, Entry 6-8) compared to Cat 1 – a 
Entrya 11C-Product No Cat [dr; %] b,c TBAB [dr; %]b,c 
1 11 Ala-L-Val 60:40 (D,L:L,L) n.d.d 
2 13 Ala-D-Val 60:40 (L,D:D,D) n.d. 
3 12 Ala-L-Leu 62:38 (D,L:L,L) 47:53 (D,L:L,L) 
4 14 Ala-D-Leu 67:33 (L,D:D,D) 57:43 (L,D:D,D) 
5 17 Phe-L-Val 54:46 (D,L:L,L) n.d. 
6 19 Phe-D-Val 47:53 (L,D:D,D) n.d. 
7 18 Phe-L-Leu 50:50 (D,L:L,L) 52:48 (D,L:L,L) 
8 20 Phe-D-Leu 51:49 (L,D:D,D) 56:44 (L,D:D,D) 
aReactions were performed with 40-60 mM of precursor 3-4, 7-8 and 80-110 eq CsOH·H2O, 
compared to precursor, at 0-10 °C for 5 min; b40-60 mM TBAB; cReported as  dr; dn.d. = not 
determined. 
Entrya 11C-alkyl halide Cat Cat [Eq]b Temp [°C] D,L:L,L [%] RCC [%] 
1 [11C]MeI 1 1 10 42:52 94 
2 [11C]MeI 1 1 -10 40:60 35 
3 [11C]BnI 6 1 0 79:21 97 
4 [11C]BnI 6 1 -20 62:38 62 
5 [11C]BnI 6 1 -40 50:50 32 
6 [11C]BnI 5 0.5 0 28:72 82 
7 [11C]BnI 5 1 0 23:77 97 
8 [11C]BnI 5 2 0 27:73 79 
aReactions were performed with 40-60 mM of precursor 4 and 80-110 eq of  CsOH·H2O for 5 
min; bCompared to 4; Entry 1-2 yielding product 12 and Entry 3-8 yielding product 18; in general: 
D,L+L,L=100. 
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Gratified by the excellent conversion rates, the stereoselectivity of the 11C-alkylations was 
examined. Table 1 presents the results of the analysis of alkylation reactions comparing 
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single unit catalyst in the [11C]benzylation reaction. They have both resulted in more LL-
product with Gly-L-AA Schiff base precursors. As shown in Table 3 (Entry 1-2, Cat 1 and 6), 
the outcome in [11C]methylation reactions with Cinchona catalysts were leading to lower 
dr, henceforth the use of Cat 5 was abandoned. Closer inspection of Table 3 specifically 
Maruoka’s first generation catalysts[20], Cat 2 and 3, which performed outstandingly in the 
synthesis of amino acids [11C]alanine and [11C]phenylalanine, unfortunately yielded 
unfavorable results for the diastereoselective synthesis of [11C]alanine-based dipeptides 
(Table 3, Entry 1-2) and were therefore discarded for the use with [11C]BnI. The tartrate-
derived Cat 8 and Cat 9, (TaDiAs) published by Shibuguchi et al.[15,16] did not result in a 
decent stereochemical control, however gave different ratios compared to no catalyst 
(Table 3, Entry 1-2) and as these were insignificant differences, the use with [11C]BnI was 
discarded. Likewise, Cat 2 and Cat 3 did not increase the diastereoselectivity of the 
reaction and were thus not further investigated during this study.  
 
 
Figure 2: Chiral phase-transfer catalysts explored for the radiosynthesis of 11C-dipeptides. 
A: Cinchona-based catalysts; B: Maruoka’s quaternary ammonium based and C: Tartrate-
derived catalysts. 
To differentiate the results for the [11C]methylations on a precursor with a bigger adjacent 
side chain, namely leucine, best results were obtained for precursor 4 with Cat 1 
summarized in Table 4 (Entry 1). In contrast, the best result for 11C-benzylation reactions 
were achieved with Cat 6, also here we observed a match/mismatch situation with Cat 1 
(Table 4, Entry 3). A significant difference is clearly obtained with Cat 6 and the two chiral 
precursors 4 and 8. Here, depending upon which chiral precursor is preferred, the favored 
catalyst can be successfully employed. Here as well, the bigger sidechain did not yield 
better dr with the other catalysts employed. 
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Table 3: Diastereoselective N-terminal 11C-alkylation with precursor 3 and 7. 
Entrya 11C-Product 
Cat 1 
[dr; %] 
Cat 6 
[dr; %] 
Cat 2 
[dr; %] 
Cat 3 
[dr; %] 
Cat 8 
[dr; %] 
Cat 9 
[dr; %] 
1 
11 Ala-L-Val 
(D,L:L,L) 
41:59 69:31 66:37 38:62 63:37 46:54 
2 
13 Ala-D-Val 
(L,D:D,D) 
62:38 27:73 68:32 58:42 63:37 39:61 
3 
17 Phe-L-Val 
(D,L:L,L) 
37:63 79:21 n.d. 
4 
19 Phe-D-Val 
(L,D:D,D) 
77:23 22:78 n.d. 
aReactions were performed with 40-60 mM of 3 or 7 with 80-110 eq of CsOH·H2O, compared to 
precursor, at 0-10 °C for 5 min; in general: D,L+L,L=100. 
 
Table 4: Diastereoselective N-terminal 11C-alkylation with precursor 4 and 8. 
Entrya 11C-Product 
Cat 1 
[dr; %] 
Cat 6 
[dr; %] 
Cat 2 
[dr; %] 
Cat 3 
[dr; %] 
Cat 8 
[dr; %] 
Cat 9 
[dr; %] 
1 
12 Ala-L-Leu 
(D,L:L,L) 
22:78 61:39 57:43 54:46 57:43 43:57 
2 
14 Ala-D-Leu 
(L,D:D,D) 
64:36 33:67 63:37 67:33 n.d. 
3 
18 Phe-L-Leu 
(D,L:L,L) 
35:65 79:21 71:29 48:52 52:48 34:66 
4 
20 Phe-D-Leu 
(L,D:D,D) 
54:46 12:88 48:52 59:41 n.d. 
aReactions were performed with 40-60 mM of 4 or 8 with 80-110 eq CsOH·H2O compared to 
precursor, at 0-10 °C for 5 min; in general: D,L+L,L=100. 
 
Figure 3: A: Diastereomeric ratio of Cat 7 with Schiff base precursor 4 to product 12 and 
18; B: Exemplified radioactive HPLC of a reaction with 4 to 18 using Cat 7; C: Exemplified 
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precursor, at 0-10 °C for 5 min; in general: D,L+L,L=100. 
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Figure 3: A: Diastereomeric ratio of Cat 7 with Schiff base precursor 4 to product 12 and 
18; B: Exemplified radioactive HPLC of a reaction with 4 to 18 using Cat 7; C: Exemplified 
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radioactive HPLC of a reaction with 8 to 20 using Cat 4; D: Diastereomeric ratio of Cat 4 
with Schiff base precursor 8 to product 14 and 20.  
We have also successfully evaluated the use of Maruoka’s dedicated di- and tetrapeptide 
catalysts for alkylation,[22,23] Cat 4 and Cat 7, with results summarized in Figure 3. The (S,S) 
version, Cat 7, worked highly successful especially with precursor 4 yielding preferably DL-
dipeptide (Figure 3A, 3C). Whereas for complexes of 4 with Cat 4 the dr for methylated 
product 12 and benzylated product 18 was 50:50. In contrast, the formation of precursor-
catalyst complex of 8 with (R,R)-Cat 4 (see Figure 3D) is preferred to yield preferably L,D-
dipeptide, whereas with Cat 7 it has the reversed outcome yielding for 11C-benzylation 
31:69 and for [11C]methylation resulted in 52:48. Moreover, as outlined in Table 5 
outstanding results have been obtained with [11C]MeI and 3 supporting our previous 
findings. To summarize, (S,S)-Cat 7 yielded high diastereoselectivities with precursor 3 and 
4, whereas with the (R,R)-Cat 4 better results were obtained with D-dipeptide precursor 7 
and 8. Furthermore, from these results we concluded that the configuration and 
confirmation of Cat 7 is more favorable for a good outcome, which might be explained by 
the more bulky character of the catalyst whit the two –CF3 groups instead of single 
fluorine atoms (such as for Cat 2, 3 and 4). Nonetheless, these catalysts are favorable for 
good enantioselectivities due to the strengthened internal hydrogen-bonding by the F 
atoms involving water which leads to more rigid conformations of catalysts.[25,26] 
Furthermore, Kamachi et al. performed density functional theory (DFT) calculations, which 
provided lowest energy transition structures leading to preferred products and is in 
accordance with our findings.[27] The slightly lower dr obtained with bigger catalysts for 
the 11C-benzylation in comparison with [11C]MeI we believe is due to the steric hindrance 
of penetrating effectively the enolate-catalyst system.  
Table 5: Diastereomeric ratio of reactions with glycine-D/L-valine Schiff base with [11C]MeI. 
Entrya 11C-Product Cat 7 [dr; %] Cat 4 [dr; %] 
1 11 Ala-L-Val (D,L:L,L) 95:5 57:43 
2 13 Ala-D-Val (L,D:D,D) 61:39 79:21 
aReactions were performed with 40-60 mM of 3 or 7 with 80-110 eq of CsOH·H2O 
compared to precursor, at 0-10 °C for 5 min; in general: D,L+L,L=100. 
 
The acidic cleavage of obtained protected dipeptides is achieved conveniently. The 
obtained radioactive alkylated products have been quantitatively deprotected in short 
time with 6M HCl at elevated temperatures yielding the free 11C-dipeptide (see 
Experimental Section). In light of molar activity, where the present work was focused on 
radiochemistry method development, that is established to be dependent upon the 
starting alkylation agent and is estimated to be 50[12] to 135[13] GBq·µmol-1 of tracer ready 
for biological studies based on similar publications. As soon as an authentic PET tracer 
candidate is achieved by implementing this methodology, the molar activity will be 
determined.  
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Summary and Conclusions 
 
In conclusion, the best dr was obtained using Cat 7 with [11C]MeI and [11C]BnI resulting in 
95:5 and 90:10 diastereomeric ratio with RCC of > 80 %, respectively. Hence, the herein 
presented radiosynthetic method enables a reliable and reproducible strategy to obtain 
pure diastereomerically enriched carbon-11 labeled dipeptides. This methodology 
provides a general and versatile procedure to be applied for peptide-based PET tracer 
development, stimulating their application and translation towards preclinical and 
potentially also clinical studies. 
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Experimental Section 
 
 
Materials and Methods 
 
General 
Free dipeptide reference materials were obtained from ABCR (Karlsruhe, Germany), 
Bachem (Bubendorf, Switzerland) and Sigma Aldrich (Zwijndrecht, The Netherlands). 
Starting material for dipeptdie syntheses were obtained enantiomerically pure from ABCR 
and Sigma Aldrich. Catalysts were purchased from Sigma Aldrich and Wako Pure Chemical 
Industries (Osaka, Japan). All commercially available chemicals were used without further 
purification. The non-radioactive reference compounds were synthesized according to 
reported methods and were used to verify the identity of radiolabeled compounds. 1H and 
13C nuclear magnetic resonance (NMR) spectra were obtained using a Bruker AC 500.23, 
400.13 or 250.13 MHz(Billerica, USA) and chemical shifts (δ) were defined relative to the 
signal of the solvent (7.27 ppm for CDCl3, 3.31 ppm for MeOD, 2.50 ppm for DMSO-d6) and 
tetramethylsilane as an internal standard (δ=0). NMRs were measured at ambient 
temperature. High resolution mass spectra (HRMS) were carried out using a Bruker 
microTOF-Q instrument in positive or negative ion mode (capillary potential of 4500 V). 
Flash chromatography purifications were performed on a Buchi system operated by 
SepacoreControl. Analytical HPLC systems used were equipped with: a Waters 600E pump, 
a manual Rheodyne injector (20-100 µL loop), a Waters PDA and GinaStar software from 
Raytest (Straubenhardt, Germany) and SHIMADZU Prominence (Kyoto, Japan) operated 
with Labsolutions Version 5.85. The radioactive profile was monitored with a Raytest 2.5 
inch radioactivity detector (Raytest, Germany). Analytical HPLC columns used in this study 
were a Grace Smart C18 (column A) (5µm, 4.6 x 250 mm) with a mixture consisting of 
acetonitrile/4mM sodium formate + 4 % DMF (buffer 1) (70/30, v/v) and Luna C18 (column 
B) (5µm, 4.6 x 250 mm) with a gradient of 35 to 7 % buffer 1 in acetonitrile in 25 min or 
isocratic in 82/18 (acetonitrile/buffer 1, v/v) at a constant flow rate of 1 mL/min for the 
analysis of protected dipeptide references, UV monitoring at 254 nm. Enantiomeric purity 
of the free dipeptides was determined using an analytical Reprosil chiral-aa (column C) (8 
µm; 4.6 x 250 mm) from Dr. Maisch GmbH (Ammerbuch, Germany) at 214 nm as well as 
Astec Chirobiotic T (column D) (5 µm; 4.6 x 250 mm) from Supelco (Sigma Aldrich, 
Zwijndrecht, The Netherlands). The product was eluted with methanol/water (70/30, v/v) 
(column C) and acetonitrile/water (65/35, v/v) for column D and all flow rates were 1 
mL/min or as stated otherwise.  
Radiochemical conversions are based on the AUC of the radioactivity profile of HPLC 
analysis. The [11C]MeI and [11C]BnI synthesis was performed before every radiochemical 
reaction on synthesis devices and according to procedures described in literature.  
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Synthesis of reference compounds 
General procedure for the coupling of amino acids 
The coupling reaction of 2-(((benzyloxy)carbonyl)amino)propanoic acid (807 mg, 3.44 
mmol) with tert-butyl 2-aminopropanoate (500 mg, 3.44 mmol) in the presence of BOP 
(1523 mg, 3.44 mmol) and DIPEA (1335 mg, 1.8 mL, 10.33 mmol) in DCM (10 mL) was 
finished in 4-16 hours. The solvent was removed under reduced pressure and the residue 
was dissolved in ethylacetate (25 mL). The ethylacetate solution was washed with 1M 
KHSO4 (3x 20 mL), 10% Na2CO3 (3x 20 mL), and brine (1x 20 mL), dried with Na2SO4, 
filtrated and evaporated in vacuo. The crude product was purified by flash 
chromatography (2-30% ethylacetate in n-hexane), before it was analyzed by 1H-NMR, 13C-
NMR and ESI-HRMS. In general the yield is around 65-80% of a clear oil. All the dipeptides 
references and precursor material have been analyzed and verified according to published 
procedures.1,2  
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.35-7.31 (m, 5H), 5.05 (s, 2H), 4.36 (q, 1H, J=7.25 Hz), 4.16 
(q, 1H, J=7.25 Hz), 1.39 (s, 9H), 1.22 (t, 6H, J=7.25 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 
171.87, 171.54, 128.54, 128.18, 128.07, 82.13, 66.98, 48.73, 27.96, 18.52 ppm; HRMS (ESI) 
calculated for C18H28N2O5: 351.1920 ([M+H]
+), found 351.1854 ([M+H]+), 373.1670 
([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.34-7.29 (m, 5H), 5.07 (s, 2H), 4.39 (q, 1H, J=7.25 Hz), 1.39 
(s, 9H), 1.22 (d, 3H, J=7.25 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.99, 171.82, 
149.93, 136.15, 128.55, 128.22, 128.11, 82.25, 67.19, 48.68, 44.44, 27.96, 18.57 ppm; 
HRMS (ESI) calculated for C17H24N2O5: 337.1763 ([M+H]
+), found 337.1742 ([M+H]+), 
359.1572 ([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 5H), 7.17 (s, 3H), 7.07 (d, 2H, J=7.5 Hz), 5.06 
(s, 2H), 4.73 (q, 1H, J=7.5 Hz), 3.82 (t, 2H, J=5 Hz), 3.03 (d, 2H, J=7.5 Hz), 1.33 (s, 9H) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 182.28, 145.64, 135.84, 129.51, 129.57, 128.43, 128.26, 
128.07, 82.64, 67.22, 53.46, 44.46, 38.01, 27.96 ppm; HRMS (ESI) calculated for 
C23H28N2O5: 413.2076 ([M+H]
+), found 413.2065 ([M+H]+), 435.1886 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 7H), 7.31-7.229 (m, 1H), 7.19 (dd, 2H, J=2.5 
Hz), 5.41 (d, 1H, 7.5 Hz), 5.15 (d, 2H, J=2.5 Hz), 4.80 (q, 1H, J=5 Hz), 3.14 (d, 2H, J=7.5 Hz), 
1.45 (s, 9H), 1.41 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.50, 170.16, 
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Experimental Section 
 
 
Materials and Methods 
 
General 
Free dipeptide reference materials were obtained from ABCR (Karlsruhe, Germany), 
Bachem (Bubendorf, Switzerland) and Sigma Aldrich (Zwijndrecht, The Netherlands). 
Starting material for dipeptdie syntheses were obtained enantiomerically pure from ABCR 
and Sigma Aldrich. Catalysts were purchased from Sigma Aldrich and Wako Pure Chemical 
Industries (Osaka, Japan). All commercially available chemicals were used without further 
purification. The non-radioactive reference compounds were synthesized according to 
reported methods and were used to verify the identity of radiolabeled compounds. 1H and 
13C nuclear magnetic resonance (NMR) spectra were obtained using a Bruker AC 500.23, 
400.13 or 250.13 MHz(Billerica, USA) and chemical shifts (δ) were defined relative to the 
signal of the solvent (7.27 ppm for CDCl3, 3.31 ppm for MeOD, 2.50 ppm for DMSO-d6) and 
tetramethylsilane as an internal standard (δ=0). NMRs were measured at ambient 
temperature. High resolution mass spectra (HRMS) were carried out using a Bruker 
microTOF-Q instrument in positive or negative ion mode (capillary potential of 4500 V). 
Flash chromatography purifications were performed on a Buchi system operated by 
SepacoreControl. Analytical HPLC systems used were equipped with: a Waters 600E pump, 
a manual Rheodyne injector (20-100 µL loop), a Waters PDA and GinaStar software from 
Raytest (Straubenhardt, Germany) and SHIMADZU Prominence (Kyoto, Japan) operated 
with Labsolutions Version 5.85. The radioactive profile was monitored with a Raytest 2.5 
inch radioactivity detector (Raytest, Germany). Analytical HPLC columns used in this study 
were a Grace Smart C18 (column A) (5µm, 4.6 x 250 mm) with a mixture consisting of 
acetonitrile/4mM sodium formate + 4 % DMF (buffer 1) (70/30, v/v) and Luna C18 (column 
B) (5µm, 4.6 x 250 mm) with a gradient of 35 to 7 % buffer 1 in acetonitrile in 25 min or 
isocratic in 82/18 (acetonitrile/buffer 1, v/v) at a constant flow rate of 1 mL/min for the 
analysis of protected dipeptide references, UV monitoring at 254 nm. Enantiomeric purity 
of the free dipeptides was determined using an analytical Reprosil chiral-aa (column C) (8 
µm; 4.6 x 250 mm) from Dr. Maisch GmbH (Ammerbuch, Germany) at 214 nm as well as 
Astec Chirobiotic T (column D) (5 µm; 4.6 x 250 mm) from Supelco (Sigma Aldrich, 
Zwijndrecht, The Netherlands). The product was eluted with methanol/water (70/30, v/v) 
(column C) and acetonitrile/water (65/35, v/v) for column D and all flow rates were 1 
mL/min or as stated otherwise.  
Radiochemical conversions are based on the AUC of the radioactivity profile of HPLC 
analysis. The [11C]MeI and [11C]BnI synthesis was performed before every radiochemical 
reaction on synthesis devices and according to procedures described in literature.  
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Synthesis of reference compounds 
General procedure for the coupling of amino acids 
The coupling reaction of 2-(((benzyloxy)carbonyl)amino)propanoic acid (807 mg, 3.44 
mmol) with tert-butyl 2-aminopropanoate (500 mg, 3.44 mmol) in the presence of BOP 
(1523 mg, 3.44 mmol) and DIPEA (1335 mg, 1.8 mL, 10.33 mmol) in DCM (10 mL) was 
finished in 4-16 hours. The solvent was removed under reduced pressure and the residue 
was dissolved in ethylacetate (25 mL). The ethylacetate solution was washed with 1M 
KHSO4 (3x 20 mL), 10% Na2CO3 (3x 20 mL), and brine (1x 20 mL), dried with Na2SO4, 
filtrated and evaporated in vacuo. The crude product was purified by flash 
chromatography (2-30% ethylacetate in n-hexane), before it was analyzed by 1H-NMR, 13C-
NMR and ESI-HRMS. In general the yield is around 65-80% of a clear oil. All the dipeptides 
references and precursor material have been analyzed and verified according to published 
procedures.1,2  
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.35-7.31 (m, 5H), 5.05 (s, 2H), 4.36 (q, 1H, J=7.25 Hz), 4.16 
(q, 1H, J=7.25 Hz), 1.39 (s, 9H), 1.22 (t, 6H, J=7.25 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 
171.87, 171.54, 128.54, 128.18, 128.07, 82.13, 66.98, 48.73, 27.96, 18.52 ppm; HRMS (ESI) 
calculated for C18H28N2O5: 351.1920 ([M+H]
+), found 351.1854 ([M+H]+), 373.1670 
([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.34-7.29 (m, 5H), 5.07 (s, 2H), 4.39 (q, 1H, J=7.25 Hz), 1.39 
(s, 9H), 1.22 (d, 3H, J=7.25 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.99, 171.82, 
149.93, 136.15, 128.55, 128.22, 128.11, 82.25, 67.19, 48.68, 44.44, 27.96, 18.57 ppm; 
HRMS (ESI) calculated for C17H24N2O5: 337.1763 ([M+H]
+), found 337.1742 ([M+H]+), 
359.1572 ([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 5H), 7.17 (s, 3H), 7.07 (d, 2H, J=7.5 Hz), 5.06 
(s, 2H), 4.73 (q, 1H, J=7.5 Hz), 3.82 (t, 2H, J=5 Hz), 3.03 (d, 2H, J=7.5 Hz), 1.33 (s, 9H) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 182.28, 145.64, 135.84, 129.51, 129.57, 128.43, 128.26, 
128.07, 82.64, 67.22, 53.46, 44.46, 38.01, 27.96 ppm; HRMS (ESI) calculated for 
C23H28N2O5: 413.2076 ([M+H]
+), found 413.2065 ([M+H]+), 435.1886 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 7H), 7.31-7.229 (m, 1H), 7.19 (dd, 2H, J=2.5 
Hz), 5.41 (d, 1H, 7.5 Hz), 5.15 (d, 2H, J=2.5 Hz), 4.80 (q, 1H, J=5 Hz), 3.14 (d, 2H, J=7.5 Hz), 
1.45 (s, 9H), 1.41 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.50, 170.16, 
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135.92, 129.46, 128.33, 128.15, 126.94, 89.12, 82.44, 66.94, 53.52, 50.38, 37.87, 27.91 
ppm; HRMS (ESI) calculated for C24H30N2O5: 427.2233 ([M+H]
+), found 427.2212 ([M+H]+), 
449.2033 ([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 5H), 5.16 (s, 2H), 4.50 (dd, 1H, J=5 Hz), 3.96-
3.92 (m, 2H), 2.21-2.13 (m, 1H), 1.48 (s, 9H), 0.95 (dd, 6H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 176.28, 170.87, 163.81, 135.10, 128.55, 82.23, 67.19, 57.36, 44.58, 31.46, 
28.04, 18.87, 17.57 ppm; HRMS (ESI) calculated for C19H28N2O5: 365.2076 ([M+H]
+), found 
365.2059 ([M+H]+), 387.1884 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.31-7.28 (m, 5H), 5.05 (s, 2H), 4.39 (dd, 1H, J=5 Hz), 4.27 
(t, 1H, J=5 Hz), 2.09 (m, 1H), 1.39 (s, 9H), 1.36 (d, 3H, J=7.5 Hz), 0.86 (dd, 5H, J=7.5 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 184.02, 181.46, 170.73, 138.95, 128.54, 128.18, 
128.08, 115.84, 96.08, 82.09, 66.98, 57.44, 31.38, 28.04, 18.87, 17.51 ppm; HRMS (ESI) 
calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 379.2210 ([M+H]+), 401.2033 
([M+Na]+). 
(R)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.36-7.31 (m, 5H), 7.28-7.26 (m, 3H), 7.17-7.14 (m, 2H), 
5.15 (s, 2H), 4.82 (q, 1H, J=12 Hz), 3.91 (t, 2H, J=8 Hz), 3.12 (d, 2H, J=12 Hz), 1.41 (s, 9H) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 182.28, 145.64, 135.84, 129.51, 129.57, 128.43, 
128.26, 128.07, 82.64, 67.22, 53.46, 44.46, 38.01, 27.96 ppm; HRMS (ESI) calculated for 
C23H28N2O5: 413.2076 ([M+H]
+), found 413.2065 ([M+H]+), 435.1886 ([M+Na]+). 
 
(R)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)propanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.34 (m, 5H), 5.15 (s, 2H), 4.52 (quint, 1H, J=8 Hz), 
1.48 (s, 9H), 1.39 (d, 3H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.99, 171.82, 
149.93, 136.15, 128.55, 128.22, 128.11, 82.25, 67.19, 48.68, 44.44, 27.96, 18.57 ppm; 
HRMS (ESI) calculated for C17H24N2O5: 337.1763 ([M+H]
+), found 337.1745 ([M+H]+), 
359.1573 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.50-7.46 (m, 5H), 7.41-7.38 (m, 2H), 7.29-7.27 (m, 2H), 
5.28 (m, 2H), 4.89 (q, 1H, J=8 Hz), 3.23 (s, 2H), 1.55 (s, 9H), 1.50 (d, 3H, J=4 Hz) ppm; 13C-
NMR (100.62 MHz, CDCl3) δ 171.16, 135.61, 129.15, 128.01, 126.63, 82.13, 66.64, 53.22, 
37.57, 27.60 ppm; HRMS (ESI) calculated for C21H32N2O5: 427.2233 ([M+H]
+), found 
427.2160 ([M+H]+), 449.1977 ([M+Na]+). 
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(R)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.24-7.22 (m, 5H), 5.01 (s, 2H), 4.35 (m, 2H), 1.37 (s, 9H), 
1.31 (m, 6H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.92, 155.92, 136.33, 128.48, 128.08, 
81.88, 66.82, 50.42, 48.69, 27.95, 18.97, 18.28 ppm; HRMS (ESI) calculated for C18H28N2O5: 
351.1920 ([M+H]+), found 351.1854 ([M+H]+), 373.1670 ([M+Na]+). 
(S)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.26-7.24 (m, 5H), 7.18-7.14 (m, 3H), 7.06-7.04 (m, 2H), 
5.01 (d, 2H, J=8 Hz), 4.69 (q, 1H, J=12 Hz), 3.00 (d, 2H, J=8 Hz), 2.16 (m, 1H), 1.32 (s, 9H), 
1.27 (d, 3H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.72, 170.27, 136.04, 129.52, 
128.36, 126.96, 82.41, 66.95, 53.62, 50.44, 37.97, 27.94, 27.89, 18.65 ppm; HRMS (ESI) 
calculated for C24H30N2O5: 427.2233 ([M+H]
+), found 365.2059 ([M+H]+), 387.1884 
([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.38-7.35 (m, 5H), 5.32 (s, 2H), 5.15 (s, 2H), 4.56 (q, 1H, J=8 
Hz), 3.94-3.91 (m, 2H), 1.48 (s, 9H), 0.96 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) 
δ 192.35, 185.75, 171.06, 169.46, 136.69, 129.81, 128.63, 127.10, 82.57, 54.30, 43.19, 
38.31, 28.19 ppm; HRMS (ESI) calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 
379.2221 ([M+H]+), 401.2048 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.30 (m, 5H), 5.32 (s, 1H), 5.13 (s, 2H), 4.52 (q, 1H, J=8 
Hz), 4.29-4.27 (m, 1H), 1.66-1.64 (m, 2H), 1.48 (s, 9H), 1.42 (d, 3H, J=4 Hz), 0.95 (d, 6H, J=4 
Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 177.17, 171.68, 162.21, 128.54, 128.19, 128.06, 
51.43, 41.78, 27.99, 24.91, 22.79, 22.09 ppm; HRMS (ESI) calculated for C21H32N2O5: 
393.2389 ([M+H]+), found 393.2382 ([M+H]+), 415.2199 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.28 (m, 5H), 7.27-7.23 (m, 3H), 7.21-7.19 (m, 2H), 
5.31 (s, 1H), 5.10 (s, 2H), 4.48 (q, 2H, J=8 Hz), 3.11 (m, 2H), 1.59-1.56 (m, 2H), 1.47 (s, 9H), 
0.93 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.56, 170.28, 166.51, 134.67, 
132.66, 129.40, 128.54, 128.19, 128.03, 127.03, 81.94, 67.03, 51.46, 41.85, 27.99, 24.80, 
22.71, 22.14 ppm; HRMS (ESI) calculated for C27H36N2O5: 469.2702 ([M+H]
+), found 
469.2687 ([M+H]+), 491.2507 ([M+Na]+).  
(R)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-4-methylpentanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.37-7.35 (m, 5H), 5.15 (s, 2H), 4.56 (q, 1H, J=8 Hz), 3.92-
3.89 (m, 2H), 2.93 (d, 1H, J=12 Hz), 1.64-1.61 (m, 2H), 1.47 (s, 9H), 0.95 (d, 6H, J=4 Hz) 
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135.92, 129.46, 128.33, 128.15, 126.94, 89.12, 82.44, 66.94, 53.52, 50.38, 37.87, 27.91 
ppm; HRMS (ESI) calculated for C24H30N2O5: 427.2233 ([M+H]
+), found 427.2212 ([M+H]+), 
449.2033 ([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 5H), 5.16 (s, 2H), 4.50 (dd, 1H, J=5 Hz), 3.96-
3.92 (m, 2H), 2.21-2.13 (m, 1H), 1.48 (s, 9H), 0.95 (dd, 6H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 176.28, 170.87, 163.81, 135.10, 128.55, 82.23, 67.19, 57.36, 44.58, 31.46, 
28.04, 18.87, 17.57 ppm; HRMS (ESI) calculated for C19H28N2O5: 365.2076 ([M+H]
+), found 
365.2059 ([M+H]+), 387.1884 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.31-7.28 (m, 5H), 5.05 (s, 2H), 4.39 (dd, 1H, J=5 Hz), 4.27 
(t, 1H, J=5 Hz), 2.09 (m, 1H), 1.39 (s, 9H), 1.36 (d, 3H, J=7.5 Hz), 0.86 (dd, 5H, J=7.5 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 184.02, 181.46, 170.73, 138.95, 128.54, 128.18, 
128.08, 115.84, 96.08, 82.09, 66.98, 57.44, 31.38, 28.04, 18.87, 17.51 ppm; HRMS (ESI) 
calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 379.2210 ([M+H]+), 401.2033 
([M+Na]+). 
(R)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.36-7.31 (m, 5H), 7.28-7.26 (m, 3H), 7.17-7.14 (m, 2H), 
5.15 (s, 2H), 4.82 (q, 1H, J=12 Hz), 3.91 (t, 2H, J=8 Hz), 3.12 (d, 2H, J=12 Hz), 1.41 (s, 9H) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 182.28, 145.64, 135.84, 129.51, 129.57, 128.43, 
128.26, 128.07, 82.64, 67.22, 53.46, 44.46, 38.01, 27.96 ppm; HRMS (ESI) calculated for 
C23H28N2O5: 413.2076 ([M+H]
+), found 413.2065 ([M+H]+), 435.1886 ([M+Na]+). 
 
(R)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)propanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.34 (m, 5H), 5.15 (s, 2H), 4.52 (quint, 1H, J=8 Hz), 
1.48 (s, 9H), 1.39 (d, 3H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.99, 171.82, 
149.93, 136.15, 128.55, 128.22, 128.11, 82.25, 67.19, 48.68, 44.44, 27.96, 18.57 ppm; 
HRMS (ESI) calculated for C17H24N2O5: 337.1763 ([M+H]
+), found 337.1745 ([M+H]+), 
359.1573 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.50-7.46 (m, 5H), 7.41-7.38 (m, 2H), 7.29-7.27 (m, 2H), 
5.28 (m, 2H), 4.89 (q, 1H, J=8 Hz), 3.23 (s, 2H), 1.55 (s, 9H), 1.50 (d, 3H, J=4 Hz) ppm; 13C-
NMR (100.62 MHz, CDCl3) δ 171.16, 135.61, 129.15, 128.01, 126.63, 82.13, 66.64, 53.22, 
37.57, 27.60 ppm; HRMS (ESI) calculated for C21H32N2O5: 427.2233 ([M+H]
+), found 
427.2160 ([M+H]+), 449.1977 ([M+Na]+). 
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(R)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.24-7.22 (m, 5H), 5.01 (s, 2H), 4.35 (m, 2H), 1.37 (s, 9H), 
1.31 (m, 6H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.92, 155.92, 136.33, 128.48, 128.08, 
81.88, 66.82, 50.42, 48.69, 27.95, 18.97, 18.28 ppm; HRMS (ESI) calculated for C18H28N2O5: 
351.1920 ([M+H]+), found 351.1854 ([M+H]+), 373.1670 ([M+Na]+). 
(S)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.26-7.24 (m, 5H), 7.18-7.14 (m, 3H), 7.06-7.04 (m, 2H), 
5.01 (d, 2H, J=8 Hz), 4.69 (q, 1H, J=12 Hz), 3.00 (d, 2H, J=8 Hz), 2.16 (m, 1H), 1.32 (s, 9H), 
1.27 (d, 3H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.72, 170.27, 136.04, 129.52, 
128.36, 126.96, 82.41, 66.95, 53.62, 50.44, 37.97, 27.94, 27.89, 18.65 ppm; HRMS (ESI) 
calculated for C24H30N2O5: 427.2233 ([M+H]
+), found 365.2059 ([M+H]+), 387.1884 
([M+Na]+). 
(S)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.38-7.35 (m, 5H), 5.32 (s, 2H), 5.15 (s, 2H), 4.56 (q, 1H, J=8 
Hz), 3.94-3.91 (m, 2H), 1.48 (s, 9H), 0.96 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) 
δ 192.35, 185.75, 171.06, 169.46, 136.69, 129.81, 128.63, 127.10, 82.57, 54.30, 43.19, 
38.31, 28.19 ppm; HRMS (ESI) calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 
379.2221 ([M+H]+), 401.2048 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.30 (m, 5H), 5.32 (s, 1H), 5.13 (s, 2H), 4.52 (q, 1H, J=8 
Hz), 4.29-4.27 (m, 1H), 1.66-1.64 (m, 2H), 1.48 (s, 9H), 1.42 (d, 3H, J=4 Hz), 0.95 (d, 6H, J=4 
Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 177.17, 171.68, 162.21, 128.54, 128.19, 128.06, 
51.43, 41.78, 27.99, 24.91, 22.79, 22.09 ppm; HRMS (ESI) calculated for C21H32N2O5: 
393.2389 ([M+H]+), found 393.2382 ([M+H]+), 415.2199 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.28 (m, 5H), 7.27-7.23 (m, 3H), 7.21-7.19 (m, 2H), 
5.31 (s, 1H), 5.10 (s, 2H), 4.48 (q, 2H, J=8 Hz), 3.11 (m, 2H), 1.59-1.56 (m, 2H), 1.47 (s, 9H), 
0.93 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.56, 170.28, 166.51, 134.67, 
132.66, 129.40, 128.54, 128.19, 128.03, 127.03, 81.94, 67.03, 51.46, 41.85, 27.99, 24.80, 
22.71, 22.14 ppm; HRMS (ESI) calculated for C27H36N2O5: 469.2702 ([M+H]
+), found 
469.2687 ([M+H]+), 491.2507 ([M+Na]+).  
(R)-tert-butyl 2-(2-(((benzyloxy)carbonyl)amino)acetamido)-4-methylpentanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.37-7.35 (m, 5H), 5.15 (s, 2H), 4.56 (q, 1H, J=8 Hz), 3.92-
3.89 (m, 2H), 2.93 (d, 1H, J=12 Hz), 1.64-1.61 (m, 2H), 1.47 (s, 9H), 0.95 (d, 6H, J=4 Hz) 
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ppm; 13C-NMR (100.62 MHz, CDCl3) δ 175.11, 171.98, 168.51, 148.70, 142.86, 128.54, 
128.22, 128.08, 95.80, 82.12, 77.39, 67.17, 51.35, 44.46, 41.81, 27.98, 24.90, 22.78, 22.07 
ppm; HRMS (ESI) calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 379.2240 ([M+H]+), 
401.2062 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-4-methylpentanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.36-7.33 (m, 5H), 5.13 (s, 2H), 4.53 (q, 1H, J=8 Hz), 4.32-
4.30 (m, 1H), 1.64-1.61 (m, 2H), 1.47 (s, 9H), 1.42 (d, 3H, J=8 Hz), 0.95 (d, 6H, J=4 Hz) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 171.92, 164.82, 136.33, 128.54, 128.18, 128.06, 67.02, 
51.35, 41.75, 27.99, 24.95, 22.82, 22.08 ppm; HRMS (ESI) calculated for C21H32N2O5: 
393.2389 ([M+H]+), found 393.2401 ([M+H]+), 415.2222 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.35-7.21 (m, 10H), 5.30 (s, 3H), 5.08 (s, 2H), 4.51-4.50 (m, 
1H), 4.45 (q, 1H, J=8 Hz), 3.10 (d, 2H, J=4 Hz), 1.44 (s, 9H), 1.43-1.27 (m, 2H), 0.88 (d, 6H, 
J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.77, 170.42, 136.39, 129.28, 128.67, 
128.51, 127.98, 126.96, 81.92, 66.96, 53.47, 51.43, 41.62, 38.76, 27.96, 24.67, 22.70, 
21.99 ppm; HRMS (ESI) calculated for C27H36N2O5: 469.7207 ([M+H]
+), found 469.2709 
([M+H]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-3-
phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.28-7.19 (m, 6H), 7.17-7.11 (m, 7H), 6.97-6.94 (m, 2H), 
6.19 (d, 1H, J=7.5 Hz), 5.17 (d, 1H, J=7.5 Hz), 5.01 (s, 2H), 4.58 (q, 1H, J1=7.5 Hz, J2=5 Hz), 
4.33 (q, 1H, J=7.5 Hz,), 2.99 (d, 2H, J=7.5 Hz), 2.95 (d, 2H, J=7.5 Hz), 1.29 (s, 9H) ppm; 13C-
NMR (100.62 MHz, CDCl3) δ 175.48, 170.06, 158.07, 135.89, 133.46, 129.47, 129.35, 
128.70, 128.33, 128.03, 127.08, 126.95, 82.44, 53.64, 44.40, 38.09, 27.91 ppm; HRMS (ESI) 
calculated for for C30H34N2O5: 503.2546 ([M+H]
+), found: 525.2277 ([M+Na]+). 
(S)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-3-
methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.36-7.24 (m, 10H), 5.11 (d, 2H,  J=8 Hz,), 5.12 (s, 2H), 4.64 
(d, 1H, J=8 Hz), 3.11 (d,  2H,  J=8 Hz), 2.05-2.01 (m, 1H), 1.46 (s, 9H), 0.78 (t, 6H, J=8 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 187.62, 181.00, 170.59, 159.03, 153.00, 129.23, 
128.80, 128.54, 128.07, 95.83, 49.49, 40.52, 31.30, 28.07, 17.53 ppm; HRMS (ESI) 
calculated for C26H34N2O5: 455.2546 ([M+H]
+), found: 455.2465 ([M+H]+) and 477.2285 
([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-3-
methylbutanoate  
Stereocontrolled 11C-Alkylation of Dipeptides 
119 
 
1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.35 (m, 6H), 7.28-7.19 (m, 4H), 6.33 (d, 1H, J=8 Hz), 
5.36 (d, 1H,  J=8 Hz,), 5.12 (s, 2H), 4.48 (d, 1H, J=8 Hz), 4.38-4.35 (m, 1H), 3.49 (q, 1H,  J1=8 
Hz, J2=4 Hz), 3.11 (d, 1H, J=8 Hz), 2.12-2.07 (m, 1H), 1.47 (s, 9H), 0.88 (d, 6H, J=8 Hz) ppm;
 
13C-NMR (100.62 MHz, CDCl3) δ 176.77, 176.44, 152.68, 135.82, 129.47, 129.31, 128.76, 
128.54, 128.38, 128.04, 127.00, 95.83, 67.90, 66.57, 55.65, 53.43, 38.26, 38.07 ppm; 
HRMS (ESI) calculated for C26H34N2O5: 455.2546 ([M+H]
+), found: 455.2465 ([M+H]+) and 
477.2285 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido) propanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.39-7.19 (m, 10H), 6.35 (d,  1H,  J=4 Hz), 5.31 (d, 1H, J=8 
Hz),  5.11 (s, 2H), 4.46-4.41 (m, 1H), 4.39-4.34 (m, 1H), 3.17 (dd, 1H, J=8 Hz), 3.07 (dd, 1H, 
J=8 Hz), 1.46 (s, 9H), 1.31 (d, 3H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.02, 
129.34, 128.19, 128.05, 99.99, 77.36, 77.04, 76.72, 56.05, 54.08, 48.78, 36.65, 27.93, 
27.96, 18.59 ppm; HRMS (ESI) calculated for C24H30N2O5: 427.2233 ([M+H]
+), found: 
449.1983 ([M+Na]+). 
(R)-tert-butyl 2-(2-aminoacetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 5H), 5.16 (s, 2H), 4.50 (dd, 1H, J=5 Hz), 3.96-
3.92 (m, 2H), 2.21-2.13 (m, 1H), 1.48 (s, 9H), 0.95 (dd, 6H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 176.28, 170.87, 163.81, 135.10, 128.55, 82.23, 67.19, 57.36, 44.58, 31.46, 
28.04, 18.87, 17.57 ppm; HRMS (ESI) calculated for C19H28N2O5: 365.2076 ([M+H]
+), found 
365.2059 ([M+H]+), 387.1884 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.36-7.30 (m, 5H), 5.13 (s, 2H), 4.45 (dd, 1H, J=4 Hz), 4.32-
4.29 (m, 1H), 2.19-2.13 (m, 1H), 1.48 (s, 9H), 1.42 (d, 3H, J=8 Hz), 0.93 (t, 6H, J=8 Hz) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 185.99, 180.11, 172.00, 170.73, 143.21, 137.24, 128.52, 
128.15, 128.06, 96.08, 82.09, 67.00, 57.45, 31.37, 28.04, 18.66, 17.52 ppm; HRMS (ESI) 
calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 379.2210 ([M+H]+), 401.2033 
([M+Na]+). 
Procedure for the deprotection of the Cbz-group 
The amine protection group was removed with Pd/C in methanol by bubbling through 
hydrogen for 2-4 hours.  The Pd/C mixture was filtrated over celite and the organic solvent 
evaporated to dryness. The obtained crude product was analyzed by TLC (coloring with 
ninhydrin), flash silica purification was performed with methanol-dichloromethane (1-10 
% methanol) and the reaction was quantitative yielding clear oil. 
(S)-tert-butyl 2-(2-aminopropanamido)propanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.31 (q, 1H, J=7.5 Hz), 3.31 (s, 2H), 1.49 (s, 9H), 1.40 (d, 
3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CD3OD) δ 177.99, 173.79, 83.00, 51.47, 50.43, 
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ppm; 13C-NMR (100.62 MHz, CDCl3) δ 175.11, 171.98, 168.51, 148.70, 142.86, 128.54, 
128.22, 128.08, 95.80, 82.12, 77.39, 67.17, 51.35, 44.46, 41.81, 27.98, 24.90, 22.78, 22.07 
ppm; HRMS (ESI) calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 379.2240 ([M+H]+), 
401.2062 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-4-methylpentanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.36-7.33 (m, 5H), 5.13 (s, 2H), 4.53 (q, 1H, J=8 Hz), 4.32-
4.30 (m, 1H), 1.64-1.61 (m, 2H), 1.47 (s, 9H), 1.42 (d, 3H, J=8 Hz), 0.95 (d, 6H, J=4 Hz) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 171.92, 164.82, 136.33, 128.54, 128.18, 128.06, 67.02, 
51.35, 41.75, 27.99, 24.95, 22.82, 22.08 ppm; HRMS (ESI) calculated for C21H32N2O5: 
393.2389 ([M+H]+), found 393.2401 ([M+H]+), 415.2222 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.35-7.21 (m, 10H), 5.30 (s, 3H), 5.08 (s, 2H), 4.51-4.50 (m, 
1H), 4.45 (q, 1H, J=8 Hz), 3.10 (d, 2H, J=4 Hz), 1.44 (s, 9H), 1.43-1.27 (m, 2H), 0.88 (d, 6H, 
J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.77, 170.42, 136.39, 129.28, 128.67, 
128.51, 127.98, 126.96, 81.92, 66.96, 53.47, 51.43, 41.62, 38.76, 27.96, 24.67, 22.70, 
21.99 ppm; HRMS (ESI) calculated for C27H36N2O5: 469.7207 ([M+H]
+), found 469.2709 
([M+H]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-3-
phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.28-7.19 (m, 6H), 7.17-7.11 (m, 7H), 6.97-6.94 (m, 2H), 
6.19 (d, 1H, J=7.5 Hz), 5.17 (d, 1H, J=7.5 Hz), 5.01 (s, 2H), 4.58 (q, 1H, J1=7.5 Hz, J2=5 Hz), 
4.33 (q, 1H, J=7.5 Hz,), 2.99 (d, 2H, J=7.5 Hz), 2.95 (d, 2H, J=7.5 Hz), 1.29 (s, 9H) ppm; 13C-
NMR (100.62 MHz, CDCl3) δ 175.48, 170.06, 158.07, 135.89, 133.46, 129.47, 129.35, 
128.70, 128.33, 128.03, 127.08, 126.95, 82.44, 53.64, 44.40, 38.09, 27.91 ppm; HRMS (ESI) 
calculated for for C30H34N2O5: 503.2546 ([M+H]
+), found: 525.2277 ([M+Na]+). 
(S)-tert-butyl 2-((R)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-3-
methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.36-7.24 (m, 10H), 5.11 (d, 2H,  J=8 Hz,), 5.12 (s, 2H), 4.64 
(d, 1H, J=8 Hz), 3.11 (d,  2H,  J=8 Hz), 2.05-2.01 (m, 1H), 1.46 (s, 9H), 0.78 (t, 6H, J=8 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 187.62, 181.00, 170.59, 159.03, 153.00, 129.23, 
128.80, 128.54, 128.07, 95.83, 49.49, 40.52, 31.30, 28.07, 17.53 ppm; HRMS (ESI) 
calculated for C26H34N2O5: 455.2546 ([M+H]
+), found: 455.2465 ([M+H]+) and 477.2285 
([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-3-
methylbutanoate  
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1H-NMR (400.13 MHz, CDCl3) δ 7.37-7.35 (m, 6H), 7.28-7.19 (m, 4H), 6.33 (d, 1H, J=8 Hz), 
5.36 (d, 1H,  J=8 Hz,), 5.12 (s, 2H), 4.48 (d, 1H, J=8 Hz), 4.38-4.35 (m, 1H), 3.49 (q, 1H,  J1=8 
Hz, J2=4 Hz), 3.11 (d, 1H, J=8 Hz), 2.12-2.07 (m, 1H), 1.47 (s, 9H), 0.88 (d, 6H, J=8 Hz) ppm;
 
13C-NMR (100.62 MHz, CDCl3) δ 176.77, 176.44, 152.68, 135.82, 129.47, 129.31, 128.76, 
128.54, 128.38, 128.04, 127.00, 95.83, 67.90, 66.57, 55.65, 53.43, 38.26, 38.07 ppm; 
HRMS (ESI) calculated for C26H34N2O5: 455.2546 ([M+H]
+), found: 455.2465 ([M+H]+) and 
477.2285 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido) propanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.39-7.19 (m, 10H), 6.35 (d,  1H,  J=4 Hz), 5.31 (d, 1H, J=8 
Hz),  5.11 (s, 2H), 4.46-4.41 (m, 1H), 4.39-4.34 (m, 1H), 3.17 (dd, 1H, J=8 Hz), 3.07 (dd, 1H, 
J=8 Hz), 1.46 (s, 9H), 1.31 (d, 3H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.02, 
129.34, 128.19, 128.05, 99.99, 77.36, 77.04, 76.72, 56.05, 54.08, 48.78, 36.65, 27.93, 
27.96, 18.59 ppm; HRMS (ESI) calculated for C24H30N2O5: 427.2233 ([M+H]
+), found: 
449.1983 ([M+Na]+). 
(R)-tert-butyl 2-(2-aminoacetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.39-7.37 (m, 5H), 5.16 (s, 2H), 4.50 (dd, 1H, J=5 Hz), 3.96-
3.92 (m, 2H), 2.21-2.13 (m, 1H), 1.48 (s, 9H), 0.95 (dd, 6H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 176.28, 170.87, 163.81, 135.10, 128.55, 82.23, 67.19, 57.36, 44.58, 31.46, 
28.04, 18.87, 17.57 ppm; HRMS (ESI) calculated for C19H28N2O5: 365.2076 ([M+H]
+), found 
365.2059 ([M+H]+), 387.1884 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.36-7.30 (m, 5H), 5.13 (s, 2H), 4.45 (dd, 1H, J=4 Hz), 4.32-
4.29 (m, 1H), 2.19-2.13 (m, 1H), 1.48 (s, 9H), 1.42 (d, 3H, J=8 Hz), 0.93 (t, 6H, J=8 Hz) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 185.99, 180.11, 172.00, 170.73, 143.21, 137.24, 128.52, 
128.15, 128.06, 96.08, 82.09, 67.00, 57.45, 31.37, 28.04, 18.66, 17.52 ppm; HRMS (ESI) 
calculated for C20H30N2O5: 379.2233 ([M+H]
+), found 379.2210 ([M+H]+), 401.2033 
([M+Na]+). 
Procedure for the deprotection of the Cbz-group 
The amine protection group was removed with Pd/C in methanol by bubbling through 
hydrogen for 2-4 hours.  The Pd/C mixture was filtrated over celite and the organic solvent 
evaporated to dryness. The obtained crude product was analyzed by TLC (coloring with 
ninhydrin), flash silica purification was performed with methanol-dichloromethane (1-10 
% methanol) and the reaction was quantitative yielding clear oil. 
(S)-tert-butyl 2-(2-aminopropanamido)propanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.31 (q, 1H, J=7.5 Hz), 3.31 (s, 2H), 1.49 (s, 9H), 1.40 (d, 
3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CD3OD) δ 177.99, 173.79, 83.00, 51.47, 50.43, 
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28.55, 21.69, 17.88 ppm; HRMS (ESI) calculated for C10H20N2O3: 217.1552 ([M+H]
+), found 
217.1557 ([M+H]+), 239.1363 ([M+Na]+). 
(S)-tert-butyl 2-(2-aminoacetamido)propanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.37 (q, 1H, J=7.5 Hz), 3.50 (q, 1H, J=7.5 Hz), 1.48 (s, 9H), 
1.37 (d, 3H, J=5 Hz), 1.31 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.32, 
172.10, 81.92, 48.17, 44.56, 27.96, 18.68 ppm; HRMS (ESI) calculated for C9H18N2O3: 
203.1396 ([M+H]+), found 203.1400.13 ([M+H]+), 225.1209 ([M+Na]+).  
(S)-tert-butyl 2-(2-aminoacetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.28 (d, 1H, J=5 Hz), 3.37 (s, 2H), 2.18 (m, 1H), 1.50 (s, 
9H), 1.00 (dd, 6H, J=2.5 Hz) ppm, 13C-NMR (100.62 MHz, CDCl3) δ 172.67, 171.14, 81.79, 
56.87, 44.76, 31.40, 28.04, 19.98, 17.60 ppm; HRMS (ESI) calculated for C11H22N2O3: 
231.1709 ([M+H]+), found 231.1707 ([M+H]+), 253.1513 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-aminopropanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CD3OD) δ 7.27 (m, 5H), 4.60 (dd, 1H, J1=5 Hz, J2=2.5 Hz), 3.47 (q, 1H, 
J=7.5 Hz), 3.17 (dd, 1H, J=7.5 Hz), 3.05 (dd, 1H, J=7.5 Hz) 1.43 (s, 9H), 1.26 (d, 3H, J=7.5 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 174.77, 170.34, 135.90, 129.08, 127.84, 126.42, 
81.69, 52.61, 50.25, 37.77, 27.52, 21.14 ppm; HRMS (ESI) calculated for C16H24N2O3: 
292.373 ([M+H]+), found 293.19 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-aminopropanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.43 (d, 1H, J=5 Hz), 3.56 (q, 1H, J=7.5 Hz), 2.16 (m, 1H, 
J=2.5 Hz), 1.46 (s, 9H), 1.29 (d, 3H, J=7.5 Hz), 0.97 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CD3Cl) δ 175.61, 171.20, 104.30, 56.79, 50.92, 31.42, 28.04, 21.93, 18.98, 17.50 ppm; 
HRMS (ESI) calculated for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1821 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-aminopropanamido)-3-methylbutanoate  
 1H-NMR (250.13 MHz, CD3OD) δ 4.42 (d, 1H, J=5 Hz), 3.54 (q, 1H, J=7.5 Hz), 2.16 (m, 1H, 
J=2.5 Hz), 1.46 (s, 9H), 1.29 (d, 3H, J=7.5 Hz), 0.97 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CD3Cl) δ 175.61, 171.20, 104.30, 56.79, 50.92, 31.42, 28.04, 21.93, 18.98, 17.50 ppm; 
HRMS (ESI) calculated for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1821 ([M+H]+). 
 (R)-tert-butyl 2-(2-aminoacetamido)-3-phenylpropanoate  
 1H-NMR (400.13 MHz, CDCl3) δ 7.33 (m, 5H), 4.80 (q, 1H, J=8 Hz), 3.81 (q, 2H, J=12 Hz), 
3.15 (d, 2H, J=8 Hz), 1.41 (s, 9H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 192.35, 185.75, 
171.06, 169.46, 136.69, 129.81, 128.63, 127.10, 82.57, 54.30, 43.19, 38.31, 28.19; HRMS 
(ESI) calculated for C15H22N2O3: 279.1709 ([M+H]
+), found 279.1695 ([M+H]+). 
(R)-tert-butyl 2-(2-aminoacetamido)propanoate  
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 1H-NMR (400.13 MHz, CDCl3) δ 4.52 (q, 1H, J=8 Hz), 3.35 (s, 1H), 1.46 (s, 9H), 1.39 (d, 3H, 
J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.30, 165.02, 81.87, 48.11, 44.71, 27.94, 
18.71 ppm; HRMS (ESI) calculated for C9H18N2O3: 203.1396 ([M+H]
+), found 203.1404 
([M+H]+).  
(R)-tert-butyl 2-((R)-2-aminopropanamido)-3-phenylpropanoate  
 1H-NMR (400.13 MHz, CDCl3) δ 7.28 (m, 5H), 7.18 (m, 2H), 4.75 (q, 1H, J=8 Hz), 3.53 (q, 1H, 
J=4 Hz), 3.11 (m, 2H), 1.41 (s, 9H), 1.28 (d, 3H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) 
δ 175.03, 170.77, 136.29, 129.50, 128.30, 126.88, 82.22, 53.14, 50.60, 38.14, 27.94, 21.33 
ppm; HRMS (ESI) calculated for C16H24N2O3: 293.1685 ([M+H]
+), found 293.1858 ([M+H]+). 
(R)-tert-butyl 2-((R)-2-aminopropanamido)propanoate  
1H-NMR (400.13 MHz, CDCl3) δ 8.32 (s, 1H), 4.31 (q, 1H, J=7.5 Hz), 3.31 (q, 1H, J=7.5 Hz), 
1.49 (s, 9H), 1.40 (d, 6H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CD3OD) δ 171.61, 169.64, 
81.77, 49.48, 34.43, 27.96, 17.82, 17.36 ppm; HRMS (ESI) calculated for C10H20N2O3: 
217.1552 ([M+H]+), found 217.1557 ([M+H]+), 239.1363 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-aminopropanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.27 (m, 5H), 4.60 (dd, 1H, J1=5 Hz, J2=2.5 Hz), 3.47 (q, 1H, 
J=7.5 Hz), 3.17 (dd, 1H, J=7.5 Hz), 3.05 (dd, 1H, J=7.5 Hz) 1.43 (s, 9H), 1.26 (d, 3H, J=7.5 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.14, 169.72, 136.26, 129.61, 128.38, 126.83, 
82.16, 54.92, 49.64, 48.20, 27.88, 17.78 ppm; HRMS (ESI) calculated for C16H24N2O3: 
293.1865 ([M+H]+), found 293.1842 ([M+H]+). 
(S)-tert-butyl 2-(2-amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 4.57-4.51 (m, 1H, J=8 Hz), 3.47 (s, 1H), 3.37 (s, 2H), 1.63-
1.61 (m, 2H), 1.47 (s, 9H), 0.96 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 
172.29, 157.72, 81.75, 50.84, 44.71, 41.90, 27.99, 27.98, 24.97, 22.15, 22.07 ppm; HRMS 
(ESI) calculated for C12H24N2O3: 244.1787 ([M+H]
+), found 245.1861 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-aminopropanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CD3OD) δ 4.43 (q, 1H, J=4 Hz), 3.58-3.56 (m, 1H), 2.21-2.16 (m, 1H), 
1.48 (s, 9H), 1.38 (d, 3H, J=8 Hz), 0.97 (dd, 6H, J1=4 Hz, J2=8 Hz) ppm; 
13C-NMR (100.62 
MHz, CD3Cl) δ 175.61, 171.20, 104.30, 56.79, 50.92, 31.42, 28.04, 21.93, 18.98, 17.50 ppm; 
HRMS (ESI) calculated for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1821 ([M+H]+). 
(R)-tert-butyl 2-(2-aminoacetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.49 (q, 1H, J=4 Hz), 3.43 (s, 2H), 2.24-2.16 (m, 1H), 1.48 
(s, 9H), 0.97 (t, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 178.19, 176.18, 108.63, 
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28.55, 21.69, 17.88 ppm; HRMS (ESI) calculated for C10H20N2O3: 217.1552 ([M+H]
+), found 
217.1557 ([M+H]+), 239.1363 ([M+Na]+). 
(S)-tert-butyl 2-(2-aminoacetamido)propanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.37 (q, 1H, J=7.5 Hz), 3.50 (q, 1H, J=7.5 Hz), 1.48 (s, 9H), 
1.37 (d, 3H, J=5 Hz), 1.31 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.32, 
172.10, 81.92, 48.17, 44.56, 27.96, 18.68 ppm; HRMS (ESI) calculated for C9H18N2O3: 
203.1396 ([M+H]+), found 203.1400.13 ([M+H]+), 225.1209 ([M+Na]+).  
(S)-tert-butyl 2-(2-aminoacetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.28 (d, 1H, J=5 Hz), 3.37 (s, 2H), 2.18 (m, 1H), 1.50 (s, 
9H), 1.00 (dd, 6H, J=2.5 Hz) ppm, 13C-NMR (100.62 MHz, CDCl3) δ 172.67, 171.14, 81.79, 
56.87, 44.76, 31.40, 28.04, 19.98, 17.60 ppm; HRMS (ESI) calculated for C11H22N2O3: 
231.1709 ([M+H]+), found 231.1707 ([M+H]+), 253.1513 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-aminopropanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CD3OD) δ 7.27 (m, 5H), 4.60 (dd, 1H, J1=5 Hz, J2=2.5 Hz), 3.47 (q, 1H, 
J=7.5 Hz), 3.17 (dd, 1H, J=7.5 Hz), 3.05 (dd, 1H, J=7.5 Hz) 1.43 (s, 9H), 1.26 (d, 3H, J=7.5 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 174.77, 170.34, 135.90, 129.08, 127.84, 126.42, 
81.69, 52.61, 50.25, 37.77, 27.52, 21.14 ppm; HRMS (ESI) calculated for C16H24N2O3: 
292.373 ([M+H]+), found 293.19 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-aminopropanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.43 (d, 1H, J=5 Hz), 3.56 (q, 1H, J=7.5 Hz), 2.16 (m, 1H, 
J=2.5 Hz), 1.46 (s, 9H), 1.29 (d, 3H, J=7.5 Hz), 0.97 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CD3Cl) δ 175.61, 171.20, 104.30, 56.79, 50.92, 31.42, 28.04, 21.93, 18.98, 17.50 ppm; 
HRMS (ESI) calculated for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1821 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-aminopropanamido)-3-methylbutanoate  
 1H-NMR (250.13 MHz, CD3OD) δ 4.42 (d, 1H, J=5 Hz), 3.54 (q, 1H, J=7.5 Hz), 2.16 (m, 1H, 
J=2.5 Hz), 1.46 (s, 9H), 1.29 (d, 3H, J=7.5 Hz), 0.97 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CD3Cl) δ 175.61, 171.20, 104.30, 56.79, 50.92, 31.42, 28.04, 21.93, 18.98, 17.50 ppm; 
HRMS (ESI) calculated for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1821 ([M+H]+). 
 (R)-tert-butyl 2-(2-aminoacetamido)-3-phenylpropanoate  
 1H-NMR (400.13 MHz, CDCl3) δ 7.33 (m, 5H), 4.80 (q, 1H, J=8 Hz), 3.81 (q, 2H, J=12 Hz), 
3.15 (d, 2H, J=8 Hz), 1.41 (s, 9H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 192.35, 185.75, 
171.06, 169.46, 136.69, 129.81, 128.63, 127.10, 82.57, 54.30, 43.19, 38.31, 28.19; HRMS 
(ESI) calculated for C15H22N2O3: 279.1709 ([M+H]
+), found 279.1695 ([M+H]+). 
(R)-tert-butyl 2-(2-aminoacetamido)propanoate  
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 1H-NMR (400.13 MHz, CDCl3) δ 4.52 (q, 1H, J=8 Hz), 3.35 (s, 1H), 1.46 (s, 9H), 1.39 (d, 3H, 
J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.30, 165.02, 81.87, 48.11, 44.71, 27.94, 
18.71 ppm; HRMS (ESI) calculated for C9H18N2O3: 203.1396 ([M+H]
+), found 203.1404 
([M+H]+).  
(R)-tert-butyl 2-((R)-2-aminopropanamido)-3-phenylpropanoate  
 1H-NMR (400.13 MHz, CDCl3) δ 7.28 (m, 5H), 7.18 (m, 2H), 4.75 (q, 1H, J=8 Hz), 3.53 (q, 1H, 
J=4 Hz), 3.11 (m, 2H), 1.41 (s, 9H), 1.28 (d, 3H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) 
δ 175.03, 170.77, 136.29, 129.50, 128.30, 126.88, 82.22, 53.14, 50.60, 38.14, 27.94, 21.33 
ppm; HRMS (ESI) calculated for C16H24N2O3: 293.1685 ([M+H]
+), found 293.1858 ([M+H]+). 
(R)-tert-butyl 2-((R)-2-aminopropanamido)propanoate  
1H-NMR (400.13 MHz, CDCl3) δ 8.32 (s, 1H), 4.31 (q, 1H, J=7.5 Hz), 3.31 (q, 1H, J=7.5 Hz), 
1.49 (s, 9H), 1.40 (d, 6H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CD3OD) δ 171.61, 169.64, 
81.77, 49.48, 34.43, 27.96, 17.82, 17.36 ppm; HRMS (ESI) calculated for C10H20N2O3: 
217.1552 ([M+H]+), found 217.1557 ([M+H]+), 239.1363 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-aminopropanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.27 (m, 5H), 4.60 (dd, 1H, J1=5 Hz, J2=2.5 Hz), 3.47 (q, 1H, 
J=7.5 Hz), 3.17 (dd, 1H, J=7.5 Hz), 3.05 (dd, 1H, J=7.5 Hz) 1.43 (s, 9H), 1.26 (d, 3H, J=7.5 Hz) 
ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.14, 169.72, 136.26, 129.61, 128.38, 126.83, 
82.16, 54.92, 49.64, 48.20, 27.88, 17.78 ppm; HRMS (ESI) calculated for C16H24N2O3: 
293.1865 ([M+H]+), found 293.1842 ([M+H]+). 
(S)-tert-butyl 2-(2-amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 4.57-4.51 (m, 1H, J=8 Hz), 3.47 (s, 1H), 3.37 (s, 2H), 1.63-
1.61 (m, 2H), 1.47 (s, 9H), 0.96 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 
172.29, 157.72, 81.75, 50.84, 44.71, 41.90, 27.99, 27.98, 24.97, 22.15, 22.07 ppm; HRMS 
(ESI) calculated for C12H24N2O3: 244.1787 ([M+H]
+), found 245.1861 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-aminopropanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CD3OD) δ 4.43 (q, 1H, J=4 Hz), 3.58-3.56 (m, 1H), 2.21-2.16 (m, 1H), 
1.48 (s, 9H), 1.38 (d, 3H, J=8 Hz), 0.97 (dd, 6H, J1=4 Hz, J2=8 Hz) ppm; 
13C-NMR (100.62 
MHz, CD3Cl) δ 175.61, 171.20, 104.30, 56.79, 50.92, 31.42, 28.04, 21.93, 18.98, 17.50 ppm; 
HRMS (ESI) calculated for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1821 ([M+H]+). 
(R)-tert-butyl 2-(2-aminoacetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CD3OD) δ 4.49 (q, 1H, J=4 Hz), 3.43 (s, 2H), 2.24-2.16 (m, 1H), 1.48 
(s, 9H), 0.97 (t, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 178.19, 176.18, 108.63, 
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90.35, 73.19, 56.98, 56.78, 44.76, 31.41, 28.06, 19.00, 17.63 ppm; HRMS (ESI) calculated 
for C11H22N2O3: 231.1709 ([M+H]
+), found 231.1707 ([M+H]+), 253.1513 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-aminopropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 4.51 (q, 1H, J=8 Hz), 3.55 (q, 1H, J=8 Hz), 3.49 (s, 2H), 1.66-
1.64 (m, 2H), 1.47 (s, 9H), 1.35 (d, 3H, J=8 Hz), 0.96 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 172.34, 169.32, 81.65, 50.87, 50.77, 41.68, 28.01, 25.01, 22.88, 22.13, 21.76 
ppm; HRMS (ESI) calculated for C13H26N2O3: 259.2022 ([M+H]
+), found 259.2014 ([M+H]+), 
275.2357 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.35-7.22 (m, 5H), 4.41-4.39 (m, 1H), 4.33 (q, 1H, J=4 Hz), 
3.28 (d, 2H, J=4 Hz), 163-1.55 (m, 3H), 1.44 (s, 9H), 0.90 (d, 6H, J=8 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 171.63, 169.02, 134.73, 129.89, 128.81, 127.42, 81.94, 54.85, 52.20, 
40.87, 37.75, 27.96, 27.94, 24.74, 22.57, 22.14 ppm; HRMS (ESI) calculated for C19H30N2O3: 
335.2335 ([M+H]+), found 335.2333 ([M+H]+). 
(R)-tert-butyl 2-(2-aminoacetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.54 (d, 1H, J=8 Hz), 4.46 (q, 1H, J=8 Hz), 3.34 (s, 2H),  1.66-
1.46 (m, 3H), 1.41 (s, 9H), 0.90 (t, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.31, 
81.96, 51.06, 50.14, 44.15, 41.48, 27.88, 24.87, 22.74, 21.89 ppm; HRMS (ESI) calculated 
for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1880 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-aminopropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 4.51 (q, 1H, J=8 Hz), 3.55 (q, 1H, J=8 Hz), 3.49 (s, 2H), 1.66-
1.64 (m, 2H), 1.47 (s, 9H), 1.35 (d, 3H, J=8 Hz), 0.96 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 172.34, 169.32, 81.65, 50.87, 50.77, 41.68, 28.01, 25.01, 22.88, 22.13, 21.76 
ppm; HRMS (ESI) calculated for C13H26N2O3: 259.2022 ([M+H]
+), found 259.2039 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3+MeOD) δ 7.10-7.02 (m, 5H), 3.95-3.88 (m, 2H), 3,15 (m, 1H), 
3.01-2.98 (m, 1H), 2.97-2.82 (m, 1H), 1.22 (s, 9H), 1.19-1.11 (m, 2H), 0.60 (d, 3H, J=8 Hz),  
0.53 (d, 3H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.31, 169.67, 133.83, 129.04, 
128.57, 127.29, 123.82, 94.95, 54.16, 51.38, 43.17, 39.68, 37.03, 27.35, 24.04, 22.30, 
20.82 ppm; HRMS (ESI) calculated for C19H30N2O3: 335.2335 ([M+H]
+), found 335.2339 
([M+H]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido) propanoate  
1H-NMR (250.13 MHz, (CD3)2SO) δ 8.19 (d, 1H, J=7.5 Hz,), 7.25-7.17 (m, 5H), 4.12 (q, 1H, 
J=5 Hz), 3.40 (q, 1H, J=5 Hz), 2.94 (dd, 1H, J1=5Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 
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Hz), 1.37 (s, 9H), 1.22 (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, (CD3)2SO) δ 174.68, 
172.27, 138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 
ppm; HRMS (ESI) calculated for C16H24N2O3: 293.1865 ([M+H]
+), found: 293.2087 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, (CD3)2SO) δ 8.04 (d, 1H, J=10 Hz), 7.27-7.16 (m, 5H), 4.06 (q, 1H, J=5 
Hz), 3.49-3.45 (m, 1H), 2.95 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.60 (q, 1H, J1=10Hz, J2=5 Hz), 1.99 
(q, 1H , J1=7.5 Hz, J2=5 Hz), 1.38 (s, 9H), 0.82 (d, 6H, J=5 Hz) ppm;
 13C-NMR (100.62 MHz, 
(CD3)2SO) δ 174.91, 174.89, 138.85, 129.82, 128.55, 126.60, 81.89, 57.79, 56.08, 39.14, 
30.84, 28.07, 19.26, 18.35 ppm; HRMS (ESI) calculated for C18H28N2O3: 321.2178 ([M+H]
+), 
found: 321.2104 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, (CD3)2SO) δ 8.18 (d, 1H, J=8 Hz), 7.29-7.20 (m, 8H), 7.15-7.14 (m, 
2H), 4.44 (q, 1H, J=8 Hz), 4.03 (q, 1H, J1=8 Hz, J2=4 Hz), 2.94 (d, 2H, J=4 Hz), 2,90 (d, 1H, J=4 
Hz), 2.57 (q, 1H, J=8 Hz), 1.33 (s, 9H) ppm; 13C-NMR (100.62 MHz, (CD3)2SO) δ 174.52, 
170.88, 138.94, 137.34, 129.84, 128.62, 127.01, 126.60, 81.36, 56.21, 53.92, 41.15, 37.68, 
27.99 ppm; HRMS (ESI) calculated for C22H28N2O3: 369.2178 ([M+H]
+), found: 369.2111 
([M+H]+). 
(S)-tert-butyl 2-((R)-2-amino-3-phenylpropanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, (CD3)2SO) δ 8.04 (d, 1H, J=10 Hz), 7.27-7.16 (m, 5H), 4.06 (q, 1H, J=5 
Hz), 3.49-3.45 (m, 1H), 2.95 (dd, 1H, J1=5Hz, J2=7.5 Hz), 2.60 (q, 1H , J1=10 Hz, J2=5 Hz), 1.99 
(q, 1H , J1=7.5 Hz, J2=5 Hz), 1.38 (s, 9H), 0.82 (d, 6H, J=5 Hz) ppm;
 13C-NMR (100.62 MHz, 
(CD3)2SO) δ 174.91, 174.89, 138.85, 129.82, 128.55, 126.60, 81.89, 57.79, 56.08, 39.14, 
30.84, 28.07, 19.26, 18.35 ppm; HRMS (ESI) calculated for C18H28N2O3: 321.2178 ([M+H]
+), 
found: 321.2104 ([M+H]+). 
Procedure for the activation of dipeptides as Schiff base 
After the deprotection of the Cbz-group, the reaction with benzophenone imine to the 
protected dipeptide took place in dichloromethane with 1.1 eq of benzophenone imine at 
room temperature for 2-4 hours. The progress of the reaction was followed with TLC. The 
solvent was evaporated and the residue purified via flash chromatograghy (2-30% 
ethylacetate in n-hexane). The isolated product is either white solid or clear oil and 
yielded around 50-70% of pure product. 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.10 (dd, 2H, J=5 Hz), 4.43 (q, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 1.40 (d, 3H, J=10 Hz), 1.39 (s, 9H), 1.27 (d, 3H, J=5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 173.64, 171.94, 168.97, 139.20, 135.76, 130.54, 128.78, 128.70, 128.57, 
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90.35, 73.19, 56.98, 56.78, 44.76, 31.41, 28.06, 19.00, 17.63 ppm; HRMS (ESI) calculated 
for C11H22N2O3: 231.1709 ([M+H]
+), found 231.1707 ([M+H]+), 253.1513 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-aminopropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 4.51 (q, 1H, J=8 Hz), 3.55 (q, 1H, J=8 Hz), 3.49 (s, 2H), 1.66-
1.64 (m, 2H), 1.47 (s, 9H), 1.35 (d, 3H, J=8 Hz), 0.96 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 172.34, 169.32, 81.65, 50.87, 50.77, 41.68, 28.01, 25.01, 22.88, 22.13, 21.76 
ppm; HRMS (ESI) calculated for C13H26N2O3: 259.2022 ([M+H]
+), found 259.2014 ([M+H]+), 
275.2357 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.35-7.22 (m, 5H), 4.41-4.39 (m, 1H), 4.33 (q, 1H, J=4 Hz), 
3.28 (d, 2H, J=4 Hz), 163-1.55 (m, 3H), 1.44 (s, 9H), 0.90 (d, 6H, J=8 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 171.63, 169.02, 134.73, 129.89, 128.81, 127.42, 81.94, 54.85, 52.20, 
40.87, 37.75, 27.96, 27.94, 24.74, 22.57, 22.14 ppm; HRMS (ESI) calculated for C19H30N2O3: 
335.2335 ([M+H]+), found 335.2333 ([M+H]+). 
(R)-tert-butyl 2-(2-aminoacetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.54 (d, 1H, J=8 Hz), 4.46 (q, 1H, J=8 Hz), 3.34 (s, 2H),  1.66-
1.46 (m, 3H), 1.41 (s, 9H), 0.90 (t, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.31, 
81.96, 51.06, 50.14, 44.15, 41.48, 27.88, 24.87, 22.74, 21.89 ppm; HRMS (ESI) calculated 
for C12H24N2O3: 245.1865 ([M+H]
+), found 245.1880 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-aminopropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 4.51 (q, 1H, J=8 Hz), 3.55 (q, 1H, J=8 Hz), 3.49 (s, 2H), 1.66-
1.64 (m, 2H), 1.47 (s, 9H), 1.35 (d, 3H, J=8 Hz), 0.96 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 172.34, 169.32, 81.65, 50.87, 50.77, 41.68, 28.01, 25.01, 22.88, 22.13, 21.76 
ppm; HRMS (ESI) calculated for C13H26N2O3: 259.2022 ([M+H]
+), found 259.2039 ([M+H]+). 
(R)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3+MeOD) δ 7.10-7.02 (m, 5H), 3.95-3.88 (m, 2H), 3,15 (m, 1H), 
3.01-2.98 (m, 1H), 2.97-2.82 (m, 1H), 1.22 (s, 9H), 1.19-1.11 (m, 2H), 0.60 (d, 3H, J=8 Hz),  
0.53 (d, 3H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.31, 169.67, 133.83, 129.04, 
128.57, 127.29, 123.82, 94.95, 54.16, 51.38, 43.17, 39.68, 37.03, 27.35, 24.04, 22.30, 
20.82 ppm; HRMS (ESI) calculated for C19H30N2O3: 335.2335 ([M+H]
+), found 335.2339 
([M+H]+). 
(S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido) propanoate  
1H-NMR (250.13 MHz, (CD3)2SO) δ 8.19 (d, 1H, J=7.5 Hz,), 7.25-7.17 (m, 5H), 4.12 (q, 1H, 
J=5 Hz), 3.40 (q, 1H, J=5 Hz), 2.94 (dd, 1H, J1=5Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 
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Hz), 1.37 (s, 9H), 1.22 (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, (CD3)2SO) δ 174.68, 
172.27, 138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 
ppm; HRMS (ESI) calculated for C16H24N2O3: 293.1865 ([M+H]
+), found: 293.2087 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, (CD3)2SO) δ 8.04 (d, 1H, J=10 Hz), 7.27-7.16 (m, 5H), 4.06 (q, 1H, J=5 
Hz), 3.49-3.45 (m, 1H), 2.95 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.60 (q, 1H, J1=10Hz, J2=5 Hz), 1.99 
(q, 1H , J1=7.5 Hz, J2=5 Hz), 1.38 (s, 9H), 0.82 (d, 6H, J=5 Hz) ppm;
 13C-NMR (100.62 MHz, 
(CD3)2SO) δ 174.91, 174.89, 138.85, 129.82, 128.55, 126.60, 81.89, 57.79, 56.08, 39.14, 
30.84, 28.07, 19.26, 18.35 ppm; HRMS (ESI) calculated for C18H28N2O3: 321.2178 ([M+H]
+), 
found: 321.2104 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-amino-3-phenylpropanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, (CD3)2SO) δ 8.18 (d, 1H, J=8 Hz), 7.29-7.20 (m, 8H), 7.15-7.14 (m, 
2H), 4.44 (q, 1H, J=8 Hz), 4.03 (q, 1H, J1=8 Hz, J2=4 Hz), 2.94 (d, 2H, J=4 Hz), 2,90 (d, 1H, J=4 
Hz), 2.57 (q, 1H, J=8 Hz), 1.33 (s, 9H) ppm; 13C-NMR (100.62 MHz, (CD3)2SO) δ 174.52, 
170.88, 138.94, 137.34, 129.84, 128.62, 127.01, 126.60, 81.36, 56.21, 53.92, 41.15, 37.68, 
27.99 ppm; HRMS (ESI) calculated for C22H28N2O3: 369.2178 ([M+H]
+), found: 369.2111 
([M+H]+). 
(S)-tert-butyl 2-((R)-2-amino-3-phenylpropanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, (CD3)2SO) δ 8.04 (d, 1H, J=10 Hz), 7.27-7.16 (m, 5H), 4.06 (q, 1H, J=5 
Hz), 3.49-3.45 (m, 1H), 2.95 (dd, 1H, J1=5Hz, J2=7.5 Hz), 2.60 (q, 1H , J1=10 Hz, J2=5 Hz), 1.99 
(q, 1H , J1=7.5 Hz, J2=5 Hz), 1.38 (s, 9H), 0.82 (d, 6H, J=5 Hz) ppm;
 13C-NMR (100.62 MHz, 
(CD3)2SO) δ 174.91, 174.89, 138.85, 129.82, 128.55, 126.60, 81.89, 57.79, 56.08, 39.14, 
30.84, 28.07, 19.26, 18.35 ppm; HRMS (ESI) calculated for C18H28N2O3: 321.2178 ([M+H]
+), 
found: 321.2104 ([M+H]+). 
Procedure for the activation of dipeptides as Schiff base 
After the deprotection of the Cbz-group, the reaction with benzophenone imine to the 
protected dipeptide took place in dichloromethane with 1.1 eq of benzophenone imine at 
room temperature for 2-4 hours. The progress of the reaction was followed with TLC. The 
solvent was evaporated and the residue purified via flash chromatograghy (2-30% 
ethylacetate in n-hexane). The isolated product is either white solid or clear oil and 
yielded around 50-70% of pure product. 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.10 (dd, 2H, J=5 Hz), 4.43 (q, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 1.40 (d, 3H, J=10 Hz), 1.39 (s, 9H), 1.27 (d, 3H, J=5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 173.64, 171.94, 168.97, 139.20, 135.76, 130.54, 128.78, 128.70, 128.57, 
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128.21, 127.48, 81.70, 61.24, 48.42, 27.99, 20.99, 18.85 ppm; HRMS (ESI) calculated for 
C23H28N2O3: 381.2178 ([M+H]
+), found 381.2167 ([M+H]+), 403.1978 ([M+Na]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.64 (dd, 2H, J=2.5 Hz), 7.38 (m, 6H), 7.09 (dd, 2H, J=2.5 
Hz), 4.52 (q, 1H, J=7.5 Hz), 3.90 (s, 2H), 1.44 (s, 9H), 1.41 (d, 3H, J=7.5 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 172.29, 17092, 139.00, 136.35, 132.68, 130.94, 129.24, 129.13, 
129.52, 127.52, 82.11, 56.80, 48.69, 26.29, 19.23 ppm; HRMS (ESI) calculated for 
C22H26N2O3: 367.2022 ([M+H]
+), found 367.1959  ([M+H]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.49 (dd, 2H, J=2.5 Hz), 7.40 (dd, 4H, J=2.5 Hz), 7.30 (d, 2H, 
J=7.5 Hz), 7.19 (d, 5H, J=2.5 Hz), 7.06 (m, 2H), 4.83-4.76 (m, 1H), 3.90 (s, 2H), 3.10 (d, 2H, 
J=5 Hz), 1.35 (s, 9H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.21, 170.36, 138.96, 136.30, 
130.90, 129.19, 129.09, 128.73, 128.47, 127.48, 82.06, 57.77, 48.64, 28.25, 19.19 ppm; 
HRMS (ESI) calculated for C22H26N2O3: 367.2022 ([M+H]+), found 367.1956 ([M+H]+), 
389.1773 ([M+Na]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.68-7.65 (m, 2H), 7.47-7.47 (m, 8H), 4.58-4.56 (m, 1H), 
4.02-3.99 (m, 2H), 2.27-2.25 (m, 1H), 1.52 (s, 9H), 1.04 (d, 6H, J=7.5 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 170.76, 170.47, 138.73, 136.06, 132.38, 130.62, 130.03, 128.95, 
128.84, 128.23, 127.24, 81.73, 57.12, 56.53, 31.62, 28.08, 27.95, 19.98, 17.79 ppm; HRMS 
(ESI) calculated for C24H30N2O3: 395.2335 ([M+H]
+), found 395.2399 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.73-7.67 (m, 2H), 7.46-7.35 (m, 8H),  4.49 (q, 1H, J=2.5 
Hz), 4.03 (q, 1H, J=5 Hz), 2.29-2.25 (m, 1H), 1.46 (s, 9H), 1.37 (s, 3H), 1.03 (s, 6H) ppm; 13C-
NMR (100.62 MHz, CDCl3) δ 170.03, 166.72, 164.95, 135.26, 131.84, 126.58, 124.75, 
123.55, 77.66, 57.53, 53.08, 27.80, 24.12, 17.37, 15.08, 13.81 ppm; HRMS (ESI) calculated 
for C25H32N2O3: 409.2491 ([M+H]
+), found 409.2426 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.52 (d, 2H, J=2.5 Hz), 7.43-7.39 (m, 3H), 7.37-7.36 (m, 5H), 
7.25-7.23 (m, 3H), 7.19 (s, 2H), 7.06 (dd, 2H, J=5 Hz), 4.77 (d, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 3.11 (d, 2H, J=5 Hz), 1.30 (s, 9H), 1.22 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 186.57, 182.60, 169.33, 155.18, 132.41, 130.48, 129.73, 128.67, 128.39, 
128.13, 127.43, 126.91, 61.14, 59.14, 53.06, 38.28, 27.96, 20.80 ppm; HRMS (ESI) 
calculated for C29H32N2O3: 457.2491 ([M+H]
+), found 457.2421 ([M+H]+), 479.2231 
([M+Na]+). 
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(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.49-7.44 (m, 15H), 4.85 (q, 1H, J=7.5 Hz), 3.99 (s, 2H), 3.19 
(m, 2H), 1.44 (s, 9H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.24, 170.08, 138.67, 136.29, 
136.01, 130.63, 129.61, 128.85, 128.54, 128.16, 127.28, 126.94, 82.09, 56.55, 53.08, 
38.36, 28.00 ppm; HRMS (ESI) calculated for C28H30N2O3: 443.2335 ([M+H]
+), found 
457.2419 ([M+H]+), 479.2235 ([M+Na]+). 
(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)propanoate  
1H-NMR (400.13.13 MHz, CDCl3) δ 7.71 (d, 2H, J=8 Hz), 7.47-7.44 (m, 6H), 7.15 (d, 2H, J=8 
Hz), 4.64 (q, 1H, J=8 Hz), 3.99 (s, 2H), 1.51 (s, 9H), 1.49 (d, 3H, J=8 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 172.21, 170.36, 138.96, 136.30, 130.90, 129.19, 129.09, 128.73, 
128.47, 127.48, 82.06, 57.77, 48.64, 28.25, 19.19 ppm; HRMS (ESI) calculated for 
C22H26N2O3: 367.2022 ([M+H]
+), found 367.1956 ([M+H]+), 389.1773 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-((diphenylmethylene)amino)propanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.62 (d, 1H, J=8 Hz), 7.56 (d, 2H, J=8 Hz), 7.43-7.40 (m, 4H), 
7.32-7.29 (m, 6H), 7.12 (d, 2H, J=8 Hz), 4.83 (q, 1H, J=8 Hz), 3.99 (q, 1H, J=8 Hz), 3.18 (d, 
2H, J=4 Hz), 1.37 (s, 9H), 1.29 (d, 3H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 175.03, 
170.77, 136.29, 129.50, 128.30, 126.88, 82.22, 53.14, 50.60, 38.14, 27.94, 21.33 ppm; 
HRMS (ESI) calculated for C29H32N2O3: 457.2491 ([M+H]
+), found 457.2419 ([M+H]+), 
479.2235 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-((diphenylmethylene)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.10 (dd, 2H, J=5 Hz), 4.43 (quint, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 1.40 (d, 3H, J=10 Hz), 1.39 (s, 9H), 1.27 (d, 3H, J=5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 173.63, 171.90, 168.97, 139.21, 135.77, 130.54, 128.77, 128.70, 128.57, 
128.21, 127.48, 81.70, 61.24, 48.44, 27.96, 20.99, 18.85 ppm; HRMS (ESI) calculated for 
C23H28N2O3: 381.2178 ([M+H]
+), found 381.2167 ([M+H]+), 403.1978 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.52 (d, 2H, J=2.5 Hz), 7.43-7.39 (m, 3H), 7.37-7.33 (m, 5H), 
7.25-7.22 (m, 3H), 7.19 (s, 2H), 7.06 (dd, 2H, J=5 Hz), 4.77 (d, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 3.11 (d, 2H, J=5 Hz), 1.30 (s, 9H), 1.22 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 173.56, 170.27, 168.79, 139.05, 136.29, 135.67, 130.50, 129.77, 128.40, 
128.14, 127.44, 126.93, 61.16,  53.07, 36.28, 27.98, 20.81 ppm; HRMS (ESI) calculated for 
C29H32N2O3: 457.2491 ([M+H]
+), found 457.2421 ([M+H]+), 479.2231 ([M+Na]+). 
(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.71-7.69 (m, 2H), 7.50-7.40 (m, 6H), 7.19-7.17 (m, 2H), 
4.59 (q, 1H, J=8 Hz), 4.03 (d, 2H, J=4 Hz), 2.23-2.13 (m, 1H), 1.52 (s, 9H), 1.04 (d, 6H, J=8 
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128.21, 127.48, 81.70, 61.24, 48.42, 27.99, 20.99, 18.85 ppm; HRMS (ESI) calculated for 
C23H28N2O3: 381.2178 ([M+H]
+), found 381.2167 ([M+H]+), 403.1978 ([M+Na]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.64 (dd, 2H, J=2.5 Hz), 7.38 (m, 6H), 7.09 (dd, 2H, J=2.5 
Hz), 4.52 (q, 1H, J=7.5 Hz), 3.90 (s, 2H), 1.44 (s, 9H), 1.41 (d, 3H, J=7.5 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 172.29, 17092, 139.00, 136.35, 132.68, 130.94, 129.24, 129.13, 
129.52, 127.52, 82.11, 56.80, 48.69, 26.29, 19.23 ppm; HRMS (ESI) calculated for 
C22H26N2O3: 367.2022 ([M+H]
+), found 367.1959  ([M+H]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.49 (dd, 2H, J=2.5 Hz), 7.40 (dd, 4H, J=2.5 Hz), 7.30 (d, 2H, 
J=7.5 Hz), 7.19 (d, 5H, J=2.5 Hz), 7.06 (m, 2H), 4.83-4.76 (m, 1H), 3.90 (s, 2H), 3.10 (d, 2H, 
J=5 Hz), 1.35 (s, 9H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 172.21, 170.36, 138.96, 136.30, 
130.90, 129.19, 129.09, 128.73, 128.47, 127.48, 82.06, 57.77, 48.64, 28.25, 19.19 ppm; 
HRMS (ESI) calculated for C22H26N2O3: 367.2022 ([M+H]+), found 367.1956 ([M+H]+), 
389.1773 ([M+Na]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.68-7.65 (m, 2H), 7.47-7.47 (m, 8H), 4.58-4.56 (m, 1H), 
4.02-3.99 (m, 2H), 2.27-2.25 (m, 1H), 1.52 (s, 9H), 1.04 (d, 6H, J=7.5 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 170.76, 170.47, 138.73, 136.06, 132.38, 130.62, 130.03, 128.95, 
128.84, 128.23, 127.24, 81.73, 57.12, 56.53, 31.62, 28.08, 27.95, 19.98, 17.79 ppm; HRMS 
(ESI) calculated for C24H30N2O3: 395.2335 ([M+H]
+), found 395.2399 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-methylbutanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.73-7.67 (m, 2H), 7.46-7.35 (m, 8H),  4.49 (q, 1H, J=2.5 
Hz), 4.03 (q, 1H, J=5 Hz), 2.29-2.25 (m, 1H), 1.46 (s, 9H), 1.37 (s, 3H), 1.03 (s, 6H) ppm; 13C-
NMR (100.62 MHz, CDCl3) δ 170.03, 166.72, 164.95, 135.26, 131.84, 126.58, 124.75, 
123.55, 77.66, 57.53, 53.08, 27.80, 24.12, 17.37, 15.08, 13.81 ppm; HRMS (ESI) calculated 
for C25H32N2O3: 409.2491 ([M+H]
+), found 409.2426 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.52 (d, 2H, J=2.5 Hz), 7.43-7.39 (m, 3H), 7.37-7.36 (m, 5H), 
7.25-7.23 (m, 3H), 7.19 (s, 2H), 7.06 (dd, 2H, J=5 Hz), 4.77 (d, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 3.11 (d, 2H, J=5 Hz), 1.30 (s, 9H), 1.22 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 186.57, 182.60, 169.33, 155.18, 132.41, 130.48, 129.73, 128.67, 128.39, 
128.13, 127.43, 126.91, 61.14, 59.14, 53.06, 38.28, 27.96, 20.80 ppm; HRMS (ESI) 
calculated for C29H32N2O3: 457.2491 ([M+H]
+), found 457.2421 ([M+H]+), 479.2231 
([M+Na]+). 
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(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.49-7.44 (m, 15H), 4.85 (q, 1H, J=7.5 Hz), 3.99 (s, 2H), 3.19 
(m, 2H), 1.44 (s, 9H) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.24, 170.08, 138.67, 136.29, 
136.01, 130.63, 129.61, 128.85, 128.54, 128.16, 127.28, 126.94, 82.09, 56.55, 53.08, 
38.36, 28.00 ppm; HRMS (ESI) calculated for C28H30N2O3: 443.2335 ([M+H]
+), found 
457.2419 ([M+H]+), 479.2235 ([M+Na]+). 
(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)propanoate  
1H-NMR (400.13.13 MHz, CDCl3) δ 7.71 (d, 2H, J=8 Hz), 7.47-7.44 (m, 6H), 7.15 (d, 2H, J=8 
Hz), 4.64 (q, 1H, J=8 Hz), 3.99 (s, 2H), 1.51 (s, 9H), 1.49 (d, 3H, J=8 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 172.21, 170.36, 138.96, 136.30, 130.90, 129.19, 129.09, 128.73, 
128.47, 127.48, 82.06, 57.77, 48.64, 28.25, 19.19 ppm; HRMS (ESI) calculated for 
C22H26N2O3: 367.2022 ([M+H]
+), found 367.1956 ([M+H]+), 389.1773 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-((diphenylmethylene)amino)propanamido)-3-phenylpropanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.62 (d, 1H, J=8 Hz), 7.56 (d, 2H, J=8 Hz), 7.43-7.40 (m, 4H), 
7.32-7.29 (m, 6H), 7.12 (d, 2H, J=8 Hz), 4.83 (q, 1H, J=8 Hz), 3.99 (q, 1H, J=8 Hz), 3.18 (d, 
2H, J=4 Hz), 1.37 (s, 9H), 1.29 (d, 3H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 175.03, 
170.77, 136.29, 129.50, 128.30, 126.88, 82.22, 53.14, 50.60, 38.14, 27.94, 21.33 ppm; 
HRMS (ESI) calculated for C29H32N2O3: 457.2491 ([M+H]
+), found 457.2419 ([M+H]+), 
479.2235 ([M+Na]+). 
(R)-tert-butyl 2-((R)-2-((diphenylmethylene)amino)propanamido)propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.10 (dd, 2H, J=5 Hz), 4.43 (quint, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 1.40 (d, 3H, J=10 Hz), 1.39 (s, 9H), 1.27 (d, 3H, J=5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 173.63, 171.90, 168.97, 139.21, 135.77, 130.54, 128.77, 128.70, 128.57, 
128.21, 127.48, 81.70, 61.24, 48.44, 27.96, 20.99, 18.85 ppm; HRMS (ESI) calculated for 
C23H28N2O3: 381.2178 ([M+H]
+), found 381.2167 ([M+H]+), 403.1978 ([M+Na]+). 
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-phenylpropanoate  
1H-NMR (250.13 MHz, CDCl3) δ 7.52 (d, 2H, J=2.5 Hz), 7.43-7.39 (m, 3H), 7.37-7.33 (m, 5H), 
7.25-7.22 (m, 3H), 7.19 (s, 2H), 7.06 (dd, 2H, J=5 Hz), 4.77 (d, 1H, J=7.5 Hz), 3.93 (q, 1H, 
J=7.5 Hz), 3.11 (d, 2H, J=5 Hz), 1.30 (s, 9H), 1.22 (d, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 
MHz, CDCl3) δ 173.56, 170.27, 168.79, 139.05, 136.29, 135.67, 130.50, 129.77, 128.40, 
128.14, 127.44, 126.93, 61.16,  53.07, 36.28, 27.98, 20.81 ppm; HRMS (ESI) calculated for 
C29H32N2O3: 457.2491 ([M+H]
+), found 457.2421 ([M+H]+), 479.2231 ([M+Na]+). 
(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.71-7.69 (m, 2H), 7.50-7.40 (m, 6H), 7.19-7.17 (m, 2H), 
4.59 (q, 1H, J=8 Hz), 4.03 (d, 2H, J=4 Hz), 2.23-2.13 (m, 1H), 1.52 (s, 9H), 1.04 (d, 6H, J=8 
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Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.78, 162.26, 132.42, 130.06, 128.88, 128.29, 
127.31, 81.77, 57.19, 56.53, 31.64, 28.12, 19.03, 17.83 ppm; HRMS (ESI) calculated for 
C24H30N2O3: 395.2335 ([M+H]
+), found 395.2399 ([M+H]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.70 (d, 2H, J=8 Hz), 7.49-7.40 (m, 6H), 7.17 (d, 2H, J=4 Hz), 
4.70 (q, 1H, J=8 Hz), 4.00 (s, 2H), 1.75-1.69 (m, 2H), 1.52 (s, 9H), 1.02 (d, 6H, J=8 Hz) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 176.86, 171.66, 165.10, 139.29, 130.67, 128.98, 128.87, 
128.49, 128.24, 127.27, 120.85, 56.54, 51.10, 43.12, 42.20, 28.06, 25.09, 22.32 ppm; 
HRMS (ESI) calculated for C25H32N2O3: 409.2491, found 409.2487 ([M+H]
+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.70 (d, 2H, J=8 Hz), 7.49-7.38 (m, 6H), 7.18-7.16 (m, 2H), 
4.61 (q, 1H, J=8 Hz), 4.04 (q, 1H, J=8 Hz), 1.78-1.67 (m, 3H), 1.46 (s, 9H), 1.37 (d, 3H, J=8 
Hz), 1.03 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 173.86, 171.79, 169.02, 
139.24, 135.76, 130.52, 128.69, 128.55, 128.19, 127.50, 81.53, 61.34, 51.13, 43.12, 42.02, 
28.01, 25.11, 22.90, 22.39, 21.03 ppm; HRMS (ESI) calculated for C26H34N2O3: 423.2648, 
found 423.2641 ([M+H]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-3-
methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.65 (d, 2H, J=8 Hz), 7.45-7.20 (m, 11H), 7.19 (m, 2H), 4.49-
4.45 (m, 1H, J=8 Hz), 4.21-4.18 (m, 1H), 3.26-3.23 (m, 1H), 3.11-3.05 (m, 1H), 2.22-2.17 (m, 
1H), 1.42 (s, 9H), 0.98 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 195.70, 178.42, 
172.28,  170.46, 170.15, 139.15, 137.84, 135.55, 130.46, 130.16, 128.60, 128.30, 128.11, 
127.42, 126.30, 81.58, 67.83, 57.30, 43.12, 42.02, 41.70, 31.50, 28.00, 18.95, 17.85 ppm; 
HRMS (ESI) calculated for C31H36N2O3: 485.2804, found 485.2797 ([M+H]
+), 507.2612 
([M+Na]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.70 (d, 2H, J=4 Hz), 7.47-7.37 (m, 6H), 7.18 (m, 2H), 4.52-
4.48 (m, 1H), 4.04 (q, 1H, J=4 Hz), 2.30-2.22 (m, 1H), 1.46 (s, 9H), 1.39 (d, 3H, J=4 Hz), 1.05 
(t, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.03, 166.72, 164.95, 135.26, 
131.84, 126.58, 124.75, 123.55, 77.66, 57.53, 53.08, 27.80, 24.12, 17.37, 15.08, 13.81 
ppm; HRMS (ESI) calculated for C25H32N2O3: 409.2491 ([M+H]
+), found 409.2481 ([M+H]+), 
431.2299 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.63 (d, 2H, J=8 Hz), 7.52-7.20 (m, 10H), 7.09-7.07 (m, 3H), 
4.58 (q, 1H, J=8 Hz, , J2=4 Hz), 4.21-4.18 (m, 1H), 3.23-3.19 (m, 1H), 3.08-3.05 (m, 1H), 
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1.69-1.66 (m, 3H), 1.43 (s, 9H), 1.00 (t, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 
172.13, 170.33,  139.23, 137.85, 135.55, 132.43, 130.47, 130.14, 128.67, 128.30, 128.08, 
127.46, 126.67, 81.49, 80.46, 67.69, 51.21, 41.75, 41.50, 42.02, 27.96, 25.00, 22.57, 22.27 
ppm; HRMS (ESI) calculated for C32H38N2O3: 499.2961, found 499.2942 ([M+H]
+), 521.2757 
([M+Na]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.65 (d, 2H, J=8 Hz), 7.44-7.16 (m, 12H), 7.04 (m, 2H), 6.37 
(d, 2H, J=4 Hz), 4.64 (q, 1H, J1=8 Hz, J2=4 Hz), 4.19 (d, 1H), 3.28 (dd, 1H, J1=8 Hz, J2=4 Hz), 
3.12 (t, 1H, J=12 Hz), 1.69-1.56 (m, 3H), 1.53 (s, 9H), 0.97 (t, 6H, J=4 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 188.38, 173.13, 172.31, 171.73, 169.82, 139.40, 138.00, 135.45, 
130.49, 130.13, 128.64, 128.13, 127.31, 126.24, 81.71, 67.95, 51.16, 41.95, 41.46, 28.07, 
25.16, 22.86, 22.26 ppm; HRMS (ESI) calculated for C32H38N2O3: 499.2961, found 499.2968 
([M+H]+), 521.2757 ([M+Na]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.84 (d, 1H, J=8 Hz), 7.70 (d, 2H, J=4 Hz), 7.50-7.39 (m, 6H), 
7.15 (d, 2H, J=8 Hz), 4.60 (q, 1H, J=8 Hz), 4.05 (q, 1H, J=8 Hz), 1.72-1.57 (m, 3H), 1.53 (s, 
9H), 1.36 (d, 3H, J=8 Hz), 0.97 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 173.75, 
171.84, 168.53, 139.07, 135.70, 132.42, 130.56, 130.06, 128.75, 128.49, 128.22, 127.38, 
81.62, 61.24, 51.19, 41.87, 28.07, 25.14, 22.84, 22.31, 20.69 ppm; HRMS (ESI) calculated 
for C26H34N2O3: 423.2648, found 423.2657 ([M+H]
+).  
(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.91 (d, 1H, J=8 Hz), 7.70 (d, 2H, J=8 Hz),  7.49-7.38 (m, 6H), 
7.18 (d, 2H, J=8 Hz), 4.69 (q, 1H, J=8 Hz, J2=4 Hz), 4.00 (s, 2H), 1.80-1.64 (m, 3H), 1.51 (s, 
9H), 1.02 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.96, 170.21, 153.26, 
130.72, 129.02, 128.88, 128.26, 127.29, 81.71, 56.50, 51.12, 42.18, 28.06, 25.08, 22.87, 
22.32 ppm; HRMS (ESI) calculated for C25H32N2O3: 409.2491, found 409.2502 ([M+H]
+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido) propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 8.19 (d, 1H, J=7.5 Hz), 7.25-7.17 (m, 5H), 4.12 (q, 1H, J=5 
Hz), 3.40 (q, J=5 Hz, 1H), 2.94 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 
1.37 (s, 9H), 1.22 (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 174.68, 172.27, 
138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 ppm; 
HRMS (ESI) calculated for C29H32N2O3: 457.2491 ([M+H]
+), found: 457.2416 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-3-
methylbutanoate  
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Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.78, 162.26, 132.42, 130.06, 128.88, 128.29, 
127.31, 81.77, 57.19, 56.53, 31.64, 28.12, 19.03, 17.83 ppm; HRMS (ESI) calculated for 
C24H30N2O3: 395.2335 ([M+H]
+), found 395.2399 ([M+H]+). 
(S)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.70 (d, 2H, J=8 Hz), 7.49-7.40 (m, 6H), 7.17 (d, 2H, J=4 Hz), 
4.70 (q, 1H, J=8 Hz), 4.00 (s, 2H), 1.75-1.69 (m, 2H), 1.52 (s, 9H), 1.02 (d, 6H, J=8 Hz) ppm; 
13C-NMR (100.62 MHz, CDCl3) δ 176.86, 171.66, 165.10, 139.29, 130.67, 128.98, 128.87, 
128.49, 128.24, 127.27, 120.85, 56.54, 51.10, 43.12, 42.20, 28.06, 25.09, 22.32 ppm; 
HRMS (ESI) calculated for C25H32N2O3: 409.2491, found 409.2487 ([M+H]
+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.70 (d, 2H, J=8 Hz), 7.49-7.38 (m, 6H), 7.18-7.16 (m, 2H), 
4.61 (q, 1H, J=8 Hz), 4.04 (q, 1H, J=8 Hz), 1.78-1.67 (m, 3H), 1.46 (s, 9H), 1.37 (d, 3H, J=8 
Hz), 1.03 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 173.86, 171.79, 169.02, 
139.24, 135.76, 130.52, 128.69, 128.55, 128.19, 127.50, 81.53, 61.34, 51.13, 43.12, 42.02, 
28.01, 25.11, 22.90, 22.39, 21.03 ppm; HRMS (ESI) calculated for C26H34N2O3: 423.2648, 
found 423.2641 ([M+H]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-3-
methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.65 (d, 2H, J=8 Hz), 7.45-7.20 (m, 11H), 7.19 (m, 2H), 4.49-
4.45 (m, 1H, J=8 Hz), 4.21-4.18 (m, 1H), 3.26-3.23 (m, 1H), 3.11-3.05 (m, 1H), 2.22-2.17 (m, 
1H), 1.42 (s, 9H), 0.98 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 195.70, 178.42, 
172.28,  170.46, 170.15, 139.15, 137.84, 135.55, 130.46, 130.16, 128.60, 128.30, 128.11, 
127.42, 126.30, 81.58, 67.83, 57.30, 43.12, 42.02, 41.70, 31.50, 28.00, 18.95, 17.85 ppm; 
HRMS (ESI) calculated for C31H36N2O3: 485.2804, found 485.2797 ([M+H]
+), 507.2612 
([M+Na]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-3-methylbutanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.70 (d, 2H, J=4 Hz), 7.47-7.37 (m, 6H), 7.18 (m, 2H), 4.52-
4.48 (m, 1H), 4.04 (q, 1H, J=4 Hz), 2.30-2.22 (m, 1H), 1.46 (s, 9H), 1.39 (d, 3H, J=4 Hz), 1.05 
(t, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 170.03, 166.72, 164.95, 135.26, 
131.84, 126.58, 124.75, 123.55, 77.66, 57.53, 53.08, 27.80, 24.12, 17.37, 15.08, 13.81 
ppm; HRMS (ESI) calculated for C25H32N2O3: 409.2491 ([M+H]
+), found 409.2481 ([M+H]+), 
431.2299 ([M+Na]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.63 (d, 2H, J=8 Hz), 7.52-7.20 (m, 10H), 7.09-7.07 (m, 3H), 
4.58 (q, 1H, J=8 Hz, , J2=4 Hz), 4.21-4.18 (m, 1H), 3.23-3.19 (m, 1H), 3.08-3.05 (m, 1H), 
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1.69-1.66 (m, 3H), 1.43 (s, 9H), 1.00 (t, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 
172.13, 170.33,  139.23, 137.85, 135.55, 132.43, 130.47, 130.14, 128.67, 128.30, 128.08, 
127.46, 126.67, 81.49, 80.46, 67.69, 51.21, 41.75, 41.50, 42.02, 27.96, 25.00, 22.57, 22.27 
ppm; HRMS (ESI) calculated for C32H38N2O3: 499.2961, found 499.2942 ([M+H]
+), 521.2757 
([M+Na]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-4-
methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.65 (d, 2H, J=8 Hz), 7.44-7.16 (m, 12H), 7.04 (m, 2H), 6.37 
(d, 2H, J=4 Hz), 4.64 (q, 1H, J1=8 Hz, J2=4 Hz), 4.19 (d, 1H), 3.28 (dd, 1H, J1=8 Hz, J2=4 Hz), 
3.12 (t, 1H, J=12 Hz), 1.69-1.56 (m, 3H), 1.53 (s, 9H), 0.97 (t, 6H, J=4 Hz) ppm; 13C-NMR 
(100.62 MHz, CDCl3) δ 188.38, 173.13, 172.31, 171.73, 169.82, 139.40, 138.00, 135.45, 
130.49, 130.13, 128.64, 128.13, 127.31, 126.24, 81.71, 67.95, 51.16, 41.95, 41.46, 28.07, 
25.16, 22.86, 22.26 ppm; HRMS (ESI) calculated for C32H38N2O3: 499.2961, found 499.2968 
([M+H]+), 521.2757 ([M+Na]+).  
(R)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)propanamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.84 (d, 1H, J=8 Hz), 7.70 (d, 2H, J=4 Hz), 7.50-7.39 (m, 6H), 
7.15 (d, 2H, J=8 Hz), 4.60 (q, 1H, J=8 Hz), 4.05 (q, 1H, J=8 Hz), 1.72-1.57 (m, 3H), 1.53 (s, 
9H), 1.36 (d, 3H, J=8 Hz), 0.97 (d, 6H, J=4 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 173.75, 
171.84, 168.53, 139.07, 135.70, 132.42, 130.56, 130.06, 128.75, 128.49, 128.22, 127.38, 
81.62, 61.24, 51.19, 41.87, 28.07, 25.14, 22.84, 22.31, 20.69 ppm; HRMS (ESI) calculated 
for C26H34N2O3: 423.2648, found 423.2657 ([M+H]
+).  
(R)-tert-butyl 2-(2-((diphenylmethylene)amino)acetamido)-4-methylpentanoate  
1H-NMR (400.13 MHz, CDCl3) δ 7.91 (d, 1H, J=8 Hz), 7.70 (d, 2H, J=8 Hz),  7.49-7.38 (m, 6H), 
7.18 (d, 2H, J=8 Hz), 4.69 (q, 1H, J=8 Hz, J2=4 Hz), 4.00 (s, 2H), 1.80-1.64 (m, 3H), 1.51 (s, 
9H), 1.02 (d, 6H, J=8 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 171.96, 170.21, 153.26, 
130.72, 129.02, 128.88, 128.26, 127.29, 81.71, 56.50, 51.12, 42.18, 28.06, 25.08, 22.87, 
22.32 ppm; HRMS (ESI) calculated for C25H32N2O3: 409.2491, found 409.2502 ([M+H]
+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido) propanoate  
1H-NMR (250.13 MHz, CDCl3) δ 8.19 (d, 1H, J=7.5 Hz), 7.25-7.17 (m, 5H), 4.12 (q, 1H, J=5 
Hz), 3.40 (q, J=5 Hz, 1H), 2.94 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 
1.37 (s, 9H), 1.22 (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 174.68, 172.27, 
138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 ppm; 
HRMS (ESI) calculated for C29H32N2O3: 457.2491 ([M+H]
+), found: 457.2416 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-3-
methylbutanoate  
15299 - Pekosak_BNW.indd   127 16-02-18   16:22
Chapter 5 
128 
 
1H-NMR (250.13 MHz, CDCl3) δ 8.19 (d, 1H, J=7.5 Hz), 7.25-7.17 (m, 5H), 4.12 (q, 1H, J=5 
Hz), 3.40 (q, 1H, J=5 Hz), 2.94 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 
1.37 (s, 9H), 1.22 (d, (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 174.68, 
172.27, 138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 
ppm; HRMS (ESI) calculated for C31H36N2O3: 485.2804 ([M+H]
+), found: 485.2715 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-3-
phenylpropanoate 
1H-NMR (250.13 MHz, CDCl3) δ 8.19 (d, 1H, J=7.5 Hz), 7.25-7.17 (m, 5H), 4.12 (q, 1H, J=5 
Hz), 3.40 (q, 1H, J=5 Hz), 2.94 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 
1.37 (s, 9H), 1.22 (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz,  CDCl3) δ 174.68, 172.27, 
138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 ppm; 
HRMS (ESI) calculated for C35H36N2O3: 533.2804 ([M+H]
+), found: 533.2712 ([M+H]+). 
Procedure for the removal of protecting groups of dipeptides 
The starting material was dissolved in 4M HCl in dioxane, stirred at room temperature for 
several hours and progress monitored by TLC and coloring of spots with ninhydrin. The 
samples were purified by semi-preparative chromatography resulting in a white solid in 
low yields.  
(S)-2-((R)-2-aminopropanamido)-3-methylbutanoic acid  
1H-NMR (500.23 MHz, MeOD) δ 4.13 (q, 1H, J=5 Hz), 2.27-2.24 (m, 1H), 1.57 (d, 3H, J=10 
Hz), 1.00 (d, 6H, J=5 Hz) ppm; 13C-NMR (125.80 MHz, MeOD) δ 174.28, 171.37, 68.07, 
58.91, 50.19, 31.66, 19.61, 18.07 ppm; HRMS (ESI) calculated for C8H16N2O3: 189.1239 
([M+H]+), found 189.12626 ([M+H]+). 
(S)-2-((R)-2-amino-3-phenylpropanamido)-3-phenylpropanoic acid  
1H-NMR (500.23 MHz, (CD3)2SO) δ 8.23 (d, 1H, J=10 Hz), 7.29-7.12 (m, 10H), 4.41 (q, 1H, 
J=5 Hz), 3.44 (q, 1H, J1=10 Hz, J2=5 Hz), 3.30 (br s, 2H), 2.91 (m, 4H) ppm;
 13C-NMR (125.80 
MHz, (CD3)2SO) δ 174.34, 170.94, 138.91, 137.41, 129.78, 128.65, 128.52, 127.00, 126.55, 
65.06, 56.21, 54.06 ppm; HRMS (ESI) calculated for for C18H20N2O3: 313.1552 ([M+H]
+), 
found: 313.1623 ([M+H]+). 
Synthesis of phase-transfer Catalyst 6 
Synthesis of N-(9-anthracenylmethyl)cinchoninium chloride  
Compound Cat 8 was prepared and characterized according to O'Donnell et al.3 and Corey 
et al.4.  To a suspension of cinchonine (1.00 g, 3.40 mmol) in toluene (14 mL) was added 9-
(chloromethyl)anthracene (770 mg, 3.74 mmol). The reaction mixture was stirred at reflux 
overnight. The mixture was then cooled to ambient T and poured onto 40 mL of diethyl 
ether and filtered to afford a light yellow solid (1.43 g, 2.75 mmol, 81.0 %). Smaller 
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fraction of filtered solid (180 mg) was purified by flash chromatography (0–100 % 
MeOH/DCM) to yield a yellow solid (169 mg, 94.0 %). 
1H NMR (300.13 MHz, CDCl3): δ 9.21 (d, 1 H, J=8.9 Hz), 8.91-8.85 (m, 2 H), 8.44 (d, 1 H, 
J=9.1 Hz), 8.19 (d, 1 H, J=4.2 Hz), 8.05 (d, 1 H, J=4.5 Hz), 7.88 (s, 1 H), 7.61-7.55 (m, 2 H), 
7.48 (d, 1 H, J=8.3 Hz), 7.24-7.05 (m, 4 H), 7.00-6.89 (m, 3 H), 6.50 (d, 1H, J=13.4 Hz), 5.64-
5.54 (m, 1 H), 5.03 (d, 1 H, J=10.5 Hz), 4.88 (d, 1 H, J=17.2 Hz), 4.72 (m, 1 H), 4.44 (m, 1 H), 
4.25 (m, 1 H), 2.53-2.49 (m, 1 H), 2.34-2.30 (m, 1 H), 2.01-1.93 (m, 1 H), 1.75-1.66 (m, 2 H), 
1.53 (s, 1 H), 1.25-1.21 (m, 2 H) ppm; HRMS (ESI) calculated for C34H33N2O
+ 485.2593 
([M+H]+); found 485.4012 ([M+H]+).  
Synthesis of O-Allyl-N-(9-anthracenylmethyl)cinchoninium bromide – Cat 6  
Compound Cat 7 was prepared and characterized according to O'Donnell et al.3 To a 
suspension of compound Cat 8 (150 mg, 288 µmol) in DCM (2 mL) was added allyl bromide 
(78.0 µL, 684 µmol) and aqueous 50% KOH (0.2 mL). The resulting mixture was stirred 
vigorously at ambient T for 8 h, during which time the solid dissolved. The mixture was 
diluted with water (10 mL) and extracted with dichloromethane (3x 15 mL). The combined 
organic fractions were dried over Na2SO4, filtered and concentrated to dryness in vacuo to 
give an orange solid. The solid was suspended in ice cold diethylether, placed in the 
freezer (-23 ° C) for several hours and filtered to give crude product as a light orange solid 
(66.0 mg, 109 µmol, 37.8 %). 
1H NMR (300.13 MHz, CD3OD): δ 9.05 (d, 1 H, J=4.6 Hz), 8.90 (s, 1 H), 8.81 (d, 1 H, J=6.4 
Hz), 8.58-8.49 (m, 1 H), 8.36 (d, 1 H , J=8.9 Hz,), 8.29-8.20 (m, 3 H), 8.03-7.93 (m, 3 H), 
7.84-7.62 (m, 4 H), 6.90 (s, 1 H), 6.16-6.11 (m, 1 H), 6.04-5.98 (m, 3 H), 5.72 (dd, 1 H, 
J1=15.9 Hz, J2=1.5 Hz), 5.62 (d, 1 H, J=13.4 Hz), 5.22 (d, 1 H, J=6.4 Hz), 5.08 (d, 1 H, J=17.2 
Hz), 4.51-4.41 (m, 4 H), 4.20-3.92 (m, 1 H), 3.25-3.18 (m, 1 H), 2.86-2.60 (m, 2 H), 2.32-2.29 
(m, 1 H), 1.88-1.23 (m, 4 H) ppm; 13C NMR (75.62 MHz, CD3OD): δ 149.8, 148.1, 141.1, 
136.2, 133.5, 133.4, 132.7, 131.9, 131.8, 131.7, 130.3, 130.2, 129.9, 129.3, 128.7, 128.1, 
128.0, 125.4, 125.3, 125.0, 124.6, 124.1, 123.6, 123.2, 117.9, 116.7, 70.0, 65.7, 57.8, 56.0, 
37.6, 26.2, 23.5, 22.1 ppm; HRMS (ESI): calculated for C37H37N2O
+: 525.2906 ([M+H]+); 
found 525.2837 ([M+H]+). 
Radiochemistry 
Radiochemical yield of the crude reaction mixture defined as radiochemical conversion 
(RCC), was determined by HPLC analysis as the percentage of converted [11C]methyl iodide 
([11C]MeI) or [11C]benzyl iodide ([11C]BnI) to desired product (dipeptide intermediate) 
using an analytical HPLC method described in the radiochemistry section under each 
procedure and is based on the AUC of the radioactivity profile of the HPLC analysis. 
Diastereomeric ratio is used to describe effectively the amount of one diastereomere (e.g. 
D,L) to another (L,L). Diastereomeric ratio (dr) of dipeptides was determined by HPLC 
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1H-NMR (250.13 MHz, CDCl3) δ 8.19 (d, 1H, J=7.5 Hz), 7.25-7.17 (m, 5H), 4.12 (q, 1H, J=5 
Hz), 3.40 (q, 1H, J=5 Hz), 2.94 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 
1.37 (s, 9H), 1.22 (d, (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz, CDCl3) δ 174.68, 
172.27, 138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 
ppm; HRMS (ESI) calculated for C31H36N2O3: 485.2804 ([M+H]
+), found: 485.2715 ([M+H]+). 
(S)-tert-butyl 2-((S)-2-((diphenylmethylene)amino)-3-phenylpropanamido)-3-
phenylpropanoate 
1H-NMR (250.13 MHz, CDCl3) δ 8.19 (d, 1H, J=7.5 Hz), 7.25-7.17 (m, 5H), 4.12 (q, 1H, J=5 
Hz), 3.40 (q, 1H, J=5 Hz), 2.94 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 2.58 (dd, 1H, J1=5 Hz, J2=7.5 Hz), 
1.37 (s, 9H), 1.22 (dd, 3H, J=7.5 Hz) ppm; 13C-NMR (100.62 MHz,  CDCl3) δ 174.68, 172.27, 
138.96, 129.82, 128.51, 126.59, 81.08, 56.15, 54.33, 48.52, 39.11, 28.04, 17.79 ppm; 
HRMS (ESI) calculated for C35H36N2O3: 533.2804 ([M+H]
+), found: 533.2712 ([M+H]+). 
Procedure for the removal of protecting groups of dipeptides 
The starting material was dissolved in 4M HCl in dioxane, stirred at room temperature for 
several hours and progress monitored by TLC and coloring of spots with ninhydrin. The 
samples were purified by semi-preparative chromatography resulting in a white solid in 
low yields.  
(S)-2-((R)-2-aminopropanamido)-3-methylbutanoic acid  
1H-NMR (500.23 MHz, MeOD) δ 4.13 (q, 1H, J=5 Hz), 2.27-2.24 (m, 1H), 1.57 (d, 3H, J=10 
Hz), 1.00 (d, 6H, J=5 Hz) ppm; 13C-NMR (125.80 MHz, MeOD) δ 174.28, 171.37, 68.07, 
58.91, 50.19, 31.66, 19.61, 18.07 ppm; HRMS (ESI) calculated for C8H16N2O3: 189.1239 
([M+H]+), found 189.12626 ([M+H]+). 
(S)-2-((R)-2-amino-3-phenylpropanamido)-3-phenylpropanoic acid  
1H-NMR (500.23 MHz, (CD3)2SO) δ 8.23 (d, 1H, J=10 Hz), 7.29-7.12 (m, 10H), 4.41 (q, 1H, 
J=5 Hz), 3.44 (q, 1H, J1=10 Hz, J2=5 Hz), 3.30 (br s, 2H), 2.91 (m, 4H) ppm;
 13C-NMR (125.80 
MHz, (CD3)2SO) δ 174.34, 170.94, 138.91, 137.41, 129.78, 128.65, 128.52, 127.00, 126.55, 
65.06, 56.21, 54.06 ppm; HRMS (ESI) calculated for for C18H20N2O3: 313.1552 ([M+H]
+), 
found: 313.1623 ([M+H]+). 
Synthesis of phase-transfer Catalyst 6 
Synthesis of N-(9-anthracenylmethyl)cinchoninium chloride  
Compound Cat 8 was prepared and characterized according to O'Donnell et al.3 and Corey 
et al.4.  To a suspension of cinchonine (1.00 g, 3.40 mmol) in toluene (14 mL) was added 9-
(chloromethyl)anthracene (770 mg, 3.74 mmol). The reaction mixture was stirred at reflux 
overnight. The mixture was then cooled to ambient T and poured onto 40 mL of diethyl 
ether and filtered to afford a light yellow solid (1.43 g, 2.75 mmol, 81.0 %). Smaller 
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fraction of filtered solid (180 mg) was purified by flash chromatography (0–100 % 
MeOH/DCM) to yield a yellow solid (169 mg, 94.0 %). 
1H NMR (300.13 MHz, CDCl3): δ 9.21 (d, 1 H, J=8.9 Hz), 8.91-8.85 (m, 2 H), 8.44 (d, 1 H, 
J=9.1 Hz), 8.19 (d, 1 H, J=4.2 Hz), 8.05 (d, 1 H, J=4.5 Hz), 7.88 (s, 1 H), 7.61-7.55 (m, 2 H), 
7.48 (d, 1 H, J=8.3 Hz), 7.24-7.05 (m, 4 H), 7.00-6.89 (m, 3 H), 6.50 (d, 1H, J=13.4 Hz), 5.64-
5.54 (m, 1 H), 5.03 (d, 1 H, J=10.5 Hz), 4.88 (d, 1 H, J=17.2 Hz), 4.72 (m, 1 H), 4.44 (m, 1 H), 
4.25 (m, 1 H), 2.53-2.49 (m, 1 H), 2.34-2.30 (m, 1 H), 2.01-1.93 (m, 1 H), 1.75-1.66 (m, 2 H), 
1.53 (s, 1 H), 1.25-1.21 (m, 2 H) ppm; HRMS (ESI) calculated for C34H33N2O
+ 485.2593 
([M+H]+); found 485.4012 ([M+H]+).  
Synthesis of O-Allyl-N-(9-anthracenylmethyl)cinchoninium bromide – Cat 6  
Compound Cat 7 was prepared and characterized according to O'Donnell et al.3 To a 
suspension of compound Cat 8 (150 mg, 288 µmol) in DCM (2 mL) was added allyl bromide 
(78.0 µL, 684 µmol) and aqueous 50% KOH (0.2 mL). The resulting mixture was stirred 
vigorously at ambient T for 8 h, during which time the solid dissolved. The mixture was 
diluted with water (10 mL) and extracted with dichloromethane (3x 15 mL). The combined 
organic fractions were dried over Na2SO4, filtered and concentrated to dryness in vacuo to 
give an orange solid. The solid was suspended in ice cold diethylether, placed in the 
freezer (-23 ° C) for several hours and filtered to give crude product as a light orange solid 
(66.0 mg, 109 µmol, 37.8 %). 
1H NMR (300.13 MHz, CD3OD): δ 9.05 (d, 1 H, J=4.6 Hz), 8.90 (s, 1 H), 8.81 (d, 1 H, J=6.4 
Hz), 8.58-8.49 (m, 1 H), 8.36 (d, 1 H , J=8.9 Hz,), 8.29-8.20 (m, 3 H), 8.03-7.93 (m, 3 H), 
7.84-7.62 (m, 4 H), 6.90 (s, 1 H), 6.16-6.11 (m, 1 H), 6.04-5.98 (m, 3 H), 5.72 (dd, 1 H, 
J1=15.9 Hz, J2=1.5 Hz), 5.62 (d, 1 H, J=13.4 Hz), 5.22 (d, 1 H, J=6.4 Hz), 5.08 (d, 1 H, J=17.2 
Hz), 4.51-4.41 (m, 4 H), 4.20-3.92 (m, 1 H), 3.25-3.18 (m, 1 H), 2.86-2.60 (m, 2 H), 2.32-2.29 
(m, 1 H), 1.88-1.23 (m, 4 H) ppm; 13C NMR (75.62 MHz, CD3OD): δ 149.8, 148.1, 141.1, 
136.2, 133.5, 133.4, 132.7, 131.9, 131.8, 131.7, 130.3, 130.2, 129.9, 129.3, 128.7, 128.1, 
128.0, 125.4, 125.3, 125.0, 124.6, 124.1, 123.6, 123.2, 117.9, 116.7, 70.0, 65.7, 57.8, 56.0, 
37.6, 26.2, 23.5, 22.1 ppm; HRMS (ESI): calculated for C37H37N2O
+: 525.2906 ([M+H]+); 
found 525.2837 ([M+H]+). 
Radiochemistry 
Radiochemical yield of the crude reaction mixture defined as radiochemical conversion 
(RCC), was determined by HPLC analysis as the percentage of converted [11C]methyl iodide 
([11C]MeI) or [11C]benzyl iodide ([11C]BnI) to desired product (dipeptide intermediate) 
using an analytical HPLC method described in the radiochemistry section under each 
procedure and is based on the AUC of the radioactivity profile of the HPLC analysis. 
Diastereomeric ratio is used to describe effectively the amount of one diastereomere (e.g. 
D,L) to another (L,L). Diastereomeric ratio (dr) of dipeptides was determined by HPLC 
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analysis based on the AUC of the radioactivity profile of HPLC analysis of the protected 
dipeptide in the crude reaction mixture using an analytical HPLC column. For the 
calculations of diastereomeric excess (de) following formula has been used: de (%) = ((D-
L)/(D+L)) x 100 ; D+L=1 for preferential D-[11C]alkylation and de (%) = ((L-D)/(D+L)) x 100 ; 
D+L=1 for preferential L-11C-alkylation. 
Radiochemical procedure for the production of [11C]methyl iodide 
[11C]CO2 was produced by the 
14N(p,α)11C nuclear reaction performed in a 0.5% O2/N2 gas 
mixture using IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium). [11C]CO2 was carried in a 
stream of helium and trapped in 0.1 mL of a 0.1M lithium aluminium hydride solution in 
THF in a glass reaction vessel at room temperature. After trapping, the gas flow was 
increased to 20 mL·min-1 and the THF evaporated at 130 °C. After evaporation to dryness 
0.2 mL of 57% hydriodic acid (HI) was added the [11C]MeI was distilled from the reaction 
vessel under a stream of helium (flow 20 mL·min-1) to the second reaction vessel for the 
alkylation reaction.5  
Radiochemical procedure for the production of [11C]benzyl iodide 
[11C]Benzyl iodide was synthesized according to the procedure in Chapter 3.6 
Optimization of amount of used Schiff base for optimal RCC 
 
Graph 1: Determination of optimal concentration for the alkylation reaction to obtain 
[11C]10 or [11C]14. 
Resulting in optimal concentration of approx. 30-40 mM for methylation reactions, and 
best conditions for benyzlation were established to be between 50-60 mM of starting 
Schiff base 1-8. 
Alkylation procedure of Schiff base XX 
A closed reaction vessel containing the Schiff base precursor, phase transfer catalyst and 
base, in a mixture of toluene (100 µL) is prepared prior of obtaining [11C]MeI or [11C]BnI. 
The color changed instantly to yellow. [11C]MeI was trapped in this second reaction vessel 
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preceding heating or cooling of the reaction mixture. At set time points, samples 
quenched/diluted with acetonitrile, were taken from the reaction mixture for analysis by 
radioHPLC to determine the RCC and dr.  
Procedure for the alkylation with [11C]MeI or [11C]BnI to obtain dipeptides  
In a reaction vessel, Schiff base X (1.2-1.7 mg, 4-7 µmol), catalyst Y (1-2 mg, 2-3 µmol) and 
CsOH·H2O (55-60 mg, 180-200 µmol) are suspended in toluene (100 µL). After distilling 
[11C]MeI / addition of [11C]BnI in the reaction vial, the mixture is cooled to 0-10 °C and 
stirred for 5 min. A sample is taken for analysis, quenched/diluted with acetonitrile and 
injected on Phenomenex Luna 5u RP18 column (250 x 4.5 mm, 
acetonitrile/sodiumformate 4mM, gradient) with a retention time (tR) of around 20 min 
for diastereomeric product Ph2C=N-[
11C]Ala-Xxx-OtBu or Ph2C=N-[
11C]Phe-XXX-OtBu (L,D-
product before D,D, D,L before L,L). The deprotection is initialized by the addition of 0.1 mL 
of 6M HCl solution and heating to 100 °C for 2 min. A second sample is taken for analysis 
on chiral radioHPLC. 
Influence of magnetic stirrer on RCC 
Table 1: Influence of the mixing on the 11C-benzylation towards Ph2C=N-[
11C]Phe-L-
Phe-OtBu without presence of the phase-transfer catalyst. 
Entry Time Stirring RCC [%]a 
1 7 min Small stirrer and Helium flow of 25 mL·min-1 89.7 
2 7 min Helium flow of 25 mL·min-1 81.6 
3 7 min Helium flow of 25 mL·min-1 87.9 
4 7 min Big stirrer 71.7 
5 7 min No stirrer* 76.2 
6 40 s Vortex mixer** 80.4 
aRadiochemical conversions were determined by HPLC. *Reaction mixture is mixed in 
the syringe when taking the sample for effective dilution. **Manual use of Vortex mixer is 
not justified due to the radioation dose radiochemist is exposed during the experiment. 
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analysis based on the AUC of the radioactivity profile of HPLC analysis of the protected 
dipeptide in the crude reaction mixture using an analytical HPLC column. For the 
calculations of diastereomeric excess (de) following formula has been used: de (%) = ((D-
L)/(D+L)) x 100 ; D+L=1 for preferential D-[11C]alkylation and de (%) = ((L-D)/(D+L)) x 100 ; 
D+L=1 for preferential L-11C-alkylation. 
Radiochemical procedure for the production of [11C]methyl iodide 
[11C]CO2 was produced by the 
14N(p,α)11C nuclear reaction performed in a 0.5% O2/N2 gas 
mixture using IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium). [11C]CO2 was carried in a 
stream of helium and trapped in 0.1 mL of a 0.1M lithium aluminium hydride solution in 
THF in a glass reaction vessel at room temperature. After trapping, the gas flow was 
increased to 20 mL·min-1 and the THF evaporated at 130 °C. After evaporation to dryness 
0.2 mL of 57% hydriodic acid (HI) was added the [11C]MeI was distilled from the reaction 
vessel under a stream of helium (flow 20 mL·min-1) to the second reaction vessel for the 
alkylation reaction.5  
Radiochemical procedure for the production of [11C]benzyl iodide 
[11C]Benzyl iodide was synthesized according to the procedure in Chapter 3.6 
Optimization of amount of used Schiff base for optimal RCC 
 
Graph 1: Determination of optimal concentration for the alkylation reaction to obtain 
[11C]10 or [11C]14. 
Resulting in optimal concentration of approx. 30-40 mM for methylation reactions, and 
best conditions for benyzlation were established to be between 50-60 mM of starting 
Schiff base 1-8. 
Alkylation procedure of Schiff base XX 
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base, in a mixture of toluene (100 µL) is prepared prior of obtaining [11C]MeI or [11C]BnI. 
The color changed instantly to yellow. [11C]MeI was trapped in this second reaction vessel 
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preceding heating or cooling of the reaction mixture. At set time points, samples 
quenched/diluted with acetonitrile, were taken from the reaction mixture for analysis by 
radioHPLC to determine the RCC and dr.  
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Entry Time Stirring RCC [%]a 
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Optimization of base amount 
We performed thorough screening of reaction conditions, pre-based on our previous work 
(e.g. choice of solvent, more than 40 eq of base required).  
Table 2: Determination of amount of base CsOH·H2O.  
Entry Precursor Base [eq] RCC [%] 
1 1 16.0 17.0 
2 2 16.5 11.4 
3 3 24.5 20.0 
4 1 50.7 56.2 
5 4 46.6 87.5 
6 3 80.3 85.5 
Reaction with [11C]MeI were performed with 40-60 mM of precursor for 5 min at 10 °C. 
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Abstract 
 
The first 11C-labeled unmodified (“native”) peptide is described by alkylation of a 
tetrapeptide Schiff base, which was achieved by an automated 5-step radiochemical 
reaction. In a proof-of-concept study, [11C]Phe-D-Trp-Lys-Thr was synthesized. This 
tetrapeptide is the essential pharmacophore of octreotide, an antagonist of somatostatin 
receptors. The asymmetric alkylation using chiral phase-transfer catalysts enables direct 
labeling of a variety of isolated 11C-peptides in a highly stereoselective manner (de of 94%) 
with acceptable radiochemical yield (9-10%) and practical molar activities (15-35 
GBq·µmol-1) at the end of synthesis. This novel methodology provides a powerful new 
radiosynthetic method to access novel stereochemically pure carbon-11 labeled native 
small peptides ready for in vivo studies. 
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Introduction 
 
Peptides possess many favorable properties as molecular imaging tracers, such as high 
affinity and specificity, and rapid clearance from the blood and non-targeted tissue. 
Radiolabeled peptides are versatile molecules to visualize numerous disease specific 
processes, using single-photon emission computed tomography (SPECT) and positron 
emission tomography (PET) and have gained strong attention as cancer imaging agents 
due to the over-expression of specific peptide receptors on tumor cells leading to high 
uptake and target-to-background ratios.[1–3]  
Specifically, radiolabeled somatostatin (SST) analogues have become indispensable tools 
for in vivo localization of tumors, their treatment and real-time monitoring of therapeutic 
response. SST is a naturally occurring peptide, existing in two biologically active forms with 
14 or 28 amino acids (AAs) residues, binding to SST receptors highly expressed on 
neuroendocrine tumors (NETs). Systematic truncation of STT-14 (plasma t1/2 = 2–3 min) led 
to the development of metabolically stabilized octapeptides, such as registered 111In-
labeled DTPA-octreotide for SPECT imaging of NETs and recent octreotide derivative 
[68Ga]DOTA-TATE.[4–6] 
 
Figure 1: Current approaches for octreotide radiolabeling and our proposed strategy for 
direct “native” 11C-radiolabeling. 
Subsequently, octreotide derivatives have been labeled with radiometals 68Ga (t1/2 = 
1.1h), 111In (t1/2 = 67.2h), 
177Lu (t1/2 = 160.8h), and 
99mTc (t1/2 = 6.0h), and non-metal 
isotopes, 18F (t1/2 = 1.8h) and 
11C (t1/2 = 20.4min).
[7–11] Since these octreotide derivatives 
are so successful, they provide an excellent case for a proof-of-principle radiolabeling with 
carbon-11 of our newly developed methology for introducing a carbon-11 label to yield a 
native radiolabeled peptide.  
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Subsequently, octreotide derivatives have been labeled with radiometals 68Ga (t1/2 = 
1.1h), 111In (t1/2 = 67.2h), 
177Lu (t1/2 = 160.8h), and 
99mTc (t1/2 = 6.0h), and non-metal 
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To date, peptide radiolabeling techniques to prepare  PET tracers have relied on 
introducing prosthetic groups on to the lead peptide (Figure 1) influencing 
pharmacokinetics, receptor affinity and selectivity.[3,8] Ideally, a radionuclide should be 
introduced into the native structure, in order to preserve its biological behavior. Despite 
these obvious advantages, direct labeling of “native” peptides without changing the 
molecular structure of the lead compound has rarely been examined in PET and thus far 
without success.[3,10] The presence of carbon in all AAs and peptides makes carbon-11 
(99% β+, 0.96 MeV) an ideal radionuclide for the synthesis of isotopologs of peptides.[12]  
Nevertheless, 11C remains almost unexplored in peptide labeling mainly due its short 
half-life and comparatively challenging radiolabeling procedures.[12–14]  
Previously, we reported the highly stereoselective synthesis of L/D-[11C]alanine[15] and L/D-
[11C]phenylalanine[16], using a commercially available quaternary ammonium salt phase-
transfer catalysts (PTC) with [11C]methyl iodide or [11C]benzyl iodide ([11C]BnI)[17]. 
Encouraged by reports of non-radioactive stereoselective peptide alkylation[18,19], we 
identified PTC alkylation of a prochiral glycine residue as a powerful approach towards 
native 11C-labeled small peptides, such as the SST pharmacophore.[18–21] To our knowledge 
no studies have described the native labeling of peptides with carbon-11 by employing an 
asymmetric alkylation reaction. 
The goal of this work is to develop a general methodology to obtain carbon-11 labeled 
“native” peptides, thus without structural changes, for PET imaging by asymmetric 
alkylation of peptides via [11C]BnI. As such we have investigated phase-transfer catalysis 
for diastereoselective alkylation of peptide backbones. The application of this 
methodology is demonstrated by the synthesis of tetrapeptide [11C]Phe-D-Trp-Lys-Thr, in 
its “native” form, which is the essential pharmacophore to image the SST receptor.[22,23]  
 
Results and Discussion 
 
To achieve stereoselective phase-transfer alkylation of the tetrapeptide, we 
constructed novel Schiff base-activated precursors 27 and 42 (Scheme 1A), as well as the 
two possible alkylation products as reference compounds for radiolabeling (30, 33, 45, 48; 
Scheme 1B). Peptide side-chains were acid-labile Boc/tBu protected for compatibility with 
PTC alkylation and rapid deprotection of the final 11C-labeled product. Solution-phase 
peptide synthesis was performed in 6 or 7 steps using standard coupling reactions, 
followed by hydrogenation or base deprotection (see Experimental Section).[24] In the final 
step to obtain precursor 27 and 42, free N-terminal amines were converted to the Schiff 
base by reaction with a benzophenone imine. 
[11C]BnI, required to synthesize our “native” peptide [11C]Phe-D-Trp-Lys-Thr,  was 
prepared manually from cyclotron produced [11C]CO2. The 3 step one-pot synthesis 
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involved an initial Grignard reaction with [11C]CO2 to yield a [
11C]benzoic acid, which has 
been further reduced and iodinated to  [11C]BnI, according to our previously report.[17] 
Based on the results of our enantioselective synthesis of L-[11C]phenylalanine[16], initial 
experiments of N-terminal glycine residue 11C-benzylation of 27 involved the 
combination of [11C]BnI in toluene and CsOH·H2O(s) with the aid of the chiral 
quaternary ammonium bromide catalyst, Cat 3. High radiochemical conversion 
(RCC) of [11C]BnI towards intermediate [11C]33 was achieved in 10 min (Scheme 2). 
Vigorous mixing using a helium flow (≈50 mL·min-1), excess of base and high 
precursor concentration did allow the formation of a diastereomeric mixture of 
L,D,L,L-[11C]30 and D,D,L,L-[11C]33 in >90% RCC. The highest incorporation was 
achieved when using 350 eq of CsOH·H2O(s) (relative to 27; Table 1) and further 
screening revealed an optimal concentration of 27 of >30 mM (Table 1; Entries 7-9). 
The excess base in the reaction was required for sufficient interfacial area between 
the two phases (solid-liquid PTC).  
 
Table 1: Investigation of N-terminal [11C]benzylation towards the diastereomeric mixture 
of  [11C]30 and [11C]33. 
Entry CsOH•H2O [equiv] [27] [mmol·L
-1] RCC [±SD;%][a] 
1 330 8 0* 
2 50 8 4 
3 150 8 25±10 (n=2) 
4 250 8 37 
5 350 8 61 
6 450 8 2 
7 350 10 22±1 (n=2) 
8 350 16 67 
9 350 31 93±2 (n=2) 
All reactions were conducted with 3.1 µmol of 27, [11C]BnI in toluene, CsOH•H2O and 25% of Cat 
3 at 0 °C for 10 min. [a]Radiochemical conversions were determined by HPLC. *No helium flow 
was used. 
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Scheme 2: Multi-step radiosynthesis of [11C]37. 
Gratified by rapid and near quantitative alkylation of 27 along with separation of both 
diastereomers, we turned our attention to inducing high diastereoselectivity with 
alternative PTCs (Figure 2) and reaction conditions. As control reactions, 11C-benzylation 
was achieved using the achiral catalyst TBAB (Table 2; Entries 1–5), resulting in excellent 
RCC and moderate diastereomeric excesses (de) of the D-isomer [11C]33 (63% de) at -10 
⁰C. Commercially available Maruoka catalysts[25] successfully maintained highly selective 
alkylation, but only moderate levels of stereochemical control using 2–4 equivalents of Cat 
2 and Cat 3 (Table 2; Entries 6-11; and Figure 3). 
 
 
Figure 2: Chiral PTCs explored in asymmetric phase-transfer alkylation. Cat 1, 3 and 5 are 
predicted to be L-isomer yielding catalysts, the others D-isomer, alkylating the precursor 
27. 
We did not observe sufficient chiral induction in utilizing [11C]BnI using Cat 1[26] and Cat 
5[27] (Figure 3). Importantly, among Cat 1, 3, and 5, all predicted to favor L-11C-alkylation, 
Cat 1 and Cat 5 have stronger effects on stereoselectivity, as compared to the reaction 
with no chiral catalyst present. C2-symmetric rigid quaternary spiro-ammonium salt 
Cat 7 induced mediocre levels of de and RCC (Figure 3), the latter likely a result of 
increased steric demand. Tartrate-derived diammonium Cat 8[28] exhibited a significant 
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catalytic efficiency affording the preferred formation of D-isomer in 75% de in high RCC 
(>90%) without undesired by-products (Figure 3). Once Cinchona alkaloid Cat 1 was 
found to be the privileged chiral inducer having the biggest influence on the de of 
the obtained product, pseudo-enantiomer cinchonine Cat 6 was synthesized, 
presuming it would improve stereo-induction towards D-product.[20] Indeed, Cat 6 
led to the highest diastereoselectivity of 94%, accompanied by high RCC without 
concomitant formation of by-products (Figure 3). Additionally, Cinchona alkaloid 
Cat 10, reported by Lygo[29], resulted in lower RCC and de (Figure 3), demonstrating 
the importance of O-alkylation in this class of catalysts.  
Table 2: Screening the conditions for Cat 2. 
Entry PTC [mol%]a T 
[⁰C] 
Time 
[min] 
RCC [±SD; %]b de 
[±SD; %]c
1 / 0 10 89.5±6.3 38.8±1.8 (n=2) 
2 / -10 10 94.1±1.3 63.3±1.4 (n=3) 
3 / -50 10 51.5±5.9 54.3±2.9 (n=2) 
4 / -78 10 18 55.8 
5 TBAB (200) -10 10 88.5±2.7 54.3±2.3 (n=3) 
6 Cat 2 (25) 0 10 94.9±0.5 39.7±1.9 (n=3) 
7 Cat 2 (25) -10 10 84.4±5.5 51.7±1.1 (n=3) 
8 Cat 2 (50) -10 10 93.1±2.7 54.2±6.1 (n=3) 
9 Cat 2 (120) -10 10 71.0±19.3 65.0±4.1 (n=3) 
10 Cat 2 (200) -10 10 95.4±2.0 66.7±2.4 (n=3) 
11 Cat 2 (400) -10 10 74.3±27.5 69.5±0.5 (n=3) 
12 Cat 2 (200) -10 5 77.6±12.7 68.7±3.2 (n=3) 
All reactions were conducted with 3.1 µmol of 27, 330-350 eq of CsOH•H2O and 100 µL of 
toluene for 10 min. [a]% of Cat is compared to precursor. [b]Radiochemical conversions were 
determined by HPLC. [c]Diastereomeric excess was determined by HPLC and calculated using 
the following formula: de (%)=((D-L)/(D+L)*100; D+L = 1, where D-isomer was dominant. 
As observed in initial alkylation reactions, the influence of the substrate peptidic 
backbone on diastereoselectivity was significant. To further investigate this 
precursor Gly-L,L,L-42 was subjected to alkyation with [11C]BnI in the presence and 
absence of Cinchona PTCs. Preferential formation of [11C]L,L,L,L-45 was achieved 
with superior Cat 1 and without PTC in 73-75% de with high RCC (Figure 4). On the 
other hand, alkylation using pseudo-enantiomer Cat 6 now proceeded in low de (17%; 
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Figure 4), clearly indicating the remote chirality control of the n+2/n+3 amino acids, and 
consistent with trends previously reported by Maruoka et al.[18] While the n+1 amino 
acid (in this case Trp(Boc)) appears to dominate diastereoselectivity in alkylation of the 
prochiral glycine residue. 
 
Figure 3: PTCs surveyed for the synthesis of [11C]33 (de is reported towards major D-
isomer). All reactions (n>3) were conducted with 3.1 µmol of 27, 2 eq of Cat, 350 eq 
of CsOH·H2O and 100 µL of toluene for 10 min at -10 ⁰C.  
Figure 4: Influence of the peptidic backbone on the stereoselectivity of the 
alkylation reaction and the stereoselective control of the matched and mismatched 
pseudo-enantiomer Cat 1 and Cat 6. 
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To translate our methodology and demonstrate the potential of this stereoselective 
alkylation for native peptide radiolabeling, 11C-benzylation of 27 with the aid of Cat 
3 was performed on a preparative scale followed by subsequent HPLC isolation to 
yield [11C]33 in a radiochemical purity (RCP) of ˃98% (n>3). Quantitative 
deprotection was achieved (RCC of ˃99%; n>3) in one step using a HCl at elevated T 
of 70 ⁰C. A fully automated radiosynthesis of [11C]37 resulted in an absolute yield of 
500-600 MBq (13-16 MCi), starting from 40 GBq (1.08 Ci), corresponding to a decay-
corrected radiochemical yield of 9-10%, calculated from [11C]CO2 (t1/2 20.4 min), and 
a molar activity of 15-35 GBq·µmol-1 all within 57 min (n>3).  
 
Summary and Conclusions 
 
Herein the first native 11C-labeled peptide is described by alkylation of a tetrapeptide 
Schiff base, which was achieved by an efficient 5-step reaction. A one-pot preparation 
of [11C]BnI, was followed by subsequent asymmetric phase-transfer catalysis of a 
Schiff base-activated tetrapeptide 27 with the aid of cinchonine Cat 6 and final 
acidic deprotection. Automation of a highly stereoselective N-terminal alkylation 
using Cinchona alkaloids enabled a reproducible and reliable new radiosynthetic 
method to access novel stereochemically pure carbon-11 labeled native small 
peptides ready for in vivo evaluation. 
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Experimental Section 
 
Materials and Methods 
 
General 
Chemicals were obtained commercially from Sigma-Aldrich, Bachem, Oakwood Chemicals, 
Novabiochem, Alfa Aesar, Tokyo Chemical Industry, Combi-Blocks, Chem-Impex and Wako 
Chemicals GmbH and used without further purification, unless otherwise stated. Solvents 
were purchased from Fisher (USA) and Sigma-Aldrich (USA) and used as received, unless 
otherwise stated. All deuterated solvents were purchased from Cambridge Isotopes 
(Cambridge, MA, USA). Reactions were performed at ambient T unless stated otherwise. 
Reactions were monitored by thin layer chromatography on pre-coated silica 60 F254 
aluminum or glass plates (Merck, Darmstadt, Germany). Spots were visualized by UV light 
(254 nm) and ninhydrine or bromocresol green stain. Solvents were evaporated under 
reduced pressure using a rotary evaporator (Heidolph, Laborota 4000, USA). Flash column 
chromatography was performed on a Biotage Isolera™ Prime (Biotage, USA) equipped 
with Biotage ZIP pre-packed flash cartridges. Yields refer to purified and spectroscopically 
pure compounds. 
NMR spectroscopy was performed on a Bruker 300 MHz spectrometer (Billerica, MA, USA) 
with chemical shifts (δ) reported in parts per million (ppm) relative to the solvent (CDCl3: 
1H 7.26 ppm, 13C 77.16 ppm; (CD3)2SO: 
1H 2.50 ppm (H2O: 
1H 3.33 ppm), 13C 39.52 ppm; 
CD3OD: 
1H 3.31 ppm, 13C 49.00 ppm), used as an internal standard (δ=0). Splitting patterns 
are indicated as s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet and br: broad 
peak, and J, coupling constant in Hz.  
In Boston-based laboratory, MA, USA, the analytical isocratic and gradient HPLC was 
performed on a Shimadzu SCL-10A station and LC-10AD pump with a Luna C18 5 μm (250 
x 4.6 mm) (A), Chirobiotic T2 5 µm (250*4.6 mm) (B) and Chiralcel OD 10 µm (250*4.6 
mm) (C) column with Shimadzu SPD-10AV detector (254 nm) and NaI radioactivity 
detector at ambient T. Acetonitrile (CH3CN) (D), methanol (MeOH) (E), n-hexane (F), 2-
propanol (G), water (H), buffer 1 (4 mM sodium formate and 4 % dimethylformamide 
(DMF) (I) and buffer 2 (10 mM phosphate buffer) (J) were used as mobile phases*. 
Chromatograms were acquired with Shimadzu Clarity software (version 6.1.0.130). Semi-
preparative isocratic HPLC was performed on TRACERlab FxN station and SYKAM S1122 
isocratic HPLC pump with Luna C18 10 μm (250 x 10 mm) column (K) using CH3CN/buffer 1 
(94/6, v/v) as a mobile phase, flow rate 5 mL·min-1 (Method 1) a TRACERlab FxN 
radioactivity detector and a TRACERlab FX software (version 2.2.2).  
*Method 2: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-96 % D; 10-
13 min: 96 % D; 13-15 min: 96-90 % D.  
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Method 3: solvents D/J (v/v), linear gradient, 0-1 min: 10 % D; 1-10 min:  10-90 % D; 10-11 
min: 90 % D; 11-12 min: 90-10 % D. 
In Amsterdam-based laboratory, the Netherlands, the analytical gradient HPLC was 
performed on a Jasco PU-2089 Plus station with a Luna C18 5 μm (250 x 4.6 mm) (A) and 
ReproSil 100 Chiral-AA 8 μm  (250 x 4.0 mm) (L) column with Jasco UV-2075 Plus UV 
detector and NaI Rayetest radioactivity detector at ambient temperature. CH3CN (D), 
buffer 1 (4 mM sodium formate and 4 % DMF) (I), MeOH (E) and water (H) were used as 
mobile phase. Chromatograms were acquired with Raytest GINA Star software (version 
5.8). Semi-preparative isocratic HPLC was performed on Jasco UV-2087 Plus station with 
Luna C18 10 μm (250 x 10 mm) column (K) CH3CN/buffer 3 (4 mM sodium formate) (M) 
(94/6, v/v) as a mobile phase, flow rate 6 mL·min-1 (Method 4), a homemade radioactivity 
detector and Jasco ChromNAV CFR software (version 1.14.01). 
*Method 5: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-97 % D; 10-
13 min: 97 % D; 13-15 min: 97-90 % D.  
Electrospray ionization (ESI) and atmospheric-pressure ionization (API) liquid 
chromatography–mass spectrometry (LC-MS) was carried out using Advion expression L 
Compact Mass Spectrometer instrument in a positive ion mode (see Figure 1 for 
instrument setting) and Hitachi L-6200A gradient pump with Agilent Zorbax XBC-C18 (2.1 x 
50 mm) (N) column. CH3CN (D) and water with 0.1 % formic acid (O) were used as mobile 
phase (Method 6). Spectra were acquired with Advion Mass Express and Advion Data 
Express (version 2.2.29.2).  
Method 6: solvents D/O (v/v), linear gradient, 0-2 min: 80 % D; 2-8 min:  80-99 % D; 8-10 
min: 99-80 % D; 10-15 min: 80 % D. 
 
Figure 5: Electrospray ionization (ESI) and atmospheric-pressure ionization (API) 
instrument setting using Advion Mass Express.  
 Electrospray ionization-high resolution mass spectrometry (ESI-HRMS) was carried out 
using Bruker microTOF-Q instrument in a positive ion mode (capillary potential of 4500 V).  
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Synthesis procedures and characterization data 
1. Preparation of precursor to Ph2N=C-Gly-D-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-OtBu 
Precursor synthesis has been repeated 4 times following same procedure. 
tert-butyl (3S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-6-((tert-butoxycarbonyl) 
amino)hexanamido)-3-(tert-butoxy)butanoate (21) 
The Cbz-Lys(Boc)-OH (2.47 g, 6.48 mmol, 1 equiv) was coupled to the H-Thr(tBu)-OtBu 
(1.50 g, 6.48 mmol, 1 equiv) in the presence of BOP (3.15 g, 7.13 mmol, 1.1 equiv) and 
DIPEA (2.80 mL, 16.2 mmol, 3 equiv) as a coupling reagents in DCM (60 mL) as a solvent. 
Coupling time was 24 h at ambient T. After the completion of the reaction, reaction 
mixture was concentrated and the residue was dissolved in ehtyl acetate (EtOAc) (70 mL). 
The EtOAc solution was washed with 1 M KHSO4 (3 x 30 mL), 10 % K2CO3 (3 x 30 mL) and 
brine (3 x 30 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue was 
purified using column chromatography to yield colorless precipitate (3.74 g, 97.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 7.37-7.30 (m, 5 H), 6.44 (d, J=8.9 Hz, 1 H), 5.51 (d, 
J=7.3 Hz, 1 H), 5.11 (s, 2 H), 4.72 (br s, 1 H), 4.32 (dd, J1=2.0 Hz, J2=8.2 Hz, 1 H), 4.27-4.23 
(m, 1 H), 4.22-4.18 (m, 1 H), 3.11 (br s, 2 H), 1.94-1.82 (m, 1 H), 1.72-1.68 (m, 1 H), 1.66-
1.64 (m, 2 H), 1.46 (s, 9 H), 1.43 (s, 9 H), 1.16 (s, 9 H), 1.13 (s, 3 H) ppm. 13C NMR (75 MHz, 
CDCl3, ambient T): δ 171.8, 169.7, 156.2, 136.5, 128.6, 128.2, 82.2, 79.2, 74.1, 67.2, 58.6, 
54.8, 40.2, 33.0, 29.7, 28.6, 28.3, 22.4, 21.1 ppm. MS (m/z): calculated for C31H52N3O8, 
594.37; found 594.6 [M+H]+; 616.7 [M+Na]+. 
tert-butyl (3S)-2-((S)-2-amino-6-((tert-butoxycarbonyl)amino)hexanamido)-3-(tert-
butoxy)butanoate (22) 
The Cbz-Lys(Boc)-Thr(tBu)-OtBu (1.65 g, 2.78 mmol, 1 equiv) was dissolved in 13 mL of 
MeOH and stirred under argon atmosphere for 10 min. Afterwards 10 % Pd/C (m/m) was 
added to the reaction vessel and argon atmosphere was replaced with hydrogen. The 
reaction mixture was vigorously stirred overnight at ambient T under ordinary hydrogen 
pressure (2 balloons) for 24 h. The mixture was filtered and concentrated to afford the 
colorless oil (1.14 g, 89.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 7.59 (d, J=9.1 Hz, 5 H), 4.60 (br s, 1 H), 4.29 (dd, 
J1=2.5 Hz, J2=9.1 Hz, 1 H), 4.22-4.16 (m, 1 H), 3.42 (q, J1=4.5 Hz, J2=3.1 Hz, 1 H), 3.14-3.10 
(m, 2 H), 1.89-1.80 (m, 1 H), 1.60-1.52 (m, 3 H), 1.46 (s, 9 H), 1.43 (s, 9 H), 1.18 (s, 9 H), 
1.15 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 175.5, 170.2, 156.2, 
81.9, 73.9, 67.4, 58.3, 55.5, 40.4, 34.9, 30.0, 28.9, 28.6, 28.3, 23.1, 21.1 ppm. MS (m/z): 
calculated for C23H46N3O6, 460.34; found 460.0 [M+H]
+. 
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Method 3: solvents D/J (v/v), linear gradient, 0-1 min: 10 % D; 1-10 min:  10-90 % D; 10-11 
min: 90 % D; 11-12 min: 90-10 % D. 
In Amsterdam-based laboratory, the Netherlands, the analytical gradient HPLC was 
performed on a Jasco PU-2089 Plus station with a Luna C18 5 μm (250 x 4.6 mm) (A) and 
ReproSil 100 Chiral-AA 8 μm  (250 x 4.0 mm) (L) column with Jasco UV-2075 Plus UV 
detector and NaI Rayetest radioactivity detector at ambient temperature. CH3CN (D), 
buffer 1 (4 mM sodium formate and 4 % DMF) (I), MeOH (E) and water (H) were used as 
mobile phase. Chromatograms were acquired with Raytest GINA Star software (version 
5.8). Semi-preparative isocratic HPLC was performed on Jasco UV-2087 Plus station with 
Luna C18 10 μm (250 x 10 mm) column (K) CH3CN/buffer 3 (4 mM sodium formate) (M) 
(94/6, v/v) as a mobile phase, flow rate 6 mL·min-1 (Method 4), a homemade radioactivity 
detector and Jasco ChromNAV CFR software (version 1.14.01). 
*Method 5: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-97 % D; 10-
13 min: 97 % D; 13-15 min: 97-90 % D.  
Electrospray ionization (ESI) and atmospheric-pressure ionization (API) liquid 
chromatography–mass spectrometry (LC-MS) was carried out using Advion expression L 
Compact Mass Spectrometer instrument in a positive ion mode (see Figure 1 for 
instrument setting) and Hitachi L-6200A gradient pump with Agilent Zorbax XBC-C18 (2.1 x 
50 mm) (N) column. CH3CN (D) and water with 0.1 % formic acid (O) were used as mobile 
phase (Method 6). Spectra were acquired with Advion Mass Express and Advion Data 
Express (version 2.2.29.2).  
Method 6: solvents D/O (v/v), linear gradient, 0-2 min: 80 % D; 2-8 min:  80-99 % D; 8-10 
min: 99-80 % D; 10-15 min: 80 % D. 
 
Figure 5: Electrospray ionization (ESI) and atmospheric-pressure ionization (API) 
instrument setting using Advion Mass Express.  
 Electrospray ionization-high resolution mass spectrometry (ESI-HRMS) was carried out 
using Bruker microTOF-Q instrument in a positive ion mode (capillary potential of 4500 V).  
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Synthesis procedures and characterization data 
1. Preparation of precursor to Ph2N=C-Gly-D-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-OtBu 
Precursor synthesis has been repeated 4 times following same procedure. 
tert-butyl (3S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-6-((tert-butoxycarbonyl) 
amino)hexanamido)-3-(tert-butoxy)butanoate (21) 
The Cbz-Lys(Boc)-OH (2.47 g, 6.48 mmol, 1 equiv) was coupled to the H-Thr(tBu)-OtBu 
(1.50 g, 6.48 mmol, 1 equiv) in the presence of BOP (3.15 g, 7.13 mmol, 1.1 equiv) and 
DIPEA (2.80 mL, 16.2 mmol, 3 equiv) as a coupling reagents in DCM (60 mL) as a solvent. 
Coupling time was 24 h at ambient T. After the completion of the reaction, reaction 
mixture was concentrated and the residue was dissolved in ehtyl acetate (EtOAc) (70 mL). 
The EtOAc solution was washed with 1 M KHSO4 (3 x 30 mL), 10 % K2CO3 (3 x 30 mL) and 
brine (3 x 30 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue was 
purified using column chromatography to yield colorless precipitate (3.74 g, 97.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 7.37-7.30 (m, 5 H), 6.44 (d, J=8.9 Hz, 1 H), 5.51 (d, 
J=7.3 Hz, 1 H), 5.11 (s, 2 H), 4.72 (br s, 1 H), 4.32 (dd, J1=2.0 Hz, J2=8.2 Hz, 1 H), 4.27-4.23 
(m, 1 H), 4.22-4.18 (m, 1 H), 3.11 (br s, 2 H), 1.94-1.82 (m, 1 H), 1.72-1.68 (m, 1 H), 1.66-
1.64 (m, 2 H), 1.46 (s, 9 H), 1.43 (s, 9 H), 1.16 (s, 9 H), 1.13 (s, 3 H) ppm. 13C NMR (75 MHz, 
CDCl3, ambient T): δ 171.8, 169.7, 156.2, 136.5, 128.6, 128.2, 82.2, 79.2, 74.1, 67.2, 58.6, 
54.8, 40.2, 33.0, 29.7, 28.6, 28.3, 22.4, 21.1 ppm. MS (m/z): calculated for C31H52N3O8, 
594.37; found 594.6 [M+H]+; 616.7 [M+Na]+. 
tert-butyl (3S)-2-((S)-2-amino-6-((tert-butoxycarbonyl)amino)hexanamido)-3-(tert-
butoxy)butanoate (22) 
The Cbz-Lys(Boc)-Thr(tBu)-OtBu (1.65 g, 2.78 mmol, 1 equiv) was dissolved in 13 mL of 
MeOH and stirred under argon atmosphere for 10 min. Afterwards 10 % Pd/C (m/m) was 
added to the reaction vessel and argon atmosphere was replaced with hydrogen. The 
reaction mixture was vigorously stirred overnight at ambient T under ordinary hydrogen 
pressure (2 balloons) for 24 h. The mixture was filtered and concentrated to afford the 
colorless oil (1.14 g, 89.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 7.59 (d, J=9.1 Hz, 5 H), 4.60 (br s, 1 H), 4.29 (dd, 
J1=2.5 Hz, J2=9.1 Hz, 1 H), 4.22-4.16 (m, 1 H), 3.42 (q, J1=4.5 Hz, J2=3.1 Hz, 1 H), 3.14-3.10 
(m, 2 H), 1.89-1.80 (m, 1 H), 1.60-1.52 (m, 3 H), 1.46 (s, 9 H), 1.43 (s, 9 H), 1.18 (s, 9 H), 
1.15 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 175.5, 170.2, 156.2, 
81.9, 73.9, 67.4, 58.3, 55.5, 40.4, 34.9, 30.0, 28.9, 28.6, 28.3, 23.1, 21.1 ppm. MS (m/z): 
calculated for C23H46N3O6, 460.34; found 460.0 [M+H]
+. 
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tert-butyl 3-((2R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(((10S)-13-((S)-1-
(tert-butoxy)ethyl) -2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-
diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (23) 
The Fmoc-D-Trp(Boc)-OH (1.26 g, 2.40 mmol, 1 equiv) was coupled to the H-Lys(Boc)-
Thr(tBu)-OtBu (1.10 g, 2.40 mmol, 1 equiv) in the presence of HATU (1.37 g, 3.59 mmol, 1.5 
equiv) and DIPEA (1.26 mL, 7.19 mmol, 3 equiv) as a coupling reagents in DCM (13 mL) and 
DMF (2 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (30 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 30 mL), 10 % K2CO3 (3 x 15 mL) 
and brine (3 x 15 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (1.33 g, 80.2 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.5 Hz, 1 H), 7.75 (d, J=7.5 Hz, 2 H), 7.67-
7.65 (m, 1 H), 7.56-7.52 (m, 2 H), 7.47 (s, 1 H), 7.42-7.29 (m, 6 H), 6.39 (d, J=9.8 Hz, 1 H), 
5.55 (br s, 1 H), 4.86 (br s, 1 H), 4.54- (br s, 1 H), 4.44-4.359 (m, 3 H), 4.26-4.16 (m, 3 H), 
3.22-3.20 (m, 2 H), 3.04-2.97 (m, 3 H), 1.65 (s, 9 H), 1.44 (s, 9 H), 1.42 (s, 9 H), 1.34 (m, 2 H) 
1.15 (s, 9 H), 1.11 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.1, 
170.5, 169.6, 156.2, 149.7, 143.9, 141.4, 135.6, 130.3, 127.9, 127.3, 125.2, 124.9, 124.4, 
123.0, 120.1, 119.2, 115.5, 83.99, 82.3, 79.0, 74.1, 67.4, 67.1, 58.6, 55.4, 47.2, 40.0, 32.4, 
29.5, 28.8, 28.6, 28.3, 28.2, 22.1, 21.2 ppm. MS (m/z): calculated for C54H74N5O11, 968.54; 
found 968.0 [M+H]+; 990.0 [M+Na]+. 
tert-butyl 3-((2R)-2-amino-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (24) 
The Fmoc-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (1.27 g, 1.31 mmol, 1 equiv) was dissolved in 
DCM (10 mL). TAEA (9.20 mL, 61.4 mmol, 50 equiv) was added and stirred for 15 min at 
ambient T. After completion, the reaction mixture was extracted with brine (1 x 5 mL) and 
phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was performed with 
DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, filtrated and 
evaporated in vacuo. The residue was purified using column chromatography to yield 
white precipitate (860 mg, 95.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.13 (d, J=7.5 Hz, 1 H), 7.80 (d, J=8.2 Hz, 1 H), 7.63 
(d, J=7.7 Hz, 1 H), 7.41 (s, 1 H), 7.36-7.31 (m, 2 H), 6.53 (d, J=8.9 Hz, 1 H), 4.75 (br s, 1 H),  
4.56-4.49 (m, 1 H), 4.33 (dd, J1=2.0 Hz, J2=7.3 Hz, 1 H), 4.26-4.20 (m, 1 H), 3.75 (dd, J1=3.8 
Hz, J2=6.5 Hz, 1 H), 3.43 (dd, J1=3.9 Hz, J2=10.7 Hz, 1 H),  3.13-3.07 (m, 2 H), 2.69 (q,  J1=4.1 
Hz, J2=10.4 Hz, 1 H), 1.91-1.85 (m, 1 H), 1.68 (s, 9 H), 1.47 (s, 9 H), 1.43 (s, 9 H), 1.17 (s, 9 
H), 1.16 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 174.5, 171.7, 169.7, 156.2, 
149.8, 135.8, 130.3, 124.8, 124.3, 122.8, 119.3, 117.0, 115.5, 83.6, 82.2, 79.1, 74.0, 67.2, 
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58.6, 55.2, 52.7, 40.5, 32.5, 29.8, 28.9, 28.6, 28.4, 28.3, 22.7, 21.2 ppm. MS (m/z): 
calculated for C39H64N5O9, 746.47; found 746.7 [M+H]
+. 
tert-butyl 3-((2R)-2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)-3-(((10S)-
13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-
diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (25) 
The Cbz-Gly-OH (299 mg, 1.00 mmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (500 mg, 670 µmol, 1 equiv) in the presence of HATU (382 mg, 1.00 mmol, 
1.5 equiv) and DIPEA (350 µL, 2.01 mmol, 3 equiv) as a coupling reagents in DCM (10 mL) 
and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of 
the reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc 
(10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (468 mg, 75.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=8.2 Hz, 1 H), 7.76 (d, J=7.5 Hz, 2 H), 7.65-
7.61 (m, 3 H), 7.59 (s, 1 H), 7.46-7.40 (m, 2 H), 7.38-7.29 (m, 3 H), 7.24-7.22 (m, 1 H), 6.86 
(d, J=7.2 Hz, 1 H), 6.59 (d, J=7.0 Hz, 1 H), 6.51 (d, J=8.88 Hz, 1 H), 5.62 (br s, 1 H), 4.88-4.82 
(m, 2 H), 4.42-4.39 (m, 3 H), 4.22 (d, J1=7.0 Hz, 1 H), 4.21-4.14 (m, 2 H), 3.97-3.81 (m, 2 H), 
3.27-3.12 (m, 2 H), 2.98-2.94 (m, 2 H), 1.65 (s, 9 H), 1.43 (s, 18 H), 1.37-1.31 (m, 2 H), 1.14 
(s, 9 H), 1.10 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.3, 170.4, 
169.8, 169.0, 156.2, 149.7, 143.9, 141.4, 135.5, 130.4, 127.9, 127.2, 125.2, 124.9, 124.4, 
123.0, 120.1, 119.1, 115.5, 84.0, 82.3, 79.1, 74.1, 67.5, 67.3, 58.5, 53.8, 53.3, 47.2, 44.7, 
40.0, 32.2, 29.5, 28.8, 28.6, 28.3, 28.2, 22.2, 21.0 ppm. MS (m/z): calculated for 
C54H77N6O12, 1025.56; found 1025.4 [M+H]
+. 
tert-butyl 3-((2R)-2-(2-aminoacetamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-
tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-
1H-indole-1-carboxylate (26) 
The Fmoc-Gly-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (415 mg, 404 µmol, 1 equiv) was 
dissolved in DCM (3 mL). TAEA (3.03 mL, 20.0 mmol, 50 equiv) was added and stirred for 
15 min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 
5 mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (205 mg, 63.0 %).  
1H NMR (300 MHz, CDCl3, ambient  T): δ 8.10 (d, J=7.8 Hz, 1 H), 7.82 (d, J=6.6 Hz, 1 H), 7.65 
(d, J=7.4 Hz, 1 H), 7.47 (s, 1 H), 7.34-7.29 (m, 1 H), 7.25-7.23 (m, 1 H), 6.62 (d, J=6.7 Hz, 1 
H), 6.39 (d, J=8.8 Hz, 1 H), 4.89 (br s, 1 H), 4.76 (q, J1=7.4 Hz, J2=7.2 Hz, 1 H), 4.44 (q, J1=7.3 
Hz, J2=7.2 Hz, 1 H), 4.19 (d, J1=4.0 Hz, J2=2.1 Hz, 1 H), 4.15 (q, J1=4.3 Hz, J2=2.0 Hz, 1 H), 
3.35-3.30 (m, 2 H), 3.27-3.14 (m, 2 H), 3.04-2.97 (m, 2 H), 1.67 (s, 9 H), 1.44 (s, 9 H), 1.43 
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tert-butyl 3-((2R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(((10S)-13-((S)-1-
(tert-butoxy)ethyl) -2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-
diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (23) 
The Fmoc-D-Trp(Boc)-OH (1.26 g, 2.40 mmol, 1 equiv) was coupled to the H-Lys(Boc)-
Thr(tBu)-OtBu (1.10 g, 2.40 mmol, 1 equiv) in the presence of HATU (1.37 g, 3.59 mmol, 1.5 
equiv) and DIPEA (1.26 mL, 7.19 mmol, 3 equiv) as a coupling reagents in DCM (13 mL) and 
DMF (2 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (30 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 30 mL), 10 % K2CO3 (3 x 15 mL) 
and brine (3 x 15 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (1.33 g, 80.2 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.5 Hz, 1 H), 7.75 (d, J=7.5 Hz, 2 H), 7.67-
7.65 (m, 1 H), 7.56-7.52 (m, 2 H), 7.47 (s, 1 H), 7.42-7.29 (m, 6 H), 6.39 (d, J=9.8 Hz, 1 H), 
5.55 (br s, 1 H), 4.86 (br s, 1 H), 4.54- (br s, 1 H), 4.44-4.359 (m, 3 H), 4.26-4.16 (m, 3 H), 
3.22-3.20 (m, 2 H), 3.04-2.97 (m, 3 H), 1.65 (s, 9 H), 1.44 (s, 9 H), 1.42 (s, 9 H), 1.34 (m, 2 H) 
1.15 (s, 9 H), 1.11 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.1, 
170.5, 169.6, 156.2, 149.7, 143.9, 141.4, 135.6, 130.3, 127.9, 127.3, 125.2, 124.9, 124.4, 
123.0, 120.1, 119.2, 115.5, 83.99, 82.3, 79.0, 74.1, 67.4, 67.1, 58.6, 55.4, 47.2, 40.0, 32.4, 
29.5, 28.8, 28.6, 28.3, 28.2, 22.1, 21.2 ppm. MS (m/z): calculated for C54H74N5O11, 968.54; 
found 968.0 [M+H]+; 990.0 [M+Na]+. 
tert-butyl 3-((2R)-2-amino-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (24) 
The Fmoc-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (1.27 g, 1.31 mmol, 1 equiv) was dissolved in 
DCM (10 mL). TAEA (9.20 mL, 61.4 mmol, 50 equiv) was added and stirred for 15 min at 
ambient T. After completion, the reaction mixture was extracted with brine (1 x 5 mL) and 
phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was performed with 
DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, filtrated and 
evaporated in vacuo. The residue was purified using column chromatography to yield 
white precipitate (860 mg, 95.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.13 (d, J=7.5 Hz, 1 H), 7.80 (d, J=8.2 Hz, 1 H), 7.63 
(d, J=7.7 Hz, 1 H), 7.41 (s, 1 H), 7.36-7.31 (m, 2 H), 6.53 (d, J=8.9 Hz, 1 H), 4.75 (br s, 1 H),  
4.56-4.49 (m, 1 H), 4.33 (dd, J1=2.0 Hz, J2=7.3 Hz, 1 H), 4.26-4.20 (m, 1 H), 3.75 (dd, J1=3.8 
Hz, J2=6.5 Hz, 1 H), 3.43 (dd, J1=3.9 Hz, J2=10.7 Hz, 1 H),  3.13-3.07 (m, 2 H), 2.69 (q,  J1=4.1 
Hz, J2=10.4 Hz, 1 H), 1.91-1.85 (m, 1 H), 1.68 (s, 9 H), 1.47 (s, 9 H), 1.43 (s, 9 H), 1.17 (s, 9 
H), 1.16 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 174.5, 171.7, 169.7, 156.2, 
149.8, 135.8, 130.3, 124.8, 124.3, 122.8, 119.3, 117.0, 115.5, 83.6, 82.2, 79.1, 74.0, 67.2, 
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58.6, 55.2, 52.7, 40.5, 32.5, 29.8, 28.9, 28.6, 28.4, 28.3, 22.7, 21.2 ppm. MS (m/z): 
calculated for C39H64N5O9, 746.47; found 746.7 [M+H]
+. 
tert-butyl 3-((2R)-2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)-3-(((10S)-
13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-
diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (25) 
The Cbz-Gly-OH (299 mg, 1.00 mmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (500 mg, 670 µmol, 1 equiv) in the presence of HATU (382 mg, 1.00 mmol, 
1.5 equiv) and DIPEA (350 µL, 2.01 mmol, 3 equiv) as a coupling reagents in DCM (10 mL) 
and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of 
the reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc 
(10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (468 mg, 75.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=8.2 Hz, 1 H), 7.76 (d, J=7.5 Hz, 2 H), 7.65-
7.61 (m, 3 H), 7.59 (s, 1 H), 7.46-7.40 (m, 2 H), 7.38-7.29 (m, 3 H), 7.24-7.22 (m, 1 H), 6.86 
(d, J=7.2 Hz, 1 H), 6.59 (d, J=7.0 Hz, 1 H), 6.51 (d, J=8.88 Hz, 1 H), 5.62 (br s, 1 H), 4.88-4.82 
(m, 2 H), 4.42-4.39 (m, 3 H), 4.22 (d, J1=7.0 Hz, 1 H), 4.21-4.14 (m, 2 H), 3.97-3.81 (m, 2 H), 
3.27-3.12 (m, 2 H), 2.98-2.94 (m, 2 H), 1.65 (s, 9 H), 1.43 (s, 18 H), 1.37-1.31 (m, 2 H), 1.14 
(s, 9 H), 1.10 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.3, 170.4, 
169.8, 169.0, 156.2, 149.7, 143.9, 141.4, 135.5, 130.4, 127.9, 127.2, 125.2, 124.9, 124.4, 
123.0, 120.1, 119.1, 115.5, 84.0, 82.3, 79.1, 74.1, 67.5, 67.3, 58.5, 53.8, 53.3, 47.2, 44.7, 
40.0, 32.2, 29.5, 28.8, 28.6, 28.3, 28.2, 22.2, 21.0 ppm. MS (m/z): calculated for 
C54H77N6O12, 1025.56; found 1025.4 [M+H]
+. 
tert-butyl 3-((2R)-2-(2-aminoacetamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-
tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-
1H-indole-1-carboxylate (26) 
The Fmoc-Gly-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (415 mg, 404 µmol, 1 equiv) was 
dissolved in DCM (3 mL). TAEA (3.03 mL, 20.0 mmol, 50 equiv) was added and stirred for 
15 min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 
5 mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (205 mg, 63.0 %).  
1H NMR (300 MHz, CDCl3, ambient  T): δ 8.10 (d, J=7.8 Hz, 1 H), 7.82 (d, J=6.6 Hz, 1 H), 7.65 
(d, J=7.4 Hz, 1 H), 7.47 (s, 1 H), 7.34-7.29 (m, 1 H), 7.25-7.23 (m, 1 H), 6.62 (d, J=6.7 Hz, 1 
H), 6.39 (d, J=8.8 Hz, 1 H), 4.89 (br s, 1 H), 4.76 (q, J1=7.4 Hz, J2=7.2 Hz, 1 H), 4.44 (q, J1=7.3 
Hz, J2=7.2 Hz, 1 H), 4.19 (d, J1=4.0 Hz, J2=2.1 Hz, 1 H), 4.15 (q, J1=4.3 Hz, J2=2.0 Hz, 1 H), 
3.35-3.30 (m, 2 H), 3.27-3.14 (m, 2 H), 3.04-2.97 (m, 2 H), 1.67 (s, 9 H), 1.44 (s, 9 H), 1.43 
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(s, 9 H), 1.39-1.37 (m, 2 H), 1.16 (s, 9 H), 1.12 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, 
CDCl3, ambient T): δ 173.2, 171.2, 170.7, 169.6, 156.2, 149.8, 135.5, 130.5, 124.8, 124.3, 
122.8, 119.3, 115.4, 83.9, 82.2, 79.0, 74.1, 67.2, 58.5, 53.5, 53.1, 44.8, 40.1, 32.4, 29.5, 
28.8, 28.6, 28.4, 28.3, 27.9, 22.2, 21.1 ppm. MS (m/z): calculated for C41H67N6O10, 803.49; 
found 803.6 [M+H]+. 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-(2-
((diphenylmethylene)amino)acetamido)-3-oxopropyl)-1H-indole-1-carboxylate (27) 
To a solution of the H-Gly-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (190 mg, 237 µmol, 1 equiv) 
in DCM (3 mL) was added benzophenone imine (83.0 µL, 495 µmol, 2 equiv), dissolved in 
DCM (3 mL). Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (153 
mg, 67.0 %, ˃98 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=15.1 min]).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.15 (d, J=7.7 Hz, 1 H), 8.11 (d, J=7.9 Hz, 1 H), 7.68 
(d, J=7.5 Hz, 1 H), 7.57-7.28 (m, 11 H), 7.20 (t, J=7.8 Hz, 1 H), 7.10-7.07 (m, 2 H), 6.53 (d, 
J=7.9 Hz, 1 H), 6.39 (d, J=8.8 Hz, 1 H), 4.92 (br s, 1 H), 4.89-4.82 (m, 1 H), 4.43 (q, J1=6.5 Hz, 
J2=7.3 Hz, 1 H), 4.25 (dd, J1=1.9 Hz, J2=6.9 Hz, 1 H), 4.19-4.14 (m, 1 H), 3.95 (d, J=5.0 Hz, 2 
H), 3.28 (d, J=5.0 Hz, 2 H), 3.02-2.99 (m, 2 H), 1.63 (s, 9 H), 1.43 (s, 9 H), 1.42 (s, 9 H), 1.37-
1.33 (m, 2 H), 1.14 (s, 9 H), 1.10 (d, J=6.9 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient 
T): δ 171.1, 170.6, 170.5, 169.6, 156.2, 149.7, 138.7, 136.2, 130.8, 130.4, 129.1, 129.0, 
128.6, 128.4, 127.3, 124.8, 124.4, 122.9, 119.4, 115.9, 115.4, 83.9, 82.2, 74.1, 67.1, 58.6, 
56.5, 53.6, 53.1, 32.4, 28.8, 28.6, 28.5, 28.3, 22.1, 21.1 ppm. MS (m/z): calculated for 
C54H75N6O10, 967.56; found 967.1 [M+H]
+; 998.1 [M+Na]+. HR-MS (m/z): calculated for 
C54H75N6O10, 967.56; found 967.5524 [M+H]
+.  
2. Preparation of intermediate to Ph2N=C-L-Phe-D-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-
OtBu 
tert-butyl 3-((2R)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (28) 
The Fmoc-L-Phe-OH (117 mg, 302 µmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-
Lys(Boc)-Thr(tBu)-OtBu (150 mg, 201 µmol, 1 equiv) in the presence of HATU (115 mg, 302 
µmol, 1.5 equiv) and DIPEA (105 µL, 603 µmol, 3 equiv) as a coupling reagents in DCM (2 
mL) and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the 
completion of the reaction, reaction mixture was concentrated and the residue was 
dissolved in EtOAc (10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 
% K2CO3 (3 x 5 mL) and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in 
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vacuo. The residue was purified using column chromatography to yield colorless oil (102 
mg, 46.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.12 (d, J=7.1 Hz, 1 H), 7.79-7.75 (m, 3 H), 7.61-
7.52 (m, 4 H), 7.42-7.40 (m, 3 H), 7.38-7.34 (m, 4 H), 7.32-7.30 (m, 2 H), 7.17-7.09 (m, 2 H), 
6.53 (br s, 1 H), 6.45 (d, J=9.2 Hz, 1 H), 5.53 (br s, 1 H), 4.89 (br s, 1 H), 4.70-4.68 (m, 1 H), 
4.48-4.36 (m, 5 H), 4.31-4.17 (m, 2 H), 2.99 (br s, 6 H), 1.67 (s, 9 H), 1.43 (s, 9 H), 1.42 (s, 9 
H), 1.35-1.30 (m, 3 H), 1.11 (s, 9 H), 1.09 (d, J=6.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 178.2, 171.4, 170.0, 156.2, 149.6, 143.8, 141.4, 136.2, 129.5, 129.2, 128.8, 
127.9, 127.3, 125.2, 124.9, 122.9, 120.1, 119.1, 115.5, 83.9, 82.3, 74.0, 67.3, 58.4, 56.9, 
53.6, 52.5, 47.2, 40.1, 32.0, 29.6, 28.8, 28.6, 28.4, 22.3, 21.0 ppm. MS (m/z): calculated for 
C63H83N6O12, 1115.61; found 1115.9 [M+H]
+. 
tert-butyl 3-((2R)-2-((S)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (29) 
The Fmoc-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (90.0 mg, 80.0 µmol, 1 equiv) was 
dissolved in DCM (2 mL). TAEA (0.60 mL, 4.00 mmol, 50 equiv) was added and stirred for 
15 min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 
5 mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (33.0 mg, 46.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.10 (d, J=7.9 Hz, 1 H), 7.81 (d, J=7.5 Hz, 1 H), 7.66 
(d, J=7.2 Hz, 1 H), 7.46 (s, 1 H), 7.34-7.29 (m, 3 H), 7.25-7.18 (m, 4 H), 6.59 (d, J=7.1 Hz, 1 
H), 6.39 (d, J=9.1 Hz, 1 H), 4.93 (br s, 1 H), 4.72 (q, J1=7.7 Hz, J2=7.0 Hz, 1 H), 4.41 (q, J1=7.1 
Hz, J2=6.7 Hz,  1 H), 4.27 (d, J=7.4 Hz, 1 H), 4.21-4.17 (m, 1 H), 3.56-3.52 (m, 1 H), 3.31-3.25 
(m, 3 H), 3.19-2.99 (m, 3 H), 2.65-2.58 (m, 1 H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.43 (s, 9 H), 
1.38-1.32 (m, 2 H), 1.16 (s, 9 H), 1.13 (d, J=6.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 177.6, 170.6, 169.6, 156.2, 154.1, 149.8, 135.7, 130.5, 129.4, 128.8, 124.8, 
124.3, 122.9, 119.3, 115.9, 115.4, 82.2, 79.1, 74.1, 67.2, 58.5, 57.6, 56.4, 53.4, 32.4, 28.8, 
28.6, 28.4, 28.3, 27.7, 21.0 ppm. MS (m/z): calculated for C48H73N6O10, 893.54; found 893.9 
[M+H]+; 915.9 [M+Na]+.  
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (30) 
To a solution of the H-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (28.0 mg, 32.0 µmol, 1 equiv) 
in DCM (1 mL) was added benzophenone imine (11.8 µL, 64.0 µmol, 2 equiv), dissolved in 
1 mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
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(s, 9 H), 1.39-1.37 (m, 2 H), 1.16 (s, 9 H), 1.12 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, 
CDCl3, ambient T): δ 173.2, 171.2, 170.7, 169.6, 156.2, 149.8, 135.5, 130.5, 124.8, 124.3, 
122.8, 119.3, 115.4, 83.9, 82.2, 79.0, 74.1, 67.2, 58.5, 53.5, 53.1, 44.8, 40.1, 32.4, 29.5, 
28.8, 28.6, 28.4, 28.3, 27.9, 22.2, 21.1 ppm. MS (m/z): calculated for C41H67N6O10, 803.49; 
found 803.6 [M+H]+. 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-(2-
((diphenylmethylene)amino)acetamido)-3-oxopropyl)-1H-indole-1-carboxylate (27) 
To a solution of the H-Gly-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (190 mg, 237 µmol, 1 equiv) 
in DCM (3 mL) was added benzophenone imine (83.0 µL, 495 µmol, 2 equiv), dissolved in 
DCM (3 mL). Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (153 
mg, 67.0 %, ˃98 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=15.1 min]).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.15 (d, J=7.7 Hz, 1 H), 8.11 (d, J=7.9 Hz, 1 H), 7.68 
(d, J=7.5 Hz, 1 H), 7.57-7.28 (m, 11 H), 7.20 (t, J=7.8 Hz, 1 H), 7.10-7.07 (m, 2 H), 6.53 (d, 
J=7.9 Hz, 1 H), 6.39 (d, J=8.8 Hz, 1 H), 4.92 (br s, 1 H), 4.89-4.82 (m, 1 H), 4.43 (q, J1=6.5 Hz, 
J2=7.3 Hz, 1 H), 4.25 (dd, J1=1.9 Hz, J2=6.9 Hz, 1 H), 4.19-4.14 (m, 1 H), 3.95 (d, J=5.0 Hz, 2 
H), 3.28 (d, J=5.0 Hz, 2 H), 3.02-2.99 (m, 2 H), 1.63 (s, 9 H), 1.43 (s, 9 H), 1.42 (s, 9 H), 1.37-
1.33 (m, 2 H), 1.14 (s, 9 H), 1.10 (d, J=6.9 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient 
T): δ 171.1, 170.6, 170.5, 169.6, 156.2, 149.7, 138.7, 136.2, 130.8, 130.4, 129.1, 129.0, 
128.6, 128.4, 127.3, 124.8, 124.4, 122.9, 119.4, 115.9, 115.4, 83.9, 82.2, 74.1, 67.1, 58.6, 
56.5, 53.6, 53.1, 32.4, 28.8, 28.6, 28.5, 28.3, 22.1, 21.1 ppm. MS (m/z): calculated for 
C54H75N6O10, 967.56; found 967.1 [M+H]
+; 998.1 [M+Na]+. HR-MS (m/z): calculated for 
C54H75N6O10, 967.56; found 967.5524 [M+H]
+.  
2. Preparation of intermediate to Ph2N=C-L-Phe-D-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-
OtBu 
tert-butyl 3-((2R)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (28) 
The Fmoc-L-Phe-OH (117 mg, 302 µmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-
Lys(Boc)-Thr(tBu)-OtBu (150 mg, 201 µmol, 1 equiv) in the presence of HATU (115 mg, 302 
µmol, 1.5 equiv) and DIPEA (105 µL, 603 µmol, 3 equiv) as a coupling reagents in DCM (2 
mL) and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the 
completion of the reaction, reaction mixture was concentrated and the residue was 
dissolved in EtOAc (10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 
% K2CO3 (3 x 5 mL) and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in 
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vacuo. The residue was purified using column chromatography to yield colorless oil (102 
mg, 46.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.12 (d, J=7.1 Hz, 1 H), 7.79-7.75 (m, 3 H), 7.61-
7.52 (m, 4 H), 7.42-7.40 (m, 3 H), 7.38-7.34 (m, 4 H), 7.32-7.30 (m, 2 H), 7.17-7.09 (m, 2 H), 
6.53 (br s, 1 H), 6.45 (d, J=9.2 Hz, 1 H), 5.53 (br s, 1 H), 4.89 (br s, 1 H), 4.70-4.68 (m, 1 H), 
4.48-4.36 (m, 5 H), 4.31-4.17 (m, 2 H), 2.99 (br s, 6 H), 1.67 (s, 9 H), 1.43 (s, 9 H), 1.42 (s, 9 
H), 1.35-1.30 (m, 3 H), 1.11 (s, 9 H), 1.09 (d, J=6.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 178.2, 171.4, 170.0, 156.2, 149.6, 143.8, 141.4, 136.2, 129.5, 129.2, 128.8, 
127.9, 127.3, 125.2, 124.9, 122.9, 120.1, 119.1, 115.5, 83.9, 82.3, 74.0, 67.3, 58.4, 56.9, 
53.6, 52.5, 47.2, 40.1, 32.0, 29.6, 28.8, 28.6, 28.4, 22.3, 21.0 ppm. MS (m/z): calculated for 
C63H83N6O12, 1115.61; found 1115.9 [M+H]
+. 
tert-butyl 3-((2R)-2-((S)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (29) 
The Fmoc-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (90.0 mg, 80.0 µmol, 1 equiv) was 
dissolved in DCM (2 mL). TAEA (0.60 mL, 4.00 mmol, 50 equiv) was added and stirred for 
15 min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 
5 mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (33.0 mg, 46.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.10 (d, J=7.9 Hz, 1 H), 7.81 (d, J=7.5 Hz, 1 H), 7.66 
(d, J=7.2 Hz, 1 H), 7.46 (s, 1 H), 7.34-7.29 (m, 3 H), 7.25-7.18 (m, 4 H), 6.59 (d, J=7.1 Hz, 1 
H), 6.39 (d, J=9.1 Hz, 1 H), 4.93 (br s, 1 H), 4.72 (q, J1=7.7 Hz, J2=7.0 Hz, 1 H), 4.41 (q, J1=7.1 
Hz, J2=6.7 Hz,  1 H), 4.27 (d, J=7.4 Hz, 1 H), 4.21-4.17 (m, 1 H), 3.56-3.52 (m, 1 H), 3.31-3.25 
(m, 3 H), 3.19-2.99 (m, 3 H), 2.65-2.58 (m, 1 H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.43 (s, 9 H), 
1.38-1.32 (m, 2 H), 1.16 (s, 9 H), 1.13 (d, J=6.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 177.6, 170.6, 169.6, 156.2, 154.1, 149.8, 135.7, 130.5, 129.4, 128.8, 124.8, 
124.3, 122.9, 119.3, 115.9, 115.4, 82.2, 79.1, 74.1, 67.2, 58.5, 57.6, 56.4, 53.4, 32.4, 28.8, 
28.6, 28.4, 28.3, 27.7, 21.0 ppm. MS (m/z): calculated for C48H73N6O10, 893.54; found 893.9 
[M+H]+; 915.9 [M+Na]+.  
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (30) 
To a solution of the H-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (28.0 mg, 32.0 µmol, 1 equiv) 
in DCM (1 mL) was added benzophenone imine (11.8 µL, 64.0 µmol, 2 equiv), dissolved in 
1 mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
15299 - Pekosak_BNW.indd   151 16-02-18   16:22
Chapter 6 
152 
 
mixture was concentrated and purified by flash chromatography to yield white solid (25.1 
mg, 75.0 %, ˃92 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=25.5 min]) and ˃97 % purity 
[determined by HPLC: column C, F/G, 95/5, v/v, wavelength 254 nm, column T – ambient, 
flow 0.5 mL·min-1, tR=18.7 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.04 (d, J=8.1 Hz, 1 H), 7.57 (d, J=7.8 Hz, 1 H), 7.49 
(d, J=7.1 Hz, 2 H), 7.48-7.39 (m, 3 H), 7.34-7.29 (m, 3 H), 7.25-7.20 (m, 2 H), 7.17-7.94 (m, 8 
H), 6.66 (d, J=7.8 Hz, 1 H), 6.42 (d, J=8.9 Hz, 1 H), 4.93 (br s, 1 H), 4.84 (q, 1 H), 4.48 (q, 1 
H), 4.31 (dd, J1=1.8 Hz, J2=7.1 Hz, 1 H), 4.22 (m, 1 H), 4.04 (dd, J1=2.9 Hz, J2=7.0 Hz, 1 H), 
3.20 (m, 3 H), 2.97 (m, 3 H), 1.61 (s, 9 H), 1.52 (m, 1 H), 1.45 (s, 9 H), 1.42 (s, 9 H), 1.22 (s, 3 
H), 1.18 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.2, 171.1, 170.6, 169.6, 
156.2, 149.6, 139.0, 138.0, 135.4, 130.7, 130.2, 128.8, 128.3, 127.4, 126.4, 124.7, 124.3, 
123.0, 119.2, 115.9, 115.4, 83.8, 82.2, 79.0, 74.1, 68.0, 67.2, 58.6, 53.7, 53.1, 41.7, 32.6, 
29.6, 28.9, 28.6, 28.3, 22.2, 21.2 ppm. MS (m/z): calculated for C61H81N6O10, 1057.60; 
found 1057.3 [M+H]+; 1079.5 [M+Na]+. HR-MS (m/z): calculated for C61H81N6O10, 1057.60; 
found 1057.5998 [M+H]+. 
3. Preparation of intermediate to Ph2N=C-D-Phe-D-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-
OtBu 
tert-butyl 3-((2R)-2-((R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (31) 
The Fmoc-D-Phe-OH (155 mg, 400 µmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-
Lys(Boc)-Thr(tBu)-OtBu (200 mg, 268 µmol, 1 equiv) in the presence of HATU (153 mg, 400 
µmol, 1.5 equiv) and DIPEA (104 µL, 804 µmol, 3 equiv) as a coupling reagents in DCM (3 
mL) and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the 
completion of the reaction, reaction mixture was concentrated and the residue was 
dissolved in EtOAc (10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 
% K2CO3 (3 x 5 mL) and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in 
vacuo. The residue was purified using column chromatography to yield colorless oil (106 
mg, 36.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=8.0 Hz, 1 H), 7.76 (d, J=7.5 Hz, 2 H), 7.55-
50 (m, 3 H), 7.42-7.38 (m, 4 H), 7.33-30 (m, 3 H), 7.24-7.18 (m, 4 H), 7.11 (br s, 2 H), 6.50 
(br s,  1 H), 6.39 (d, J=8.7 Hz, 1 H), 5.20 (br s, 1 H), 4.93 (br s, 1 H), 4.68 (d, J=6.4 Hz, 1 H), 
4.44-4.38 (m, 3 H), 4.28-4.20 (m, 2 H), 4.16-4.14 (m, 2 H), 3.13-2.98 (m, 6 H), 1.65 (s, 9 H), 
1.44 (s, 9 H), 1.42 (s, 9 H), 1.37-1.35 (m, 2 H), 1.15 (s, 9 H), 1.14 (s, 3 H) ppm. 13C NMR (75 
MHz, CDCl3, ambient T): δ 171.2, 169.6, 156.2, 149.7, 143.9, 143.8, 141.4, 129.3, 128.9, 
127.9, 127.2, 125.2, 124.9, 124.4, 123.0, 120.1, 119.1, 115.5, 84.0, 82.2, 74.1, 67.1, 67.2, 
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58.6, 56.5, 54.0, 53.1, 47.2, 32.3, 29.5, 28.8, 28.6, 28.3, 22.2, 21.0 ppm. MS (m/z): 
calculated for C63H83N6O12, 1115.61; found 1115.9 [M+H]
+. 
tert-butyl 3-((2R)-2-((R)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (32) 
The Fmoc-D-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (90.0 mg, 81.0 µmol, 1 equiv) was 
dissolved in DCM (600 µL). TAEA (600 µL, 4.00 mmol, 50 equiv) was added and stirred for 
15 min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 
5 mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (45.0 mg, 63.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=8.0 Hz, 1 H), 7.94 (d, J=7.9 Hz, 2 H), 7.62 
(d, J=7.7 Hz, 1 H), 7.44 (s, 1 H), 7.35-7.28 (m, 2 H), 7.24-7.20 (m, 2 H), 7.15-7.12 (m, 2 H), 
6.64 (d, J=7.9 Hz, 1 H), 6.37 (d, J=8.8 Hz, 1 H), 4.90 (br s, 1 H), 4.75 (q, J1=7.7 Hz, J2=7.1 Hz, 
1 H), 4.41 (q, J1=6.2 Hz, J2=7.1 Hz, 1 H), 4.27 (dd, J1=6.9 Hz, J2=2.0 Hz, 1 H), 4.20-4.13 (m, 1 
H), 4.63 (dd, J1=5.6 Hz, J2=3.8 Hz, 1 H), 3.26-3.00 (m, 5 H), 2.50 (q, J1=9.5 Hz, J2=4.2 Hz, 1 
H), 1.66 (s, 9 H), 1.43 (s, 9 H), 1.38 (s, 9 H), 1.38-1.36 (m, 2 H), 1.16 (s, 9 H), 1.11 (d, J=6.2 
Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 175.0, 171.2, 170.7, 169.7, 156.2, 
149.7, 137.7, 130.5, 129.4, 128.8, 127.0, 124.9, 124.3, 122.9, 119.3, 115.9, 115.4, 83.9, 
82.2, 74.0, 67.2, 58.5, 56.4, 53.4, 53.1, 40.7, 40.1, 32.5, 28.6, 28.4, 28.3, 27.7, 22.3, 21.1 
ppm. MS (m/z): calculated for C48H73N6O10, 893.54; found 893.8 [M+H]
+.  
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((R)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (33) 
To a solution of the H-D-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (40 mg, 45 µmol, 1 equiv) 
in DCM (1 mL), was added benzophenone imine (15 µL, 90 µmol, 2 equiv), dissolved in 
DCM (1 mL). Reaction was stirred 24 h at ambient T. After completion, reaction mixture 
was concentrated and purified by flash chromatography to yield white solid (30.0 mg, 63.0 
%, ˃96 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, wavelength 210 
nm, column T – ambient, flow 1 mL·min-1, tR=28.4 min]) and ˃97 % purity [determined by 
HPLC: column C, F/G, 95/5, v/v, wavelength 254 nm, column T – ambient, flow 0.5 mL·min-
1, tR=21.7 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.15 (d, J=7.9 Hz, 1 H), 7.72-7.69 (m, 1 H), 7.51-
4.47 (m, 4 H), 7.39-7.29 (m, 7 H), 7.25-7.20 (m, 2 H), 7.13-7.11 (m, 3 H), 6.97-6.94 (m, 2 H), 
6.49 (d, J=7.7 Hz, 2 H), 6.27 (d, J=8.8 Hz, 1 H), 4.94 (br s, 1 H), 4.76 (q, J1=7.4 Hz, J2=7.3 Hz, 
1 H), 4.38-4.35 (m, 1 H), 4.20-4.09 (m, 3 H), 3.17 (d, J=7.1 Hz, 2 H), 3.08-2.99 (m, 3 H), 2.97-
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mixture was concentrated and purified by flash chromatography to yield white solid (25.1 
mg, 75.0 %, ˃92 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=25.5 min]) and ˃97 % purity 
[determined by HPLC: column C, F/G, 95/5, v/v, wavelength 254 nm, column T – ambient, 
flow 0.5 mL·min-1, tR=18.7 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.04 (d, J=8.1 Hz, 1 H), 7.57 (d, J=7.8 Hz, 1 H), 7.49 
(d, J=7.1 Hz, 2 H), 7.48-7.39 (m, 3 H), 7.34-7.29 (m, 3 H), 7.25-7.20 (m, 2 H), 7.17-7.94 (m, 8 
H), 6.66 (d, J=7.8 Hz, 1 H), 6.42 (d, J=8.9 Hz, 1 H), 4.93 (br s, 1 H), 4.84 (q, 1 H), 4.48 (q, 1 
H), 4.31 (dd, J1=1.8 Hz, J2=7.1 Hz, 1 H), 4.22 (m, 1 H), 4.04 (dd, J1=2.9 Hz, J2=7.0 Hz, 1 H), 
3.20 (m, 3 H), 2.97 (m, 3 H), 1.61 (s, 9 H), 1.52 (m, 1 H), 1.45 (s, 9 H), 1.42 (s, 9 H), 1.22 (s, 3 
H), 1.18 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.2, 171.1, 170.6, 169.6, 
156.2, 149.6, 139.0, 138.0, 135.4, 130.7, 130.2, 128.8, 128.3, 127.4, 126.4, 124.7, 124.3, 
123.0, 119.2, 115.9, 115.4, 83.8, 82.2, 79.0, 74.1, 68.0, 67.2, 58.6, 53.7, 53.1, 41.7, 32.6, 
29.6, 28.9, 28.6, 28.3, 22.2, 21.2 ppm. MS (m/z): calculated for C61H81N6O10, 1057.60; 
found 1057.3 [M+H]+; 1079.5 [M+Na]+. HR-MS (m/z): calculated for C61H81N6O10, 1057.60; 
found 1057.5998 [M+H]+. 
3. Preparation of intermediate to Ph2N=C-D-Phe-D-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-
OtBu 
tert-butyl 3-((2R)-2-((R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (31) 
The Fmoc-D-Phe-OH (155 mg, 400 µmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-
Lys(Boc)-Thr(tBu)-OtBu (200 mg, 268 µmol, 1 equiv) in the presence of HATU (153 mg, 400 
µmol, 1.5 equiv) and DIPEA (104 µL, 804 µmol, 3 equiv) as a coupling reagents in DCM (3 
mL) and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the 
completion of the reaction, reaction mixture was concentrated and the residue was 
dissolved in EtOAc (10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 
% K2CO3 (3 x 5 mL) and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in 
vacuo. The residue was purified using column chromatography to yield colorless oil (106 
mg, 36.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=8.0 Hz, 1 H), 7.76 (d, J=7.5 Hz, 2 H), 7.55-
50 (m, 3 H), 7.42-7.38 (m, 4 H), 7.33-30 (m, 3 H), 7.24-7.18 (m, 4 H), 7.11 (br s, 2 H), 6.50 
(br s,  1 H), 6.39 (d, J=8.7 Hz, 1 H), 5.20 (br s, 1 H), 4.93 (br s, 1 H), 4.68 (d, J=6.4 Hz, 1 H), 
4.44-4.38 (m, 3 H), 4.28-4.20 (m, 2 H), 4.16-4.14 (m, 2 H), 3.13-2.98 (m, 6 H), 1.65 (s, 9 H), 
1.44 (s, 9 H), 1.42 (s, 9 H), 1.37-1.35 (m, 2 H), 1.15 (s, 9 H), 1.14 (s, 3 H) ppm. 13C NMR (75 
MHz, CDCl3, ambient T): δ 171.2, 169.6, 156.2, 149.7, 143.9, 143.8, 141.4, 129.3, 128.9, 
127.9, 127.2, 125.2, 124.9, 124.4, 123.0, 120.1, 119.1, 115.5, 84.0, 82.2, 74.1, 67.1, 67.2, 
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58.6, 56.5, 54.0, 53.1, 47.2, 32.3, 29.5, 28.8, 28.6, 28.3, 22.2, 21.0 ppm. MS (m/z): 
calculated for C63H83N6O12, 1115.61; found 1115.9 [M+H]
+. 
tert-butyl 3-((2R)-2-((R)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (32) 
The Fmoc-D-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (90.0 mg, 81.0 µmol, 1 equiv) was 
dissolved in DCM (600 µL). TAEA (600 µL, 4.00 mmol, 50 equiv) was added and stirred for 
15 min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 
5 mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (45.0 mg, 63.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=8.0 Hz, 1 H), 7.94 (d, J=7.9 Hz, 2 H), 7.62 
(d, J=7.7 Hz, 1 H), 7.44 (s, 1 H), 7.35-7.28 (m, 2 H), 7.24-7.20 (m, 2 H), 7.15-7.12 (m, 2 H), 
6.64 (d, J=7.9 Hz, 1 H), 6.37 (d, J=8.8 Hz, 1 H), 4.90 (br s, 1 H), 4.75 (q, J1=7.7 Hz, J2=7.1 Hz, 
1 H), 4.41 (q, J1=6.2 Hz, J2=7.1 Hz, 1 H), 4.27 (dd, J1=6.9 Hz, J2=2.0 Hz, 1 H), 4.20-4.13 (m, 1 
H), 4.63 (dd, J1=5.6 Hz, J2=3.8 Hz, 1 H), 3.26-3.00 (m, 5 H), 2.50 (q, J1=9.5 Hz, J2=4.2 Hz, 1 
H), 1.66 (s, 9 H), 1.43 (s, 9 H), 1.38 (s, 9 H), 1.38-1.36 (m, 2 H), 1.16 (s, 9 H), 1.11 (d, J=6.2 
Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 175.0, 171.2, 170.7, 169.7, 156.2, 
149.7, 137.7, 130.5, 129.4, 128.8, 127.0, 124.9, 124.3, 122.9, 119.3, 115.9, 115.4, 83.9, 
82.2, 74.0, 67.2, 58.5, 56.4, 53.4, 53.1, 40.7, 40.1, 32.5, 28.6, 28.4, 28.3, 27.7, 22.3, 21.1 
ppm. MS (m/z): calculated for C48H73N6O10, 893.54; found 893.8 [M+H]
+.  
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((R)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (33) 
To a solution of the H-D-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (40 mg, 45 µmol, 1 equiv) 
in DCM (1 mL), was added benzophenone imine (15 µL, 90 µmol, 2 equiv), dissolved in 
DCM (1 mL). Reaction was stirred 24 h at ambient T. After completion, reaction mixture 
was concentrated and purified by flash chromatography to yield white solid (30.0 mg, 63.0 
%, ˃96 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, wavelength 210 
nm, column T – ambient, flow 1 mL·min-1, tR=28.4 min]) and ˃97 % purity [determined by 
HPLC: column C, F/G, 95/5, v/v, wavelength 254 nm, column T – ambient, flow 0.5 mL·min-
1, tR=21.7 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.15 (d, J=7.9 Hz, 1 H), 7.72-7.69 (m, 1 H), 7.51-
4.47 (m, 4 H), 7.39-7.29 (m, 7 H), 7.25-7.20 (m, 2 H), 7.13-7.11 (m, 3 H), 6.97-6.94 (m, 2 H), 
6.49 (d, J=7.7 Hz, 2 H), 6.27 (d, J=8.8 Hz, 1 H), 4.94 (br s, 1 H), 4.76 (q, J1=7.4 Hz, J2=7.3 Hz, 
1 H), 4.38-4.35 (m, 1 H), 4.20-4.09 (m, 3 H), 3.17 (d, J=7.1 Hz, 2 H), 3.08-2.99 (m, 3 H), 2.97-
15299 - Pekosak_BNW.indd   153 16-02-18   16:22
Chapter 6 
154 
 
2.79 (m, 1 H), 1.67 (s, 9 H), 1.43 (s, 9 H), 1.42 (s, 9 H), 1.40-1.35 (m, 3 H), 1.10 (s, 9 H), 1.00 
(d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.1, 171.0, 170.4, 169.6, 
156.2, 149.8, 139.1, 137.6, 135.6, 130.6, 130.5, 103.3, 128.8, 128.4, 128.3, 128.2, 127.6, 
126.5, 124.9, 124.4, 123.0, 119.5, 115.9, 115.5, 83.8, 82.1, 79.0, 74.0, 67.5, 67.0, 58.6, 
53.4, 52.9, 41.5, 40.1, 32.6, 29.5, 28.8, 28.6, 28.4, 28.3, 28.0, 22.1, 21.1 ppm. MS (m/z): 
calculated for C61H81N6O10, 1057.60; found 1057.6 [M+H]
+. HR-MS (m/z): calculated for 
C61H81N6O10, 1057.60; found 1057.6006 [M+H]
+. 
4. Preparation of reference to H-L-Phe-D-Trp-L-Lys-L-Thr-OH 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-((tert-
butoxycarbonyl)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-carboxylate 
(34) 
The Boc-L-Phe-OH (42.0 mg, 159 µmol, 1.2 equiv) was couple to the H-D-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (99.0 mg, 133 µmol, 1 equiv) in the presence of HATU (67.0 mg, 176 µmol, 
1.3 equiv) and DIPEA (0.84 mL, 481 µmol, 3.6 equiv) as a coupling reagents in DCM (1 mL) 
and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of 
the reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (5 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (80.0 mg, 60.0 %, ˃95 % 
purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, wavelength 210 nm, 
column T – ambient, flow 1 mL·min-1, tR=9.7 min]).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.9 Hz, 1 H), 7.60 (d, J=7.5 Hz, 1 H), 7.38-
7.29 (m, 4 H), 7.25-7.11 (m, 6 H), 6.68-6.53 (m, 1 H), 6.53 (br s, 1 H), 5.20 (br s, 1 H), 4.96 
(br s, 1 H), 4.71-4.68 (m, 1 H), 4.39-4.30 (m, 2 H), 4.24-4.16 (m, 2 H), 3.02-2.86 (m, 6 H), 
1.87-1.72 (m, 4H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.43 (s, 9 H), 1.38 (s, 9 H), 1.28-1.25 (m, 2H), 
1.14 (s, 9 H), 1.10 (d, J=6.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.5, 
170.0, 156.2, 149.7, 136.5, 135.6, 130.3, 129.2, 128.7, 127.1, 124.8, 124.2, 122.9, 119.2, 
115.7, 115.5, 83.9, 82.3, 80.5, 79.1, 74.1, 67.4, 58.5, 53.5, 40.1, 38.4, 31.9, 29.5, 28.8, 28.6, 
28.4, 28.3, 22.4, 20.9 ppm. MS (m/z): calculated for C53H82N6O12, 993.59; found 994.0 
[M+H]+; 1015.0 [M+Na]+. 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-((tert-
butoxycarbonyl)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-carboxylate 
(35) 
Boc-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (58.0 mg, 58.0 µmol, 1 equiv) was dissolved in 
DCM (300 µL) and equal amount of fresh cleavage cocktail (TFA/Thioanisole/EDT/Anisole, 
95/5/3/2, v/v; 300 µL) was added. After few minutes argon atmosphere has been 
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introduced to the reaction vessel. After 30 min reaction was completed and solvent 
concentrated. Peptide-TFA mixture was dissolved in 10 % aqueous acetic acid (300 µL) and 
extracted with at least doubled amount of chloroform (1 mL). Organic layer has been 
removed and aqueous layer has been extracted twice. Aqueous phase containing 
tetrapeptide has been dried under high vacuum (AP-68, 26.0 mg, 93.0 %, ˃98 % purity 
[determined by HPLC: column B, D/H, 90/10, v/v, wavelength 210 nm, column T – 
ambient, flow 1 mL·min-1, tR=5.3 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 10.81 (s, 1 H), 8.80 (d, J=8.0 Hz, 1 H), 8.51 (d, J=7.9 
Hz, 1 H),  8.05-7.92 (m, 3 H), 7.74 (d, J=8.0 Hz, 1 H), 7.34 (m, 4 H), 7.20 (m, 6 H), 6.67 (d, 
J=6.8 Hz, 1 H), 6.53 (m, 1 H), 5.20 (s, 1 H), 4.96 (m, 1 H), 4.69 (m, 1 H), 4.34 (m, 2 H), 4.20 
(m, 2 H), 2.94 (m, 6 H), 1.77 (m, 4H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.43 (s, 9 H), 1.38 (s, 9 H), 
1.26 (m, 2H), 1.14 (s, 9 H), 1.05 (d, J=5.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient 
T): δ MS (m/z): calculated for C30H42N6O6, 581.31; found 531.3 [M+H]
+. HR-MS (m/z): 
calculated for C30H42N6O6, 581.31; found 531.3064 [M+H]
+. 
Compound 35 was confirmed by 1H NMR and HR-MS and haven’t been used as a 
reference compound after isolation and purification of the carbon-11 labeled H-Phe-D-
Trp-Lys-Thr-OH. 
5. Preparation of reference to H-D-Phe-D-Trp-L-Lys-L-Thr-OH 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-carboxylate 
(36) 
The Boc-D-Phe-OH (80.0 mg, 302 µmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-
Lys(Boc)-Thr(tBu)-OtBu (150 mg, 201 µmol, 1 equiv) in the presence of HATU (115 mg, 302 
µmol, 1.5 equiv) and DIPEA (740 µL, 603 µmol, 3 equiv) as a coupling reagents in DCM (1 
mL) and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the 
completion of the reaction, reaction mixture was concentrated and the residue was 
dissolved in EtOAc (5 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 
% K2CO3 (3 x 5 mL) and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in 
vacuo. The residue was purified using column chromatography to yield colorless oil (AP-
60, 111 mg, 56.1 %, ˃96 % purity [determined by HPLC: column A, ACN/water, 90/10, v/v, 
wavelength 210 nm, flow 1 mL·min-1, tR=9.3 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.9 Hz, 1 H), 7.47-7.44 (m, 1 H), 7.39-
7.29 (m, 6 H), 7.23-7.11 (m, 2 H), 6.52-6.49 (m, 2 H), 6.42 (d, J=7.8 Hz, 1 H), 5.00 (br s, 1 H), 
4.82 (br s, 1 H), 4.67 (q, J1=6.9 Hz, J2=7.1 Hz, 1 H), 4.37-4.28 (m, 3 H), 4.23-4.16 (m, 1 H), 
3.12 (d, J=6.9 Hz, 3 H), 3.00-2.89 (m, 2 H), 1.67 (s, 9 H), 1.44 (s, 9 H), 1.42 (s, 9 H), 1.34 (s, 9 
H), 1.28-1.24 (m, 2H), 1.15 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ  171.2, 
169.7, 156.2, 149.7, 136.3, 135.5, 130.3, 129.3, 128.9, 127.3, 124.8, 124.5, 123.0, 119.0, 
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2.79 (m, 1 H), 1.67 (s, 9 H), 1.43 (s, 9 H), 1.42 (s, 9 H), 1.40-1.35 (m, 3 H), 1.10 (s, 9 H), 1.00 
(d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.1, 171.0, 170.4, 169.6, 
156.2, 149.8, 139.1, 137.6, 135.6, 130.6, 130.5, 103.3, 128.8, 128.4, 128.3, 128.2, 127.6, 
126.5, 124.9, 124.4, 123.0, 119.5, 115.9, 115.5, 83.8, 82.1, 79.0, 74.0, 67.5, 67.0, 58.6, 
53.4, 52.9, 41.5, 40.1, 32.6, 29.5, 28.8, 28.6, 28.4, 28.3, 28.0, 22.1, 21.1 ppm. MS (m/z): 
calculated for C61H81N6O10, 1057.60; found 1057.6 [M+H]
+. HR-MS (m/z): calculated for 
C61H81N6O10, 1057.60; found 1057.6006 [M+H]
+. 
4. Preparation of reference to H-L-Phe-D-Trp-L-Lys-L-Thr-OH 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-((tert-
butoxycarbonyl)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-carboxylate 
(34) 
The Boc-L-Phe-OH (42.0 mg, 159 µmol, 1.2 equiv) was couple to the H-D-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (99.0 mg, 133 µmol, 1 equiv) in the presence of HATU (67.0 mg, 176 µmol, 
1.3 equiv) and DIPEA (0.84 mL, 481 µmol, 3.6 equiv) as a coupling reagents in DCM (1 mL) 
and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of 
the reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (5 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (80.0 mg, 60.0 %, ˃95 % 
purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, wavelength 210 nm, 
column T – ambient, flow 1 mL·min-1, tR=9.7 min]).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.9 Hz, 1 H), 7.60 (d, J=7.5 Hz, 1 H), 7.38-
7.29 (m, 4 H), 7.25-7.11 (m, 6 H), 6.68-6.53 (m, 1 H), 6.53 (br s, 1 H), 5.20 (br s, 1 H), 4.96 
(br s, 1 H), 4.71-4.68 (m, 1 H), 4.39-4.30 (m, 2 H), 4.24-4.16 (m, 2 H), 3.02-2.86 (m, 6 H), 
1.87-1.72 (m, 4H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.43 (s, 9 H), 1.38 (s, 9 H), 1.28-1.25 (m, 2H), 
1.14 (s, 9 H), 1.10 (d, J=6.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.5, 
170.0, 156.2, 149.7, 136.5, 135.6, 130.3, 129.2, 128.7, 127.1, 124.8, 124.2, 122.9, 119.2, 
115.7, 115.5, 83.9, 82.3, 80.5, 79.1, 74.1, 67.4, 58.5, 53.5, 40.1, 38.4, 31.9, 29.5, 28.8, 28.6, 
28.4, 28.3, 22.4, 20.9 ppm. MS (m/z): calculated for C53H82N6O12, 993.59; found 994.0 
[M+H]+; 1015.0 [M+Na]+. 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-((tert-
butoxycarbonyl)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-carboxylate 
(35) 
Boc-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (58.0 mg, 58.0 µmol, 1 equiv) was dissolved in 
DCM (300 µL) and equal amount of fresh cleavage cocktail (TFA/Thioanisole/EDT/Anisole, 
95/5/3/2, v/v; 300 µL) was added. After few minutes argon atmosphere has been 
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introduced to the reaction vessel. After 30 min reaction was completed and solvent 
concentrated. Peptide-TFA mixture was dissolved in 10 % aqueous acetic acid (300 µL) and 
extracted with at least doubled amount of chloroform (1 mL). Organic layer has been 
removed and aqueous layer has been extracted twice. Aqueous phase containing 
tetrapeptide has been dried under high vacuum (AP-68, 26.0 mg, 93.0 %, ˃98 % purity 
[determined by HPLC: column B, D/H, 90/10, v/v, wavelength 210 nm, column T – 
ambient, flow 1 mL·min-1, tR=5.3 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 10.81 (s, 1 H), 8.80 (d, J=8.0 Hz, 1 H), 8.51 (d, J=7.9 
Hz, 1 H),  8.05-7.92 (m, 3 H), 7.74 (d, J=8.0 Hz, 1 H), 7.34 (m, 4 H), 7.20 (m, 6 H), 6.67 (d, 
J=6.8 Hz, 1 H), 6.53 (m, 1 H), 5.20 (s, 1 H), 4.96 (m, 1 H), 4.69 (m, 1 H), 4.34 (m, 2 H), 4.20 
(m, 2 H), 2.94 (m, 6 H), 1.77 (m, 4H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.43 (s, 9 H), 1.38 (s, 9 H), 
1.26 (m, 2H), 1.14 (s, 9 H), 1.05 (d, J=5.3 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient 
T): δ MS (m/z): calculated for C30H42N6O6, 581.31; found 531.3 [M+H]
+. HR-MS (m/z): 
calculated for C30H42N6O6, 581.31; found 531.3064 [M+H]
+. 
Compound 35 was confirmed by 1H NMR and HR-MS and haven’t been used as a 
reference compound after isolation and purification of the carbon-11 labeled H-Phe-D-
Trp-Lys-Thr-OH. 
5. Preparation of reference to H-D-Phe-D-Trp-L-Lys-L-Thr-OH 
tert-butyl 3-((2R)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-carboxylate 
(36) 
The Boc-D-Phe-OH (80.0 mg, 302 µmol, 1.5 equiv) was couple to the H-D-Trp(Boc)-
Lys(Boc)-Thr(tBu)-OtBu (150 mg, 201 µmol, 1 equiv) in the presence of HATU (115 mg, 302 
µmol, 1.5 equiv) and DIPEA (740 µL, 603 µmol, 3 equiv) as a coupling reagents in DCM (1 
mL) and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the 
completion of the reaction, reaction mixture was concentrated and the residue was 
dissolved in EtOAc (5 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 
% K2CO3 (3 x 5 mL) and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in 
vacuo. The residue was purified using column chromatography to yield colorless oil (AP-
60, 111 mg, 56.1 %, ˃96 % purity [determined by HPLC: column A, ACN/water, 90/10, v/v, 
wavelength 210 nm, flow 1 mL·min-1, tR=9.3 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.9 Hz, 1 H), 7.47-7.44 (m, 1 H), 7.39-
7.29 (m, 6 H), 7.23-7.11 (m, 2 H), 6.52-6.49 (m, 2 H), 6.42 (d, J=7.8 Hz, 1 H), 5.00 (br s, 1 H), 
4.82 (br s, 1 H), 4.67 (q, J1=6.9 Hz, J2=7.1 Hz, 1 H), 4.37-4.28 (m, 3 H), 4.23-4.16 (m, 1 H), 
3.12 (d, J=6.9 Hz, 3 H), 3.00-2.89 (m, 2 H), 1.67 (s, 9 H), 1.44 (s, 9 H), 1.42 (s, 9 H), 1.34 (s, 9 
H), 1.28-1.24 (m, 2H), 1.15 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ  171.2, 
169.7, 156.2, 149.7, 136.3, 135.5, 130.3, 129.3, 128.9, 127.3, 124.8, 124.5, 123.0, 119.0, 
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115.6, 115.3, 83.9, 82.1, 80.8, 74.1, 67.2, 58.6, 56.2, 54.0, 53.4, 29.4, 28.9, 28.6, 28.4, 28.3, 
22.3, 21.1 ppm. MS (m/z): calculated for C53H82N6O12, 993.59; found 993.9 [M+H]
+; 1014.9 
[M+Na]+. 
(3S)-2-((S)-6-amino-2-((R)-2-((R)-2-amino-3-phenylpropanamido)-3-(1H-indol-3-
yl)propanamido) hexanamido)-3-hydroxybutanoic acid (37) 
Boc-D-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (16.0 mg, 16.0 µmol, 1 equiv) was dissolved 
in DCM (300 µL) and equal amount of fresh cleavage cocktail 
(TFA/Thioanisole/EDT/Anisole, 95/5/3/2, v/v; 300 µL) was added. After few minutes argon 
atmosphere has been introduced to the reaction vessel. After 30 min reaction was 
completed and solvent concentrated. Peptide-TFA mixture was dissolved in 10% aqueous 
acetic acid (300 µL) and extracted with at least doubled amount of chloroform (1 mL). 
Organic layer has been removed and aqueous layer has been extracted twice. Aqueous 
phase containing tetrapeptide has been dried under high vacuum to yield white solid (11 
mg, 95 %, ˃92 % purity [determined by HPLC: column B, D/H, 90/10, v/v, wavelength 210 
nm, column T – ambient, flow 1 mL·min-1, tR=5.3 min]).   
1H NMR (300 MHz, DMSO, ambient T): δ 10.87 (s, 1 H), 8.83 (d, J=8.4 Hz, 1 H), 8.31 (d, 
J=7.5 Hz, 1 H), 8.04 (br s, 1 H), 7.90 (d, J=8.4 Hz, 1 H), 7.69-7.63 (m, 2 H), 7.34-7.26 (m, 3 
H), 7.23-7.20 (m, 2 H), 7.09-6.98 (m, 1 H), 4.79 (q, J1=7.8 Hz, J1=7.3 Hz, 1 H), 4.38-4.36 (m, 1 
H), 4.21 (7 (d, J=5.2 Hz, 1 H), 4.18-4.12  (m, 1 H), 4.03 (br s, 1 H), 3.15-3.08 (m, 2 H), 3.01-
2.97 (m, 1 H), 2.94-2.85 (m, 1 H), 2.62 (br s, 1 H), 1.54-1.43 (m, 1H), 1.41-1.36 (m, 3 H), 
1.02 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 172.6, 172.5, 171.2, 
168.3, 136.6, 135.3, 130.2, 129.2, 127.9, 127.7, 124.5, 121.5, 119.1, 118.8, 111.9, 110.0, 
66.7, 58.2, 54.0, 52.7, 37.6, 32.1, 27.3, 22.4, 21.7, 21.1 ppm. MS (m/z): calculated for 
C30H42N6O6, 581.31; found 581.3 [M+H]
+. HR-MS (m/z): calculated for C30H42N6O6, 581.31; 
found 581.3073 [M+H]+. 
6. Preparation of precursor to Ph2N=C-Gly-L-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-OtBu 
tert-butyl 3-((2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (38) 
The Fmoc-Trp(Boc)-OH (2.20 g, 4.31 mmol, 1.2 equiv) was coupled to the H-Lys(Boc)-
Thr(tBu)-OtBu (1.61 g, 3.60 mmol, 1 equiv) in the presence of HATU (2.00 g, 3.50 mmol, 1.5 
equiv) and DIPEA (1.80 mL, 10.7 mmol, 3 equiv) as a coupling reagents in DCM (20 mL) and 
DMF (1 mL) as a solvent. Coupling time was 4 h at RT. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (15 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 30 mL), 10 % K2CO3 (3 x 15 mL) 
and brine (3 x 15 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (2.00 g, 58.7 %).  
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1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.9 Hz, 1 H), 7.75 (d, J=7.4 Hz, 2 H), 7.64-
7.61 (m, 1 H), 7.54-7.50 (m, 3 H), 7.41-7.30 (m, 5 H), 7.29-7.27 (m, 1 H), 6.67 (d, J=7.5 Hz, 
1H),6.35 (d, J=8.7 Hz, 1 H), 5.55 (br s, 1 H), 4.87 (br s, 1 H), 4.58-4.56 (m, 1 H), 4.44-4.33 
(m, 3 H), 4.30-4.19 (m, 3 H), 3.26-3.19 (m, 2 H), 3.16-3.05 (m, 2 H), 1.65 (s, 9 H), 1.86-1.78 
(m, 1 H), 1.45 (s, 9 H), 1.40 (s, 9 H), 1.33-1.30 (m, 2 H) 1.17 (s, 12 H) ppm. 13C NMR (75 
MHz, CDCl3, ambient T): δ 171.1, 170.7, 169.6, 156.2, 149.7, 143.9, 141.4, 135.6, 130.4, 
127.8, 127.3, 125.3, 124.8, 124.7, 122.9, 120.1, 119.2, 115.5, 115.3, 83.8, 82.2, 79.1, 74.1, 
67.5, 67.1, 58.7, 55.0, 53.1, 47.2, 40.1, 32.7, 29.5, 28.9, 28.6, 28.3, 22.1, 21.4 ppm. MS 
(m/z): calculated for C54H74N5O11, 968.54; found 968.9 [M+H]
+; 989.9 [M+Na]+. 
tert-butyl 3-((2S)-2-amino-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (39) 
The Fmoc-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (2.00 g, 2.00 mmol, 1 equiv) was dissolved in 
DCM. TAEA (15.0 mL, 100 µmol, 50 equiv) was added and stirred for 15 min at ambient T. 
After completion, the reaction mixture was extracted with brine (1 x 5 mL) and phosphate 
buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was performed with DMC (3 x 5 
mL). Collected organic phases were dried over Na2SO4, filtrated and evaporated in vacuo. 
The residue was purified using column chromatography to yield white precipitate (1.20 g, 
81.5 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.13 (d, J=7.7 Hz, 1 H), 7.93 (d, J=8.3 Hz, 1 H), 7.64 
(d, J=7.6 Hz, 1 H), 7.48 (s, 1 H), 7.39-7.31 (m, 1 H), 7.24-7.22 (m, 1 H), 6.48 (d, J=8.9 Hz, 1 
H), 4.78 (br s, 1 H),  4.52-4.46 (m, 1 H), 4.31 (dd, J1=1.9 Hz, J2= 7.0 Hz, 1 H), 4.24-4.18 (m, 1 
H), 3.37 (dd, J1=3.5 Hz, J2=11.0 Hz, 1 H), 3.11-3.05 (m, 2 H), 2.86 (q,  J1=5.0 Hz, J2=9.5 Hz, 1 
H), 1.91-1.79 (m, 1 H), 1.68 (s, 9 H), 1.47 (s, 9 H), 1.43 (s, 9 H), 1.38-1.31 (m, 2 H), 1.17 (s, 9 
H), 1.15 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 174.4, 171.8, 169.7, 156.2, 
149.8, 135.8, 130.4, 128.9, 127.2, 124.8, 124.4, 122.8, 121.1, 119.9, 119.5, 116.7, 115.4, 
83.9, 82.2, 79.1, 74.1, 67.2, 58.6, 54.9, 52.7, 40.3, 32.7, 30.8, 29.6, 28.9, 28.6, 28.4, 28.3, 
22.6, 21.2 ppm. MS (m/z): calculated for C39H64N5O9, 746.47; found 746.8 [M+H]
+. 
tert-butyl 3-((2S)-2-amino-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (40) 
The Cbz-Gly-OH (214 mg, 1.00 mmol, 1.5 equiv) was couple to the H-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (500 mg, 671 µmol, 1 equiv) in the presence of HATU (400 mg, 1.00 mmol, 
1.5 equiv) and DIPEA (0.40 mL, 2.00 mmol, 3 equiv) as a coupling reagents in DCM (3 mL) 
and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of 
the reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc 
(10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
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115.6, 115.3, 83.9, 82.1, 80.8, 74.1, 67.2, 58.6, 56.2, 54.0, 53.4, 29.4, 28.9, 28.6, 28.4, 28.3, 
22.3, 21.1 ppm. MS (m/z): calculated for C53H82N6O12, 993.59; found 993.9 [M+H]
+; 1014.9 
[M+Na]+. 
(3S)-2-((S)-6-amino-2-((R)-2-((R)-2-amino-3-phenylpropanamido)-3-(1H-indol-3-
yl)propanamido) hexanamido)-3-hydroxybutanoic acid (37) 
Boc-D-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (16.0 mg, 16.0 µmol, 1 equiv) was dissolved 
in DCM (300 µL) and equal amount of fresh cleavage cocktail 
(TFA/Thioanisole/EDT/Anisole, 95/5/3/2, v/v; 300 µL) was added. After few minutes argon 
atmosphere has been introduced to the reaction vessel. After 30 min reaction was 
completed and solvent concentrated. Peptide-TFA mixture was dissolved in 10% aqueous 
acetic acid (300 µL) and extracted with at least doubled amount of chloroform (1 mL). 
Organic layer has been removed and aqueous layer has been extracted twice. Aqueous 
phase containing tetrapeptide has been dried under high vacuum to yield white solid (11 
mg, 95 %, ˃92 % purity [determined by HPLC: column B, D/H, 90/10, v/v, wavelength 210 
nm, column T – ambient, flow 1 mL·min-1, tR=5.3 min]).   
1H NMR (300 MHz, DMSO, ambient T): δ 10.87 (s, 1 H), 8.83 (d, J=8.4 Hz, 1 H), 8.31 (d, 
J=7.5 Hz, 1 H), 8.04 (br s, 1 H), 7.90 (d, J=8.4 Hz, 1 H), 7.69-7.63 (m, 2 H), 7.34-7.26 (m, 3 
H), 7.23-7.20 (m, 2 H), 7.09-6.98 (m, 1 H), 4.79 (q, J1=7.8 Hz, J1=7.3 Hz, 1 H), 4.38-4.36 (m, 1 
H), 4.21 (7 (d, J=5.2 Hz, 1 H), 4.18-4.12  (m, 1 H), 4.03 (br s, 1 H), 3.15-3.08 (m, 2 H), 3.01-
2.97 (m, 1 H), 2.94-2.85 (m, 1 H), 2.62 (br s, 1 H), 1.54-1.43 (m, 1H), 1.41-1.36 (m, 3 H), 
1.02 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 172.6, 172.5, 171.2, 
168.3, 136.6, 135.3, 130.2, 129.2, 127.9, 127.7, 124.5, 121.5, 119.1, 118.8, 111.9, 110.0, 
66.7, 58.2, 54.0, 52.7, 37.6, 32.1, 27.3, 22.4, 21.7, 21.1 ppm. MS (m/z): calculated for 
C30H42N6O6, 581.31; found 581.3 [M+H]
+. HR-MS (m/z): calculated for C30H42N6O6, 581.31; 
found 581.3073 [M+H]+. 
6. Preparation of precursor to Ph2N=C-Gly-L-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-OtBu 
tert-butyl 3-((2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (38) 
The Fmoc-Trp(Boc)-OH (2.20 g, 4.31 mmol, 1.2 equiv) was coupled to the H-Lys(Boc)-
Thr(tBu)-OtBu (1.61 g, 3.60 mmol, 1 equiv) in the presence of HATU (2.00 g, 3.50 mmol, 1.5 
equiv) and DIPEA (1.80 mL, 10.7 mmol, 3 equiv) as a coupling reagents in DCM (20 mL) and 
DMF (1 mL) as a solvent. Coupling time was 4 h at RT. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (15 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 30 mL), 10 % K2CO3 (3 x 15 mL) 
and brine (3 x 15 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (2.00 g, 58.7 %).  
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1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=7.9 Hz, 1 H), 7.75 (d, J=7.4 Hz, 2 H), 7.64-
7.61 (m, 1 H), 7.54-7.50 (m, 3 H), 7.41-7.30 (m, 5 H), 7.29-7.27 (m, 1 H), 6.67 (d, J=7.5 Hz, 
1H),6.35 (d, J=8.7 Hz, 1 H), 5.55 (br s, 1 H), 4.87 (br s, 1 H), 4.58-4.56 (m, 1 H), 4.44-4.33 
(m, 3 H), 4.30-4.19 (m, 3 H), 3.26-3.19 (m, 2 H), 3.16-3.05 (m, 2 H), 1.65 (s, 9 H), 1.86-1.78 
(m, 1 H), 1.45 (s, 9 H), 1.40 (s, 9 H), 1.33-1.30 (m, 2 H) 1.17 (s, 12 H) ppm. 13C NMR (75 
MHz, CDCl3, ambient T): δ 171.1, 170.7, 169.6, 156.2, 149.7, 143.9, 141.4, 135.6, 130.4, 
127.8, 127.3, 125.3, 124.8, 124.7, 122.9, 120.1, 119.2, 115.5, 115.3, 83.8, 82.2, 79.1, 74.1, 
67.5, 67.1, 58.7, 55.0, 53.1, 47.2, 40.1, 32.7, 29.5, 28.9, 28.6, 28.3, 22.1, 21.4 ppm. MS 
(m/z): calculated for C54H74N5O11, 968.54; found 968.9 [M+H]
+; 989.9 [M+Na]+. 
tert-butyl 3-((2S)-2-amino-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (39) 
The Fmoc-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (2.00 g, 2.00 mmol, 1 equiv) was dissolved in 
DCM. TAEA (15.0 mL, 100 µmol, 50 equiv) was added and stirred for 15 min at ambient T. 
After completion, the reaction mixture was extracted with brine (1 x 5 mL) and phosphate 
buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was performed with DMC (3 x 5 
mL). Collected organic phases were dried over Na2SO4, filtrated and evaporated in vacuo. 
The residue was purified using column chromatography to yield white precipitate (1.20 g, 
81.5 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.13 (d, J=7.7 Hz, 1 H), 7.93 (d, J=8.3 Hz, 1 H), 7.64 
(d, J=7.6 Hz, 1 H), 7.48 (s, 1 H), 7.39-7.31 (m, 1 H), 7.24-7.22 (m, 1 H), 6.48 (d, J=8.9 Hz, 1 
H), 4.78 (br s, 1 H),  4.52-4.46 (m, 1 H), 4.31 (dd, J1=1.9 Hz, J2= 7.0 Hz, 1 H), 4.24-4.18 (m, 1 
H), 3.37 (dd, J1=3.5 Hz, J2=11.0 Hz, 1 H), 3.11-3.05 (m, 2 H), 2.86 (q,  J1=5.0 Hz, J2=9.5 Hz, 1 
H), 1.91-1.79 (m, 1 H), 1.68 (s, 9 H), 1.47 (s, 9 H), 1.43 (s, 9 H), 1.38-1.31 (m, 2 H), 1.17 (s, 9 
H), 1.15 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 174.4, 171.8, 169.7, 156.2, 
149.8, 135.8, 130.4, 128.9, 127.2, 124.8, 124.4, 122.8, 121.1, 119.9, 119.5, 116.7, 115.4, 
83.9, 82.2, 79.1, 74.1, 67.2, 58.6, 54.9, 52.7, 40.3, 32.7, 30.8, 29.6, 28.9, 28.6, 28.4, 28.3, 
22.6, 21.2 ppm. MS (m/z): calculated for C39H64N5O9, 746.47; found 746.8 [M+H]
+. 
tert-butyl 3-((2S)-2-amino-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (40) 
The Cbz-Gly-OH (214 mg, 1.00 mmol, 1.5 equiv) was couple to the H-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (500 mg, 671 µmol, 1 equiv) in the presence of HATU (400 mg, 1.00 mmol, 
1.5 equiv) and DIPEA (0.40 mL, 2.00 mmol, 3 equiv) as a coupling reagents in DCM (3 mL) 
and DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of 
the reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc 
(10 mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
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and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (400 mg, 57.8 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.7 Hz, 1 H), 7.79 (d, J=7.4 Hz, 1 H), 7.47 
(s, 1 H), 7.36-7.27 (m, 4 H), 7.24-7.19 (m, 3 H), 6.83 (br s, 2 H), 6.44 (d, J=7.8 Hz, 1 H), 5.70 
(br s, 1 H), 5.13-5.09 (m, 3H), 4.91 (br s, 1 H), 4.79-4.72 (m, 1 H), 4.42 (br s, 1 H), 4.29 (dd, 
J1=1.6 Hz, J2=7.2 Hz, 1 H), 4.21-4.18 (m, 1 H), 4.00-3.87 (m, 3 H), 3.19 (br s, 2 H), 3.04-3.02 
(m, 2 H), 1.66 (s, 9 H), 1.45 (s, 1 H), 1.41 (s, 9 H), 1.33-1.26 (m, 4 H), 1.16 (s, 9 H), 1.14 (s, 3 
H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.8, 171.2, 170.6, 169.7, 169.5, 156.9, 
156.3, 149.7, 136.3, 135.6, 130.4, 128.6, 128.4, 128.3, 128.2, 124.7, 122.8, 119.1, 115.5, 
115.3, 83.8, 82.2, 79.3, 74.1, 67.3, 67.2, 58.6, 53.5, 53.2, 44.7, 40.3, 32.3, 29.7, 28.9, 28.6, 
28.4, 28.3, 27.6, 22.3, 21.2 ppm. MS (m/z): calculated for C49H73N6O12, 937.53; found 937.0 
[M+H]+. 
tert-butyl 3-((2S)-2-(2-aminoacetamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-
tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-
1H-indole-1-carboxylate (41) 
The Cbz-Gly-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (190 mg, 196 µmol, 1 equiv) was dissolved in 
5 mL of MeOH and stirred under argon atmosphere for 10 min. Afterwards 10 % Pd/C 
(19.0 mg, 10 % m/m) was added to the reaction vessel and argon atmosphere was 
replaced with hydrogen. The reaction mixture was vigorously stirred overnight at ambient 
T under ordinary hydrogen pressure (2 balloons). The mixture was filtered and 
concentrated to afford the colorless oil (129 mg, 82.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.5 Hz, 1 H), 7.79 (d, J=7.7 Hz, 1 H), 7.61 
(d, J=7.4 Hz, 1 H), 7.48 (s, 1 H), 7.33 – 7.30 (m, 1 H), 7.25-7.23 (m, 1 H), 6.83 (d, J=7.4 Hz, 1 
H), 6.40 (d, J=8.7 Hz, 1 H), 4.93 (s, 1 H), 4.74 (q, J1=6.8 Hz, J2=7.3 Hz, 1 H), 4.42 (q, J1=6.4 
Hz, J2=6.7 Hz, 1 H), 4.29 (dd, J1=1.4 Hz, J2=7.4 Hz, 1 H), 4.24-4.18 (m, 1 H), 3.73 (d, J=9.5 Hz, 
1 H), 3.33 (d, J=4.8 Hz, 2 H), 3.24-3.22 (m, 2 H), 3.05 (br s, 1 H), 1.88-1.77 (m, 1 H), 1.67 (s, 
9 H), 1.61-1.57 (m, 2 H), 1.45 (s, 9 H), 1.42 (s, 9 H), 1.35-1.25 (m, 3 H), 1.16 (s, 9 H), 1.15 (s, 
3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.4, 171.3, 170.8, 169.7, 156.2, 149.8, 
135.5, 130.5, 124.7, 124.4, 122.7, 119.2, 115.7, 83.8, 82.2, 79.1, 74.1, 67.2, 58.6, 53.2, 
44.7, 32.5, 29.5, 28.9, 28.6, 28.4, 28.3, 27.3, 22.2, 21.3 ppm. MS (m/z): calculated for 
C41H67N6O10, 803.49; found 804.0 [M+H]
+; 826.0 [M+Na]+. 
tert-butyl 3-((2S)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-(2-
((diphenylmethylene)amino)acetamido)-3-oxopropyl)-1H-indole-1-carboxylate (42) 
To a solution of the H-Gly-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (113 mg, 141 µmol, 1 equiv) in 
DCM (3 mL), was added benzophenone imine (47.0 µL, 282 µmol, 2 equiv), dissolved in 2 
mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (99.0 
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mg, 72.7 %, ˃96 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=15.8 min]).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11-8.05 (m, 2 H), 7.65 (d, J=7.7 Hz, 1 H), 7.52 (s, 
1 H), 7.46-7.41 (m, 7 H), 7.38-7.28 (m, 3 H), 7.18-7.13 (m, 1 H), 7.07-7.04 (m, 2 H), 6.79 (d, 
J=7.7 Hz, 1 H), 6.41 (d, J=8.7 Hz, 1 H), 4.92 (br s, 1 H), 4.85 (q, J1=7.2 Hz, J2=6.8 Hz, 1 H), 
4.46 (q, J1=J2=6.8 Hz, 1 H), 4.27 (dd, J1=2.1 Hz, J2=6.9 Hz, 1 H), 4.23-4.19 (m, 1 H), 3.93 (d, 
J=11.5 Hz, 2 H), 3.40-3.22 (m, 2 H), 3.06-3.02 (m, 2 H), 1.87-1.80 (m, 1 H), 1.61 (s, 9 H), 
1.45 (s, 9 H), 1.39 (s, 9 H), 1.33-1.31 (m, 2 H), 1.18 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 171.2, 170.7, 170.6, 169.7, 156.2, 149.8, 138.7, 136.1, 130.8, 130.6, 129.1, 
129.0, 128.5, 128.4, 127.3, 124.7, 124.6, 122.8, 119.3, 115.6, 115.4, 83.7, 82.1, 74.1, 67.2, 
58.6, 56.5, 53.5, 28.9, 28.6, 28.3, 22.2, 21.3 ppm. MS (m/z): calculated for C54H75N6O10, 
967.56; found 967.8 [M+H]+. HR-MS (m/z): calculated for C54H75N6O10, 967.56; found 
967.5521 [M+H]+.  
7. Preparation of intermediate to Ph2N=C-L-Phe-L-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-OtBu 
tert-butyl 3-((2S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (43) 
The Fmoc-Phe-OH (187 mg, 483 µmol, 1.5 equiv) was couple to the H-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (240 mg, 322 µmol, 1 equiv) in the presence of HATU (183 µmol, 483 µmol, 
1.5 equiv) and DIPEA (200 µL, 966 µmol, 3 equiv) as a coupling reagents in DCM (8 mL) and 
DMF (1 mL) as a solvent. Coupling time was 4 h at ambient T. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (10 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (216 mg, 60.2 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.7 Hz, 1 H), 7.76 (d, J=7.4 Hz, 2 H), 7.53-
7.48 (m, 3 H), 7.40-7.38 (m, 4 H), 7.32-7.29 (m, 3 H), 7.22-7.14 (m, 6 H), 6.61 (br s, 1 H), 
6.53 (br s, 1 H), 6.39 (d, J=8.6 Hz, 1 H), 5.21 (br s, 1 H), 4.91 (br s, 1 H), 4.65 (br s, 1 H), 
4.37-4.27 (m, 3 H), 4.23-4.19 (m, 3 H), 3.1-3.04 (m, 6 H), 1.86-1.82 (m, 1 H), 1.65 (s, 9 H), 
1.45 (s, 9 H), 1.41 (s, 9 H), 1.34-1.29 (m, 3 H), 1.14 (s, 12) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 171.1, 169.7, 156.2, 149.7, 143.9, 141.4, 130.4, 129.3, 128.9, 127.9, 127.2, 
125.2, 124.8, 124.6, 122.8, 120.1, 119.0, 115.5, 115.2, 83.8, 82.1, 74.1, 67.2, 58.6, 47.2, 
29.6, 28.9, 28.6, 28.4, 28.3, 21.3 ppm. MS (m/z): calculated for C63H83N6O12, 1115.61; 
found 1115.8 [M+H].  
 tert-butyl 3-((2S)-2-((S)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (44) 
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and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (400 mg, 57.8 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.7 Hz, 1 H), 7.79 (d, J=7.4 Hz, 1 H), 7.47 
(s, 1 H), 7.36-7.27 (m, 4 H), 7.24-7.19 (m, 3 H), 6.83 (br s, 2 H), 6.44 (d, J=7.8 Hz, 1 H), 5.70 
(br s, 1 H), 5.13-5.09 (m, 3H), 4.91 (br s, 1 H), 4.79-4.72 (m, 1 H), 4.42 (br s, 1 H), 4.29 (dd, 
J1=1.6 Hz, J2=7.2 Hz, 1 H), 4.21-4.18 (m, 1 H), 4.00-3.87 (m, 3 H), 3.19 (br s, 2 H), 3.04-3.02 
(m, 2 H), 1.66 (s, 9 H), 1.45 (s, 1 H), 1.41 (s, 9 H), 1.33-1.26 (m, 4 H), 1.16 (s, 9 H), 1.14 (s, 3 
H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 171.8, 171.2, 170.6, 169.7, 169.5, 156.9, 
156.3, 149.7, 136.3, 135.6, 130.4, 128.6, 128.4, 128.3, 128.2, 124.7, 122.8, 119.1, 115.5, 
115.3, 83.8, 82.2, 79.3, 74.1, 67.3, 67.2, 58.6, 53.5, 53.2, 44.7, 40.3, 32.3, 29.7, 28.9, 28.6, 
28.4, 28.3, 27.6, 22.3, 21.2 ppm. MS (m/z): calculated for C49H73N6O12, 937.53; found 937.0 
[M+H]+. 
tert-butyl 3-((2S)-2-(2-aminoacetamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-
tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-
1H-indole-1-carboxylate (41) 
The Cbz-Gly-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (190 mg, 196 µmol, 1 equiv) was dissolved in 
5 mL of MeOH and stirred under argon atmosphere for 10 min. Afterwards 10 % Pd/C 
(19.0 mg, 10 % m/m) was added to the reaction vessel and argon atmosphere was 
replaced with hydrogen. The reaction mixture was vigorously stirred overnight at ambient 
T under ordinary hydrogen pressure (2 balloons). The mixture was filtered and 
concentrated to afford the colorless oil (129 mg, 82.0 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.5 Hz, 1 H), 7.79 (d, J=7.7 Hz, 1 H), 7.61 
(d, J=7.4 Hz, 1 H), 7.48 (s, 1 H), 7.33 – 7.30 (m, 1 H), 7.25-7.23 (m, 1 H), 6.83 (d, J=7.4 Hz, 1 
H), 6.40 (d, J=8.7 Hz, 1 H), 4.93 (s, 1 H), 4.74 (q, J1=6.8 Hz, J2=7.3 Hz, 1 H), 4.42 (q, J1=6.4 
Hz, J2=6.7 Hz, 1 H), 4.29 (dd, J1=1.4 Hz, J2=7.4 Hz, 1 H), 4.24-4.18 (m, 1 H), 3.73 (d, J=9.5 Hz, 
1 H), 3.33 (d, J=4.8 Hz, 2 H), 3.24-3.22 (m, 2 H), 3.05 (br s, 1 H), 1.88-1.77 (m, 1 H), 1.67 (s, 
9 H), 1.61-1.57 (m, 2 H), 1.45 (s, 9 H), 1.42 (s, 9 H), 1.35-1.25 (m, 3 H), 1.16 (s, 9 H), 1.15 (s, 
3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.4, 171.3, 170.8, 169.7, 156.2, 149.8, 
135.5, 130.5, 124.7, 124.4, 122.7, 119.2, 115.7, 83.8, 82.2, 79.1, 74.1, 67.2, 58.6, 53.2, 
44.7, 32.5, 29.5, 28.9, 28.6, 28.4, 28.3, 27.3, 22.2, 21.3 ppm. MS (m/z): calculated for 
C41H67N6O10, 803.49; found 804.0 [M+H]
+; 826.0 [M+Na]+. 
tert-butyl 3-((2S)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-(2-
((diphenylmethylene)amino)acetamido)-3-oxopropyl)-1H-indole-1-carboxylate (42) 
To a solution of the H-Gly-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (113 mg, 141 µmol, 1 equiv) in 
DCM (3 mL), was added benzophenone imine (47.0 µL, 282 µmol, 2 equiv), dissolved in 2 
mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (99.0 
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mg, 72.7 %, ˃96 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=15.8 min]).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11-8.05 (m, 2 H), 7.65 (d, J=7.7 Hz, 1 H), 7.52 (s, 
1 H), 7.46-7.41 (m, 7 H), 7.38-7.28 (m, 3 H), 7.18-7.13 (m, 1 H), 7.07-7.04 (m, 2 H), 6.79 (d, 
J=7.7 Hz, 1 H), 6.41 (d, J=8.7 Hz, 1 H), 4.92 (br s, 1 H), 4.85 (q, J1=7.2 Hz, J2=6.8 Hz, 1 H), 
4.46 (q, J1=J2=6.8 Hz, 1 H), 4.27 (dd, J1=2.1 Hz, J2=6.9 Hz, 1 H), 4.23-4.19 (m, 1 H), 3.93 (d, 
J=11.5 Hz, 2 H), 3.40-3.22 (m, 2 H), 3.06-3.02 (m, 2 H), 1.87-1.80 (m, 1 H), 1.61 (s, 9 H), 
1.45 (s, 9 H), 1.39 (s, 9 H), 1.33-1.31 (m, 2 H), 1.18 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 171.2, 170.7, 170.6, 169.7, 156.2, 149.8, 138.7, 136.1, 130.8, 130.6, 129.1, 
129.0, 128.5, 128.4, 127.3, 124.7, 124.6, 122.8, 119.3, 115.6, 115.4, 83.7, 82.1, 74.1, 67.2, 
58.6, 56.5, 53.5, 28.9, 28.6, 28.3, 22.2, 21.3 ppm. MS (m/z): calculated for C54H75N6O10, 
967.56; found 967.8 [M+H]+. HR-MS (m/z): calculated for C54H75N6O10, 967.56; found 
967.5521 [M+H]+.  
7. Preparation of intermediate to Ph2N=C-L-Phe-L-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-OtBu 
tert-butyl 3-((2S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (43) 
The Fmoc-Phe-OH (187 mg, 483 µmol, 1.5 equiv) was couple to the H-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (240 mg, 322 µmol, 1 equiv) in the presence of HATU (183 µmol, 483 µmol, 
1.5 equiv) and DIPEA (200 µL, 966 µmol, 3 equiv) as a coupling reagents in DCM (8 mL) and 
DMF (1 mL) as a solvent. Coupling time was 4 h at ambient T. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (10 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (216 mg, 60.2 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.7 Hz, 1 H), 7.76 (d, J=7.4 Hz, 2 H), 7.53-
7.48 (m, 3 H), 7.40-7.38 (m, 4 H), 7.32-7.29 (m, 3 H), 7.22-7.14 (m, 6 H), 6.61 (br s, 1 H), 
6.53 (br s, 1 H), 6.39 (d, J=8.6 Hz, 1 H), 5.21 (br s, 1 H), 4.91 (br s, 1 H), 4.65 (br s, 1 H), 
4.37-4.27 (m, 3 H), 4.23-4.19 (m, 3 H), 3.1-3.04 (m, 6 H), 1.86-1.82 (m, 1 H), 1.65 (s, 9 H), 
1.45 (s, 9 H), 1.41 (s, 9 H), 1.34-1.29 (m, 3 H), 1.14 (s, 12) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 171.1, 169.7, 156.2, 149.7, 143.9, 141.4, 130.4, 129.3, 128.9, 127.9, 127.2, 
125.2, 124.8, 124.6, 122.8, 120.1, 119.0, 115.5, 115.2, 83.8, 82.1, 74.1, 67.2, 58.6, 47.2, 
29.6, 28.9, 28.6, 28.4, 28.3, 21.3 ppm. MS (m/z): calculated for C63H83N6O12, 1115.61; 
found 1115.8 [M+H].  
 tert-butyl 3-((2S)-2-((S)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (44) 
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The Fmoc-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (152 mg, 136 µmol, 1 equiv) was dissolved 
in DCM (1 mL). TAEA (1.01 mL, 6.80 mmol, 50 equiv) was added and stirred for 15 min at 
ambient T. After completion, the reaction mixture was extracted with brine (1 x 5 mL) and 
phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was performed with 
DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, filtrated and 
evaporated in vacuo. The residue was purified using column chromatography to yield 
white precipitate (97.9 mg, 80.4 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=8.1 Hz, 1 H), 7.93 (d, J=7.8 Hz, 1 H), 7.56 
(d, J=7.5 Hz, 1 H), 7.44 (s, 1 H), 7.34-7.29 (m, 2 H), 7.25-7.21 (m, 4 H), 7.13-7.11 (m, 2 H), 
6.82 (d, J=7.5 Hz, 1 H), 6.39 (d, J=8.8 Hz, 1 H), 4.93 (br s, 1 H), 4.74 (q, J1=6.9 Hz, J2=7.3 Hz, 
1 H), 4.42 (q, J1=6.2 Hz, J2=6.8 Hz,  1 H), 4.29 (d, J=1.7 Hz, 1 H), 4.27-4.19 (m, 1 H), 3.64-
3.60 (m, 1 H), 3.52-3.45 (m, 1 H), 3.21-3.16 (m, 3 H), 3.15-3.05 (m, 3 H), 2.50 (q, J1=4.3 Hz, 
J2=9.4 Hz,  1 H), 1.87-1.79 (m, 1 H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.40 (s, 9 H), 1.34-1.29 (m, 3 
H) (m, 2 H), 1.17 (s, 9 H), 1.16 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 174.9, 
171.2, 170.8, 169.7, 156.2, 149.7, 137.7, 135.6, 130.5, 129.4, 128.8, 127.0, 124.7, 124.4, 
122.7, 119.3, 115.7, 115.4, 83.7, 82.2, 79.1, 74.1, 67.2, 58.6, 56.3, 53.1, 40.7, 32.6, 31.1, 
29.5, 28.9, 28.6, 28.4, 28.3, 27.3, 22.2, 21.3 ppm. MS (m/z): calculated for C48H73N6O10, 
893.54; found 893.9 [M+H]+. 
tert-butyl 3-((2S)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (45) 
To a solution of the H-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (89.0 mg, 101 µmol, 1 equiv) in 
DCM (1 mL), was added benzophenone imine (30.0 µL, 202 µmol, 2 equiv), dissolved in 1 
mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (32.7 
mg, 30.8 %, ˃96 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=31.1 min]). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.03 (d, J=8.1 Hz, 1 H), 7.62 (d, J=7.1 Hz, 1 H), 7.51 
(s, 1 H), 7.45-7.30 (m, 9 H), 7.24-7.21 (m, 3 H), 7.17-7.11 (m, 3 H), 6.95-6.92 (m, 2 H), 6.72 
(d, J=7.6 Hz, 1 H), 6.47 (d, J=6.6 Hz, 2 H), 6.34 (d, J=8.7 Hz, 1 H), 4.84-4.78 (m, 1 H), 4.42-
4.35 (m, 1 H), 4.27-4.17 (m, 3 H), 3.35-3.28 (m, 1 H), 3.17-3.01 (m, 3 H), 2.91-2.79 (m, 3 H), 
1.67 (s, 9 H), 1.43 (s, 9 H), 1.41 (s, 9 H), 1.16 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 173.2, 171.0, 170.5, 170.4, 169.7, 156.1, 149.8, 139.0, 137.5, 135.4, 130.7, 
130.2, 128.7, 128.4, 128.3, 128.2, 127.6, 126.5, 124.8, 124.7, 122.9, 119.5, 115.6, 115.5, 
83.8, 82.1, 74.1, 67.5, 67.1, 60.5, 58.6, 52.8, 41.5, 32.4, 28.9, 28.6, 28.4, 28.3, 27.1, 21.8, 
21.3 ppm. MS (m/z): calculated for C61H81N6O10, 1057.60; found 1058.0 [M+H]
+. HR-MS 
(m/z): calculated for C61H81N6O10, 1057.60; found 1057.6021 [M+H]
+. 
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8. Preparation of intermediate to Ph2N=C-D-Phe-L-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-
OtBu 
tert-butyl 3-((2S)-2-((R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (46) 
The Fmoc-D-Phe-OH (195 mg, 503 µmol, 1.5 equiv) was couple to the H-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (250 mg, 335 µmol, 1 equiv) in the presence of HATU (190 mg, 503 µmol, 1.5 
equiv) and DIPEA (175 µL, 1.00 mmol, 3 equiv) as a coupling reagents in DCM (8 mL) and 
DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (10 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (173 mg, 46.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=8.4 Hz, 1 H), 7.75 (d, J=7.5 Hz, 2 H), 7.55-
7.50 (m, 3 H), 7.42-7.36 (m, 7 H), 7.23-7.12 (m, 6 H), 6.75 (br s, 1 H), 6.51 (br s, 1 H), 6.43 
(d, J=8.3 Hz, 1 H), 5.54 (br s, 1 H), 4.86 (br s, 1 H), 4.68 (br s, 1 H), 4.38-4.35 (m, 3 H), 4.28-
4.25 (m, 2 H), 4.19-4.15 (m, 2 H), 3.11–2.89 (m, 6 H), 1.86-1.80 (m, 1 H), 1.65 (s, 9 H), 1.44 
(s, 9 H), 1.41 (s, 9 H), 1.16 (s, 9 H), 1.13 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): 
δ 171.1, 169.7, 156.2, 149.7, 144.0, 141.4, 135.6, 130.3, 129.3, 128.8, 127.8, 125.3, 124.8, 
124.6, 122.8, 120.1, 119.2, 115.5, 83.8, 82.0, 74.0, 67.4, 67.2, 58.6, 53.3, 47.2, 28.9, 28.6, 
28.4, 28.3, 21.2, 21.1 ppm. MS (m/z): calculated for C63H83N6O12, 1115.61; found 1116.0 
[M+H]+; 1137.9 [M+Na]+. 
tert-butyl 3-((2S)-2-((R)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (47) 
The Fmoc-D-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (130 mg, 118 µmol, 1 equiv) was 
dissolved in DCM (1 mL). TAEA (880 µL, 5.90 mmol, 50 equiv) was added and stirred for 15 
min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 5 
mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (72.5 mg, 69.6 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.9 Hz, 1 H), 7.80 (d, J=7.8 Hz, 1 H), 7.62 
(d, J=6.9 Hz, 1 H), 7.46 (s, 1 H), 7.41-7.30 (m, 3 H), 7.25-7.18 (m, 4 H), 6.80 (d, J=7.5 Hz, 1 
H), 6.38 (d, J=8.9 Hz, 1 H), 4.95 (br s, 1 H), 4.70 (q, J1=7.4 Hz, J2=7.0 Hz, 1 H), 4.42 (q, J1=6.9 
Hz, J2=6.8 Hz, 1 H), 4.29 (dd, J1=7.2 Hz, J2=1.6 Hz, 1 H), 4.23-4.19 (m, 1 H), 3.56-3.50 (m, 1 
H), 3.27-3.22 (m, 3 H), 3.21-06 (m, 3 H), 2.60 (q, J1=9.9 Hz, J2=3.6 Hz, 1 H), 1.86-1.77 (m, 1 
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The Fmoc-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (152 mg, 136 µmol, 1 equiv) was dissolved 
in DCM (1 mL). TAEA (1.01 mL, 6.80 mmol, 50 equiv) was added and stirred for 15 min at 
ambient T. After completion, the reaction mixture was extracted with brine (1 x 5 mL) and 
phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was performed with 
DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, filtrated and 
evaporated in vacuo. The residue was purified using column chromatography to yield 
white precipitate (97.9 mg, 80.4 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.11 (d, J=8.1 Hz, 1 H), 7.93 (d, J=7.8 Hz, 1 H), 7.56 
(d, J=7.5 Hz, 1 H), 7.44 (s, 1 H), 7.34-7.29 (m, 2 H), 7.25-7.21 (m, 4 H), 7.13-7.11 (m, 2 H), 
6.82 (d, J=7.5 Hz, 1 H), 6.39 (d, J=8.8 Hz, 1 H), 4.93 (br s, 1 H), 4.74 (q, J1=6.9 Hz, J2=7.3 Hz, 
1 H), 4.42 (q, J1=6.2 Hz, J2=6.8 Hz,  1 H), 4.29 (d, J=1.7 Hz, 1 H), 4.27-4.19 (m, 1 H), 3.64-
3.60 (m, 1 H), 3.52-3.45 (m, 1 H), 3.21-3.16 (m, 3 H), 3.15-3.05 (m, 3 H), 2.50 (q, J1=4.3 Hz, 
J2=9.4 Hz,  1 H), 1.87-1.79 (m, 1 H), 1.66 (s, 9 H), 1.45 (s, 9 H), 1.40 (s, 9 H), 1.34-1.29 (m, 3 
H) (m, 2 H), 1.17 (s, 9 H), 1.16 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 174.9, 
171.2, 170.8, 169.7, 156.2, 149.7, 137.7, 135.6, 130.5, 129.4, 128.8, 127.0, 124.7, 124.4, 
122.7, 119.3, 115.7, 115.4, 83.7, 82.2, 79.1, 74.1, 67.2, 58.6, 56.3, 53.1, 40.7, 32.6, 31.1, 
29.5, 28.9, 28.6, 28.4, 28.3, 27.3, 22.2, 21.3 ppm. MS (m/z): calculated for C48H73N6O10, 
893.54; found 893.9 [M+H]+. 
tert-butyl 3-((2S)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((S)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (45) 
To a solution of the H-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (89.0 mg, 101 µmol, 1 equiv) in 
DCM (1 mL), was added benzophenone imine (30.0 µL, 202 µmol, 2 equiv), dissolved in 1 
mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (32.7 
mg, 30.8 %, ˃96 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=31.1 min]). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.03 (d, J=8.1 Hz, 1 H), 7.62 (d, J=7.1 Hz, 1 H), 7.51 
(s, 1 H), 7.45-7.30 (m, 9 H), 7.24-7.21 (m, 3 H), 7.17-7.11 (m, 3 H), 6.95-6.92 (m, 2 H), 6.72 
(d, J=7.6 Hz, 1 H), 6.47 (d, J=6.6 Hz, 2 H), 6.34 (d, J=8.7 Hz, 1 H), 4.84-4.78 (m, 1 H), 4.42-
4.35 (m, 1 H), 4.27-4.17 (m, 3 H), 3.35-3.28 (m, 1 H), 3.17-3.01 (m, 3 H), 2.91-2.79 (m, 3 H), 
1.67 (s, 9 H), 1.43 (s, 9 H), 1.41 (s, 9 H), 1.16 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, 
ambient T): δ 173.2, 171.0, 170.5, 170.4, 169.7, 156.1, 149.8, 139.0, 137.5, 135.4, 130.7, 
130.2, 128.7, 128.4, 128.3, 128.2, 127.6, 126.5, 124.8, 124.7, 122.9, 119.5, 115.6, 115.5, 
83.8, 82.1, 74.1, 67.5, 67.1, 60.5, 58.6, 52.8, 41.5, 32.4, 28.9, 28.6, 28.4, 28.3, 27.1, 21.8, 
21.3 ppm. MS (m/z): calculated for C61H81N6O10, 1057.60; found 1058.0 [M+H]
+. HR-MS 
(m/z): calculated for C61H81N6O10, 1057.60; found 1057.6021 [M+H]
+. 
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8. Preparation of intermediate to Ph2N=C-D-Phe-L-Trp(Boc)-L-Lys(Boc)-L-Thr(OtBu)-
OtBu 
tert-butyl 3-((2S)-2-((R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-
4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-3-oxopropyl)-1H-indole-1-
carboxylate (46) 
The Fmoc-D-Phe-OH (195 mg, 503 µmol, 1.5 equiv) was couple to the H-Trp(Boc)-Lys(Boc)-
Thr(tBu)-OtBu (250 mg, 335 µmol, 1 equiv) in the presence of HATU (190 mg, 503 µmol, 1.5 
equiv) and DIPEA (175 µL, 1.00 mmol, 3 equiv) as a coupling reagents in DCM (8 mL) and 
DMF (1 mL) as a solvent. Coupling time was 3 h at ambient T. After the completion of the 
reaction, reaction mixture was concentrated and the residue was dissolved in EtOAc (10 
mL). The EtOAc solution was washed with 1 M KHSO4 (3 x 5 mL), 10 % K2CO3 (3 x 5 mL) 
and brine (3 x 5 mL), dried over Na2SO4, filtrated and evaporated in vacuo. The residue 
was purified using column chromatography to yield colorless oil (173 mg, 46.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=8.4 Hz, 1 H), 7.75 (d, J=7.5 Hz, 2 H), 7.55-
7.50 (m, 3 H), 7.42-7.36 (m, 7 H), 7.23-7.12 (m, 6 H), 6.75 (br s, 1 H), 6.51 (br s, 1 H), 6.43 
(d, J=8.3 Hz, 1 H), 5.54 (br s, 1 H), 4.86 (br s, 1 H), 4.68 (br s, 1 H), 4.38-4.35 (m, 3 H), 4.28-
4.25 (m, 2 H), 4.19-4.15 (m, 2 H), 3.11–2.89 (m, 6 H), 1.86-1.80 (m, 1 H), 1.65 (s, 9 H), 1.44 
(s, 9 H), 1.41 (s, 9 H), 1.16 (s, 9 H), 1.13 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): 
δ 171.1, 169.7, 156.2, 149.7, 144.0, 141.4, 135.6, 130.3, 129.3, 128.8, 127.8, 125.3, 124.8, 
124.6, 122.8, 120.1, 119.2, 115.5, 83.8, 82.0, 74.0, 67.4, 67.2, 58.6, 53.3, 47.2, 28.9, 28.6, 
28.4, 28.3, 21.2, 21.1 ppm. MS (m/z): calculated for C63H83N6O12, 1115.61; found 1116.0 
[M+H]+; 1137.9 [M+Na]+. 
tert-butyl 3-((2S)-2-((R)-2-amino-3-phenylpropanamido)-3-(((10S)-13-((S)-1-(tert-
butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-trioxo-3,15-dioxa-5,12-diazaheptadecan-
10-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (47) 
The Fmoc-D-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (130 mg, 118 µmol, 1 equiv) was 
dissolved in DCM (1 mL). TAEA (880 µL, 5.90 mmol, 50 equiv) was added and stirred for 15 
min at ambient T. After completion, the reaction mixture was extracted with brine (1 x 5 
mL) and phosphate buffer (pH=5.5) (3 x 5 mL). Additional back up extraction was 
performed with DCM (3 x 5 mL). Collected organic phases were dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified using column chromatography 
to yield white precipitate (72.5 mg, 69.6 %).  
1H NMR (300 MHz, CDCl3, ambient T): δ 8.09 (d, J=7.9 Hz, 1 H), 7.80 (d, J=7.8 Hz, 1 H), 7.62 
(d, J=6.9 Hz, 1 H), 7.46 (s, 1 H), 7.41-7.30 (m, 3 H), 7.25-7.18 (m, 4 H), 6.80 (d, J=7.5 Hz, 1 
H), 6.38 (d, J=8.9 Hz, 1 H), 4.95 (br s, 1 H), 4.70 (q, J1=7.4 Hz, J2=7.0 Hz, 1 H), 4.42 (q, J1=6.9 
Hz, J2=6.8 Hz, 1 H), 4.29 (dd, J1=7.2 Hz, J2=1.6 Hz, 1 H), 4.23-4.19 (m, 1 H), 3.56-3.50 (m, 1 
H), 3.27-3.22 (m, 3 H), 3.21-06 (m, 3 H), 2.60 (q, J1=9.9 Hz, J2=3.6 Hz, 1 H), 1.86-1.77 (m, 1 
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H), 1.66 (s, 9 H), 1.58-1.54 (m, 5 H), 1.46 (s, 9 H), 1.42 (s, 9 H), 1.37-1.34 (m, 2 H), 1.17 (s, 9 
H), 1.16 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 175.0, 171.2, 170.7, 
169.7, 156.2, 149.7, 138.0, 135.5, 130.5, 129.3, 128.9, 127.0, 124.7, 124.5, 122.7, 119.2, 
115.7, 115.4, 83.8, 82.2, 74.1, 67.2, 58.6, 56.8, 53.4, 53.2, 40.2, 32.6, 31.1, 29.5, 28.9, 28.6, 
28.4, 28.3, 27.2, 22.2, 21.3 ppm. MS (m/z): calculated for C48H73N6O10, 893.54; found 893.9 
[M+H]+. 
tert-butyl 3-((2S)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((R)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (48) 
To a solution of the H-D-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (65.0 mg, 75.0 µmol, 1 equiv) 
in DCM (1 mL), was added benzophenone imine (22.0 µL, 150 µmol, 2 equiv), dissolved in 
1 mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (38.5 
mg, 48.5 %, ˃97 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=26.3 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.01 (d, J=7.9 Hz, 1 H), 7.51-7.39 (m, 5 H), 7.33-
7.30 (m, 4 H), 7.23-7.17 (m, 7 H), 7.14-6.88 (m, 4 H), 6.43 (d, J=8.8 Hz, 2 H), 5.95 (d, J=6.8 
Hz, 1 H), 4.9 (br s, 1 H), 4.82 (q, J1=7.6 Hz, J2=6.5  Hz, 1 H), 4.52 (q, J1=6.9 Hz, J2=6.6  Hz, 1 
H), 4.31 (d, J=8.9 Hz, 1 H), 4.22-4.19 (m, 1 H), 4.00 (q, J1=9.8 Hz, J2=2.7  Hz, 1 H), 3.22 (d, 
J=1.3 Hz, 2 H), 3.17 (s, 1 H), 3.11 (br s, 2 H), 1.91-1.86 (m, 1 H), 1.60 (s, 9 H), 1.47 (s, 9 H), 
1.41 (s, 9 H), 1.17 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.4, 171.2, 
170.8, 169.7, 156.2, 149.6, 139.0, 137.9, 135.3, 130.7, 130.4, 103.2, 128.8, 128.3, 128.2, 
127.3, 126.4, 124.6, 124.6, 124.4, 122.8, 119.0, 115.8, 115.3, 83.6, 82.2, 74.1, 67.7, 67.2, 
58.6, 53.4, 53.3, 41.5, 32.6, 28.9, 28.6, 27.1, 22.4, 21.3 ppm. MS (m/z): calculated for 
C61H81N6O10, 1057.60; found 1058.0 [M+H]
+. HR-MS (m/z): calculated for C61H81N6O10, 
1057.60; found 1057.5991 [M+H]+. 
9. Synthesis of N-(9-anthracenylmethyl)cinchoninium chloride – Cat 10  
The compound Cat 10 was prepared and characterized according to O'Donnell et al.[20] and 
Corey et al.[26].  To a suspension of cinchonine (1.00 g, 3.40 mmol, 1 equiv) in toluene (14 
mL) was added 9-(chloromethyl)anthracene (770 mg, 3.74 mmol, 1.1 equiv). The reaction 
mixture was stirred at reflux overnight. The mixture was then cooled to ambient T and 
poured onto 40 mL of diethyl ether and filtered to afford light yellow solid (1.43 g, 2.75 
mmol, 81.0 %). Smaller fraction of filtered solid (180 mg) was purified by flash 
chromatography (SiO2, 0–100 % MeOH/DCM) to yield a yellow solid (169 mg, 94.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 9.21 (d, J=8.9 Hz, 1 H), 8.91-8.85 (m, 2 H), 8.44 (d, 
J=9.1 Hz, 1 H), 8.19 (d, J=4.2 Hz, 1 H), 8.05 (d, J=4.5 Hz, 1 H), 7.88 (s, 1 H), 7.61-7.55 (m, 2 
H), 7.48 (d, J=8.3 Hz, 1 H), 7.24-7.05 (m, 4 H), 7.00-6.89 (m, 3 H), 6.50 (d, J=13.4 Hz, 1 H), 
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5.64-5.54 (m, 1 H), 5.03 (d, J=10.5 Hz, 1 H), 4.88 (d, J=17.2 Hz, 1 H), 4.72 (m, 1 H), 4.44 (m, 
1 H), 4.25 (m, 1 H), 2.53-2.49 (m, 1 H), 2.34-2.30 (m, 1 H), 2.01-1.93 (m, 1 H), 1.75-1.66 (m, 
2 H), 1.53 (br s, 1 H), 1.25-1.21 (m, 2 H) ppm. MS (m/z): calculated for C34H33N2O
+, 485.26; 
found 485.40 [M+H]+. 
10. Synthesis of O-Allyl-N-(9-anthracenylmethyl)cinchoninium bromide – Cat 6  
The compound Cat 10 was prepared and characterized according to O'Donnell et al.[20] To 
a suspension of the compound Cat 6 (150 mg, 288 µmol, 1 equiv) in DCM (2 mL) was 
added allyl bromide (78.0 µL, 684 µmol, 3 equiv) and aqueous 50 % KOH (0.2 mL). The 
resulting mixture was stirred vigorously at ambient T for 8 h, during which time all the 
solid dissolved. The mixture was diluted with water (10 mL) and extracted with 
dichloromethane (3 x 15 mL). The combined organic fractions were dried over Na2SO4, 
filtered and concentrated to dryness in vacuo to give an orange solid. The solid was 
suspended in ice cold diethylether, placed in the freezer (-23 ⁰C) for a few hours and 
filtered to give crude product as a light orange solid (66.0 mg,  109 µmol, 37. 8 %). 
1H NMR (300 MHz, CD3OD, ambient T): δ 9.05 (d, J=4.6 Hz, 1 H), 8.90 (s, 1 H), 8.81 (d, J=6.4 
Hz, 1 H), 8.58-8.49 (m, 1 H), 8.36 (d, J=8.9 Hz, 1 H), 8.29-8.20 (m, 3 H), 8.03-7.93 (m, 3 H), 
7.84-7.62 (m, 4 H), 6.90 (br s, 1 H), 6.16-6.11 (m, 1 H), 6.04-5.98 (m, 3 H), 5.72 (dd, J1=15.9 
Hz, J2=1.5 Hz, 1 H), 5.62 (d, J=13.4 Hz, 1 H), 5.22 (d, J=6.4 Hz, 1 H), 5.08 (d, J=17.2 Hz, 1 H), 
4.51-4.41 (m, 4 H), 4.20-3.92 (m, 1 H), 3.25-3.18 (m, 1 H), 2.86-2.60 (m, 2 H), 2.32-2.29 (m, 
1 H), 1.88-1.23 (m, 4 H),  ppm. 13C NMR (75 MHz, CD3OD, ambient T): δ 149.8, 148.1, 
141.1, 136.2, 133.5, 133.4, 132.7, 131.9, 131.8, 131.7, 130.3, 130.2, 129.9, 129.3, 128.7, 
128.1, 128.0, 125.4, 125.3, 125.0, 124.6, 124.1, 123.6, 123.2, 117.9, 116.7, 70.0, 65.7, 57.8, 
56.0, 37.6, 26.2, 23.5, 22.1 ppm. MS (m/z): calculated for C37H37N2O
+, 525.29; found 525.5 
[M+H]+. HR-MS (m/z): calculated for C37H37N2O
+, 525.29; found 525.2837 [M+H]+. 
HPLC Seperation of Standard References 
1. HPLC Separation of Compounds 30 and 33 
Stationary phase: Column A: Luna 5 µm C18(2) 250*4.6 mm.  
Mobile phase: Method 1: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  
90-96 % D; 10-13 min: 96 % D; 13-15 min: 96-90 % D; wavelength 254 nm, column T – 
ambient, flow 1 mL·min-1. 
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H), 1.66 (s, 9 H), 1.58-1.54 (m, 5 H), 1.46 (s, 9 H), 1.42 (s, 9 H), 1.37-1.34 (m, 2 H), 1.17 (s, 9 
H), 1.16 (d, J=6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 175.0, 171.2, 170.7, 
169.7, 156.2, 149.7, 138.0, 135.5, 130.5, 129.3, 128.9, 127.0, 124.7, 124.5, 122.7, 119.2, 
115.7, 115.4, 83.8, 82.2, 74.1, 67.2, 58.6, 56.8, 53.4, 53.2, 40.2, 32.6, 31.1, 29.5, 28.9, 28.6, 
28.4, 28.3, 27.2, 22.2, 21.3 ppm. MS (m/z): calculated for C48H73N6O10, 893.54; found 893.9 
[M+H]+. 
tert-butyl 3-((2S)-3-(((10S)-13-((S)-1-(tert-butoxy)ethyl)-2,2,16,16-tetramethyl-4,11,14-
trioxo-3,15-dioxa-5,12-diazaheptadecan-10-yl)amino)-2-((R)-2-
((diphenylmethylene)amino)-3-phenylpropanamido)-3-oxopropyl)-1H-indole-1-
carboxylate (48) 
To a solution of the H-D-Phe-Trp(Boc)-Lys(Boc)-Thr(tBu)-OtBu (65.0 mg, 75.0 µmol, 1 equiv) 
in DCM (1 mL), was added benzophenone imine (22.0 µL, 150 µmol, 2 equiv), dissolved in 
1 mL of DCM. Reaction was stirred overnight at ambient T. After completion, reaction 
mixture was concentrated and purified by flash chromatography to yield white solid (38.5 
mg, 48.5 %, ˃97 % purity [determined by HPLC: column A, solvents D/H, 90/10, v/v, 
wavelength 210 nm, column T – ambient, flow 1 mL·min-1, tR=26.3 min]).   
1H NMR (300 MHz, CDCl3, ambient T): δ 8.01 (d, J=7.9 Hz, 1 H), 7.51-7.39 (m, 5 H), 7.33-
7.30 (m, 4 H), 7.23-7.17 (m, 7 H), 7.14-6.88 (m, 4 H), 6.43 (d, J=8.8 Hz, 2 H), 5.95 (d, J=6.8 
Hz, 1 H), 4.9 (br s, 1 H), 4.82 (q, J1=7.6 Hz, J2=6.5  Hz, 1 H), 4.52 (q, J1=6.9 Hz, J2=6.6  Hz, 1 
H), 4.31 (d, J=8.9 Hz, 1 H), 4.22-4.19 (m, 1 H), 4.00 (q, J1=9.8 Hz, J2=2.7  Hz, 1 H), 3.22 (d, 
J=1.3 Hz, 2 H), 3.17 (s, 1 H), 3.11 (br s, 2 H), 1.91-1.86 (m, 1 H), 1.60 (s, 9 H), 1.47 (s, 9 H), 
1.41 (s, 9 H), 1.17 (s, 12 H) ppm. 13C NMR (75 MHz, CDCl3, ambient T): δ 173.4, 171.2, 
170.8, 169.7, 156.2, 149.6, 139.0, 137.9, 135.3, 130.7, 130.4, 103.2, 128.8, 128.3, 128.2, 
127.3, 126.4, 124.6, 124.6, 124.4, 122.8, 119.0, 115.8, 115.3, 83.6, 82.2, 74.1, 67.7, 67.2, 
58.6, 53.4, 53.3, 41.5, 32.6, 28.9, 28.6, 27.1, 22.4, 21.3 ppm. MS (m/z): calculated for 
C61H81N6O10, 1057.60; found 1058.0 [M+H]
+. HR-MS (m/z): calculated for C61H81N6O10, 
1057.60; found 1057.5991 [M+H]+. 
9. Synthesis of N-(9-anthracenylmethyl)cinchoninium chloride – Cat 10  
The compound Cat 10 was prepared and characterized according to O'Donnell et al.[20] and 
Corey et al.[26].  To a suspension of cinchonine (1.00 g, 3.40 mmol, 1 equiv) in toluene (14 
mL) was added 9-(chloromethyl)anthracene (770 mg, 3.74 mmol, 1.1 equiv). The reaction 
mixture was stirred at reflux overnight. The mixture was then cooled to ambient T and 
poured onto 40 mL of diethyl ether and filtered to afford light yellow solid (1.43 g, 2.75 
mmol, 81.0 %). Smaller fraction of filtered solid (180 mg) was purified by flash 
chromatography (SiO2, 0–100 % MeOH/DCM) to yield a yellow solid (169 mg, 94.0 %). 
1H NMR (300 MHz, CDCl3, ambient T): δ 9.21 (d, J=8.9 Hz, 1 H), 8.91-8.85 (m, 2 H), 8.44 (d, 
J=9.1 Hz, 1 H), 8.19 (d, J=4.2 Hz, 1 H), 8.05 (d, J=4.5 Hz, 1 H), 7.88 (s, 1 H), 7.61-7.55 (m, 2 
H), 7.48 (d, J=8.3 Hz, 1 H), 7.24-7.05 (m, 4 H), 7.00-6.89 (m, 3 H), 6.50 (d, J=13.4 Hz, 1 H), 
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5.64-5.54 (m, 1 H), 5.03 (d, J=10.5 Hz, 1 H), 4.88 (d, J=17.2 Hz, 1 H), 4.72 (m, 1 H), 4.44 (m, 
1 H), 4.25 (m, 1 H), 2.53-2.49 (m, 1 H), 2.34-2.30 (m, 1 H), 2.01-1.93 (m, 1 H), 1.75-1.66 (m, 
2 H), 1.53 (br s, 1 H), 1.25-1.21 (m, 2 H) ppm. MS (m/z): calculated for C34H33N2O
+, 485.26; 
found 485.40 [M+H]+. 
10. Synthesis of O-Allyl-N-(9-anthracenylmethyl)cinchoninium bromide – Cat 6  
The compound Cat 10 was prepared and characterized according to O'Donnell et al.[20] To 
a suspension of the compound Cat 6 (150 mg, 288 µmol, 1 equiv) in DCM (2 mL) was 
added allyl bromide (78.0 µL, 684 µmol, 3 equiv) and aqueous 50 % KOH (0.2 mL). The 
resulting mixture was stirred vigorously at ambient T for 8 h, during which time all the 
solid dissolved. The mixture was diluted with water (10 mL) and extracted with 
dichloromethane (3 x 15 mL). The combined organic fractions were dried over Na2SO4, 
filtered and concentrated to dryness in vacuo to give an orange solid. The solid was 
suspended in ice cold diethylether, placed in the freezer (-23 ⁰C) for a few hours and 
filtered to give crude product as a light orange solid (66.0 mg,  109 µmol, 37. 8 %). 
1H NMR (300 MHz, CD3OD, ambient T): δ 9.05 (d, J=4.6 Hz, 1 H), 8.90 (s, 1 H), 8.81 (d, J=6.4 
Hz, 1 H), 8.58-8.49 (m, 1 H), 8.36 (d, J=8.9 Hz, 1 H), 8.29-8.20 (m, 3 H), 8.03-7.93 (m, 3 H), 
7.84-7.62 (m, 4 H), 6.90 (br s, 1 H), 6.16-6.11 (m, 1 H), 6.04-5.98 (m, 3 H), 5.72 (dd, J1=15.9 
Hz, J2=1.5 Hz, 1 H), 5.62 (d, J=13.4 Hz, 1 H), 5.22 (d, J=6.4 Hz, 1 H), 5.08 (d, J=17.2 Hz, 1 H), 
4.51-4.41 (m, 4 H), 4.20-3.92 (m, 1 H), 3.25-3.18 (m, 1 H), 2.86-2.60 (m, 2 H), 2.32-2.29 (m, 
1 H), 1.88-1.23 (m, 4 H),  ppm. 13C NMR (75 MHz, CD3OD, ambient T): δ 149.8, 148.1, 
141.1, 136.2, 133.5, 133.4, 132.7, 131.9, 131.8, 131.7, 130.3, 130.2, 129.9, 129.3, 128.7, 
128.1, 128.0, 125.4, 125.3, 125.0, 124.6, 124.1, 123.6, 123.2, 117.9, 116.7, 70.0, 65.7, 57.8, 
56.0, 37.6, 26.2, 23.5, 22.1 ppm. MS (m/z): calculated for C37H37N2O
+, 525.29; found 525.5 
[M+H]+. HR-MS (m/z): calculated for C37H37N2O
+, 525.29; found 525.2837 [M+H]+. 
HPLC Seperation of Standard References 
1. HPLC Separation of Compounds 30 and 33 
Stationary phase: Column A: Luna 5 µm C18(2) 250*4.6 mm.  
Mobile phase: Method 1: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  
90-96 % D; 10-13 min: 96 % D; 13-15 min: 96-90 % D; wavelength 254 nm, column T – 
ambient, flow 1 mL·min-1. 
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Stationary phase: Column A: Luna 5 µm C18(2) 250*4.6 mm.  
*Method 5: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-97 % D; 10-
13 min: 97 % D; 13-15 min: 97-90 % D.   
 
Retention times: 14.3 min for Ph2C=N-L-Phe-D-Trp(Boc)-L-Lys(Boc)-L-Thr(
tBu)-OtBu 30 and 
15.4 min Ph2C=N-D-Phe-D-Trp(Boc)-L-Lys(BocC)-L-Thr(
tBu)-OtBu 33. 
2. HPLC Separation of Compounds 42, 45 and 48 
Stationary phase: Column A: Luna 5 µm C18(2) 250*4.6 mm.  
Mobile phase: Method 1: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  
90-96 % D; 10-13 min: 96 % D; 13-15 min: 96-90 % D; wavelength 254 nm, column T  – 
ambient, flow 1 mL·min-1. 
 
Catalyst Stability and Purity 
 
In light of the initial results with Cat 1 and Cat 5, where a full equivalent of phase-
transfer catalyst (PTC) (2 or 4 equiv) is required to achieve some stereochemical 
induction, it was logical to provide data for the catalyst stability under basic 
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conditions, as the catalyst decomposition was already found to be responsible for 
less selective pathways, especially for the cinchonidine-derived PTC on large 
industrial scale.[30] Results supported by liquid chromatography-mass spectrometry 
(LC-MS) lead to conclusion that catalytic amounts (25 %) of chiral PTc under 
strongly basic conditions (350 equiv of CsOH*H2O) remain intact during alkylation 
time of 10 min.  
1. Nuclear Magnetic Resonance (NMR) 
Catalysts Cat 1 – Cat 3, Cat 5, Cat 7 and Cat 8 were checked by NMR and characterized in 
accordance with the literature.  
NMR of the purchased catalyst Cat 8 revealed that undesired diastereomers (6S,10S)- or 
(6R,10S)-bis(phenylmethyl) of this catalysts are present. [31,32] 
2. Liquid Chromatography-Mass Spectrometry (LC-MS) 
 
Table 3: Overview of the catalyst stability study. 
Chiral 
PTc a 
25 
mol%a 
[mg] 
CsOH·H2O 
[mg] 
Toluene 
[µL] 
Reaction 
time 
[min] 
T 
[⁰C] 
[MW]+ 
[g·mol-1]b 
Organoleptic 
properties 
Cat 1[33] 0.5 183 100 10 0 
[C37H37N2O]+: 
525.29 
Yellow pale 
powder 
Cat 2[25] 0.6 183 100 10 0 
[C42H36F6N]+: 
668.27 
Grey white 
powder 
Cat 3[25] 0.6 183 100 10 0 
[C42H36F6N]+: 
668.27 
Off-White 
powder 
Cat 5[27] 0.8 183 100 10 0 
[C56H66N4O2]2+ 
/2: 413.26 
Orange pale 
powder 
Cat 7[34] 1.0 183 100 10 0 
[C60H36F12N]+: 
998.27 
Off-White 
powder 
Cat 8[31] 1.0 183 100 10 0 
[C58H70N2O2]2+ 
/2: 456.76 
Off-White 
powder 
a25 mol% of PTc is compared to 3.1 µmol of precursor 27 employed in the catalytic asymmetric 11C-
benzylation. bMolecular mass data provided from supplementary information. 
 
Results supported by liquid chromatography-mass spectrometry (LC-MS) shoved 
that Cat 1 and Cat 3 are stable, while Cat 2, Cat 5, Cat 7 and Cat 8 show some 
fragmentation, with possible decomposition, on mass spectra. 
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Stationary phase: Column A: Luna 5 µm C18(2) 250*4.6 mm.  
*Method 5: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-97 % D; 10-
13 min: 97 % D; 13-15 min: 97-90 % D.   
 
Retention times: 14.3 min for Ph2C=N-L-Phe-D-Trp(Boc)-L-Lys(Boc)-L-Thr(
tBu)-OtBu 30 and 
15.4 min Ph2C=N-D-Phe-D-Trp(Boc)-L-Lys(BocC)-L-Thr(
tBu)-OtBu 33. 
2. HPLC Separation of Compounds 42, 45 and 48 
Stationary phase: Column A: Luna 5 µm C18(2) 250*4.6 mm.  
Mobile phase: Method 1: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  
90-96 % D; 10-13 min: 96 % D; 13-15 min: 96-90 % D; wavelength 254 nm, column T  – 
ambient, flow 1 mL·min-1. 
 
Catalyst Stability and Purity 
 
In light of the initial results with Cat 1 and Cat 5, where a full equivalent of phase-
transfer catalyst (PTC) (2 or 4 equiv) is required to achieve some stereochemical 
induction, it was logical to provide data for the catalyst stability under basic 
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conditions, as the catalyst decomposition was already found to be responsible for 
less selective pathways, especially for the cinchonidine-derived PTC on large 
industrial scale.[30] Results supported by liquid chromatography-mass spectrometry 
(LC-MS) lead to conclusion that catalytic amounts (25 %) of chiral PTc under 
strongly basic conditions (350 equiv of CsOH*H2O) remain intact during alkylation 
time of 10 min.  
1. Nuclear Magnetic Resonance (NMR) 
Catalysts Cat 1 – Cat 3, Cat 5, Cat 7 and Cat 8 were checked by NMR and characterized in 
accordance with the literature.  
NMR of the purchased catalyst Cat 8 revealed that undesired diastereomers (6S,10S)- or 
(6R,10S)-bis(phenylmethyl) of this catalysts are present. [31,32] 
2. Liquid Chromatography-Mass Spectrometry (LC-MS) 
 
Table 3: Overview of the catalyst stability study. 
Chiral 
PTc a 
25 
mol%a 
[mg] 
CsOH·H2O 
[mg] 
Toluene 
[µL] 
Reaction 
time 
[min] 
T 
[⁰C] 
[MW]+ 
[g·mol-1]b 
Organoleptic 
properties 
Cat 1[33] 0.5 183 100 10 0 
[C37H37N2O]+: 
525.29 
Yellow pale 
powder 
Cat 2[25] 0.6 183 100 10 0 
[C42H36F6N]+: 
668.27 
Grey white 
powder 
Cat 3[25] 0.6 183 100 10 0 
[C42H36F6N]+: 
668.27 
Off-White 
powder 
Cat 5[27] 0.8 183 100 10 0 
[C56H66N4O2]2+ 
/2: 413.26 
Orange pale 
powder 
Cat 7[34] 1.0 183 100 10 0 
[C60H36F12N]+: 
998.27 
Off-White 
powder 
Cat 8[31] 1.0 183 100 10 0 
[C58H70N2O2]2+ 
/2: 456.76 
Off-White 
powder 
a25 mol% of PTc is compared to 3.1 µmol of precursor 27 employed in the catalytic asymmetric 11C-
benzylation. bMolecular mass data provided from supplementary information. 
 
Results supported by liquid chromatography-mass spectrometry (LC-MS) shoved 
that Cat 1 and Cat 3 are stable, while Cat 2, Cat 5, Cat 7 and Cat 8 show some 
fragmentation, with possible decomposition, on mass spectra. 
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Catalyst 1: O-Allyl-N-(9-anthracenylmethyl)cinchonidinium bromide 
Cat 1 – before addition of the base: 
 
 
Cat 1 – after 10 min under basic conditions: 
 
 
Catalyst 2: (11bS)-(+)-4,4-Dibutyl-4,5-dihydro-2,6-bis(3,4,5-trifluorophenyl)-3H-
dinaphth[2,1-c:1′,2′-e]azepinium 
Cat 2 – before addition of the base: 
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 Cat 2 – after 10 min under basic conditions: 
 
 
Catalyst 3: (11bR)-(–)-4,4-Dibutyl-4,5-dihydro-2,6-bis(3,4,5-trifluorophenyl)-3H-
dinaphth[2,1-c:1′,2′-e]azepinium bromide 
Cat 3 – before addition of the base: 
 
 
Cat 3 – after 10 min under basic conditions: 
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Catalyst 1: O-Allyl-N-(9-anthracenylmethyl)cinchonidinium bromide 
Cat 1 – before addition of the base: 
 
 
Cat 1 – after 10 min under basic conditions: 
 
 
Catalyst 2: (11bS)-(+)-4,4-Dibutyl-4,5-dihydro-2,6-bis(3,4,5-trifluorophenyl)-3H-
dinaphth[2,1-c:1′,2′-e]azepinium 
Cat 2 – before addition of the base: 
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 Cat 2 – after 10 min under basic conditions: 
 
 
Catalyst 3: (11bR)-(–)-4,4-Dibutyl-4,5-dihydro-2,6-bis(3,4,5-trifluorophenyl)-3H-
dinaphth[2,1-c:1′,2′-e]azepinium bromide 
Cat 3 – before addition of the base: 
 
 
Cat 3 – after 10 min under basic conditions: 
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Catalyst 5: O,O′-Diallyl-N,N′-(2,7-naphthalenediyldimethyl)bis 
(hydrocinchonidinium)dibromide 
Cat 5 – before addition of the base: 
 
 
Cat 5 – after 10 min under basic conditions: 
 
 
Catalyst 7: (S,S)-3,5-Bistrifluoromethylphenyl-NAS Bromide 
Cat 7 – before addition of the base: 
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Cat 7 – after 10 min under basic conditions: 
 
 
Catalyst 8: 6,10-Dibenzyl-N,N'-dimethyl-N,N,N',N'-tetrakis(4-methylbenzyl)-1,4-
dioxaspiro[4.5]decane-(2S,3S)-diylbis(methy lammonium) 
Tetrafluoroboratetetrafluoroborate 
Cat 8 – before addition of the base: 
 
 
Cat 8 – after 10 min under basic conditions: 
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Catalyst 5: O,O′-Diallyl-N,N′-(2,7-naphthalenediyldimethyl)bis 
(hydrocinchonidinium)dibromide 
Cat 5 – before addition of the base: 
 
 
Cat 5 – after 10 min under basic conditions: 
 
 
Catalyst 7: (S,S)-3,5-Bistrifluoromethylphenyl-NAS Bromide 
Cat 7 – before addition of the base: 
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Cat 7 – after 10 min under basic conditions: 
 
 
Catalyst 8: 6,10-Dibenzyl-N,N'-dimethyl-N,N,N',N'-tetrakis(4-methylbenzyl)-1,4-
dioxaspiro[4.5]decane-(2S,3S)-diylbis(methy lammonium) 
Tetrafluoroboratetetrafluoroborate 
Cat 8 – before addition of the base: 
 
 
Cat 8 – after 10 min under basic conditions: 
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Radiochemistry 
 
Manual Synthesis of [11C]Benzyl iodide[17]  
[11C]Benzyl iodide was synthesized according to the procedure in Chapter 3.  
Manual Synthesis of H-D-[11C]Phe-D-Trp-L-Lys-L-Thr-OH 
[11C]Benzyl iodide in toluene (100 μL) was manually transferred in a conical vial containing 
Schiff base peptide precursor 27 (1 equiv, 3.0 mg, 3.1 μmol), cesium hydroxide 
monohydrate (CsOH*H2O) (350 equiv, 183 mg, 1090 μmol), and PTC catalyst Cat 6 (2 eq, 
3.8 mg, 6.2 μmol) and vigorously stirred at -10 ⁰C for 10 min with the aid of helium flow 
(estimated 50 mL·min-1) and magnetic stirrer. After completion, the reaction was 
subsequently quenched with 1.5 mL of CH3CN, loaded onto a 5 mL injection loop, and 
purified by semi-preparative reversed-phase HPLC (Column K, Method 4). The peak eluting 
at 16.6 min was collected and 1.0 mL of freshly prepared cleavage cocktail 
(TFA/thioanisole/EDT/anisole=90/5/3/2, v/v or TFA/EDT=9/1, v/v) was added to collection 
vial. The identity of the purified product was confirmed with analytical reversed-phase 
HPLC by co-injection of the product and authentic reference of tetrapeptide. The total 
time from [11C]CO2 delivery to the end of the synthesis (EOS) was 46 ± 1 min. 
Radiochemical purity ranged from 98–99%. 
Radiochemical purities of the isolated tetrapeptide [11C]33 and deprotected final product 
[11C]37 were checked using the HPLC. Presence of the isolated product [11C]33 was 
confirmed using the following HPLC conditions (Figure 6): Column A, Method 2: solvents 
D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-96 % D; 10-13 min: 96 % D; 13-15 
min: 96-90 % D; wavelength 254 nm, column T – ambient, flow 1 mL·min-1, Rt 18.1).   
 
Figure 6: Representative HPLC UV and radioactivity chromatogram of the isolated [11C]33. 
Co-injection with the standard 33.  
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In addition, synthetic intermediates [11C]30, [11C]33, [11C]45, and [11C]48 were identified 
with analytical HPLC, where samples have been taken (<50 μL) and dissolved in 300 μL of 
CH3CN. Column A, Method 2: solvents D/I (v/v), linear gradient, 0-2 min: 90 % I; 2-10 min:  
90-96 % I; 10-13 min: 96 % I; 13-15 min: 96-90 % I; wavelength 254 nm, column T – 
ambient, flow 1 mL·min-1. The following procedure for identification and determination of 
the diastereomeric excess was followed during all radiolabeling experiments. 
1. Radiochemical Conversion Calculation: 
Radiochemical conversion (RCC) was determined by HPLC analysis as the percentage of 
converted [11C]benzyl iodide to desired product (tetrapeptide intermediate) in the crude 
reaction mixture using an analytical HPLC method described in the radiochemistry section 
under each procedure and is based on the AUC of the radioactivity profile of HPLC 
analysis. Before each RCC analysis, a sample of [11C]benzyl iodide was injected on the 
analytical HPLC using the same method, to determine purity of the [11C]alkylating agent 
and possible contaminants, which were not accounted for in the RCC calculation.  
2. Radiochemical Yield Calculation: 
Radiochemical yield (RCY) is the amount of radioactivity in the product expressed as 
the percent of related starting radioactivity used in the corresponding synthesis. 
RCY was calculated as the quotient of measured activity of the isolated product 
after final deprotection step at the end of the synthesis (EOS) and the measured 
activity at the end of the cyclotron bombardment (EOB) in the vessel at the 
beginning of the synthesis, both measured in a dose calibrator, and expressed as a 
percentage. Radiochemical yield has been corrected for decay from the end of the 
cyclotron bombardment (EOB). No corrections have been made for material losses 
(potentially volatile radioactive species, or residual activity in the vial, tubes and 
syringes).  
3. Diastereomeric Excess Calculation: 
Diastereomeric excess (de) of the Ph2C=N-[
11C]-L-Phe-D-Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-
OtBu 30 and Ph2C=N-[
11C]-D-Phe-D-Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-OtBu 33, and Ph2C=N-
[11C]-L-Phe-L-Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-OtBu 45 and Ph2C=N-[
11C]-D-Phe-L-
Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-OtBu 48 was determined by HPLC analysis based on the 
AUC of the radioactivity profile of HPLC analysis of the protected tetrapeptide in the crude 
reaction mixture using an analytical HPLC column (column A, Method 2: solvents D/I (v/v), 
linear gradient, 0-2 min: 90 % D; 2-10 min:  90-96 % D; 10-13 min: 96 % D; 13-15 min: 96-
90 % D; wavelength 254 nm, column T  – ambient, flow 1 mL·min-1, Rt 14.3 min for L,D,L,L-
30 and Rt 15.4 min for DDLL-33, and Rt 17.3 min for L,L,L,L-45 and Rt 20.8 min for DDLL-48; 
Method 5: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-97 % D; 10-13 
min: 97 % D; 13-15 min: 97-90 %; wavelength 254 nm, column T  – ambient, flow 1 
mL·min-1, Rt 14.2 min for LDLL-30 and Rt 15.3 min for DDLL-33). For the calculations 
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In addition, synthetic intermediates [11C]30, [11C]33, [11C]45, and [11C]48 were identified 
with analytical HPLC, where samples have been taken (<50 μL) and dissolved in 300 μL of 
CH3CN. Column A, Method 2: solvents D/I (v/v), linear gradient, 0-2 min: 90 % I; 2-10 min:  
90-96 % I; 10-13 min: 96 % I; 13-15 min: 96-90 % I; wavelength 254 nm, column T – 
ambient, flow 1 mL·min-1. The following procedure for identification and determination of 
the diastereomeric excess was followed during all radiolabeling experiments. 
1. Radiochemical Conversion Calculation: 
Radiochemical conversion (RCC) was determined by HPLC analysis as the percentage of 
converted [11C]benzyl iodide to desired product (tetrapeptide intermediate) in the crude 
reaction mixture using an analytical HPLC method described in the radiochemistry section 
under each procedure and is based on the AUC of the radioactivity profile of HPLC 
analysis. Before each RCC analysis, a sample of [11C]benzyl iodide was injected on the 
analytical HPLC using the same method, to determine purity of the [11C]alkylating agent 
and possible contaminants, which were not accounted for in the RCC calculation.  
2. Radiochemical Yield Calculation: 
Radiochemical yield (RCY) is the amount of radioactivity in the product expressed as 
the percent of related starting radioactivity used in the corresponding synthesis. 
RCY was calculated as the quotient of measured activity of the isolated product 
after final deprotection step at the end of the synthesis (EOS) and the measured 
activity at the end of the cyclotron bombardment (EOB) in the vessel at the 
beginning of the synthesis, both measured in a dose calibrator, and expressed as a 
percentage. Radiochemical yield has been corrected for decay from the end of the 
cyclotron bombardment (EOB). No corrections have been made for material losses 
(potentially volatile radioactive species, or residual activity in the vial, tubes and 
syringes).  
3. Diastereomeric Excess Calculation: 
Diastereomeric excess (de) of the Ph2C=N-[
11C]-L-Phe-D-Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-
OtBu 30 and Ph2C=N-[
11C]-D-Phe-D-Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-OtBu 33, and Ph2C=N-
[11C]-L-Phe-L-Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-OtBu 45 and Ph2C=N-[
11C]-D-Phe-L-
Trp(BOC)-L-Lys(BOC)-L-Thr(OtBu)-OtBu 48 was determined by HPLC analysis based on the 
AUC of the radioactivity profile of HPLC analysis of the protected tetrapeptide in the crude 
reaction mixture using an analytical HPLC column (column A, Method 2: solvents D/I (v/v), 
linear gradient, 0-2 min: 90 % D; 2-10 min:  90-96 % D; 10-13 min: 96 % D; 13-15 min: 96-
90 % D; wavelength 254 nm, column T  – ambient, flow 1 mL·min-1, Rt 14.3 min for L,D,L,L-
30 and Rt 15.4 min for DDLL-33, and Rt 17.3 min for L,L,L,L-45 and Rt 20.8 min for DDLL-48; 
Method 5: solvents D/I (v/v), linear gradient, 0-2 min: 90 % D; 2-10 min:  90-97 % D; 10-13 
min: 97 % D; 13-15 min: 97-90 %; wavelength 254 nm, column T  – ambient, flow 1 
mL·min-1, Rt 14.2 min for LDLL-30 and Rt 15.3 min for DDLL-33). For the calculations 
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following formula has been used: de (%) = ((D-L)/(D+L)*100 ; D+L=1 for preferential D-
[11C]alkylation and de (%) = ((L-D)/(D+L)*100 ; D+L=1 for preferential L-[11C]alkylation. 
4. Molar Activity Calculation:  
Molar activity (AM) of the radioactive intermediate Ph2C=N-[
11C]-D-Phe-D-Trp(Boc)-
Lys(Boc)-Thr(OtBu)-OtBu 33 after preparative HPLC purification was determined by 
measurement of the UV absorbance of a known amount of radioactivity under identical 
analytical chiral HPLC conditions used to generate a mass calibration curve for the 
corresponding non-radioactive standard. 
5. The Mass Calibration Curve: 
The mass calibration curve was performed manually based on intermediate pure Ph2C=N-
[11C]-D-Phe-D-Trp(Boc)-Lys(Boc)-Thr(OtBu)-OtBu 33 due to strong UV absorption and is 
based on the AUC of HPLC analysis. 
 
Figure 7: Calibration curve (gradient and isocratic) of UV absorbance vs. injected amount 
of D,D,L,L-peptide 33 (μmol). For raw data used to construct the curve, see supplementary 
Table 3a and Table 3b. 
Stationary phase: Column A: Luna 5 µm C18(2) 250*4.6 mm  
Mobile phase: Gradient: Method 5; wavelength 254 nm, ambient T, flow 1 mL·min-1. 
Table 4a: Data for UV calibration curve (gradient) of D,D,L,L-peptide 33. 
Entry DDLL-peptide 33 [μmol]  UV Absorbance at 254nm [mV*s] 
1 5.69E-03 6354.46 
2 5.68E-03 6279.38 
3 2.84E-03 3183.70 
4 2.84E-03 3169.95 
5 9.46E-04 923.31 
6 9.46E-04 918.22 
7 5.68E-04 556.22 
8 5.68E-04 523.91 
9 1.42E-04 140.77 
10 1.42E-04 137.973 
y = 1E+06x - 76,779 
R² = 0,9995 
y = 1E+06x - 18,351 
R² = 0,9992 
0
2000
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Isocratic: Solvents D/I (v/v), 95 % D; wavelength 254 nm, ambient T, flow 1 mL·min-1. 
 
Table 4b: Data for UV calibration curve (isocratic) of D,D,L,L-peptide 33. 
Entry DDLL-peptide 33 [μmol]   UV Absorbance at 254nm [mV*s] 
1 7.80E-03 8365.09 
2 7.80E-03 8290.19 
3 2.60E-03 2904.83 
4 2.60E-03 2884.16 
5 2.60E-03 2808.07 
6 1.95E-03 2060.14 
7 1.95E-03 2065.99 
8 1.30E-03 1434.39 
9 1.30E-03 1354.57 
10 1.30E-03 1329.41 
11 1.30E-03 1313.87 
12 6.50E-04 638.056 
13 6.50E-04 542.78 
14 6.50E-04 714.49 
15 6.50E-04 720.92 
6. Full Optimization of Asymmetric Synthesis 
 
Table 5: Investigation of N-terminal 11C-benzylation to intermediate [11C]30 and [11C]33.  
Entry 
CsOH·H2O 
[equiv] 
Toluene 
[µL] 
27  
[mmol·L-1] 
T 
[⁰C] 
Time 
[min] 
Stirring* 
RCC  
[±SD; %]b 
1 330 400 8 0 10 Stirrer 0 
2 330 400 8 0 60 Stirrer 0 
3 50 400 8 0 10 Stirrer+He flow 4 
4 100 400 8 0 10 Stirrer+He flow 12 
5 150 400 8 0 10 Stirrer+He flow 25±10 (n=2) 
6 200 400 8 0 10 Stirrer+He flow 5 
7 250 400 8 0 10 Stirrer+He flow 37 
8 300 400 8 0 10 Stirrer+He flow 10 
9 350 400 8 0 10 Stirrer+He flow 61 
10 400 400 8 0 10 Stirrer+He flow 5 
11 450 400 8 0 10 Stirrer+He flow 2 
12 500 400 8 0 10 Stirrer+He flow 7 
13 350 300 10 0 10 Stirrer+He flow 22±1 (n=2) 
14 350 200 16 0 10 Stirrer+He flow 67 
15 350 100 31 0 10 Stirrer+He flow 93±2 (n=2) 
All reactions were conducted with 3.1 µmol of precursor 27, [11C]BnI in toluene, CsOH*H2O and 25 
mol% of Cat 3. bRadiochemical conversions were determined by HPLC.*He stans for helium.    
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Isocratic: Solvents D/I (v/v), 95 % D; wavelength 254 nm, ambient T, flow 1 mL·min-1. 
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mol% of Cat 3. bRadiochemical conversions were determined by HPLC.*He stans for helium.    
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Table 6: Screening the conditions of 11C-benzylation without the aid of PTC or using TBAB, 
Cat 3 or Cat 2. 
Entry PTc 
PTc 
[mol%a] 
T 
[⁰C] 
Time 
[min] 
RCC [±SD; %]b de [±SD; %]c 
1 / / 0 10 89.5±6.3 (n=2) 38.8±1.8 (n=2) 
2 / / - 10 10 94.1±1.3 (n=3) 63.3±1.4 (n=3) 
3 / / - 50 10 51.5±5.9 (n=2) 54.3±2.9 (n=2) 
4 / / - 78 10 18 55.8 
5 TBAB 200 - 10 10 88.5±2.7 (n=3) 54.3±2.3% (n=3) 
6 Cat 3 25 0 10 93.2±2.8 (n=10) 40.8±9.8 (n=10) 
7 Cat 2 25 0 10 94.9±0.5 (n=4) 39.7±1.9 (n=3) 
8 Cat 2 25 - 10 10 84.4±5.5 (n=3) 51.7±1.1% (n=3) 
9 Cat 2 50 - 10 10 93.1±2.7 (n=3) 54.2±6.1 (n=3) 
10 Cat 2 120 - 10 10 71.0±19.3 (n=3) 65.0±4.1 (n=3) 
11 Cat 2 200 - 10 10 95.4±2.0 (n=3) 66.7±2.4 (n=3) 
12 Cat 2 400 - 10 10 74.3±27.5 (n=3) 69.5±0.5 (n=3) 
13 Cat 3 200 - 10 10 94.0±2.3 (n=3) 57.3±3.6 (n=3) 
14 Cat 3 400 - 10 10 93.8±3.0 (n=3) 58.7±2.5 (n=3) 
All reactions were conducted with 3.1 µmol of precursor 27, 330-350 eq of CsOH*H2O and 100 
µL of toluene. a% of Cat is compared to precursor. bRadiochemical conversions were determined 
by HPLC. cDiastereomeric excess was determined by HPLC. Diastereomeric excess has been 
calculated using the following formula: de (%)=((D-L)/(D+L)*100; D+L = 1. 
 
Table 7: Screening the alkylation time, solvent, and the amount of base for Cat 2. 
Entry 
PTC 
[mol%]a 
CsOH*H2O 
[equiv]a 
Solvent 
Time 
[min] 
RCC [±SD; %]b de [±SD; %]c 
1 400 350 Toluene 1 16.3 59 
2 400 350 Toluene 5 72.4 / 
3 400 350 Toluene 10 86.2 63.8 
4 200 350 Toluene 5 77.6±12.7 (n=3) 68.7±3.2 (n=3) 
5 200 350 Toluene/DCM* 5 38.4±5.0 (n=3) 55.7±1.3 (n=3) 
6 200 150 Toluene 5 30.8±6.2 (n=2) 62.1±9.7 (n=2) 
7 200 250 Toluene 5 49.2±6.9 (n=3) 52.3±10.3 (n=3) 
All reactions were conducted with 3.1 µmol of precursor 27, CsOH*H2O, Cat 2 and 100 µL of solvent at -
10 ⁰C. a% of Cat and eq of base are compared to precursor. *Combination of toluene and DCM 
(v/v=1/1). bRadiochemical conversions were determined by HPLC. cDiastereomeric excess was 
determined by HPLC. Diastereomeric excess has been calculated using the following formula: de (%)=((D-
L)/(D+L)*100; D+L = 1. 
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Table 8: Screening the other PTc under optimal conditions. 
Entry PTca 
PTc, 
[mol%]a 
CsOH*H2O 
[equiv]a 
Time 
[min] 
RCC [±SD; %]b de [±SD; %]c 
1 Cat 1 25 350 10 90.5 55.2 
2 Cat 1 200 350 10 84.7±11.4 (n=3) 13.1±2.8 (n=3) 
3 Cat 1 400 350 10 93.6 15 
4 Cat 5 200 350 5 65.8 13.4 
5 Cat 5 200 350 10 85.4±6.3 (n=3) 19.8±1.2 (n=3) 
6 Cat 5 400 350 10 96 24 
7 Cat 7 200 350 10 30.0±14.7 (n=4) 42.7±9.3 (n=4) 
8 Cat 8* 200 350 10 92.3±3.0 (n=4) 74.9±4.1 (n=4) 
9 Cat 6 200 350 10 79.0±6.0 (n=5) 93.5±1.6 (n=5) 
10 Cat 10 200 350 10 75.7±4.0 (n=2) 13.1±1.7 (n=2) 
11 Cat 11** 200 350d 10 ˂5 (n=2) 0 (n=2) 
All reactions were conducted with 3.1 µmol of 27, CsOH*H2O and 100 µL of toluene as a solvent at -
10 ⁰C. a% of Cat and eq of base are compared to precursor. bRadiochemical conversions were 
determined by HPLC. cDiastereomeric excess was determined by HPLC. Diastereomeric excess has 
been calculated using the following formula: de (%)=((D-L)/(D+L)*100; D+L = 1. dAs a base powdered NaOH 
has been used. 
*It is worth nothing that even higher asymmetric induction (>80 % de) could be achieved, 
if the commercial Cat 8 would be diastereomerically pure. As stated from the vendor, in 
the literature arrangement of two benzyl groups in TaDiAS is in the (S,S)-form, however, 
their product is a mixture of diastereomers, where there may be slight differences in their 
reactivity and enantioselectivity.[32] Shibuguchi et al. showed that 2,6-disubstituted 
cyclohexane spiroacetal (S,S)-TaDiAs catalysts, (6R,10R)-, (6S,10S)- or (6R,10S)-
bis(phenylmethyl), result in different enantiomeric excesses in a catalytic asymmetric 
Michael reaction. Surprisingly, the latest one (6R,10S), which is not C2-symmetric, yields in 
significantly lower enantioselectivity compared to (6R,10R) and (6S,10S). Therefore, a 
NMR analysis of the purchased catalyst revealed this undesired diastereomer impurity is 
indeed present in Cat 8. **Cat 11 - TADDOL appeared undesired catalyst for this 
asymmetric alkylation.[35,36] However, considering the outstanding results with Cat 
6, optimal conditions due to the predicted chelate formation with sodium ions have 
not been optimized for this class of catalyst.[36,37]  
 
Table 9: Investigation of 11C-benzylation on Gly-L,L,L-42 under optimal conditions. 
Entry PTca RCC [±SD; %]b de [±SD; %]c 
1 Cat 1 81.9±11.7 (n=5) 75.0±3.9 (n=5) 
2 / 82.1±2.4 (n=3) 72.7±1.0 (n=3) 
3 Cat 6 72.2±10.4 (n=3) 16.8±3.0 (n=3) 
All reactions were conducted with 3.1 µmol of 7, 350 equiv of CsOH*H2O, 200 mol% 
of PTC, and 100 µL of toluene as a solvent for 10 min at -10 ⁰C. a% of Cat is compared 
to precursor. bRadiochemical conversions were determined by HPLC. 
cDiastereomeric excess was determined by HPLC. Diastereomeric excess has been 
calculated using the following formula: de (%)=((L-D)/(D+L)*100; D+L = 1 
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Table 6: Screening the conditions of 11C-benzylation without the aid of PTC or using TBAB, 
Cat 3 or Cat 2. 
Entry PTc 
PTc 
[mol%a] 
T 
[⁰C] 
Time 
[min] 
RCC [±SD; %]b de [±SD; %]c 
1 / / 0 10 89.5±6.3 (n=2) 38.8±1.8 (n=2) 
2 / / - 10 10 94.1±1.3 (n=3) 63.3±1.4 (n=3) 
3 / / - 50 10 51.5±5.9 (n=2) 54.3±2.9 (n=2) 
4 / / - 78 10 18 55.8 
5 TBAB 200 - 10 10 88.5±2.7 (n=3) 54.3±2.3% (n=3) 
6 Cat 3 25 0 10 93.2±2.8 (n=10) 40.8±9.8 (n=10) 
7 Cat 2 25 0 10 94.9±0.5 (n=4) 39.7±1.9 (n=3) 
8 Cat 2 25 - 10 10 84.4±5.5 (n=3) 51.7±1.1% (n=3) 
9 Cat 2 50 - 10 10 93.1±2.7 (n=3) 54.2±6.1 (n=3) 
10 Cat 2 120 - 10 10 71.0±19.3 (n=3) 65.0±4.1 (n=3) 
11 Cat 2 200 - 10 10 95.4±2.0 (n=3) 66.7±2.4 (n=3) 
12 Cat 2 400 - 10 10 74.3±27.5 (n=3) 69.5±0.5 (n=3) 
13 Cat 3 200 - 10 10 94.0±2.3 (n=3) 57.3±3.6 (n=3) 
14 Cat 3 400 - 10 10 93.8±3.0 (n=3) 58.7±2.5 (n=3) 
All reactions were conducted with 3.1 µmol of precursor 27, 330-350 eq of CsOH*H2O and 100 
µL of toluene. a% of Cat is compared to precursor. bRadiochemical conversions were determined 
by HPLC. cDiastereomeric excess was determined by HPLC. Diastereomeric excess has been 
calculated using the following formula: de (%)=((D-L)/(D+L)*100; D+L = 1. 
 
Table 7: Screening the alkylation time, solvent, and the amount of base for Cat 2. 
Entry 
PTC 
[mol%]a 
CsOH*H2O 
[equiv]a 
Solvent 
Time 
[min] 
RCC [±SD; %]b de [±SD; %]c 
1 400 350 Toluene 1 16.3 59 
2 400 350 Toluene 5 72.4 / 
3 400 350 Toluene 10 86.2 63.8 
4 200 350 Toluene 5 77.6±12.7 (n=3) 68.7±3.2 (n=3) 
5 200 350 Toluene/DCM* 5 38.4±5.0 (n=3) 55.7±1.3 (n=3) 
6 200 150 Toluene 5 30.8±6.2 (n=2) 62.1±9.7 (n=2) 
7 200 250 Toluene 5 49.2±6.9 (n=3) 52.3±10.3 (n=3) 
All reactions were conducted with 3.1 µmol of precursor 27, CsOH*H2O, Cat 2 and 100 µL of solvent at -
10 ⁰C. a% of Cat and eq of base are compared to precursor. *Combination of toluene and DCM 
(v/v=1/1). bRadiochemical conversions were determined by HPLC. cDiastereomeric excess was 
determined by HPLC. Diastereomeric excess has been calculated using the following formula: de (%)=((D-
L)/(D+L)*100; D+L = 1. 
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Table 8: Screening the other PTc under optimal conditions. 
Entry PTca 
PTc, 
[mol%]a 
CsOH*H2O 
[equiv]a 
Time 
[min] 
RCC [±SD; %]b de [±SD; %]c 
1 Cat 1 25 350 10 90.5 55.2 
2 Cat 1 200 350 10 84.7±11.4 (n=3) 13.1±2.8 (n=3) 
3 Cat 1 400 350 10 93.6 15 
4 Cat 5 200 350 5 65.8 13.4 
5 Cat 5 200 350 10 85.4±6.3 (n=3) 19.8±1.2 (n=3) 
6 Cat 5 400 350 10 96 24 
7 Cat 7 200 350 10 30.0±14.7 (n=4) 42.7±9.3 (n=4) 
8 Cat 8* 200 350 10 92.3±3.0 (n=4) 74.9±4.1 (n=4) 
9 Cat 6 200 350 10 79.0±6.0 (n=5) 93.5±1.6 (n=5) 
10 Cat 10 200 350 10 75.7±4.0 (n=2) 13.1±1.7 (n=2) 
11 Cat 11** 200 350d 10 ˂5 (n=2) 0 (n=2) 
All reactions were conducted with 3.1 µmol of 27, CsOH*H2O and 100 µL of toluene as a solvent at -
10 ⁰C. a% of Cat and eq of base are compared to precursor. bRadiochemical conversions were 
determined by HPLC. cDiastereomeric excess was determined by HPLC. Diastereomeric excess has 
been calculated using the following formula: de (%)=((D-L)/(D+L)*100; D+L = 1. dAs a base powdered NaOH 
has been used. 
*It is worth nothing that even higher asymmetric induction (>80 % de) could be achieved, 
if the commercial Cat 8 would be diastereomerically pure. As stated from the vendor, in 
the literature arrangement of two benzyl groups in TaDiAS is in the (S,S)-form, however, 
their product is a mixture of diastereomers, where there may be slight differences in their 
reactivity and enantioselectivity.[32] Shibuguchi et al. showed that 2,6-disubstituted 
cyclohexane spiroacetal (S,S)-TaDiAs catalysts, (6R,10R)-, (6S,10S)- or (6R,10S)-
bis(phenylmethyl), result in different enantiomeric excesses in a catalytic asymmetric 
Michael reaction. Surprisingly, the latest one (6R,10S), which is not C2-symmetric, yields in 
significantly lower enantioselectivity compared to (6R,10R) and (6S,10S). Therefore, a 
NMR analysis of the purchased catalyst revealed this undesired diastereomer impurity is 
indeed present in Cat 8. **Cat 11 - TADDOL appeared undesired catalyst for this 
asymmetric alkylation.[35,36] However, considering the outstanding results with Cat 
6, optimal conditions due to the predicted chelate formation with sodium ions have 
not been optimized for this class of catalyst.[36,37]  
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2 / 82.1±2.4 (n=3) 72.7±1.0 (n=3) 
3 Cat 6 72.2±10.4 (n=3) 16.8±3.0 (n=3) 
All reactions were conducted with 3.1 µmol of 7, 350 equiv of CsOH*H2O, 200 mol% 
of PTC, and 100 µL of toluene as a solvent for 10 min at -10 ⁰C. a% of Cat is compared 
to precursor. bRadiochemical conversions were determined by HPLC. 
cDiastereomeric excess was determined by HPLC. Diastereomeric excess has been 
calculated using the following formula: de (%)=((L-D)/(D+L)*100; D+L = 1 
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7. Representative HPLC UV and Radioactivity Chromatograms 
Cat 6: O-Allyl-N-(9-anthracenylmethyl) cinchonium bromide 
 
Figure 8: Representative HPLC UV and radioactivity chromatogram of the crude reaction 
mixture after alkylation of 7 with the aid of Cat 7. Co-injection with standard 33. 
8. Automated synthesis of H-[11C]-D-Phe-D-Trp-L-Lys-L-Thr-OH - in Amsterdam-based 
laboratory 
The previously described synthesis procedure was first performed manually (whole 5-step 
radiosynthetic procedure) in the research dedicated hot-cell and was later reevaluated 
and automated using adjustable home-built synthesis units and performed according to 
state-of-the-art GMP standards at Radionuclide Center at VU Medical Center Amsterdam.  
A IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium) cyclotron was used for [11C]CO2 
production by the 14N(p,α)11C nuclear reaction performed in a 0.5 % O2/N2 gas mixture. 
After trapping of [11C]CO2 from the target in a stainless trap dispensed in liquid N2,. 
[11C]CO2 was transferred with a helium flow of 10 mL·min
-1 through a nitrogen oxides trap 
and a P2O5 column and into a 3 mL vial containing a solution of 100 μL of 1 M 
phenylmagnesium bromide in tetrahydrofuran (THF) at 35 °C. After obtaining the 
maximum radioactivity in the vessel, the reaction mixture was stirred using helium flow 
(10 mL·min-1) for 1 min and additional 1 min at increased helium flow of 50 mL·min-1. 100 
μL 1 M LiAlH4 in THF was added and immediately evaporated to dryness by heating the 
reaction vial to 130 °C under a helium flow (50 mL·min-1) for 2 min until no bulk liquid was 
visible. Subsequently, 100 μL of 57 % HI in water was added at 0 °C and the mixture was 
left to react for 2 min at 120 °C to yield [11C]benzyl iodide. The reaction mixture has been 
first cooled down to ambient T or -10 °C, dissolved in 1.0 mL of toluene and subsequently 
passed through 5 x 0.5 cm column filled with sodium hydroxide, potassium carbonate and 
magnesium sulfate (approx. 5/3/3 by volume) into a second reaction vial, precooled to -10 
°C. In this manner, precizely 100 μL of [11C]benzyl iodide in toluene has been automatically 
transferred into a second vial, containing Schiff base peptide precursor 27 (1 equiv, 3.0 
mg, 3.1 μmol), cesium hydroxide monohydrate (CsOH*H2O) (350 equiv, 183 mg, 1090 
[11C]33 [11C]30 
33 
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μmol), and PTC catalyst Cat 6 (2 eq, 3.8 mg, 6.2 μmol) and vigorously stirred at -10 ⁰C for 
10 min with the aid of helium flow (50 mL·min-1) and magnetic stirrer. After completion, 
the reaction was subsequently quenched with 2.0 mL of D/I (90/10; v/v), loaded onto a 5 
mL injection loop, and purified by semi-preparative reversed-phase HPLC (Column K, 
Method 4). The peak eluting at 14-18 min was collected and mixed with 40 mL of water in 
the formulatio unit. Aqueous solution containing [11C]33 was loaded on Sep-Pak C18, 
where product [11C]33 was eluted with 1.5 mL of CH3CN into a third reaction vial. CH3CN 
has been gently evaporated at 70 °C using vacuum. After evaporation, 0.1 mL of 12M HCl 
was was added to vessel and heated to 100 °C for 2 min.  
The identity of the isolated tetrapeptide [11C]33 (radiochemical purity) and the 
deprotection step (RCC) towards the final product [11C]37 were confirmed with analytical 
reversed-phase HPLC by co-injection of the product and authentic reference of tetrapeptid 
(Column A, Method 5; Figures  9 and 41). The identity of the final [11C]37, purified and 
deproteced peptide, was confirmed with analytical reversed-phase HPLC by co-injection of 
the product and authentic reference of tetrapeptide (Column L, Mobile phase: Solvents 
E/H (v/v), 70 % E; wavelength 254 nm, column T  – ambient, flow 1 mL·min-1) (Figures 11 
and 12).  
Automation of the [11C]benzyl iodide sythesis has been further optimized from the initial 
paper published by us in order to reduce the activity loss during this multistep 
synthesis.[17] Reevaluation of the automated design and purification step let to significant 
improvements, as can be deducted from Table 9. Radioactivity loss was decreased by the 
absence of the intermediate vessel filled with 2 pellets of KOH (compared to original 
Boston-based synthesis procedure, where batch of [11C]benzyl iodide was subdivided into 
multiple aliquots (precisely 100 μL), and our recently published [11C]phenylalanine 
method[38]), where the latter was substituted by the solid NaOH placed in the purification 
column. Reduced amount of K2CO3 turned beneficial, however total removal of the 
K2CO3 was fruitless resulting in no 
11C-benzylation.  
Table 10: Data for the automated synthesis performed at RNC – GMP laboratory. 
Entry Purification column 
Filling by 
volume 
[v/v] 
Intermediate vessel 
placed on ice 
(+additional tubbing) 
Activity (d.c.) % in the 
second vessel [±SD; %] 
1 K2CO3&MgSO4 8/2 Yes 24.9±5.4 (n=4) 
5 K2CO3&MgSO4 8/2 No 20.0 
6 NaOH&K2CO3&MgSO4 4/4/2 No 26.6 
7 NaOH&K2CO3&MgSO4 5/3/2 No 29.3±12.0 (n=4) 
8 NaOH&MgSO4 8/2 No 
35.9 
*No 11C-benzylation 
Note: During the radiosynthesis we observed that around 30-40% of activity, decay 
corrected, is lost after the addition of 57 % HI in water at 0 °C. This is in correlation with 
the »wet« procedure of the [11C]methyl iodide synthesis performed in our Amsterdam 
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7. Representative HPLC UV and Radioactivity Chromatograms 
Cat 6: O-Allyl-N-(9-anthracenylmethyl) cinchonium bromide 
 
Figure 8: Representative HPLC UV and radioactivity chromatogram of the crude reaction 
mixture after alkylation of 7 with the aid of Cat 7. Co-injection with standard 33. 
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radiosynthetic procedure) in the research dedicated hot-cell and was later reevaluated 
and automated using adjustable home-built synthesis units and performed according to 
state-of-the-art GMP standards at Radionuclide Center at VU Medical Center Amsterdam.  
A IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium) cyclotron was used for [11C]CO2 
production by the 14N(p,α)11C nuclear reaction performed in a 0.5 % O2/N2 gas mixture. 
After trapping of [11C]CO2 from the target in a stainless trap dispensed in liquid N2,. 
[11C]CO2 was transferred with a helium flow of 10 mL·min
-1 through a nitrogen oxides trap 
and a P2O5 column and into a 3 mL vial containing a solution of 100 μL of 1 M 
phenylmagnesium bromide in tetrahydrofuran (THF) at 35 °C. After obtaining the 
maximum radioactivity in the vessel, the reaction mixture was stirred using helium flow 
(10 mL·min-1) for 1 min and additional 1 min at increased helium flow of 50 mL·min-1. 100 
μL 1 M LiAlH4 in THF was added and immediately evaporated to dryness by heating the 
reaction vial to 130 °C under a helium flow (50 mL·min-1) for 2 min until no bulk liquid was 
visible. Subsequently, 100 μL of 57 % HI in water was added at 0 °C and the mixture was 
left to react for 2 min at 120 °C to yield [11C]benzyl iodide. The reaction mixture has been 
first cooled down to ambient T or -10 °C, dissolved in 1.0 mL of toluene and subsequently 
passed through 5 x 0.5 cm column filled with sodium hydroxide, potassium carbonate and 
magnesium sulfate (approx. 5/3/3 by volume) into a second reaction vial, precooled to -10 
°C. In this manner, precizely 100 μL of [11C]benzyl iodide in toluene has been automatically 
transferred into a second vial, containing Schiff base peptide precursor 27 (1 equiv, 3.0 
mg, 3.1 μmol), cesium hydroxide monohydrate (CsOH*H2O) (350 equiv, 183 mg, 1090 
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μmol), and PTC catalyst Cat 6 (2 eq, 3.8 mg, 6.2 μmol) and vigorously stirred at -10 ⁰C for 
10 min with the aid of helium flow (50 mL·min-1) and magnetic stirrer. After completion, 
the reaction was subsequently quenched with 2.0 mL of D/I (90/10; v/v), loaded onto a 5 
mL injection loop, and purified by semi-preparative reversed-phase HPLC (Column K, 
Method 4). The peak eluting at 14-18 min was collected and mixed with 40 mL of water in 
the formulatio unit. Aqueous solution containing [11C]33 was loaded on Sep-Pak C18, 
where product [11C]33 was eluted with 1.5 mL of CH3CN into a third reaction vial. CH3CN 
has been gently evaporated at 70 °C using vacuum. After evaporation, 0.1 mL of 12M HCl 
was was added to vessel and heated to 100 °C for 2 min.  
The identity of the isolated tetrapeptide [11C]33 (radiochemical purity) and the 
deprotection step (RCC) towards the final product [11C]37 were confirmed with analytical 
reversed-phase HPLC by co-injection of the product and authentic reference of tetrapeptid 
(Column A, Method 5; Figures  9 and 41). The identity of the final [11C]37, purified and 
deproteced peptide, was confirmed with analytical reversed-phase HPLC by co-injection of 
the product and authentic reference of tetrapeptide (Column L, Mobile phase: Solvents 
E/H (v/v), 70 % E; wavelength 254 nm, column T  – ambient, flow 1 mL·min-1) (Figures 11 
and 12).  
Automation of the [11C]benzyl iodide sythesis has been further optimized from the initial 
paper published by us in order to reduce the activity loss during this multistep 
synthesis.[17] Reevaluation of the automated design and purification step let to significant 
improvements, as can be deducted from Table 9. Radioactivity loss was decreased by the 
absence of the intermediate vessel filled with 2 pellets of KOH (compared to original 
Boston-based synthesis procedure, where batch of [11C]benzyl iodide was subdivided into 
multiple aliquots (precisely 100 μL), and our recently published [11C]phenylalanine 
method[38]), where the latter was substituted by the solid NaOH placed in the purification 
column. Reduced amount of K2CO3 turned beneficial, however total removal of the 
K2CO3 was fruitless resulting in no 
11C-benzylation.  
Table 10: Data for the automated synthesis performed at RNC – GMP laboratory. 
Entry Purification column 
Filling by 
volume 
[v/v] 
Intermediate vessel 
placed on ice 
(+additional tubbing) 
Activity (d.c.) % in the 
second vessel [±SD; %] 
1 K2CO3&MgSO4 8/2 Yes 24.9±5.4 (n=4) 
5 K2CO3&MgSO4 8/2 No 20.0 
6 NaOH&K2CO3&MgSO4 4/4/2 No 26.6 
7 NaOH&K2CO3&MgSO4 5/3/2 No 29.3±12.0 (n=4) 
8 NaOH&MgSO4 8/2 No 
35.9 
*No 11C-benzylation 
Note: During the radiosynthesis we observed that around 30-40% of activity, decay 
corrected, is lost after the addition of 57 % HI in water at 0 °C. This is in correlation with 
the »wet« procedure of the [11C]methyl iodide synthesis performed in our Amsterdam 
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facility. In addition, smaller volume of the solvent, 1.0 mL of toluene which results in 
precisely 100 μL of [11C]benzyl iodide in toluene, has certainly a significant effect, since the 
column cannot be »rinsed« with more solvent as initially investigated[17]. Nevertheless, 
even a 100 μL of toluene produced broad peaks during the preperative HPLC purification 
hampering the efficient and high yielding isolation of the desired product.  
H-[11C]-D-Phe-D-Trp-Lys-Thr-OH was synthesized within 57 minutes, from [11C]CO2 delivery, 
and yields were 500-600 MBq (13-16 mCi) at the end of synthesis, corresponding to a 
decay-corrected radiochemical yield of 9-10 %, calculated from the end of the production 
of [11C]CO2 (n>3). Analysis showed de of >94 % and a AM of 15-35 GBq·µmol
-1 (405-945 
mCi·µmol-1) at the end of synthesis (EOS) (n>3). Radiochemical purity was >98 % (n>3) 
(Figures 9 and 10). 
 
Figure 9: Representative HPLC UV and radioactivity chromatogram of the isolated [11C]33. 
Co-injection with the standard compound 33. Note: Radioactivity detector is placed before 
UV detector. 
 
Figure 10: Representative HPLC UV and radioactivity chromatogram of the isolated and 
deprotected [11C]37 showing quantitative acidic deprotection.  
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Figure 11: Representative HPLC UV and radioactivity chromatogram of the isolated and 
deprotected [11C]37.  
 
Figure 12: Representative HPLC UV and radioactivity chromatogram of the isolated and 
deprotected [11C]37. Co-injection with the small amount of the standard compound 37.  
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Abstract 
 
Introduction: The substance P bioactive fragment SP1-7 effects through binding to specific 
sites apart from any known neurokinin or opioid receptor, revealing its multifunctional 
role in (anti)nociception. SP1-7 is a large molecule and current radiolabeling techniques 
would strongly modify the native peptide hampering the blood-brain barrier penetration 
and thus potential target engagement. This study aims to evaluate carbon-11 labeled SP1-7 
peptidomimetics as a research tool to investigate the SP1-7 binding site to provide an 
insight in the imaging of neuropathic pain. 
Methods: Candidate SP1-7 peptidomimetics were radiolabeled at the amide carbonyl 
position by [11C]CO2-fixation. Radiotracers were administered to male healthy rats and 
brain, spinal cord and general organs uptake of radioactivity was measured ex vivo. 
Biodistribution and metabolite studies were followed by PET scanning. Specificity of brain 
uptake was explored by pretreatment with unlabeled compounds (3 µmol·kg-1, i.v.) 3 min 
prior to radiotracer administration. 
Results: Two candidate SP1-7 derived peptidomimetic radiotracers were prepared in a 
radiochemical yield of 8 - 42% and a molar activity of 58 - 115 GBq·μmol-1 in excellent 
radiochemical purity (>99%). Moderate brain (2.0 SUV; peak at 3 min) and spinal cord (1.0 
SUV; peak at 10 min) uptake was observed for both L-[11C]49 and D-[11C]50 candidates. For 
D-[11C]50, improved metabolic stability observed in the blood (80% of intact D-[11C]50 at 5 
min compared to 52% of L-[11C]1) resulted in better brain and spinal cord tracer retention. 
Blocking was not achieved by natural SP1-7 or self-blocking for both L-[
11C]49 and D-[11C]50. 
Conclusions: Two potent SP1-7 peptidomimetics have been successfully radiolabeled via 
[11C]CO2-fixation as PET radiotracers for SP1-7 binding site. Both radiotracers showed 
promising ex vivo metabolic and biodistribution profile and further PET scanning 
confirmed both peptidomimetics enter the rodent brain, where further validation of these 
two radiotracers is needed to select the most appropriate radioligand candidate. 
  
Preclinical Evaluation of the First Substance P1-7 [
11C]Peptidomimetics 
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Introduction 
 
Substance P (SP) (H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) is a 
neurotransmitter and neuromodulator that is involved in a variety of neurological 
functions and its role in pain transmission has attracted a particular interest. SP binds 
preferably to the neurokinin 1 receptor (NK-1R), however the SP N-terminal major 
bioactive fragment SP1-7 (H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH) effects through binding to a 
specific sites apart from any known neurokinin or opioid receptor. The absence of binding 
of SP1-7 to the NK-1 receptor was attributed to the lack of the amidated amino acid 
sequence Gly9-Leu10-Met11-NH2 on the C-terminus.
[1–7] 
SP1-7 has been shown to be present in various CNS areas, like hypothalamus, nucleus 
accumbens, ventral tragemental area, and in the dorsal and ventral part of spinal cord, 
confirming the heptapeptide is related to pain and reward processing when produced in 
the CNS by endopeptidases.[8,9] Even though the binding sites in mouse and rat are known, 
the receptor for SP1-7 has not yet been cloned or characterized making its mechanism of 
action remaining unclear.[8,10] While some studies have suggested that the anti-
nociceptive effects of SP1-7  are attributed due to activation of co-localized opioid 
receptors, others suggested activation of the capsaicin-mediated transient receptor 
potential vanilloid 1.[11,12] Recently, in vitro and in vivo studies showed improved binding 
affinity of C-terminal amidated SP1-7-NH2 compared to the endogenous fragment SP1-7, (rat 
spinal cord membrane: 0.3 nM and 1.6 nM, respectively; rat ventral tegmental area: 4.0 
nM and 3.9 nM, respectively), as well as increased potency effect to mediate a reduced 
expression of opioid withdrawal through the SP1-7 binding site.
[13,14] In addition, the SP1-7 
analog D-SP1-7 (D-Pro2-D-Phe7-SP1-7), so called SP1-7 antagonist, was able to block SP1-7 
induced antinociception and showed binding affinity to SP1-7 binding site equipotent to 
natural SP1-7.
[1,15,16] Interestingly, the SP1-7 amide showed higher anti-allodynic activity 
after intraperitoneal administration compared to SP1-7 despite the poor in vivo stability of 
both peptides (SP1-7 t1/2 = 4.4 min and SP1-7-NH2 t1/2 = 6.4 min).
[7] 
Aiming to develop a peptidomimetic with a long duration of action being able to cross the 
blood-brain barrier (BBB), Fransson et al. performed extensive SAR studies resulting in the 
lead dipeptide H-Phe-Phe-NH2 (Ki of 1.5 nM; rat spinal cord membrane) as small molecule 
to target the SP1-7 binding site.
[5,13] Further finetuning by replacing the N-terminal Phe with 
a benzylcarbamate group, resulted in a peptidomimetic carbamate 49 with a Ki of 5.2 nM 
determined using rat spinal cord membranes preparation (Figure 1).[1,10,17] Its reasonable 
binding affinity, excellent membrane permeability, low efflux, moderate in vitro clearance 
and ability to enter the CNS according to the in vivo infusion study, make it an interesting 
molecule for PET imaging tracer development.  
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Neuropathic pain is clinically characterized by spontaneous and evoked type of pain 
significantly impairing the quality of life of patients and its treatment represents a major 
unsolved problem.[18] Developing PET-tracers able to image and evaluate neuropathic pain 
will provide a valuable tool for better estimation of the incidence and prevalence of 
neuropathic pain, and treatment development.[19] SP1-7 is a large molecule and current 
radiolabeling techniques require a strong modification of the native peptide structure 
hampering the BBB penetration. Nonetheless, the dipeptide peptidomimetics are more 
attractive alternatives and could be viable neuro PET-tracers able to cross the BBB. PET 
imaging is a powerful technique that provides direct quantitative information on the levels 
of brain and spinal cord exposure, target engagement and pharmacological activity.[20,21] In 
our study we used dipeptide peptidomimetics (Figure 1) for radiolabeling with carbon-11 
in order to investigate the distribution of the SP1-7 binding site and provide insights in the 
potential neuropathic pain PET imaging. 
 
Figure 1: Structure of SP1-7 and SP1-7-NH2 as leads for the development of small molecules, 
H-Phe-Phe-NH2 and the peptidomimetics 49 and 50.  
The merits of carbon-11 (t1/2 = 20.4 min, 99% β+, 0.96 MeV) as a choice radionuclide for 
PET-tracer synthesis have been well recognized. The ubiquity of carbon atoms in all 
pharmacologically active compounds makes it an attractive isotope for radiolabeling, 
preserving the favorable physico-chemical properties.[22–29] With the recent developments 
in carbon-11 chemistry, routinely employed complex processes and appropriate special 
equipment, radiochemists are able to label various compounds. Direct fixation of [11C]CO2, 
published by Hooker et al.[30]and Wilson et al.[31], addressing the carbon-11 labeled 
carbamate functional group, enables us to label the SP1-7 peptidomimetic 49 (or 50; Figure 
1) to serve as a research tool to investigate the location of the SP1-7 binding site. We 
investigated the feasibility of carbon-11 radiolabeling of  compounds 49 and 50 without 
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further modifications. We evaluated their biodistribution, in vivo metabolic stability and 
assessed their  in vivo behaviour in brain using PET imaging. 
Results  
 
Chemistry 
 
Reference compounds (L-stereoisomer 49 and D-stereoisomer 50) were synthesized 
according to a published patent[32] in a one-step amidation reaction from a commercially 
available 2-(((benzyloxy)carbonyl)amino)-3-phenylpropanoic acids and characterized 
according to Fransson et al.[33] Overnight amidation at ambient temperature followed by 
extraction and pre-crystallization in ice-cold n-hexane yielded L-stereoisomer 49 in 80% 
yield and D-stereoisomer 50 in 55% yield.  
 
Figure 2: The general synthesis towards the references L-49 and D-50. 
Radiochemistry 
 
 
Figure 3: Radiosynthesis of SP1-7 carbamate analogues [
11C]49 and [11C]50. 
The general synthesis towards the SP1-7 carbamate analogues [
11C]49 and [11C]50 is 
outlined in Figure 3. The synthesis involved 2 steps: direct [11C]CO2 trapping at ambient 
temperature and 11C-carboxybenzylation at elevated temperature. The preparation of SP1-
7 carbamate analogue [
11C]49/[11C]50 was achieved without the isolation of the synthetic 
intermediate in a one-pot reaction to establish an efficient procedure for the desired 
product (Table 1). In order to optimize this procedure towards high radiochemical 
conversion, yield and specific activity, the following parameters have been thoroughly 
investigated: amount of reagents and solvent, reaction time and helium flow. These 
parameters were changed systematically one by one per experiment. 
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Neuropathic pain is clinically characterized by spontaneous and evoked type of pain 
significantly impairing the quality of life of patients and its treatment represents a major 
unsolved problem.[18] Developing PET-tracers able to image and evaluate neuropathic pain 
will provide a valuable tool for better estimation of the incidence and prevalence of 
neuropathic pain, and treatment development.[19] SP1-7 is a large molecule and current 
radiolabeling techniques require a strong modification of the native peptide structure 
hampering the BBB penetration. Nonetheless, the dipeptide peptidomimetics are more 
attractive alternatives and could be viable neuro PET-tracers able to cross the BBB. PET 
imaging is a powerful technique that provides direct quantitative information on the levels 
of brain and spinal cord exposure, target engagement and pharmacological activity.[20,21] In 
our study we used dipeptide peptidomimetics (Figure 1) for radiolabeling with carbon-11 
in order to investigate the distribution of the SP1-7 binding site and provide insights in the 
potential neuropathic pain PET imaging. 
 
Figure 1: Structure of SP1-7 and SP1-7-NH2 as leads for the development of small molecules, 
H-Phe-Phe-NH2 and the peptidomimetics 49 and 50.  
The merits of carbon-11 (t1/2 = 20.4 min, 99% β+, 0.96 MeV) as a choice radionuclide for 
PET-tracer synthesis have been well recognized. The ubiquity of carbon atoms in all 
pharmacologically active compounds makes it an attractive isotope for radiolabeling, 
preserving the favorable physico-chemical properties.[22–29] With the recent developments 
in carbon-11 chemistry, routinely employed complex processes and appropriate special 
equipment, radiochemists are able to label various compounds. Direct fixation of [11C]CO2, 
published by Hooker et al.[30]and Wilson et al.[31], addressing the carbon-11 labeled 
carbamate functional group, enables us to label the SP1-7 peptidomimetic 49 (or 50; Figure 
1) to serve as a research tool to investigate the location of the SP1-7 binding site. We 
investigated the feasibility of carbon-11 radiolabeling of  compounds 49 and 50 without 
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further modifications. We evaluated their biodistribution, in vivo metabolic stability and 
assessed their  in vivo behaviour in brain using PET imaging. 
Results  
 
Chemistry 
 
Reference compounds (L-stereoisomer 49 and D-stereoisomer 50) were synthesized 
according to a published patent[32] in a one-step amidation reaction from a commercially 
available 2-(((benzyloxy)carbonyl)amino)-3-phenylpropanoic acids and characterized 
according to Fransson et al.[33] Overnight amidation at ambient temperature followed by 
extraction and pre-crystallization in ice-cold n-hexane yielded L-stereoisomer 49 in 80% 
yield and D-stereoisomer 50 in 55% yield.  
 
Figure 2: The general synthesis towards the references L-49 and D-50. 
Radiochemistry 
 
 
Figure 3: Radiosynthesis of SP1-7 carbamate analogues [
11C]49 and [11C]50. 
The general synthesis towards the SP1-7 carbamate analogues [
11C]49 and [11C]50 is 
outlined in Figure 3. The synthesis involved 2 steps: direct [11C]CO2 trapping at ambient 
temperature and 11C-carboxybenzylation at elevated temperature. The preparation of SP1-
7 carbamate analogue [
11C]49/[11C]50 was achieved without the isolation of the synthetic 
intermediate in a one-pot reaction to establish an efficient procedure for the desired 
product (Table 1). In order to optimize this procedure towards high radiochemical 
conversion, yield and specific activity, the following parameters have been thoroughly 
investigated: amount of reagents and solvent, reaction time and helium flow. These 
parameters were changed systematically one by one per experiment. 
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Trapping of cyclotron produced [11C]CO2 was near quantitative (>90%) when [
11C]CO2 was 
bubbled through t the precursor solution in dry DMSO with the aid of 3.5 - 5.0 eq of 2-tert-
butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP), which 
served as trapping reagent and a catalyst for the carboxylation reaction.  
The 11C-carboxybenzylation to the desired product was achieved in high radiochemical 
yield (>85%), determined by analytical HPLC, using 4 - 5 eq of benzyl chloride, dissolved in 
DMSO, at 75 °C under helium stirring (10 mL·min-1). Excellent conversion rates were 
attained in a reaction time of 5 and 10 min, whereas time of 5 min was selected 
decreasing the total synthesis time. After successful manual optimization, synthesis 
automation was required to work with high amounts of radioactivity. For this reason, the 
volume of DMSO was increased to 300 µL allowing smoother automation of the synthesis 
due to residual volume of the tubing in the synthestic unit used. Importantly, N-
benzylation or other significant side products were not observed during the 11C-
carboxybenzylation reaction, performed manually or during an automated procedure 
(Figure 1, Experimental Section).  
Table 1: Screening the conditions for [11C]CO2 insertion for [
11C]49. 
Entry 
Precursor 
[µmol]a 
BEMP 
[eq]a,b 
BnCl 
[eq]a,b 
DMSO 
[µL]c 
Time 
[min] 
[11C]CO2 
trapping 
[%]d 
RCY [%]e 
1 8.0 3.5 4.0 200 10 94.2 58.0 
2 15.5 2.0 2.0 200 10 77.0 53.3 
3 8.5 3.5 4.0 300 10 87.4 91.3 
4 8.5 3.5 4.0 300 10 99.4 95.7 
5 6.0 5.0 5.5 300 5 / 90.7 
6 6.5 4.5 5.0 300 5 / 67.5 
7 6.5 4.5 5.0 300 5 / 88.7 
8 8.0 4.0 4.5 300 2 / 76.2 
10 8.5 3.5 4.0 300 5 / 94.1 
aAll reaction were conducted with 1 mg of precursor H-Phe-NH2, 8.3 µL of BEMP and 4 µL of 
benzyl chloride in DMSO at 75 ° C in a sealed reaction vessel stirred with the aid of 10 mL·min-1 of 
helium flow. bEquivalents are compared to precursor. cDry DMSO has been used and stored over 
molecular sieves. dTrapping efficiency represents decay-corrected trapped radioactivity as a % of 
dispensed radioactivity and is based on the activity balance. eRadiochemical yield of the crude 
reaction mixture, determined by analytical HPLC, is not corrected for decay. 
 
The next step, purification of the PET-tracer was achieved using a reverse-phase C18 semi-
preparative HPLC, as shown in the Figure 4. Subsequent formulation step provided [11C]49 
(1.7 – 8.2 GBq) in high radiochemical purity (>99%) and adequate molar activity (58 - 155 
GBq·µmol-1) in 23 - 29 min (n>10) with an overall radiochemical yield (RCY) of 8.4 - 42.0% 
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(corrected for decay) formulated in an i.v. injectable solution  containing 10% ethanol in 
saline, ready for in vivo experiments.  
In the same manner, we performed the reaction with H-D-Phe-NH2 as precursor. As 
expected, the D-isomer displayed the same properties and the radiosynthesis of [11C]50 
provided an isolated non-corrected yield of 1.9 - 6.4 GBq in high radiochemical purity 
(>99%) and molar activity of  48 - 92 GBq·µmol-1 in 26 - 29 min (n=5) with an overall 
radiochemical yield (RCY) of 11.3 – 38.4% (corrected for decay) formulated in an i.v. 
injectable solution (10% ethanol in saline). 
 
 
Figure 4: Representative HPLC UV and radioactivity chromatogram of the isolated and 
formulated [11C]49. Chromatogram on the right shows co-injection with the small amount 
of the standard 49. 
 
Ex Vivo Biodistribution  
 
In order to assess the brain and spinal cord penetration potential of [11C]49 an ex vivo 
biodistribution study was performed. Healthy male Wistar rats were injected with [11C]49 
(9 - 40 MBq) and were analyzed for biodistribution at 5, 15, 30 and 60 min post injection 
(p.i.) (Figure 6). [11C]49 was cleared  via kidneys  and liver and showed moderate uptake in 
well-perfused organs, like lungs and heart. Highest uptake was observed after 5 min in the 
brain regions (large brain, cerebellum, brain stem) and spinal cord, confirming rapid brain 
penetration and BBB crossing of the SP1-7 peptidomimetic. At later time point we observe 
a better retention of the [11C]49 tracer in the spinal cord compared to the brain.  
15299 - Pekosak_BNW.indd   186 16-02-18   16:23
Ch
ap
te
r 7
Chapter 7 
186 
 
Trapping of cyclotron produced [11C]CO2 was near quantitative (>90%) when [
11C]CO2 was 
bubbled through t the precursor solution in dry DMSO with the aid of 3.5 - 5.0 eq of 2-tert-
butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP), which 
served as trapping reagent and a catalyst for the carboxylation reaction.  
The 11C-carboxybenzylation to the desired product was achieved in high radiochemical 
yield (>85%), determined by analytical HPLC, using 4 - 5 eq of benzyl chloride, dissolved in 
DMSO, at 75 °C under helium stirring (10 mL·min-1). Excellent conversion rates were 
attained in a reaction time of 5 and 10 min, whereas time of 5 min was selected 
decreasing the total synthesis time. After successful manual optimization, synthesis 
automation was required to work with high amounts of radioactivity. For this reason, the 
volume of DMSO was increased to 300 µL allowing smoother automation of the synthesis 
due to residual volume of the tubing in the synthestic unit used. Importantly, N-
benzylation or other significant side products were not observed during the 11C-
carboxybenzylation reaction, performed manually or during an automated procedure 
(Figure 1, Experimental Section).  
Table 1: Screening the conditions for [11C]CO2 insertion for [
11C]49. 
Entry 
Precursor 
[µmol]a 
BEMP 
[eq]a,b 
BnCl 
[eq]a,b 
DMSO 
[µL]c 
Time 
[min] 
[11C]CO2 
trapping 
[%]d 
RCY [%]e 
1 8.0 3.5 4.0 200 10 94.2 58.0 
2 15.5 2.0 2.0 200 10 77.0 53.3 
3 8.5 3.5 4.0 300 10 87.4 91.3 
4 8.5 3.5 4.0 300 10 99.4 95.7 
5 6.0 5.0 5.5 300 5 / 90.7 
6 6.5 4.5 5.0 300 5 / 67.5 
7 6.5 4.5 5.0 300 5 / 88.7 
8 8.0 4.0 4.5 300 2 / 76.2 
10 8.5 3.5 4.0 300 5 / 94.1 
aAll reaction were conducted with 1 mg of precursor H-Phe-NH2, 8.3 µL of BEMP and 4 µL of 
benzyl chloride in DMSO at 75 ° C in a sealed reaction vessel stirred with the aid of 10 mL·min-1 of 
helium flow. bEquivalents are compared to precursor. cDry DMSO has been used and stored over 
molecular sieves. dTrapping efficiency represents decay-corrected trapped radioactivity as a % of 
dispensed radioactivity and is based on the activity balance. eRadiochemical yield of the crude 
reaction mixture, determined by analytical HPLC, is not corrected for decay. 
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Ex Vivo Biodistribution  
 
In order to assess the brain and spinal cord penetration potential of [11C]49 an ex vivo 
biodistribution study was performed. Healthy male Wistar rats were injected with [11C]49 
(9 - 40 MBq) and were analyzed for biodistribution at 5, 15, 30 and 60 min post injection 
(p.i.) (Figure 6). [11C]49 was cleared  via kidneys  and liver and showed moderate uptake in 
well-perfused organs, like lungs and heart. Highest uptake was observed after 5 min in the 
brain regions (large brain, cerebellum, brain stem) and spinal cord, confirming rapid brain 
penetration and BBB crossing of the SP1-7 peptidomimetic. At later time point we observe 
a better retention of the [11C]49 tracer in the spinal cord compared to the brain.  
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Figure 5: Biodistribution of [11C]49 at 5, 15, 30 and 60 min post-injection (p.i.) in healthy 
male Wistar rats (n = 4 per time point) following i.v. administration of ≈ 40 MBq of [11C]49 
via the tail vein under isoflurane anesthesia (2 - 2.5% in 1 L·min-1). Columns show the 
percentage of injected dose per gram (%ID/g). Errors bars are standard error of the mean 
(SEM).   
 
Metabolite Analysis (L-[11C]49) 
 
In vivo stability of [11C]49 was determined by metabolite analysis in healthy male Wistar 
rats (n = 4 per  time point). Rats were injected i.v. with the radiotracer [11C]49 (21 - 38 
MBq) and sacrificed at 5, 15 and 45 minutes p.i. followed by blood sample collection and 
brain dissection. Analysis of the plasma revealed mediocre stability of the tracer with 52, 
15 and 11% of intact tracer after 5, 15 or 45 min, respectively, suggesting extensive 
metabolic degradation (Table 2). HPLC analysis of the plasma showed the presence of one 
major metabolites of [11C]49 after 45 min. This major metabolite had a retention time of 
12.7 min and constituted more than 67% of the metabolites (Figure 6). Radioactivity 
recovery of the blood samples was 99, 70 and 66% at 5, 15 and 45 min, respectively. The 
Sep-Pak cartridge stickiness at later time points was inevitable, despite additional 
employment of MeOH. 
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Table 2: Metabolite analysis of [11C]49 in plasma and brain supernatant. 
 
Plasma Brain 
5 min 
[%; SD] 
15 min 
[%; SD] 
45 min 
[%; SD] 
5 min 
[%; SD] 
15 min 
[%; SD] 
45 min 
[%; SD] 
Intact tracer 52.3 ± 11.3 15.2 ± 7.9 10.9 ± 3.0 >99.9 97.3 ± 0.6 96.7 ± 4.5 
Non-polar 
metabolite 1 
7.8 ± 5.4 7.9 ± 2.4 7.7 ± 2.9 / 0.9 ± 0.6 1.6 ± 3.2 
Non-polar 
metabolite 2 
34.3 ± 5.0 40.8 ± 4.4 40.0 ± 1.7 / 1.8 ± 0.2 1.6 ± 3.2 
Non-polar 
metabolite 3 
/ / 1. ± 1.1 / / / 
Polar 
metabolites 
5.2 ± 1.1 6.1 ± 0.4 5.7 ± 0.3 / / / 
 
  
Figure 6: Radiochromatograms of the non-polar fraction of plasma after: A: 5 min, B: 15 
min and C: 45 min. Intact [11C]49  has a retention time of 11.7 min. 
In brain supernatant, the percentage of intact tracer in the non-polar fraction was >99.9% 
at 5 min and 97% after 15 or 45 min (Figure 8A). Radioactivity extraction of the brain 
supernatant samples was 77, 72 and 63% at 5, 15 and 45 min, respectively. These data 
confirms rapid penetration and stability of the [11C]49 tracer in brain.   
 
Metabolite Analysis (D-[11C]50) 
 
Based on the rapid metabolism of [11C]50, we were prompted to investigate the effect of 
substitution of L-phenylalanine to D-configuration on affinity and possible improved 
biological stability, as commonly observed in peptides. We synthesized the D-variant 
[11C]50 and examined the in vivo stability by metabolite analysis in healthy male Wistar 
rats (n = 3 per time point). The rodents were injected i.v. with [11C]2 tracer (28 - 35 MBq)  
and rats were sacrificed at 5, 15 and 45 minutes p.i. followed by blood collection and brain 
dissection. Plasma analysis revealed improved stability of the tracer with 80, 49 and 37% 
of intact tracer after 5, 15 or 45 min, respectively (Table 3). Radioactivity recovery of the 
blood samples was 95 - 99% at all time points. HPLC analysis of non-polar fraction 
revealed three unidentified metabolites, as can be seen in Figure 7 and Table 3.  
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percentage of injected dose per gram (%ID/g). Errors bars are standard error of the mean 
(SEM).   
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15 and 11% of intact tracer after 5, 15 or 45 min, respectively, suggesting extensive 
metabolic degradation (Table 2). HPLC analysis of the plasma showed the presence of one 
major metabolites of [11C]49 after 45 min. This major metabolite had a retention time of 
12.7 min and constituted more than 67% of the metabolites (Figure 6). Radioactivity 
recovery of the blood samples was 99, 70 and 66% at 5, 15 and 45 min, respectively. The 
Sep-Pak cartridge stickiness at later time points was inevitable, despite additional 
employment of MeOH. 
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Table 2: Metabolite analysis of [11C]49 in plasma and brain supernatant. 
 
Plasma Brain 
5 min 
[%; SD] 
15 min 
[%; SD] 
45 min 
[%; SD] 
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45 min 
[%; SD] 
Intact tracer 52.3 ± 11.3 15.2 ± 7.9 10.9 ± 3.0 >99.9 97.3 ± 0.6 96.7 ± 4.5 
Non-polar 
metabolite 1 
7.8 ± 5.4 7.9 ± 2.4 7.7 ± 2.9 / 0.9 ± 0.6 1.6 ± 3.2 
Non-polar 
metabolite 2 
34.3 ± 5.0 40.8 ± 4.4 40.0 ± 1.7 / 1.8 ± 0.2 1.6 ± 3.2 
Non-polar 
metabolite 3 
/ / 1. ± 1.1 / / / 
Polar 
metabolites 
5.2 ± 1.1 6.1 ± 0.4 5.7 ± 0.3 / / / 
 
  
Figure 6: Radiochromatograms of the non-polar fraction of plasma after: A: 5 min, B: 15 
min and C: 45 min. Intact [11C]49  has a retention time of 11.7 min. 
In brain supernatant, the percentage of intact tracer in the non-polar fraction was >99.9% 
at 5 min and 97% after 15 or 45 min (Figure 8A). Radioactivity extraction of the brain 
supernatant samples was 77, 72 and 63% at 5, 15 and 45 min, respectively. These data 
confirms rapid penetration and stability of the [11C]49 tracer in brain.   
 
Metabolite Analysis (D-[11C]50) 
 
Based on the rapid metabolism of [11C]50, we were prompted to investigate the effect of 
substitution of L-phenylalanine to D-configuration on affinity and possible improved 
biological stability, as commonly observed in peptides. We synthesized the D-variant 
[11C]50 and examined the in vivo stability by metabolite analysis in healthy male Wistar 
rats (n = 3 per time point). The rodents were injected i.v. with [11C]2 tracer (28 - 35 MBq)  
and rats were sacrificed at 5, 15 and 45 minutes p.i. followed by blood collection and brain 
dissection. Plasma analysis revealed improved stability of the tracer with 80, 49 and 37% 
of intact tracer after 5, 15 or 45 min, respectively (Table 3). Radioactivity recovery of the 
blood samples was 95 - 99% at all time points. HPLC analysis of non-polar fraction 
revealed three unidentified metabolites, as can be seen in Figure 7 and Table 3.  
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In brain supernatant, the percentage of intact D-[11C]50 tracer in the non-polar fraction 
was >96% after 5, 15 or 45 min (Figure 8B). Radioactivity extraction of the brain 
supernatant samples was 58, 55 and 63% at 5, 15 and 45 min, respectively.  
Table 3: Metabolite analysis of D-isomer [11C]50 in plasma and brain supernatant. 
 
Plasma Brain 
5 min  
[%; SD] 
15 min  
[%; SD] 
45 min  
[%; SD] 
5 min  
[%; SD] 
15 min  
[%; SD] 
45 min 
 [%; SD] 
Intact tracer 79.6 ± 2.3 49.2 ± 2.0 36.6 ± 1.7 96.4 ± 6.3 96.4 ± 5.2 >99.9 
Non-polar 
metabolite 1 
2.6 ± 0.2 9.8 ± 0.8 10.5 ± 4.8 3.6 ± 6.3 3.6 ± 5.2 / 
Non-polar 
metabolite 2 
1.8 ± 0.6 9.5 ± 1.3 7.2 ± 3.0 / / / 
Non-polar 
metabolite 3 
11.3 ± 1.1 20.9 ± 1.5 33.6 ± 0.2 / / / 
Polar 
metabolites 
3.5 ± 0.5 5.6 ± 0.9 7.3 ± 2.0 / / / 
 
   
Figure 7: Radiochromatograms of the non-polar fraction of plasma after: A: 5 min, B: 15 
min and C: 45 min. Intact D-[11C]50  has a retention time of 11.7 min. 
 
Figure 8: Radiochromatogram of the total fraction of brain supernatant after 5 min 
showing presence of intact tracer: A: L-[11C]50 (Rt of 11.5 min); B:  D-[
11C]49 (Rt of 11.1 
min). 
PET Imaging 
 
Dynamic PET imaging was carried out in healthy rats with [11C]49 and [11C]50 tracers 
(Figure 9). The time-activity-curves (TACs) of the PET imaging showing SUVs over time are 
presented in the Figure 10. Under baseline condition [11C]49 scan revealed good uptake in 
the brain, reaching a maximum of 1.5 ± 0.05 SUV at 3 min p.i., followed by a rapid 
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clearance within 60 min. [11C]49 showed consistent uptake in the brain with no variation 
between different rats (Figure 10A). Highest accumulation in the first 5 min after injection 
was found in harderian glands and whole brain. Importantly, Figures 9B&D show an 
uptake in the spinal cord (top part) reaching a peak 0.95 ± 0.03 (SUV ± SD) at 10 min p.i., 
also presented by TACs in Figure 10D.  
 
 
 
Figure 9: Static reconstruction of the PET-image scans in healthy male Wistar rat (Rat 2) 
with tracer [11C]49 (20 MBq i.v. injection via tail vein; 3% and 1 – 2.5% isoflurane in oxygen 
(1 L·min-1) for induction and maintenance). A: PET/CT between 0 - 60 min coronal image. 
B: PET/CT between 0 - 60 min sagittal image. C: PET/CT between 3 - 10 min coronal image. 
D: PET/CT between 3 - 10 min sagittal image.  
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In brain supernatant, the percentage of intact D-[11C]50 tracer in the non-polar fraction 
was >96% after 5, 15 or 45 min (Figure 8B). Radioactivity extraction of the brain 
supernatant samples was 58, 55 and 63% at 5, 15 and 45 min, respectively.  
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PET Imaging 
 
Dynamic PET imaging was carried out in healthy rats with [11C]49 and [11C]50 tracers 
(Figure 9). The time-activity-curves (TACs) of the PET imaging showing SUVs over time are 
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clearance within 60 min. [11C]49 showed consistent uptake in the brain with no variation 
between different rats (Figure 10A). Highest accumulation in the first 5 min after injection 
was found in harderian glands and whole brain. Importantly, Figures 9B&D show an 
uptake in the spinal cord (top part) reaching a peak 0.95 ± 0.03 (SUV ± SD) at 10 min p.i., 
also presented by TACs in Figure 10D.  
 
 
 
Figure 9: Static reconstruction of the PET-image scans in healthy male Wistar rat (Rat 2) 
with tracer [11C]49 (20 MBq i.v. injection via tail vein; 3% and 1 – 2.5% isoflurane in oxygen 
(1 L·min-1) for induction and maintenance). A: PET/CT between 0 - 60 min coronal image. 
B: PET/CT between 0 - 60 min sagittal image. C: PET/CT between 3 - 10 min coronal image. 
D: PET/CT between 3 - 10 min sagittal image.  
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Figure 10: Time-activity-curves (TACs) of [11C]49 and [11C]50 in healthy male Wistar rats 
expressed as SUV ± SD. A: TACs of whole brain with tracer [11C]49 (n=4). B: TACs of non-
blocking (black line) and blocking conditions (colored lines): natural SP1-7 administered 15 
min before [11C]49 (green line; n=2), compound 49 3 min prior to tracer injection (red line; 
n=3), compound 49 20 min prior to tracer injection (blue line; n=2). C: TACs of whole brain 
with tracer [11C]50 (n=3). D: TACs of whole brain regions and spinal cord (top part) of 
[11C]49 or [11C]50. E: TACs under a baseline and self-blocking conditions for [11C]49 and 
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[11C]50 in whole brain. F: TACs under a baseline and self-blocking conditions for [11C]49 
and [11C]50 in spinal cord (top part). TACs are expressed as SUV (±SD) and averaged over 4 
animals for baseline and 2 or 3 animals for the blockings studies. Whole brain and spinal 
cord were manually outlined. Scale is set from 0.0 to 2.7 (or 2.4) standardized uptake 
value (SUV).  
Blocking by pretreatment with natural SP1-7 (15 min, i.p., 185 nmol·kg
-1) did not result in 
lower brain activity levels, as well as the self-blocking by pretreatment of 1 (20 min prior 
TOI, i.v., 3 µmol·kg-1). Although, when 49 was injected 3 min prior tracer injection, we 
observed a counterintuitive increase in brain activity (SUV up to 2.0 at 3 min). Despite our 
efforts to block the [11C]49 brain uptake, and consequently also spinal cord uptake (Figure 
10F), pretreatment did not measurably decrease radiotracer uptake showing similar 
uptake pattern for all scans, as presented in Figure 10B, 10E and 10F.  
In vivo evaluation of D-[11C]50, which was also consistent (Figure 10C), showed different 
uptake in whole brain region as well as spinal cord compared to for L-[11C]49,  evident 
from TACs in Figure 10D. Despite the comparable uptake pattern at early time points 
(before 5 min), D-[11C]50 displayed slower clearance (SUV difference of approximately 0.4 
at 60 min; Figure 10D - blue and green line) revealing its better pharmacokinetics and 
retention in brain and spinal cord. Furthermore, self-blocking by pretreatment of 50 (3 
min prior TOI, i.v., 3 µmol·kg-1) again suggested a counterintuitive increase in brain activity 
(SUV up to 1.7 at 3 min p.i.; Figure 10E), whereas spinal cord activity basically remained 
unaltered (SUV up to 1.1 at 10 min p.i.; Figure10F). 
 
Discussion 
 
This study focused on the development of two SP1-7 
11C-benzylacarbamates 
peptidomimetics 49 and 50, and the in vivo assessment in healthy rats to provide an 
insight in the SP1-7 binding site. The radiolabeling of L-[
11C]50, as well as its D-analogue 
[11C]50, was successfully accomplished in an automated radiosynthesis with good yields 
and high molar activities  and purities. 
Ex vivo biodistribution results show desired brain activity concentrations of [11C]49 already 
after 5 min p.i. in cortex, cerebellum and brain stem, as well as in spinal cord (top and mid 
part). Figure 5 indicates rapid washout of activity from brain, while showing more stable 
retention in spinal cord. Owing the results from ex vivo metabolic stability of [11C]49, 
where rapid metabolic degradation in plasma was observed, we could conclude that intact 
tracers indeed quickly and effectively penetrated the BBB. Therefore, as shown in Figure 5, 
relatively high blood values from the ex vivo biodistribution suggest the radioactivity 
circulating in the after 5 min is most probably associated with the radioactive metabolites. 
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Figure 10: Time-activity-curves (TACs) of [11C]49 and [11C]50 in healthy male Wistar rats 
expressed as SUV ± SD. A: TACs of whole brain with tracer [11C]49 (n=4). B: TACs of non-
blocking (black line) and blocking conditions (colored lines): natural SP1-7 administered 15 
min before [11C]49 (green line; n=2), compound 49 3 min prior to tracer injection (red line; 
n=3), compound 49 20 min prior to tracer injection (blue line; n=2). C: TACs of whole brain 
with tracer [11C]50 (n=3). D: TACs of whole brain regions and spinal cord (top part) of 
[11C]49 or [11C]50. E: TACs under a baseline and self-blocking conditions for [11C]49 and 
A: Whole Brain: [11C]49  
A 
B: Whole Brain: [11C]49  
D: Baseline Conditions 
 
0 20 40 60
0.0
0.5
1.0
1.5
2.0 Baseline
Blocking (SP1-7): 15min
Blocking (49): 3 min
Blocking (49): 20 min
Time [min]
SU
V
C: Whole Brain: [11C]2  
0 20 40 60
0.0
0.5
1.0
1.5
2.0 Rat 7
Rat 8
Rat 9
Time [min]
SU
V
0 20 40 60
0.0
0.5
1.0
1.5
2.0
Whole Brain: [11C]1
Whole Brain: [11C]2
Spinal Cord: [11C]1
Spinal Cord: [11C]2
Time [min]
SU
V
E: Whole Brain  
 
0 20 40 60
0.0
0.5
1.0
1.5
2.0
Blocking (50): 3 min + [11C]50
Baseline: [11C]50
Blocking (49): 3 min +[11C]49
Baseline: [11C]49
Time [min]
SU
V
0 20 40 60
0.0
0.5
1.0
1.5
2.0
Baseline: [11C]49
Blocking (49): 3 min + [11C]49
Baseline: [11C]50
Blocking (50): 3 min + [11C]50
Time [min]
SU
V
F: Spinal Cord  
 
C: Whole Brain: [11C]50  
Preclinical Evaluation of the First Substance P1-7 [
11C]Peptidomimetics 
193 
 
[11C]50 in whole brain. F: TACs under a baseline and self-blocking conditions for [11C]49 
and [11C]50 in spinal cord (top part). TACs are expressed as SUV (±SD) and averaged over 4 
animals for baseline and 2 or 3 animals for the blockings studies. Whole brain and spinal 
cord were manually outlined. Scale is set from 0.0 to 2.7 (or 2.4) standardized uptake 
value (SUV).  
Blocking by pretreatment with natural SP1-7 (15 min, i.p., 185 nmol·kg
-1) did not result in 
lower brain activity levels, as well as the self-blocking by pretreatment of 1 (20 min prior 
TOI, i.v., 3 µmol·kg-1). Although, when 49 was injected 3 min prior tracer injection, we 
observed a counterintuitive increase in brain activity (SUV up to 2.0 at 3 min). Despite our 
efforts to block the [11C]49 brain uptake, and consequently also spinal cord uptake (Figure 
10F), pretreatment did not measurably decrease radiotracer uptake showing similar 
uptake pattern for all scans, as presented in Figure 10B, 10E and 10F.  
In vivo evaluation of D-[11C]50, which was also consistent (Figure 10C), showed different 
uptake in whole brain region as well as spinal cord compared to for L-[11C]49,  evident 
from TACs in Figure 10D. Despite the comparable uptake pattern at early time points 
(before 5 min), D-[11C]50 displayed slower clearance (SUV difference of approximately 0.4 
at 60 min; Figure 10D - blue and green line) revealing its better pharmacokinetics and 
retention in brain and spinal cord. Furthermore, self-blocking by pretreatment of 50 (3 
min prior TOI, i.v., 3 µmol·kg-1) again suggested a counterintuitive increase in brain activity 
(SUV up to 1.7 at 3 min p.i.; Figure 10E), whereas spinal cord activity basically remained 
unaltered (SUV up to 1.1 at 10 min p.i.; Figure10F). 
 
Discussion 
 
This study focused on the development of two SP1-7 
11C-benzylacarbamates 
peptidomimetics 49 and 50, and the in vivo assessment in healthy rats to provide an 
insight in the SP1-7 binding site. The radiolabeling of L-[
11C]50, as well as its D-analogue 
[11C]50, was successfully accomplished in an automated radiosynthesis with good yields 
and high molar activities  and purities. 
Ex vivo biodistribution results show desired brain activity concentrations of [11C]49 already 
after 5 min p.i. in cortex, cerebellum and brain stem, as well as in spinal cord (top and mid 
part). Figure 5 indicates rapid washout of activity from brain, while showing more stable 
retention in spinal cord. Owing the results from ex vivo metabolic stability of [11C]49, 
where rapid metabolic degradation in plasma was observed, we could conclude that intact 
tracers indeed quickly and effectively penetrated the BBB. Therefore, as shown in Figure 5, 
relatively high blood values from the ex vivo biodistribution suggest the radioactivity 
circulating in the after 5 min is most probably associated with the radioactive metabolites. 
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These do not cross the BBB according to the metabolite analysis in brain supernatant 
(>99% of [11C]49 after 5 min and 97% after 15 and 45 min p.i.). 
The variability in AM of [
11C]49 between experiments was observed due to external factors 
(e.g. production time of carbon-11, helium line flushing before harversting procedure, new 
or already opened bottle of BEMP…), which may affect the  pharmacokinetics. To correct 
for the variable AM, brain organ region-to-blood ratios were calculated, as presented in 
Figure 11A. Predicting that most of the tracer is un-metabolized after 5 min p.i., the brain 
region-to-blood ratio are 1.24 - 1.39 and 0.82 - 0.88 for spinal cord region-to-blood ratio of 
[11C]49 (Figure 11A). However, assuming that actually 52.3% and 15.2% of intact tracer is 
present in the blood and metabolites do not cross the BBB, meaning there is >99.9% and 
97.3% of intact tracer in brain after 5 and 15 min, respectively, (values obtained during the 
metabolite analysis), these ratios change drastically, as shown in Figure 11B.  
The in vivo plasma stability can be undoubtedly improved by substituting L-Phe for its D-
isomer, providing almost 70% more of intact tracer (e.g. 15 min p.i.: L-[11C]49: 15%; D-
[11C]50: 49%) During the HPLC analysis of the ex vivo plasma samples, same HPLC 
chromatogram pattern was observed for L- and D-carbamate tracers suggesting similar 
metabolic pathway towards several un-known non-polar metabolites. Results from Table 2 
and Table 3 indicate that both phenylalanine configurations are subjected to metabolic 
degradation very shortly after injection.  
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Figure 11: A: Organ region-to-blood ratio of [11C]49 at 5, 15, 30 and 60 min (n = 4 per time 
point). B: Organ region-to-blood ratio of [11C]49 at 5 and 15 min with corrections for % of 
intact tracer in plasma and brain. Columns show the brain region to blood ratio. Errors are 
standard error of the mean (SEM).  
Accordingly, our results confirmed the instability of carbamate peptidomimetic in rat 
plasma, as stated by Fransson et al. in 2014 (t1/2 of 24 min)
[33]. Xenobiotic metabolism 
(phase I) was anticipated using freely available MetaPrint 2D tool, which predicts 
metabolism through data-mining and statistical analysis of known metabolic 
transformations reposted in the literature (Figure 12).  
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Figure 12: Predicted rat metabolism (phase I) for [11C]49 using MetaPrint 2D tool. Same 
metabolism pathway applied for [11C]50. 
We postulated that the observed metabolites, with lower retention times on LC (Figure 6 
and 7) might be the hydroxylated [11C]49 on one of the aromatic rings. In order to test the 
hypothesis, we performed additional LC-MS/MS experiments, as the methodology is 
capable to detect the carrier amounts of ions involved in high molar activity PET-tracers. A 
product ion scan was performed for 49 to determine high intensity mass fragments in an 
MRM method. The transition of 299.1 m/z to 255.1 was chosen where the fragments 
corresponded to the intact parent ion and a loss of carboxylic fragment, and the transition 
of 315.1 m/z to 271.1 was chosen where the fragments corresponded to the hydroxylated 
parent ion and a loss of carboxylic fragment. In this manner, analysis of non-polar plasma 
fractions, after 5 and 15 min p.i., demonstrated a trace amount of 2 (Figure 13; blue) and 
two mass peaks of 315.1 (Figure 13; red) corresponding to the hydroxylated parent ion. 
Unfortunately, we were not able to distinguish between the possible phenylalanine and 
carboxybenzyl hydroxylates.  
As the most abundant metabolite (Rt = 12.7 min) for both L- and D-carbamate tracers 
increased rapidly overtime, we hypothesized glucuronidation might take place, known as 
the most important phase II metabolic pathway responsible for the clearance of many 
endogenous and exogenous compounds.[34] Additional transition of 475.1 m/z to 299.1 
was chosen where the fragments correspond to glucoronated parent ion and the intact 
parent ion. In order to accurately detect the peaks, qualitative assessment using this 
MS/MS transition method of predicted metabolites was conducted with non-polar plasma 
sample where rat was pretreated with “cold” 49, injected before 5 min PET scan as a 
blocker, confirming the glucorinated metabolite after 60 min [11C]49 p.i. (Figure 14, green).  
In addition, using this transition the non-polar plasma samples from in vivo stability study 
of [11C]50 were re-analyzed, all confirming postulated metabolites - hydroxylation and 
glucoronidation (Figure 14). To clarify, glucoronated metabolite this time showed less 
retention on Kinetex Biphenyl column compared to the parent ion, due to glucuronide 
moiety possessing less pi-electrons. These results suggest that glucuronic acid is 
transferred to another nucleophilic atom in acceptor parent molecule, where most likely 
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These do not cross the BBB according to the metabolite analysis in brain supernatant 
(>99% of [11C]49 after 5 min and 97% after 15 and 45 min p.i.). 
The variability in AM of [
11C]49 between experiments was observed due to external factors 
(e.g. production time of carbon-11, helium line flushing before harversting procedure, new 
or already opened bottle of BEMP…), which may affect the  pharmacokinetics. To correct 
for the variable AM, brain organ region-to-blood ratios were calculated, as presented in 
Figure 11A. Predicting that most of the tracer is un-metabolized after 5 min p.i., the brain 
region-to-blood ratio are 1.24 - 1.39 and 0.82 - 0.88 for spinal cord region-to-blood ratio of 
[11C]49 (Figure 11A). However, assuming that actually 52.3% and 15.2% of intact tracer is 
present in the blood and metabolites do not cross the BBB, meaning there is >99.9% and 
97.3% of intact tracer in brain after 5 and 15 min, respectively, (values obtained during the 
metabolite analysis), these ratios change drastically, as shown in Figure 11B.  
The in vivo plasma stability can be undoubtedly improved by substituting L-Phe for its D-
isomer, providing almost 70% more of intact tracer (e.g. 15 min p.i.: L-[11C]49: 15%; D-
[11C]50: 49%) During the HPLC analysis of the ex vivo plasma samples, same HPLC 
chromatogram pattern was observed for L- and D-carbamate tracers suggesting similar 
metabolic pathway towards several un-known non-polar metabolites. Results from Table 2 
and Table 3 indicate that both phenylalanine configurations are subjected to metabolic 
degradation very shortly after injection.  
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Figure 11: A: Organ region-to-blood ratio of [11C]49 at 5, 15, 30 and 60 min (n = 4 per time 
point). B: Organ region-to-blood ratio of [11C]49 at 5 and 15 min with corrections for % of 
intact tracer in plasma and brain. Columns show the brain region to blood ratio. Errors are 
standard error of the mean (SEM).  
Accordingly, our results confirmed the instability of carbamate peptidomimetic in rat 
plasma, as stated by Fransson et al. in 2014 (t1/2 of 24 min)
[33]. Xenobiotic metabolism 
(phase I) was anticipated using freely available MetaPrint 2D tool, which predicts 
metabolism through data-mining and statistical analysis of known metabolic 
transformations reposted in the literature (Figure 12).  
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Figure 12: Predicted rat metabolism (phase I) for [11C]49 using MetaPrint 2D tool. Same 
metabolism pathway applied for [11C]50. 
We postulated that the observed metabolites, with lower retention times on LC (Figure 6 
and 7) might be the hydroxylated [11C]49 on one of the aromatic rings. In order to test the 
hypothesis, we performed additional LC-MS/MS experiments, as the methodology is 
capable to detect the carrier amounts of ions involved in high molar activity PET-tracers. A 
product ion scan was performed for 49 to determine high intensity mass fragments in an 
MRM method. The transition of 299.1 m/z to 255.1 was chosen where the fragments 
corresponded to the intact parent ion and a loss of carboxylic fragment, and the transition 
of 315.1 m/z to 271.1 was chosen where the fragments corresponded to the hydroxylated 
parent ion and a loss of carboxylic fragment. In this manner, analysis of non-polar plasma 
fractions, after 5 and 15 min p.i., demonstrated a trace amount of 2 (Figure 13; blue) and 
two mass peaks of 315.1 (Figure 13; red) corresponding to the hydroxylated parent ion. 
Unfortunately, we were not able to distinguish between the possible phenylalanine and 
carboxybenzyl hydroxylates.  
As the most abundant metabolite (Rt = 12.7 min) for both L- and D-carbamate tracers 
increased rapidly overtime, we hypothesized glucuronidation might take place, known as 
the most important phase II metabolic pathway responsible for the clearance of many 
endogenous and exogenous compounds.[34] Additional transition of 475.1 m/z to 299.1 
was chosen where the fragments correspond to glucoronated parent ion and the intact 
parent ion. In order to accurately detect the peaks, qualitative assessment using this 
MS/MS transition method of predicted metabolites was conducted with non-polar plasma 
sample where rat was pretreated with “cold” 49, injected before 5 min PET scan as a 
blocker, confirming the glucorinated metabolite after 60 min [11C]49 p.i. (Figure 14, green).  
In addition, using this transition the non-polar plasma samples from in vivo stability study 
of [11C]50 were re-analyzed, all confirming postulated metabolites - hydroxylation and 
glucoronidation (Figure 14). To clarify, glucoronated metabolite this time showed less 
retention on Kinetex Biphenyl column compared to the parent ion, due to glucuronide 
moiety possessing less pi-electrons. These results suggest that glucuronic acid is 
transferred to another nucleophilic atom in acceptor parent molecule, where most likely 
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O-linked moiety (e.g. activation of the carboxylic group  in phase I) would be the most 
preferred functional group for the reaction.  
 
Figure 13: Qualitative assessment using LC-MS/MS method of predicted metabolites of 
non-polar plasma 60 min of [11C]49 p.i. with “cold” 49, injected 3 min before the PET scan 
as a blocker. 
 
Figure 14: Analysis of non-polar plasma fractions demonstrating intact parent ion (blue), 
two hydroxylated metabolites (red) and a glucoronated metabolite (green). A: 5 min 
[11C]49 p.i. and  B: 5 min, C: 15 min, D; 45 min [
11C]50 p.i. 
In accordance to the literature, we hypothesized a hydroxylation or/and glucoronidation 
reaction, which have been confirmed by employing LC-MS/MS analysis. The most 
abundant metabolite (Rt = 12.7 min), observed by the online radioactivity detection on 
HPLC in plasma samples, might be the glucoronidated metabolite. Interestingly, 
radioactivity recovery of the blood/plasma samples on Sep-Pak, enabling us to 
discriminate between polar and non-polar metabolites, was almost quantitative for 
[11C]50 at all-time points and [11C]49 at 5 min, whereas the stickiness of [11C]49 at 15 and 
45 min time point was approximately 30%. For these samples additional work up did not 
resolve the issues, therefore the remaining radioactivity on the Sep-Pak column might be 
related to non-polar fraction or an additional unknown metabolite.  
XIC of +MRM (3 pairs): 299.089/255.200 Da  from Sample 8 (Sample006) of Data170531.wiff (Turbo Spray) Max. 5.6e5 cps.
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
3.6e5
3.8e5
4.0e5
4.2e5
4.4e5
4.6e5
4.8e5
5.0e5
5.2e5
5.4e5
5.6e5
In
te
n
si
ty
, 
cp
s
2.96
1.391.13 2.04 2.64 3.21
 
 
XIC of +MRM (3 pairs): 299.089/255.200 Da  from Sample 8 (Sample006) of Data170531.wiff (Turbo Spray) Max. 5.6e5 cps.
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8
Time, min
0.0
2000.0
4000.0
6000.0
8000.0
1.0e4
1.2e4
1.4e4
1.6e4
1.8e4
2.0e4
2.2e4
2.4e4
2.6e4
2.8e4
In
te
n
si
ty
, 
cp
s
1.39
1.13
2.04 2.64 3.21
Zoom In 
 
 
 
 
 
XIC of +MRM (3 pairs): 299.089/255.200 Da  from Sample 4 (Sample002) of Data170713.wiff (Turbo Spray) Max. 1.5e4 cps.
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8
Time, min
0.0
1000.0
2000.0
3000.0
4000.0
5000.0
6000.0
7000.0
8000.0
9000.0
1.0e4
1.1e4
1.2e4
1.3e4
1.4e4
1.5e4
In
te
n
si
ty
, 
cp
s
2.88
0.90
0.56 3.29 3.520.80 4.213.112.76 3.561.14 4.020.590.48 2.60 3.912.442.132.081.741.19 4.614.56 4.943.691.64 4.700.27 2.220.15
XIC of +MRM (3 pairs): 299.089/255.200 Da  from Sample 9 (Sample001) of Data170531.wiff (Turbo Spray) Max. 3270.0 cps.
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
Time, min
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
3000
3200
In
te
n
si
ty
, 
cp
s
2.97
2.682.81 4.68
3.13
4.243.362.642.43 3.49 4.40 4.794.563.55 4.202.27 4.842.11 4.003.741.961.01 1.861.601.19 1.570.73 0.790.17 0.680.36 1.32
XIC of +MRM (3 pairs): 299.089/255.200 Da  from Sample 11 (Sample003) of Data170531.wiff (Turbo Spray) Max. 2.2e4 cps.
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
Time, min
0.0
1000.0
2000.0
3000.0
4000.0
5000.0
6000.0
7000.0
8000.0
9000.0
1.0e4
1.1e4
1.2e4
1.3e4
1.4e4
1.5e4
1.6e4
1.7e4
1.8e4
1.9e4
2.0e4
2.1e4
2.2e4
2.3e4
2.4e4
2.5e4
2.6e4
In
te
n
si
ty
, 
cp
s
2.98
2.85
2.642.27 4.273.231.40 2.070.59 1.85 3.703.52 4.471.70 4.120.810.52 3.873.47 4.914.641.14 1.631.030.06 4.674.090.16
XIC of +MRM (3 pairs): 299.089/255.200 Da  from Sample 10 (Sample002) of Data170531.wiff (Turbo Spray) Max. 1.0e4 cps.
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8
Time, min
0.0
5000.0
1.0e4
1.5e4
2.0e4
2.5e4
3.0e4
3.5e4
4.0e4
4.5e4
5.0e4
5.5e4
6.0e4
6.5e4
7.0e4
7.5e4
8.0e4
8.2e4
In
te
n
si
ty
, 
cp
s
2.99
2.660.32 1.22 2.85 3.17 4.450.51 2.27 2.490.21 2.201.01 2.050.64 0.76 3.643.211.60 1.81 3.60 4.500.15 1.57 4.17 4.764.874.333.831.26 3.91
B C D A
Q 
Preclinical Evaluation of the First Substance P1-7 [
11C]Peptidomimetics 
197 
 
Typical static PET [11C]49 images, between 0 and 60 min and 3 and 10 min, under baseline 
conditions are shown in Figure 12. Dynamic PET scanning of [11C]49 displayed rapid and 
homogenous uptake throughout the brain in 3 - 5 min (SUV 1.51 ± 0.05) and in the spinal 
cord (SUV 0.95 ± 0.03 at 10 min), followed by fast clearance. First blocking experiments 
were performed with natural heptapeptide SP1-7, in a dose 185 nmol·kg
-1, according to 
previous studies by Jonsson[1], injected i.p. 15 min prior to tracer [11C]49 administration. 
No differences between baseline and blocking scan images were observed for all three 
rats used in the blocking study. Considering the poor BBB permeability and stability of 
peptides in vivo, furthermore, a publication by Skogh et al.[7], published very shortly after 
we conducted PET scans, revealed the SP1-7 in vitro half-life in mouse plasma of 4.4 min, 
proving an important reason for the lack of blocking we observed. Pretreatment with non-
radioactive 49 (dose 3 µmol·kg-1[33]) injected i.v. in the tail vein 20 min prior time of 
injection of [11C]49 affected no measurable change in whole brain radioactivity uptake. 
Keeping in mind low metabolic stability unveiled during this investigation, non-radioactive 
49 was also injected as a blocker only 3 min prior to tracer [11C]49 bolus injection. In brain 
we observed an increase of the SUV values up to 2.0., which might be explained by the 
fact that the pretreatment with “un-labeled” compound, also subjected to rapid 
xenobiotic metabolism, preserves more of the intact [11C]49 in the blood for BBB 
penetration. summary, blocking studies showed no measurable decrease in whole brain as 
well as spinal cord uptake of [11C]49 over the duration of the scan.  
For radiotracer candidate D-[11C]50 metabolite analysis confirming BBB penetration was 
immediately followed by PET scanning. Biodistribution assessment has not been executed, 
as we predicted same biodistribution profile as for [11C]49. Interestingly, also for the D-
isomer same whole brain (SUV 1.44 ± 0.12 at 3 min) and spinal cord (SUV 1.06 ± 0.06 at 10 
min) uptake values were observed, although the clearance was slower (SUV 0.80 ± 0.02 at 
60 min), as expected for D-isomer tracer with improved metabolic stability. Again, self-
blocking with non-radioactive 50 (dose 3 µmol·kg-1[33]) injected 3 min prior time of 
injection of [11C]50 resulted in increased SUV values (1.70 ± 0.11 at 3 min p.i.) for brain 
regions and almost unaffected SUV values (1.16 ± 0.04 at 3 min p.i.) for spinal cord (top 
part).  
Taken together, rapid brain uptake of [11C]49 and [11C]50 not only confirms BBB passage, 
but also indicates that both L- and D-tracers are not likely to be a substrates for efflux 
transporters, presumably by P-glycoprotein (PGP), as it has been indicated for other 
H‑Phe-Phe-NH2 analogues by Fransson
[17]. These initial preclinical studies showed that 
both candidates have good tracer properties, e.g. excellent metabolic stability in the brain 
and favorable pharmacokinetics with a maximum brain concentration approximately 3 
min after bolus injection in rats, all important considerations for imaging of CNS. Poor 
understanding of SP1-7 binding site on molecular level hampers employment of 
appropriate blocking compounds.    
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O-linked moiety (e.g. activation of the carboxylic group  in phase I) would be the most 
preferred functional group for the reaction.  
 
Figure 13: Qualitative assessment using LC-MS/MS method of predicted metabolites of 
non-polar plasma 60 min of [11C]49 p.i. with “cold” 49, injected 3 min before the PET scan 
as a blocker. 
 
Figure 14: Analysis of non-polar plasma fractions demonstrating intact parent ion (blue), 
two hydroxylated metabolites (red) and a glucoronated metabolite (green). A: 5 min 
[11C]49 p.i. and  B: 5 min, C: 15 min, D; 45 min [
11C]50 p.i. 
In accordance to the literature, we hypothesized a hydroxylation or/and glucoronidation 
reaction, which have been confirmed by employing LC-MS/MS analysis. The most 
abundant metabolite (Rt = 12.7 min), observed by the online radioactivity detection on 
HPLC in plasma samples, might be the glucoronidated metabolite. Interestingly, 
radioactivity recovery of the blood/plasma samples on Sep-Pak, enabling us to 
discriminate between polar and non-polar metabolites, was almost quantitative for 
[11C]50 at all-time points and [11C]49 at 5 min, whereas the stickiness of [11C]49 at 15 and 
45 min time point was approximately 30%. For these samples additional work up did not 
resolve the issues, therefore the remaining radioactivity on the Sep-Pak column might be 
related to non-polar fraction or an additional unknown metabolite.  
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Typical static PET [11C]49 images, between 0 and 60 min and 3 and 10 min, under baseline 
conditions are shown in Figure 12. Dynamic PET scanning of [11C]49 displayed rapid and 
homogenous uptake throughout the brain in 3 - 5 min (SUV 1.51 ± 0.05) and in the spinal 
cord (SUV 0.95 ± 0.03 at 10 min), followed by fast clearance. First blocking experiments 
were performed with natural heptapeptide SP1-7, in a dose 185 nmol·kg
-1, according to 
previous studies by Jonsson[1], injected i.p. 15 min prior to tracer [11C]49 administration. 
No differences between baseline and blocking scan images were observed for all three 
rats used in the blocking study. Considering the poor BBB permeability and stability of 
peptides in vivo, furthermore, a publication by Skogh et al.[7], published very shortly after 
we conducted PET scans, revealed the SP1-7 in vitro half-life in mouse plasma of 4.4 min, 
proving an important reason for the lack of blocking we observed. Pretreatment with non-
radioactive 49 (dose 3 µmol·kg-1[33]) injected i.v. in the tail vein 20 min prior time of 
injection of [11C]49 affected no measurable change in whole brain radioactivity uptake. 
Keeping in mind low metabolic stability unveiled during this investigation, non-radioactive 
49 was also injected as a blocker only 3 min prior to tracer [11C]49 bolus injection. In brain 
we observed an increase of the SUV values up to 2.0., which might be explained by the 
fact that the pretreatment with “un-labeled” compound, also subjected to rapid 
xenobiotic metabolism, preserves more of the intact [11C]49 in the blood for BBB 
penetration. summary, blocking studies showed no measurable decrease in whole brain as 
well as spinal cord uptake of [11C]49 over the duration of the scan.  
For radiotracer candidate D-[11C]50 metabolite analysis confirming BBB penetration was 
immediately followed by PET scanning. Biodistribution assessment has not been executed, 
as we predicted same biodistribution profile as for [11C]49. Interestingly, also for the D-
isomer same whole brain (SUV 1.44 ± 0.12 at 3 min) and spinal cord (SUV 1.06 ± 0.06 at 10 
min) uptake values were observed, although the clearance was slower (SUV 0.80 ± 0.02 at 
60 min), as expected for D-isomer tracer with improved metabolic stability. Again, self-
blocking with non-radioactive 50 (dose 3 µmol·kg-1[33]) injected 3 min prior time of 
injection of [11C]50 resulted in increased SUV values (1.70 ± 0.11 at 3 min p.i.) for brain 
regions and almost unaffected SUV values (1.16 ± 0.04 at 3 min p.i.) for spinal cord (top 
part).  
Taken together, rapid brain uptake of [11C]49 and [11C]50 not only confirms BBB passage, 
but also indicates that both L- and D-tracers are not likely to be a substrates for efflux 
transporters, presumably by P-glycoprotein (PGP), as it has been indicated for other 
H‑Phe-Phe-NH2 analogues by Fransson
[17]. These initial preclinical studies showed that 
both candidates have good tracer properties, e.g. excellent metabolic stability in the brain 
and favorable pharmacokinetics with a maximum brain concentration approximately 3 
min after bolus injection in rats, all important considerations for imaging of CNS. Poor 
understanding of SP1-7 binding site on molecular level hampers employment of 
appropriate blocking compounds.    
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Conclusion 
 
In summary, an efficient and high yielding radiochemistry was demonstrated for two SP1-7 
11C-benzylacarbamates 49 and 50. Preclinical evaluation was performed to characterize 
the metabolic stability, biodistribution and in vivo PET imaging profile of these promising 
SP1-7 peptidomimetics 49 and 50, showing the compounds enter the rodent brain. Further 
biological evaluation is underway in our laboratories in attempt to reveal additional 
information on SP1-7 and its potential for chronic neuropathic pain. 
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Experimental – Materials and Methods 
 
General 
Chemicals were obtained commercially from Sigma-Aldrich (Zwijndrecht, the Netherlands) 
and Bachem (Bubendorf, Switzerland), and used without further purification, unless stated 
otherwise. Solvents were purchased from Biosolve (Valkenswaard, the Netherlands) and 
Acros (Landsmeer, the Netherlands), and used as received, unless stated otherwise. All 
deuterated solvents were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
Reactions were performed at ambient temperature unless stated otherwise and 
monitored by thin layer chromatography on pre-coated silica 60 F254 aluminum plates 
(Merck, Darmstadt, Germany). Spots were visualized by UV light (254 nm) and ninhydrine 
or bromocresol green staining. Solvents were evaporated under reduced pressure using a 
rotary evaporator (Rotavapor® R II, Flawil, Switzerland). Flash column chromatography 
was performed on Büchi (Flawil, Switzerland) Sepacore system (comprising a C-620 control 
unit, a C-660 fraction collector, two C-601 gradient pumps and a C-640 UV detector) 
equipped with Büchi Sepacore pre-packed flash columns. Yields refer to purified and 
spectroscopically pure compounds. 
NMR spectroscopy was performed on a Bruker Avance 250, 400 or 500 MHz (Billerica, MA, 
USA) with chemical shifts (δ) reported in parts per million (ppm) relative to the solvent 
(CDCl3, 
1H 7.26 ppm, 13C 77.16 ppm; D2O, 
1H 4.79 ppm; (CD3)2SO, 
13C 39.52 ppm). Splitting 
patterns are indicated as s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet and br: 
broad peak, and J, coupling constant in Hz. Electrospray ionization-high resolution mass 
spectrometry (ESI-HRMS) was carried out using Bruker microTOF-Q instrument in a 
positive ion mode (capillary potential of 4500 V) and interpreted with Bruker Compass 
Data Analysis 4.0 software.  
Analytical HPLC was performed on a Shimadzu SPD-20A system (Shimadzu Corporation, 
Japan) and Jasco PU-2089 Plus station (Easton, MD, USA) with a Alltima C18 5 μm (250 x 
4.6 mm) column (Grace, Breda, The Netherlands) (A) with Jasco UV-2075 Plus UV detector 
(254 nm) and NaI radioactivity detector (Raytest, Straubenhardt, Germany) at ambient 
temperature. Acetonitrile (CH3CN) (C), CH3CN+0.1% TFA (D), water (E), water+0.1% TFA (F) 
and buffer 1 (4 mM sodium formate and 4% dimethylformamide) (G) were used as mobile 
phases. Chromatograms were acquired with LabSolutions 5.85 software (Shimadzu 
Corporation, Japan) and Raytest GINA Star software (version 5.8; Straubenhardt, 
Germany).  
Semi-preparative isocratic HPLC was performed on Jasco UV-2087 Plus station with a 
Alltima C18 5 μm (250 x 10 mm) column (Grace, Breda, the Netherlands) (J) using 
CH3CN/buffer 1 (40/60, v/v) as a eluent, flow rate 5 mL·min
-1 (method A), a Jasco UV-2075 
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Conclusion 
 
In summary, an efficient and high yielding radiochemistry was demonstrated for two SP1-7 
11C-benzylacarbamates 49 and 50. Preclinical evaluation was performed to characterize 
the metabolic stability, biodistribution and in vivo PET imaging profile of these promising 
SP1-7 peptidomimetics 49 and 50, showing the compounds enter the rodent brain. Further 
biological evaluation is underway in our laboratories in attempt to reveal additional 
information on SP1-7 and its potential for chronic neuropathic pain. 
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Experimental – Materials and Methods 
 
General 
Chemicals were obtained commercially from Sigma-Aldrich (Zwijndrecht, the Netherlands) 
and Bachem (Bubendorf, Switzerland), and used without further purification, unless stated 
otherwise. Solvents were purchased from Biosolve (Valkenswaard, the Netherlands) and 
Acros (Landsmeer, the Netherlands), and used as received, unless stated otherwise. All 
deuterated solvents were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
Reactions were performed at ambient temperature unless stated otherwise and 
monitored by thin layer chromatography on pre-coated silica 60 F254 aluminum plates 
(Merck, Darmstadt, Germany). Spots were visualized by UV light (254 nm) and ninhydrine 
or bromocresol green staining. Solvents were evaporated under reduced pressure using a 
rotary evaporator (Rotavapor® R II, Flawil, Switzerland). Flash column chromatography 
was performed on Büchi (Flawil, Switzerland) Sepacore system (comprising a C-620 control 
unit, a C-660 fraction collector, two C-601 gradient pumps and a C-640 UV detector) 
equipped with Büchi Sepacore pre-packed flash columns. Yields refer to purified and 
spectroscopically pure compounds. 
NMR spectroscopy was performed on a Bruker Avance 250, 400 or 500 MHz (Billerica, MA, 
USA) with chemical shifts (δ) reported in parts per million (ppm) relative to the solvent 
(CDCl3, 
1H 7.26 ppm, 13C 77.16 ppm; D2O, 
1H 4.79 ppm; (CD3)2SO, 
13C 39.52 ppm). Splitting 
patterns are indicated as s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet and br: 
broad peak, and J, coupling constant in Hz. Electrospray ionization-high resolution mass 
spectrometry (ESI-HRMS) was carried out using Bruker microTOF-Q instrument in a 
positive ion mode (capillary potential of 4500 V) and interpreted with Bruker Compass 
Data Analysis 4.0 software.  
Analytical HPLC was performed on a Shimadzu SPD-20A system (Shimadzu Corporation, 
Japan) and Jasco PU-2089 Plus station (Easton, MD, USA) with a Alltima C18 5 μm (250 x 
4.6 mm) column (Grace, Breda, The Netherlands) (A) with Jasco UV-2075 Plus UV detector 
(254 nm) and NaI radioactivity detector (Raytest, Straubenhardt, Germany) at ambient 
temperature. Acetonitrile (CH3CN) (C), CH3CN+0.1% TFA (D), water (E), water+0.1% TFA (F) 
and buffer 1 (4 mM sodium formate and 4% dimethylformamide) (G) were used as mobile 
phases. Chromatograms were acquired with LabSolutions 5.85 software (Shimadzu 
Corporation, Japan) and Raytest GINA Star software (version 5.8; Straubenhardt, 
Germany).  
Semi-preparative isocratic HPLC was performed on Jasco UV-2087 Plus station with a 
Alltima C18 5 μm (250 x 10 mm) column (Grace, Breda, the Netherlands) (J) using 
CH3CN/buffer 1 (40/60, v/v) as a eluent, flow rate 5 mL·min
-1 (method A), a Jasco UV-2075 
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Plus UV detector (254 nm), a homemade radioactivity detector and Jasco ChromNAV CFR 
software (version 1.14.01).  
*Method B: solvents C/D (v/v), linear gradient, 0 - 1 min: 35% C; 1 - 19 min:  35-65% C; 19 - 
20 min: 65 - 35% C; 20 - 21 min: 65% C.  
 
Calculation of the Radiochemical yield by analytical HPLC 
Radiochemical yield, determined by analytical HPLC of the crude reaction mixture, defined 
as radiochemical conversion (RCC), was determined by HPLC as the percentage of 
converted [11C]CO2 to desired product [
11C]49 or [11C]50 in the crude reaction mixture 
using an analytical HPLC method described in the radiochemistry section under each 
procedure and is based on the AUC of the radioactivity profile of HPLC analysis. 
Calculation of the Radiochemical Yield 
Radiochemical yield (RCY) was calculated as the quotient of measured activity of the 
isolated product at the end of the synthesis (EOS) and the measured activity at the end of 
the cyclotron bombardment (EOB) and expressed as a percentage. Radiochemical yield 
has been corrected for decay from the end of the cyclotron bombardment (EOB). No 
corrections have been made for material losses (potentially volatile radioactive species or 
residual activity in the vial, tubes and syringes).  
Calculation of the Molar Activity 
Molar activity (AM) of the final tracer, expressed as GBq·µmol
-1, was determined by 
measurement of the UV absorbance (AUC) of a known amount of radioactivity under 
identical analytical HPLC conditions used to generate a mass calibration curve for the 
corresponding non-radioactive standard. 
The Mass Calibration Curve 
The mass calibration curve was performed using samples of the reference compound 49 
due to strong UV absorption and is based on the AUC of HPLC analysis.  
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Table 4: Calibration curve data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Calibration curve of UV absorbance (AUC) vs. injected amount of the reference 
compound 49. For raw data used to construct the curve, see supplementary Table 4. 
 
Synthesis  
 (S)-benzyl (1-amino-1-oxo-3-phenylpropan-2-yl)carbamate (49) 
Starting compound (S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanoic acid (80.0 mg, 
267 µmol, 1 eq) and di-tert-butyl dicarbonate (125 mg, 573 µmol, 2 eq) were dissolved in 3 
mL of 1,4-dioxane and placed on a magnetic mixer. Pyridine (18.0 µL, 267 µmol, 1 eq) and 
ammonium hydrogen carbonate (58.0 mg, 746 µmol, 2.8 eq) were added to the solution. 
The reaction mixture was flushed with nitrogen and left stirring overnight (17 h). Solvents 
y = 27965812x - 7461 
 
R² = 0.99698 
0
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200000
300000
400000
0 0,002 0,004 0,006 0,008 0,01 0,012 0,014
U
V
 A
re
a 
Amount (µmol) 
Entry 49 n [µmol injected] 
UV Absorbance at 254 nm 
[µV·min-1] 
1 0.0127 351077 
2 0.0064 176903 
3 0.0025 70166 
4 0.0003 3049 
5 0.0043 104367 
6 0.0043 104112 
7 0.0021 45173 
8 0.0021 45982 
9 0.0009 18062 
10 0.0009 17345 
11 0.0003 5771 
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Plus UV detector (254 nm), a homemade radioactivity detector and Jasco ChromNAV CFR 
software (version 1.14.01).  
*Method B: solvents C/D (v/v), linear gradient, 0 - 1 min: 35% C; 1 - 19 min:  35-65% C; 19 - 
20 min: 65 - 35% C; 20 - 21 min: 65% C.  
 
Calculation of the Radiochemical yield by analytical HPLC 
Radiochemical yield, determined by analytical HPLC of the crude reaction mixture, defined 
as radiochemical conversion (RCC), was determined by HPLC as the percentage of 
converted [11C]CO2 to desired product [
11C]49 or [11C]50 in the crude reaction mixture 
using an analytical HPLC method described in the radiochemistry section under each 
procedure and is based on the AUC of the radioactivity profile of HPLC analysis. 
Calculation of the Radiochemical Yield 
Radiochemical yield (RCY) was calculated as the quotient of measured activity of the 
isolated product at the end of the synthesis (EOS) and the measured activity at the end of 
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has been corrected for decay from the end of the cyclotron bombardment (EOB). No 
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Table 4: Calibration curve data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Calibration curve of UV absorbance (AUC) vs. injected amount of the reference 
compound 49. For raw data used to construct the curve, see supplementary Table 4. 
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were evaporated in vacuo. The remaining material in the vessel was dissolved in 7 mL of 
EtOAc, washed three times with 5 mL of 5 mM H2SO4 and three times with 5 mL of brine. 
The organic phases were combined, dried over MgSO4, filtered and evaporated in vacuo. 
Compound 49 was obtained in 80% yield as a white crystalline powder after precipitation 
in ice-cold n-hexane. 1H NMR (250.13 MHz, DMSO-d6): δ (ppm) = 7.50 (br s, 1H, -NH-), 7.31 
– 7.19 (m, 10H, 10x Ar-H), 7.07 (s, 2H, -NH2), 4.91 (s, 2H, -CH2-O), 4.19 – 4.10 (m, 1H, -CH-
CH2-), 3.00 (dd, J1=22 Hz, J2=8  Hz, 1H, CH2-CH-), 2.75 – 2.66 (m, 1H, CH2-CH-). 
13C NMR 
(125.81 MHz, DMSO-d6): δ (ppm) = 174.05 (-CONH2), 160.09 (-COONH-), 138.61 (Ar), 
129.61 (Ar), 128.76 (Ar), 128.53 (Ar), 127.85 (Ar), 126.74 (Ar), 74.94 (-CH2O-), 65.64 (-CH-), 
37.91 (-CH2CH-). HRMS: Calculated for C17H18N2O3 298.13, measured 299.1225 (M+H
+) and 
321.1225 (M+Na+). HPLC purity: ˃99% (determined by HPLC: column J, method B, Rt = 11.8 
min).   
Synthesis of (R)-benzyl (1-amino-1-oxo-3-phenylpropan-2-yl)carbamate (50) 
Starting compound (R)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanoic acid (100 mg, 
334 µmol, 1 eq) and di-tert-butyl dicarbonate (183 mg, 668 µmol, 2 eq) were dissolved in 3 
mL of 1,4-dioxane and placed on a magnetic mixer. Pyridine (27.0 µL, 334 µmol, 1 eq) and 
ammonium hydrogen carbonate (75.0 mg, 868 µmol, 2.6 eq) were added to the solution. 
Nitrogen athmosphere was introduced before the solution was left stirring overnight (18 
hrs). Solvents were evaporated in vacuo. The remaining material in the vessel was 
dissolved in 7 mL of EtOAc, washed three times with 5 mL of 5 mM H2SO4 and three times 
with 5 mL of brine. The organic phases were combined, dried over MgSO4, filtered and 
evaporated in vacuo.  Compound 50 was obtained in 55% yield as a white crystalline 
powder after precipitation in ice-cold n-hexane. 1H NMR (400.13 MHz, DMSO-d6): δ (ppm) 
= 7.47 (br s, 1H, -NH-), 7.41 – 7.21 (m, 10H, 10x Ar-H), 7.07 (s, 2H, -NH2), 4.94 (s, 2H, -CH2-
O), 4.19 – 4.16 (m, 1H, -CH-CH2-), 3.00 (dd, J1=16 Hz, J2=4  Hz, 1H, CH2-CH-), 2.74 (t, J=12 
Hz, 1H, CH2-CH-). 
13C NMR (125.81MHz, DMSO-d6): δ (ppm) = 173.88 (-CONH2), 153.30 (-
COONH-), 138.77 (Ar), 137.52 (Ar), 128.93 (Ar), 128.73 (Ar), 128.49 (Ar), 127.88 (Ar), 
126.66 (Ar), 65.58 (-CH2O-), 65.54 (-CH-), 37.96 (-CH2CH-). HRMS: Calculated for 
C17H18N2O3 298.13, measured 299.1378 (M+H)
+ and 321.1199 (M+Na)+. HPLC purity: ˃95% 
(determined by HPLC: column J, method B, Rt = 11.8 min).   
N-benzylation - Side product control reaction 
As a test synthesis, the reaction mimicking the radiolabeling conditions was performed, in 
the absence of radiolabeled CO2. L-Phe-NH2 (1.0 mg, 3.3 µmol) was placed in a pre-dried 
reaction vessel dissolved in DMSO (200 µL) containing BEMP (8.3 µL). Benzyl chloride (4.0 
µL) in DMSO (200 µL) was added to the reaction vessel. Reaction left to react for 5 
minutes at 75 °C under with helium (10 mL·min-1). The mixture was then cooled to 25 °C, 
quenched with a solution of acetonitrile and water ((50/50; v/v; 1.5 mL) and injected on 
an analytical HPLC (Setting1). Analysis showed no conversion of the employed reagents 
(e.g. difference in retention time) on the HPLC chromatogram, proving N-benzylation as a 
side reaction does not occur. 
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Radiosynthesis 
Radionuclide production procedure for carbon-11 
An IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium) cyclotron was used for [11C]CO2 
production by the 14N(p,α)11C nuclear reaction performed in a 0.5% O2/N2 gas mixture. 
After trapping of [11C]CO2 from the target in a stainless trap dispersed in liquid N2, [
11C]CO2 
was transferred to the desired reaction vessel using helium flow. 
Procedure of the manual synthesis  
H-L-Phe-NH2 was placed in a pre-dried reaction vessel in a research hot cell and dissolved 
in DMSO containing BEMP. [11C]CO2 (4 - 6 GBq) was transferred through a sicapent column 
to the mixture using helium flow of 10 mL·min-1 from a CO2 trap. When the activity in the 
vessel reached its maximum, DMSO containing benzyl chloride was manually added to the 
reaction vessel with a syringe, heated to 75 °C and left to stir with helium flow (10 mL·min-
1) for 2 - 10 minutes. Approximately 50 µL of the reaction mixture was then quenched with 
300 µL of solution of acetonitrile and water (1/1; v/v) and analyzed on HPLC (Column A; 
Method B) to determine the radiochemical yield expressed as radiochemical conversion of 
the reaction. 
Procedure for the automated synthesis 
L-Phe-NH2 or D-Phe-NH2 (1.0 mg, 3.3 µmol) was placed in a pre-dried reaction vessel 
dissolved in DMSO (0.15 mL) containing BEMP (8.3 µL) and fixed in the home-build 
synthesis module located in the hot-cell.[35] [11C]CO2 (45 GBq) was transferred through a 
sicapent column to the mixture using helium flow (10 mL·min-1). When the activity in the 
vessel reached its maximum, benzyl chloride (4.0 µL) in DMSO (0.15 mL) was automatically 
added to the reaction vessel, which was then heated to 75 °C and left to stir with helium 
(10 mL·min-1) for 5 minutes. The mixture was then cooled to 25 °C, quenched with a 
solution of acetonitrile and water ((1/1; v/v; 1.5 mL) and injected on a preparative HPLC 
column (Method A). The product, eluting between 12 and 14 minutes, was collected 
(Experimental Section: Figure 2), diluted in 7 mL of water and loaded on a pre-conditioned 
Sep-Pak C18 column. The Sep-Pak C18 column was washed with 5 mL of water, before the 
product was eluted with 1 mL of EtOH. Saline solution (9 mL) was added to the product, 
forming the final injectable radioactive tracer.  
[11C]49 was obtained in a decay-corrected radiochemical yield of 33 ± 16% with an isolated 
non-decay-corrected yield of 1.7 - 8.2 GBq of the product with a radiochemical purity 
>99%, an average molar activity of 115 ± 58 GBq·μmol-1 within 24 - 26 min (n>10). The 
identity of the product was confirmed with analytical HPLC (Column A; Method B) by co-
injection of the product and non-labeled 49. 
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were evaporated in vacuo. The remaining material in the vessel was dissolved in 7 mL of 
EtOAc, washed three times with 5 mL of 5 mM H2SO4 and three times with 5 mL of brine. 
The organic phases were combined, dried over MgSO4, filtered and evaporated in vacuo. 
Compound 49 was obtained in 80% yield as a white crystalline powder after precipitation 
in ice-cold n-hexane. 1H NMR (250.13 MHz, DMSO-d6): δ (ppm) = 7.50 (br s, 1H, -NH-), 7.31 
– 7.19 (m, 10H, 10x Ar-H), 7.07 (s, 2H, -NH2), 4.91 (s, 2H, -CH2-O), 4.19 – 4.10 (m, 1H, -CH-
CH2-), 3.00 (dd, J1=22 Hz, J2=8  Hz, 1H, CH2-CH-), 2.75 – 2.66 (m, 1H, CH2-CH-). 
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(125.81 MHz, DMSO-d6): δ (ppm) = 174.05 (-CONH2), 160.09 (-COONH-), 138.61 (Ar), 
129.61 (Ar), 128.76 (Ar), 128.53 (Ar), 127.85 (Ar), 126.74 (Ar), 74.94 (-CH2O-), 65.64 (-CH-), 
37.91 (-CH2CH-). HRMS: Calculated for C17H18N2O3 298.13, measured 299.1225 (M+H
+) and 
321.1225 (M+Na+). HPLC purity: ˃99% (determined by HPLC: column J, method B, Rt = 11.8 
min).   
Synthesis of (R)-benzyl (1-amino-1-oxo-3-phenylpropan-2-yl)carbamate (50) 
Starting compound (R)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanoic acid (100 mg, 
334 µmol, 1 eq) and di-tert-butyl dicarbonate (183 mg, 668 µmol, 2 eq) were dissolved in 3 
mL of 1,4-dioxane and placed on a magnetic mixer. Pyridine (27.0 µL, 334 µmol, 1 eq) and 
ammonium hydrogen carbonate (75.0 mg, 868 µmol, 2.6 eq) were added to the solution. 
Nitrogen athmosphere was introduced before the solution was left stirring overnight (18 
hrs). Solvents were evaporated in vacuo. The remaining material in the vessel was 
dissolved in 7 mL of EtOAc, washed three times with 5 mL of 5 mM H2SO4 and three times 
with 5 mL of brine. The organic phases were combined, dried over MgSO4, filtered and 
evaporated in vacuo.  Compound 50 was obtained in 55% yield as a white crystalline 
powder after precipitation in ice-cold n-hexane. 1H NMR (400.13 MHz, DMSO-d6): δ (ppm) 
= 7.47 (br s, 1H, -NH-), 7.41 – 7.21 (m, 10H, 10x Ar-H), 7.07 (s, 2H, -NH2), 4.94 (s, 2H, -CH2-
O), 4.19 – 4.16 (m, 1H, -CH-CH2-), 3.00 (dd, J1=16 Hz, J2=4  Hz, 1H, CH2-CH-), 2.74 (t, J=12 
Hz, 1H, CH2-CH-). 
13C NMR (125.81MHz, DMSO-d6): δ (ppm) = 173.88 (-CONH2), 153.30 (-
COONH-), 138.77 (Ar), 137.52 (Ar), 128.93 (Ar), 128.73 (Ar), 128.49 (Ar), 127.88 (Ar), 
126.66 (Ar), 65.58 (-CH2O-), 65.54 (-CH-), 37.96 (-CH2CH-). HRMS: Calculated for 
C17H18N2O3 298.13, measured 299.1378 (M+H)
+ and 321.1199 (M+Na)+. HPLC purity: ˃95% 
(determined by HPLC: column J, method B, Rt = 11.8 min).   
N-benzylation - Side product control reaction 
As a test synthesis, the reaction mimicking the radiolabeling conditions was performed, in 
the absence of radiolabeled CO2. L-Phe-NH2 (1.0 mg, 3.3 µmol) was placed in a pre-dried 
reaction vessel dissolved in DMSO (200 µL) containing BEMP (8.3 µL). Benzyl chloride (4.0 
µL) in DMSO (200 µL) was added to the reaction vessel. Reaction left to react for 5 
minutes at 75 °C under with helium (10 mL·min-1). The mixture was then cooled to 25 °C, 
quenched with a solution of acetonitrile and water ((50/50; v/v; 1.5 mL) and injected on 
an analytical HPLC (Setting1). Analysis showed no conversion of the employed reagents 
(e.g. difference in retention time) on the HPLC chromatogram, proving N-benzylation as a 
side reaction does not occur. 
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Radiosynthesis 
Radionuclide production procedure for carbon-11 
An IBA Cyclone 18/9 (IBA, Louvain-la Neuve, Belgium) cyclotron was used for [11C]CO2 
production by the 14N(p,α)11C nuclear reaction performed in a 0.5% O2/N2 gas mixture. 
After trapping of [11C]CO2 from the target in a stainless trap dispersed in liquid N2, [
11C]CO2 
was transferred to the desired reaction vessel using helium flow. 
Procedure of the manual synthesis  
H-L-Phe-NH2 was placed in a pre-dried reaction vessel in a research hot cell and dissolved 
in DMSO containing BEMP. [11C]CO2 (4 - 6 GBq) was transferred through a sicapent column 
to the mixture using helium flow of 10 mL·min-1 from a CO2 trap. When the activity in the 
vessel reached its maximum, DMSO containing benzyl chloride was manually added to the 
reaction vessel with a syringe, heated to 75 °C and left to stir with helium flow (10 mL·min-
1) for 2 - 10 minutes. Approximately 50 µL of the reaction mixture was then quenched with 
300 µL of solution of acetonitrile and water (1/1; v/v) and analyzed on HPLC (Column A; 
Method B) to determine the radiochemical yield expressed as radiochemical conversion of 
the reaction. 
Procedure for the automated synthesis 
L-Phe-NH2 or D-Phe-NH2 (1.0 mg, 3.3 µmol) was placed in a pre-dried reaction vessel 
dissolved in DMSO (0.15 mL) containing BEMP (8.3 µL) and fixed in the home-build 
synthesis module located in the hot-cell.[35] [11C]CO2 (45 GBq) was transferred through a 
sicapent column to the mixture using helium flow (10 mL·min-1). When the activity in the 
vessel reached its maximum, benzyl chloride (4.0 µL) in DMSO (0.15 mL) was automatically 
added to the reaction vessel, which was then heated to 75 °C and left to stir with helium 
(10 mL·min-1) for 5 minutes. The mixture was then cooled to 25 °C, quenched with a 
solution of acetonitrile and water ((1/1; v/v; 1.5 mL) and injected on a preparative HPLC 
column (Method A). The product, eluting between 12 and 14 minutes, was collected 
(Experimental Section: Figure 2), diluted in 7 mL of water and loaded on a pre-conditioned 
Sep-Pak C18 column. The Sep-Pak C18 column was washed with 5 mL of water, before the 
product was eluted with 1 mL of EtOH. Saline solution (9 mL) was added to the product, 
forming the final injectable radioactive tracer.  
[11C]49 was obtained in a decay-corrected radiochemical yield of 33 ± 16% with an isolated 
non-decay-corrected yield of 1.7 - 8.2 GBq of the product with a radiochemical purity 
>99%, an average molar activity of 115 ± 58 GBq·μmol-1 within 24 - 26 min (n>10). The 
identity of the product was confirmed with analytical HPLC (Column A; Method B) by co-
injection of the product and non-labeled 49. 
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[11C]50 was obtained in a decay-corrected radiochemical yield of 29 ± 6% with an isolated 
non-corrected  yield of 1.9 - 6.4 GBq of the product with a radiochemical purity >99%, an 
average molar activity of 76 ± 19 GBq·μmol-1 within 23 - 29 min (n=5). The identity of the 
product was confirmed with analytical HPLC (Column A; Method B) by co-injection of the 
product and non-radiolabeled 50. 
HPLC Chromatograms 
 
Figure 16: Representative HPLC UV and radioactivity chromatogram of the: A: crude 
reaction mixture of [11C]49 before prep HPLC; B: crude reaction mixture of [11C]49 with co-
injection of 49.  
 
Figure 17: Representative preparative HPLC chromatograme (UV and radioactivity profile) 
of the crude reaction mixture during purification.  [11C]49 (peak between 12 – 14 min)  
Animals 
Adult healthy male Wistar rats (Charles River International Inc, Sulzfeld, Germany) were 
housed in groups of maximal 6 in a conventional cage and kept in a room with a 12-hour 
light/dark cycle, and constant room temperature (19 - 21 °C) and humidity level (52 - 
70%). Rats were provided with water and food pellets (Teklad Global Diet 2016, Envigo; 
Horst, the Netherlands) ad libitum. The rats were allowed to adapt to the laboratory 
environment for one week before the experiment. Animal experiments were performed in 
accordance with the European Community Council Directive (2010/63/EU) for laboratory 
A B 
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UV Profile [mV] 
Preclinical Evaluation of the First Substance P1-7 [
11C]Peptidomimetics 
205 
 
animal care and the Dutch Law on animal experimentation. The experimental protocol 
was validated and approved by the local committee on animal experimentation of the VU 
University Medical Center.  
Ex vivo Biodistribution  
Healthy male Wistar rats (200 - 250 g) were injected with the radiotracer (≈ 40 MBq) via 
the tail vein under isoflurane anesthesia (2 – 2.5% in 1 L·min-1). Animals were sacrificed 
and dissected at 5, 15, 30 and 60 minutes (n=4 per time point) post-injection. Blood, heart, 
lungs, liver, kidney, duodenum, urine, tail, bone, spleen, large brain, cerebellum, brain 
stem, spinal cord top and spinal cord mid were collected, weighed and counted for 
radioactivity in a Wallac Computagama 1210 or a Wallac Universal Gamma Counter 1282. 
Biodistribution data are expressed as the percentage of injected dose per gram (%ID/g). 
Errors are standard error of the mean (SEM).   
Metabolites Analysis  
Healthy male Wistar rats (200 - 330 g) were injected with the tracer [11C]49 or [11C]50 (20 - 
40 MBq) via the tail vein under isoflurane anesthesia (2 – 2.5% in 1 L·min-1). The rodents 
were sacrificed at 5, 15 and 45 minutes post injection for the tracer [11C]49 (n=4 per time 
point) and at 5, 15 and 45 minutes post injection for the tracer [11C]50 (n=3 per time 
point). Blood (2.0 - 5.0 mL) was collected via heart puncture into heparin tubes (DB 
Vacutainer, LH, Becton Dickinson, Franklin Lakes, NY, USA) and centrifuged at 4000 rpm 
for 5 min at 4 °C (Hettich Universal 32, Andreas Hettich GmbH & Co. KG, Tuttlingen, 
Germany). The brain was dissected and one hemisphere was put in a falcon tube 
containing 50% acetonitrile in saline (4 mL), and homogenized with a dispenser (IKA T18 B 
Ultra-Turrax, IKA-Werke GmbH & Co KG, Staufen, Germany) before centrifugation at 4000 
r.p.m. for 5 min at 4 °C. The other hemisphere was counted for radioactivity for recovery 
calculations. Plasma and brain supernatant were separated from blood cells and brain 
precipitate, respectively.  
About 1 mL of plasma was diluted with 2 mL of 0.15 M hydrochloric acid and loaded onto 
a tC2 Sep-Pak cartridge, which was pre-activated by elution with 3 mL of methanol and 6 
mL of water, respectively. The cartridge was washed with 3 mL of water to collect the rest 
of the polar radioactive metabolites. The polar radioactive metabolite fraction was 
defined as the two combined fractions. Next, the tC2 Sep-Pak cartridge was eluted with 1.5 
mL of methanol and 2 mL of water to collect the mixture of non-polar radioactive 
metabolites. About 2 mL of the brain supernatant was ultra-centrifuged (Eppendorf  
5417c, Eppendorf, Hamburg, Germany) and 1 mL was injected onto an HPLC system. All 
non-polar metabolites and polar brain metabolites fractions were immediately analyzed 
using HPLC to determine the percentage of the intact [11C]49 or [11C]50. HPLC was 
performed on the Dionex Ultimate 3000 System station, equipped with 1 mL loop, with 
Phenomenex Gemini C18, 250 x 10 mm, 5 µm, column using gradient elution of A: 
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[11C]50 was obtained in a decay-corrected radiochemical yield of 29 ± 6% with an isolated 
non-corrected  yield of 1.9 - 6.4 GBq of the product with a radiochemical purity >99%, an 
average molar activity of 76 ± 19 GBq·μmol-1 within 23 - 29 min (n=5). The identity of the 
product was confirmed with analytical HPLC (Column A; Method B) by co-injection of the 
product and non-radiolabeled 50. 
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reaction mixture of [11C]49 before prep HPLC; B: crude reaction mixture of [11C]49 with co-
injection of 49.  
 
Figure 17: Representative preparative HPLC chromatograme (UV and radioactivity profile) 
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animal care and the Dutch Law on animal experimentation. The experimental protocol 
was validated and approved by the local committee on animal experimentation of the VU 
University Medical Center.  
Ex vivo Biodistribution  
Healthy male Wistar rats (200 - 250 g) were injected with the radiotracer (≈ 40 MBq) via 
the tail vein under isoflurane anesthesia (2 – 2.5% in 1 L·min-1). Animals were sacrificed 
and dissected at 5, 15, 30 and 60 minutes (n=4 per time point) post-injection. Blood, heart, 
lungs, liver, kidney, duodenum, urine, tail, bone, spleen, large brain, cerebellum, brain 
stem, spinal cord top and spinal cord mid were collected, weighed and counted for 
radioactivity in a Wallac Computagama 1210 or a Wallac Universal Gamma Counter 1282. 
Biodistribution data are expressed as the percentage of injected dose per gram (%ID/g). 
Errors are standard error of the mean (SEM).   
Metabolites Analysis  
Healthy male Wistar rats (200 - 330 g) were injected with the tracer [11C]49 or [11C]50 (20 - 
40 MBq) via the tail vein under isoflurane anesthesia (2 – 2.5% in 1 L·min-1). The rodents 
were sacrificed at 5, 15 and 45 minutes post injection for the tracer [11C]49 (n=4 per time 
point) and at 5, 15 and 45 minutes post injection for the tracer [11C]50 (n=3 per time 
point). Blood (2.0 - 5.0 mL) was collected via heart puncture into heparin tubes (DB 
Vacutainer, LH, Becton Dickinson, Franklin Lakes, NY, USA) and centrifuged at 4000 rpm 
for 5 min at 4 °C (Hettich Universal 32, Andreas Hettich GmbH & Co. KG, Tuttlingen, 
Germany). The brain was dissected and one hemisphere was put in a falcon tube 
containing 50% acetonitrile in saline (4 mL), and homogenized with a dispenser (IKA T18 B 
Ultra-Turrax, IKA-Werke GmbH & Co KG, Staufen, Germany) before centrifugation at 4000 
r.p.m. for 5 min at 4 °C. The other hemisphere was counted for radioactivity for recovery 
calculations. Plasma and brain supernatant were separated from blood cells and brain 
precipitate, respectively.  
About 1 mL of plasma was diluted with 2 mL of 0.15 M hydrochloric acid and loaded onto 
a tC2 Sep-Pak cartridge, which was pre-activated by elution with 3 mL of methanol and 6 
mL of water, respectively. The cartridge was washed with 3 mL of water to collect the rest 
of the polar radioactive metabolites. The polar radioactive metabolite fraction was 
defined as the two combined fractions. Next, the tC2 Sep-Pak cartridge was eluted with 1.5 
mL of methanol and 2 mL of water to collect the mixture of non-polar radioactive 
metabolites. About 2 mL of the brain supernatant was ultra-centrifuged (Eppendorf  
5417c, Eppendorf, Hamburg, Germany) and 1 mL was injected onto an HPLC system. All 
non-polar metabolites and polar brain metabolites fractions were immediately analyzed 
using HPLC to determine the percentage of the intact [11C]49 or [11C]50. HPLC was 
performed on the Dionex Ultimate 3000 System station, equipped with 1 mL loop, with 
Phenomenex Gemini C18, 250 x 10 mm, 5 µm, column using gradient elution of A: 
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acetonitrile and B: 0.1% TFA in water. The HPLC gradient ran for 14 min decreasing the 
concentration of eluent B from 90% to 20% in 11 min, 2 min with 20% of B and back to 
original setting (90% B) at flow 5 mL·min-1. All separated fractions of the brain supernatant 
were counted for radioactivity in a Wizard Gamma Counter 1470 or 2480 (Wallac, 
PerkinElmer, Waltham, MA, USA). The percentage of the intact tracer in the non-polar 
plasma fractions was determined by the online radioactivity detection by HPLC analysis for 
[11C]49 or [11C]50 (Rt = 11.7 min). Results are expressed as percentage of the intact tracer, 
polar metabolites, non-polar metabolites ± standard deviation. 
LC-MS/MS Method   
LC–MS/MS analysis was performed on a Jasco X-LC HPLC system (Easton, PA, USA) with an 
AB Sciex QTRAP 5500 mass spectrometer (Concorde, Ontario, Canada). The Jasco system 
consisted of two pumps (X-LC 3180PU), a degasser (X-LC 3080DG), a mixer (X-LC 3080MX), 
a column oven (X-LC 3080CO) and an auto sampler (X-LC3159AS). Data were collected 
with two data boxes (LV 2080-03 and LC-Net II/ACD).  
A Kinetex Biphenyl C18 column (2.6 μ, 100 A, 100 × 2.10 mm; Phenomenex, Torrance, CA, 
USA) at 25 °C was used for chromatographic separation. A gradient elution was used at a 
flow rate of 0.5 mL·min-1. The mobile phase consisted of a mixture of acetonitrile (A) and 
0.1% formic acid in water (B) according to the following scheme: 0 min 80% B, 10% B in 
3.5 min, 10% B for 3.6 min, 80% B in 5 min at 25 ºC. MS parameters: TurboIon Spray 
voltage was set at 5.5 kV, source temperature at 750 °C. Based of full-scan MS and MS/MS 
spectra of each analyte, the most abundant fragment ions were selected and the mass 
spectrometer was set to monitor the transitions of the precursors to the product ions as 
followed: m/z 299.1  255.1 for the intact tracer, m/z 315.1 271.1 for the hydroxylated 
metabolite and m/z 475.1  299.1 for the glucoronated metabolite. 
PET Imaging 
Dynamic PET imaging was performed on a healthy male Wistar rats (n = 10; 200 – 320 g) 
using dedicated small animal PET/CT and PET/MR scanners (half of the rats was imaged 
with the NanoScan PET/CT and half with the NanoScan PET/MR; Mediso Ltd., Budapest, 
Hungary) with identical PET components. The rats were anaesthetized with 3% and 1 – 
2.5% isoflurane in oxygen (1 L·min-1) for induction and maintenance, respectively. Rats 
were positioned on the scanner bed and respiratory rate was monitored during the entire 
time of scanning, adjusting anesthesia when required. A computed tomography (CT) or 
magnetic resonance imaging (MRI) scan was performed for respectively 5 or 15 min, 
followed by intravenous (i.v.) administration of [11C]49 (9 - 41 MBq)  or  of [11C]50  (11 - 28 
MBq) via tail vein cannula at the start of a dynamic PET scan of 60 min. PET data were 
normalized, and corrected for scatter, randomization, attenuation, decay and dead time. 
List-mode PET data were re-binned in 18 successive frames: 4 × 5, 4 x 10, 2 x 30, 3x 60, 2 x 
300, 1 x 600, 1 x 900 and 1 x 1200 s, which were reconstructed using a fully 3-dimensional 
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reconstruction algorithm (Tera-TomoTM) using 4 iterations and 6 subsets, resulting in an 
isotropic 0.4 mm voxel dimension. On the same scan also a static reconstruction was 
performed (1 h scan; time sequence: 1 x 600 s or 1 x 420 s). Images were analyzed using 
the freely available AMIDE software (A Medical Image Data Examiner; version 1.0.4), 
whereas images in Figure 9 are made using VivoQuant (version 3.0, InVicro, Boston, MA, 
USA). Regions of interest (ROI) were drawn manually around whole brain (ellipsoid) and 
spinal cord (elliptic cylinder). Results are expressed as standardized uptake values (SUVs) 
and error bars indicate standard deviation using Graph Pad Prism (Version 5.02, Graph Pad 
Software Inc., La Jolla, CA, USA). 
For blocking experiments, rats were injected with the natural heptapeptide SP1-7 or 49 or 
50, depending on the investigated PET tracer. The SP1-7 was diluted in DMSO and then 
further diluted with saline to the final concentration (5% DMSO). Peptide was injected i.p. 
in a dose 185 nmol·kg-1, according to previous experiments by Jonsson[1], 15 min prior to 
tracer [11C]49 administration. Compound 49 was dissolved in EtOH and further diluted 
with saline to the final concentration (20% EtOH). 49 was injected slowly i.v. in the tail vein 
in a dose 3 µmol·kg-1, according to previous experiments by Fransson[33], 3 and 20 min 
prior to tracer [11C]49 administration. Same dose and formulation conditions applied for 
compound 50, except that it was injected only 3 min prior to tracer [11C]50 administration.  
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tracer [11C]49 administration. Compound 49 was dissolved in EtOH and further diluted 
with saline to the final concentration (20% EtOH). 49 was injected slowly i.v. in the tail vein 
in a dose 3 µmol·kg-1, according to previous experiments by Fransson[33], 3 and 20 min 
prior to tracer [11C]49 administration. Same dose and formulation conditions applied for 
compound 50, except that it was injected only 3 min prior to tracer [11C]50 administration.  
 
 
 
 
 
 
 
 
 
References 
[1] A. Jonsson, R. Fransson, Y. Haramaki, A. Skogh, E. Brolin, H. Watanabe, G. Nordvall, M. 
Hallberg, A. Sandström, F. Nyberg, Neuroscience 2015, 298, 112–119. 
[2] H. M. Franzen, U. Ragnarsson, J. Chem. Soc. 1988, 1, 497–502. 
[3] S. P. A. Wolfensberger, B. N. M. van Berckel, A. J. Airaksinen, K. Maruyama, M. Lubberink, R. 
Boellaard, W. D. H. Carey, W. Reddingius, D. J. Veltman, A. D. Windhorst, et al., Mol. 
Imaging Biol. 2009, 11, 241–245. 
15299 - Pekosak_BNW.indd   207 16-02-18   16:23
Chapter 7 
208 
 
[4] R. Hargreaves, D. Ph, Psychiatry Interpers. Biol. Process. 2002, 63, 18–24. 
[5] R. Fransson, M. Botros, C. Sköld, F. Nyberg, G. Lindeberg, M. Hallberg, A. Sandström, J. Med. 
Chem. 2010, 53, 2383–2389. 
[6] Abba J. Kastin, Handbook of Biologically Active Peptides, 2013. 
[7] A. Skogh, A. Lesniak, F. Z. Gaugaz, R. Svensson, G. Lindeberg, R. Fransson, F. Nyberg, M. 
Hallberg, A. Sandström, Eur. J. Pharm. Sci. 2017, 106, 345–351. 
[8] Q. Zhou, Z. Liu, A. Ray, W. Huang, K. Karlsson, F. Nyberg, Neuropharmacology 1998, 37, 
1545–1552. 
[9] M. Botros, M. Hallberg, T. Johansson, Q. Zhou, G. Lindeberg, P. A. Frändberg, C. Tömböly, G. 
Tóth, P. Le Grevès, F. Nyberg, Peptides 2006, 27, 753–759. 
[10] R. Fransson, G. Nordvall, J. Bylund, A. Carlsson-Jonsson, J. M. Kratz, R. Svensson, P. 
Artursson, M. Hallberg, A. Sandstro, ACS Med. Chem. Lett. 2014, 5, 1272–1277. 
[11] T. Komatsu, H. Mizoguchi, M. Sasaki, C. Sakurada, M. Tsuzuki, S. Sakurada, T. Sakurada, 
Neuropharmacology 2011, 61, 608–613. 
[12] E. Chung, T. G. Yoon, S. Kim, M. Kang, H. J. Kim, Y. Son, Biomol. Ther. 2017, 25, 259–265. 
[13] R. Fransson, M. Botros, F. Nyberg, G. Lindeberg, A. Sandström, M. Hallberg, Neuropeptides 
2008, 42, 31–37. 
[14] Q. Zhou, A. Carlsson, M. Botros, R. Fransson, A. Sandstr??m, T. Gordh, M. Hallberg, F. 
Nyberg, Peptides 2009, 30, 2418–2422. 
[15] M. Botros, M. Hallberg, T. Johansson, Q. Zhou, G. Lindeberg, P. Fra, Peptides 2006, 27, 753–
759. 
[16] O. J. Igwe, D. C. Kim, V. S. Seybold,  a a Larson, J. Neurosci. 1990, 10, 3653–63. 
[17] R. Fransson, C. Sköld, J. M. Kratz, R. Svensson, P. Artursson, F. Nyberg, M. Hallberg, A. 
Sandström, J. Med. Chem. 2013, 56, 4953–4965. 
[18] B. R., R. Baron, Nat. Clin. Pract. Neurol. 2006, 2, 95–106. 
[19] L. Colloca, T. Ludman, D. Bouhassira, R. Baron, A. H. Dickenson, D. Yarnitsky, R. Freeman, A. 
Truini, N. Attal, N. B. Finnerup, et al., Nat. Rev. Dis. Prim. 2017, 3, 17002. 
[20] R. N. Gunn, E. A. Rabiner, Semin. Nucl. Med. 2017, 47, 89–98. 
[21] S. Z. Lever, K. H. Fan, J. R. Lever, Nucl. Med. Biol. 2017, 44, 4–30. 
[22] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chemie Int. Ed. 2008, 47, 8998–9033. 
[23] K. Dahl, C. Halldin, M. Schou, Clin. Transl. Imaging 2017, 5, 275–289. 
[24] G. Antoni, J. Label. Compd. Radiopharm. 2015, 45, 65–72. 
[25] W. Wadsak, M. Mitterhauser, Eur. J. Radiol. 2010, 73, 461–469. 
[26] S. Vallabhajosula, L. Solnes, B. Vallabhajosula, Semin. Nucl. Med. 2011, 41, 246–264. 
[27] B. H. Rotstein, S. H. Liang, M. S. Placzek, J. M. Hooker, A. A. Wilson, N. Vasdev, Chem. Soc. 
Rev. 2016, 45, 4708–4726. 
[28] A. Pekošak, B. H. Rotstein, T. L. Collier, A. D. Windhorst, N. Vasdev, A. J. Poot, European J. 
Org. Chem. 2017, 2017, 1019–1024. 
[29] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chem. Int. Ed. Engl. 2008, 47, 8998–9033. 
[30] J. M. Hooker, A. T. Reibel, S. M. Hill, M. J. Schueller, J. S. Fowler, Angew. Chemie - Int. Ed. 
2009, 48, 3482–3485. 
[31] A. a Wilson, A. Garcia, S. Houle, N. Vasdev, Org. Biomol. Chem. 2010, 8, 428–432. 
[32] T. Murata, M. Umeda, S. Yoshikawa, K. Urbahns, J. Gupta, S. Osamu, WO2004043926 (A1) - 
PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST, 
2004. 
[33] R. Fransson, G. Nordvall, J. Bylund, A. Carlsson-Jonsson, J. M. Kratz, R. Svensson, P. 
Artursson, M. Hallberg, A. Sandstro, ACS Med. Chem. Lett. 2014, 5, 1272–1277. 
[34] S. Ge, Y. Tu, M. Hu, Curr. Pharmacol. Reports 2016, 2, 326–338. 
[35] A. D. Windhorst, T. ter Linden, A. de Nooij, J. F. Keus, F. L. Buijs, P. E. Schollema, L. F. van 
Rooij, J. D. M. Herscheid, J Label Compd Radiopharm 2001, 44, S1052--S1054. 
 
  
 
 
  
 
 
 
 
 
 
 
 
15299 - Pekosak_BNW.indd   208 16-02-18   16:23
CH
AP
TE
R 
8
REFLECTIONS AND FUTURE PERSPECTIVES
Chapter 7 
208 
 
[4] R. Hargreaves, D. Ph, Psychiatry Interpers. Biol. Process. 2002, 63, 18–24. 
[5] R. Fransson, M. Botros, C. Sköld, F. Nyberg, G. Lindeberg, M. Hallberg, A. Sandström, J. Med. 
Chem. 2010, 53, 2383–2389. 
[6] Abba J. Kastin, Handbook of Biologically Active Peptides, 2013. 
[7] A. Skogh, A. Lesniak, F. Z. Gaugaz, R. Svensson, G. Lindeberg, R. Fransson, F. Nyberg, M. 
Hallberg, A. Sandström, Eur. J. Pharm. Sci. 2017, 106, 345–351. 
[8] Q. Zhou, Z. Liu, A. Ray, W. Huang, K. Karlsson, F. Nyberg, Neuropharmacology 1998, 37, 
1545–1552. 
[9] M. Botros, M. Hallberg, T. Johansson, Q. Zhou, G. Lindeberg, P. A. Frändberg, C. Tömböly, G. 
Tóth, P. Le Grevès, F. Nyberg, Peptides 2006, 27, 753–759. 
[10] R. Fransson, G. Nordvall, J. Bylund, A. Carlsson-Jonsson, J. M. Kratz, R. Svensson, P. 
Artursson, M. Hallberg, A. Sandstro, ACS Med. Chem. Lett. 2014, 5, 1272–1277. 
[11] T. Komatsu, H. Mizoguchi, M. Sasaki, C. Sakurada, M. Tsuzuki, S. Sakurada, T. Sakurada, 
Neuropharmacology 2011, 61, 608–613. 
[12] E. Chung, T. G. Yoon, S. Kim, M. Kang, H. J. Kim, Y. Son, Biomol. Ther. 2017, 25, 259–265. 
[13] R. Fransson, M. Botros, F. Nyberg, G. Lindeberg, A. Sandström, M. Hallberg, Neuropeptides 
2008, 42, 31–37. 
[14] Q. Zhou, A. Carlsson, M. Botros, R. Fransson, A. Sandstr??m, T. Gordh, M. Hallberg, F. 
Nyberg, Peptides 2009, 30, 2418–2422. 
[15] M. Botros, M. Hallberg, T. Johansson, Q. Zhou, G. Lindeberg, P. Fra, Peptides 2006, 27, 753–
759. 
[16] O. J. Igwe, D. C. Kim, V. S. Seybold,  a a Larson, J. Neurosci. 1990, 10, 3653–63. 
[17] R. Fransson, C. Sköld, J. M. Kratz, R. Svensson, P. Artursson, F. Nyberg, M. Hallberg, A. 
Sandström, J. Med. Chem. 2013, 56, 4953–4965. 
[18] B. R., R. Baron, Nat. Clin. Pract. Neurol. 2006, 2, 95–106. 
[19] L. Colloca, T. Ludman, D. Bouhassira, R. Baron, A. H. Dickenson, D. Yarnitsky, R. Freeman, A. 
Truini, N. Attal, N. B. Finnerup, et al., Nat. Rev. Dis. Prim. 2017, 3, 17002. 
[20] R. N. Gunn, E. A. Rabiner, Semin. Nucl. Med. 2017, 47, 89–98. 
[21] S. Z. Lever, K. H. Fan, J. R. Lever, Nucl. Med. Biol. 2017, 44, 4–30. 
[22] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chemie Int. Ed. 2008, 47, 8998–9033. 
[23] K. Dahl, C. Halldin, M. Schou, Clin. Transl. Imaging 2017, 5, 275–289. 
[24] G. Antoni, J. Label. Compd. Radiopharm. 2015, 45, 65–72. 
[25] W. Wadsak, M. Mitterhauser, Eur. J. Radiol. 2010, 73, 461–469. 
[26] S. Vallabhajosula, L. Solnes, B. Vallabhajosula, Semin. Nucl. Med. 2011, 41, 246–264. 
[27] B. H. Rotstein, S. H. Liang, M. S. Placzek, J. M. Hooker, A. A. Wilson, N. Vasdev, Chem. Soc. 
Rev. 2016, 45, 4708–4726. 
[28] A. Pekošak, B. H. Rotstein, T. L. Collier, A. D. Windhorst, N. Vasdev, A. J. Poot, European J. 
Org. Chem. 2017, 2017, 1019–1024. 
[29] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chem. Int. Ed. Engl. 2008, 47, 8998–9033. 
[30] J. M. Hooker, A. T. Reibel, S. M. Hill, M. J. Schueller, J. S. Fowler, Angew. Chemie - Int. Ed. 
2009, 48, 3482–3485. 
[31] A. a Wilson, A. Garcia, S. Houle, N. Vasdev, Org. Biomol. Chem. 2010, 8, 428–432. 
[32] T. Murata, M. Umeda, S. Yoshikawa, K. Urbahns, J. Gupta, S. Osamu, WO2004043926 (A1) - 
PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST, 
2004. 
[33] R. Fransson, G. Nordvall, J. Bylund, A. Carlsson-Jonsson, J. M. Kratz, R. Svensson, P. 
Artursson, M. Hallberg, A. Sandstro, ACS Med. Chem. Lett. 2014, 5, 1272–1277. 
[34] S. Ge, Y. Tu, M. Hu, Curr. Pharmacol. Reports 2016, 2, 326–338. 
[35] A. D. Windhorst, T. ter Linden, A. de Nooij, J. F. Keus, F. L. Buijs, P. E. Schollema, L. F. van 
Rooij, J. D. M. Herscheid, J Label Compd Radiopharm 2001, 44, S1052--S1054. 
 
  
 
 
  
 
 
 
 
 
 
 
 
15299 - Pekosak_BNW.indd   209 16-02-18   16:23
Chapter 8 
210 
 
Preparation of enantiomerically pure radiopharmaceuticals poses several challenges and 
therefore requires continuous demand due to the advantages of enantiopure compounds 
over their racemic forms. Based on the successfully developed rapid, multi-step, and 
stereocontrolled reactions to label  amino acids and peptides with carbon-11 proven 
earlier in this thesis, we decided to bring this work to the highest level possible and 
explore other possibilities to introduce carbon-11 radiolabel and chirality into the 
molecule using catalysis. 
Enantioselective catalysis can be divided in three main areas depending of the source of 
catalyst. These are organometallic catalysis, organocatalysis and biocatalysis. Latest, an 
enzyme driven addition of the stereoselectivity in the molecule has been already well-
recognized in radiochemistry for the synthesis of radiolabeled amino acids (e.g. L-
[11C]DOPA). A novel approach for enzyme catalyzed synthesis of 11C-amino acids will be 
further discussed in the future perspectives Part 1. On the other hand, a successful 
example of organocatalysis, namely chiral phase-transfer catalysis, has been thoroughly 
discussed in this thesis, whereas an additional approach has been also considered and will 
be exemplified in the future perspectives Part 2. Triggered by the potential of first 
Substance P1-7 derived L- and D-[
11C]-peptidomimetics, Part 3 provide our reflections on 
the past research followed by future perspectives on this interesting target for the 
treatment of neuropathic pain. Finally, Part 4 will offer alternative suggestions to use 
carbon-11 labeled peptides in clinical studies and for pharmaceutical development.  
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Part 1: Simple, but powerful: Boronic Pinacol Esters as Precursors for 
Carbon-11 Amino Acids. 
 
The demand for new 11C-labeled PET-tracers and building blocks in radiopharmaceutical 
chemistry requires novel radiochemical reactions with two primary carbon-11 precursors. 
Current applications of [11C]CO2 in PET-tracer syntheses are mostly direct [
11C]CO2-fixation 
and [11C]carboxylations of Grignard and organolithium reagents to yield [11C]carboxylic 
acids, further used in the radiosynthesis.[1–3] In one of our preliminary works to expand the 
11C-amino acid toolset, we focused on the development of a novel approach by applying 
metal-mediated [11C]carboxylation using alkenyl and alkyl boronic pinacol esters[4,5], 
illustrated in the Figure 1.  
Boronic acid esters are rather stable to air and moisture and consequently easily handled 
and stored, crucial for the success of a PET-tracer synthesis. Moreover, with the wide 
variety of commercially available boronic pinacol esters potential applications for the 
development of novel radiotracer are endless.[4,5] For more relevant comparison of 
different methodologies, we again focused on the radiosynthesis of 11C-phenylalanine in 
two steps via either an enzymatic or chemical approach (Figure 1).  
 
Figure 1: Schematic overview of boronic pinacol esters as novel precursors for 11C-amino 
acids. 
The first approach uses phenylalanine ammonia lyase (PAL), which under high ammonia 
concentration serves as a biocatalyst for the enantioselective synthesis of natural and 
non-natural amino acids.[6–8] We envisioned Cu(I)-mediated [11C]carboxylation using 
alkenyl boronic pinacol ester, where the trans-cinnamic acid is formed using CuTC as a 
catalyst, TMEDA as a base and co-ligand and TBAT as a fluoride source in dry NMP or DMF 
(Scheme 1). The preliminary results on the described step have been performed and are 
presented in Table 1. The experiments were conducted at the laboratories of the VUmc 
and partially in the Gee group at King’s College London, UK. In the second part on the 
synthesis (Scheme 1A), [11C]trans cinnamic acid should undergo the asymmetric 
hydroamination performed by PAL with predicted excellent enantioselectivity in favor of 
the L-[11C]phenylalanine. PAL is responsible for the conversion of L-phenylalanine into 
trans-cinnamic acid, however, under high ammonia conditions this deamination is 
reversible. Furthermore, using PALs variety enantiomerically pure non-natural L-amino 
acids can be synthesized.[6–9] An alternative, chemical approach would be also 
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molecule using catalysis. 
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Substance P1-7 derived L- and D-[
11C]-peptidomimetics, Part 3 provide our reflections on 
the past research followed by future perspectives on this interesting target for the 
treatment of neuropathic pain. Finally, Part 4 will offer alternative suggestions to use 
carbon-11 labeled peptides in clinical studies and for pharmaceutical development.  
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Part 1: Simple, but powerful: Boronic Pinacol Esters as Precursors for 
Carbon-11 Amino Acids. 
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11C-amino acid toolset, we focused on the development of a novel approach by applying 
metal-mediated [11C]carboxylation using alkenyl and alkyl boronic pinacol esters[4,5], 
illustrated in the Figure 1.  
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variety of commercially available boronic pinacol esters potential applications for the 
development of novel radiotracer are endless.[4,5] For more relevant comparison of 
different methodologies, we again focused on the radiosynthesis of 11C-phenylalanine in 
two steps via either an enzymatic or chemical approach (Figure 1).  
 
Figure 1: Schematic overview of boronic pinacol esters as novel precursors for 11C-amino 
acids. 
The first approach uses phenylalanine ammonia lyase (PAL), which under high ammonia 
concentration serves as a biocatalyst for the enantioselective synthesis of natural and 
non-natural amino acids.[6–8] We envisioned Cu(I)-mediated [11C]carboxylation using 
alkenyl boronic pinacol ester, where the trans-cinnamic acid is formed using CuTC as a 
catalyst, TMEDA as a base and co-ligand and TBAT as a fluoride source in dry NMP or DMF 
(Scheme 1). The preliminary results on the described step have been performed and are 
presented in Table 1. The experiments were conducted at the laboratories of the VUmc 
and partially in the Gee group at King’s College London, UK. In the second part on the 
synthesis (Scheme 1A), [11C]trans cinnamic acid should undergo the asymmetric 
hydroamination performed by PAL with predicted excellent enantioselectivity in favor of 
the L-[11C]phenylalanine. PAL is responsible for the conversion of L-phenylalanine into 
trans-cinnamic acid, however, under high ammonia conditions this deamination is 
reversible. Furthermore, using PALs variety enantiomerically pure non-natural L-amino 
acids can be synthesized.[6–9] An alternative, chemical approach would be also 
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dibromination of cinnamic acids under mild conditions to anti-2,3-dibromo-3-
phenylpropanoic acids. This procedure has been published in high yields and selectivity in 
a relatively short time.[10] 
 
Scheme 1: A: Model synthesis combining 11C-carboxylation and enzyme biocatalysis. B: 
Model synthesis of [11C]hydrocinnamic acid analogues. Step 1: [11C]CO2 is transferred with 
a hellium flow into a reaction vessel containing trans-cinnamic boronic pinacol ester. After 
obtaining the maximum radioactivity in the vessel, the reaction mixture is stirred for 5 min 
at 120 °C yielding [11C]hydro-cinnamic acid. Step 2: A: Asymmetric hydroamination by 
phenylalanine ammonia lyase. B: Acidic deprotection or ammonolysis. 
As a second approach we also anticipated the Cu(I)-mediated [11C]carboxylation, however 
this time using alkyl boronic pinacol esters, followed by an acidic deprotection of amine 
protected functional group or amminolysis of halogens to yield desired α-
[11C]phenylalanine, depicted in Scheme 1B. For this reason a simple hydro-cinnamic acid 
has been investigated as a model reaction, showing that alkyl boronic esters indeed show 
no reactivity (results are summarized in Table 1). A possible explanation for unsuccessful 
conversion to hydro-cinnamic acid might be found in the absence of double bond in the 
alkyl boronic ester precursor bond providing no possible complexation for the Cu-catalyst. 
In summary, based on preliminary experiments, high trapping efficiencies for both 
[11C]trans- and [11C]hydro-cinnamic acids can be obtained. Unfortunately, Cu(I)-mediated 
carboxylation was only successful for arylboronates, whereas alkylboronates proved 
ineffective. Nonetheless, this original approach utilizing [11C]carboxylic acid, via 
straightforward [11C]CO2-fixation, subjected to enzymatic conversion to [
11C]phenylalanine 
has demonstrated potential utility for the radiosynthesis of carbon-11 L-amino acids. 
Therefore, PAL, as well as tyrosine and histidine ammonia lyases, represents promising 
and attractive biocatalyst for the synthesis of enantiomerically pure natural and non-
natural carbon-11 amino acids using readily available achiral cinnamic acid derivatives as 
starting material.  
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Table 1: [11C]Carboxylation: Incorporation according to HPLC (expressed as RCC) and 
trapping efficiency of [11C]trans-cinnamic acid and [11C]hydro-cinnamic acid. 
Entry* 
Product 
[Cinnamic 
Acid] 
CuTC 
[eq] 
Solvent 
Time 
[min] 
RCCa 
[%] 
Trapping 
Efficiency [%] 
1 Trans 0.1 NMP 5 27 69 
2** Trans 0.5 NMP 7 71 ± 4 (n=3) 44 ± 14 (n=2) 
3 Trans 0.5 NMP 5 86 74 
4 Trans 0.5 DMF 5 67 84 
5 Hydro 0.1 NMP 10 0 83 
6 Hydro 0.5 NMP 10 0 95 
7 Hydro 1.0 NMP 10 0 99 
*
Reaction conditions: 1.0 eq of precursor, 0.13 eq of TBAT, 300 μL of solvent, 120 °C. Experiments 
performed at VUmc Amsterdam using helium flow 10 mL·min-1. **Experiments performed at 
King’s College London using helium flow of 1.4 mL·min
-1. aRCC: Radiochemical conversion; 
determined by analytical HPLC. 
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Part 2: Difficult Roads Often Lead to Beautiful Solutions: Chiral 
Coupling Reagents in Carbon-11 Peptide Chemistry 
 
Recently inspired by the great results of chiral coupling reagents for the enantioselective 
synthesis of peptides in organic chemistry, we aimed to investigate their potential for 
carbon-11 radiochemistry as well. According to the literature, an enantioselective coupling 
reagent consists of a chiral auxiliary responsible for enantio-discriminating activation of 
the carboxylic constituent and 4,6-dimethoxy-1,3,5-triazine scaffold, as in classical achiral 
reagents. The chiral auxiliary departs after the activation, avoiding any problems due to 
additional chiral center.[11] Taking this advantage, a great variety of tertiary amines were 
explored, like piperidine[11] and N-alkylprolines[12] or natural strychnine, quinine, brucine 
and nicotine[13–16], as well as phospohonium salts[17]. 
In this preliminary work we have focused on the development of a novel approach to 
radiolabel 11C-dipeptides, and lateron longer 11C-peptides as well, by applying a chiral 
coupling reagent for the enantioselective activation of a racemic 11C-amino acid substrate 
carboxylic group.[14,16] Our proposed radiolabeling strategy was based on prosperous 11C-
benzylation, of Schiff base precursor under basic conditions, and treatment of the 
obtained racemic 11C-phenylalanine with free C-terminus, with chiral coupling reagent 
yielding enantiomerically enriched activated derivative, as presented in Figure 2. First 
attempts to identify a suitable Schiff base precursor, either with protected (methyl, ethyl, 
tertbutyl and benzyl ester) or with free carboxylic group needed for further activation, 
were fruitless, mainly due to rapid cleavage of benzophenone moiety required for α-11C-
alkylation. Thus, we turned our attention to the synthesis of various enantiodifferentiating 
reagents, where, unfortunately, latest quickly underwent decomposition and were 
impossible to isolate.[18–20] 
 
Figure 2: Proposed strategy for carbon-11 dipeptide radiolabeling using chiral coupling 
reagents. 
The concept of super active esters, by facile departure of leaving group by its 
rearrangement, has been proved as a useful tool for intramolecular peptide forming 
reactions for the synthesis of constrained cyclopeptides as well as solid-phase syntheses 
for whole range of amino acids substrates, natural and un-natural. Thus, with a strong 
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demand for molecular diversity of peptides, this approach, providing a predictable 
enantiomeric enrichment into the peptide directly from racemic N-protected amino acid, 
would open a new pathway in radiochemistry, more specifically in carbon-11 
radiochemistry. Accordingly, a binary coupling reagent should be formed in situ from two 
readily accessible components just before its application in [11C]-radiochemistry 
stereoselective reaction. For the future work, [11C]carboxylation should be considered as 
the most straight forward method for introduction of carbon-11 radionuclide into the 
racemic amino acid substrate carboxylic group, advoiding other time consuming reaction 
steps. With this preliminary data in hand, implementation of these two proposed 
improvements, in situ preparation of chiral coupling reagent and [11C]carboxylation 
method, would warrant further investigation that could facilitate 11C-radiochemistry of 
small peptides. Coupling reagents could be used as complimentary approach to achieve 
high stereoselectivity when that cannot be obtained using chiral coupling reagents or 
when chiral HPLC separation, to monitor the reaction, is not successful. As experienced, 
diastereomeric separation of 11C-dipeptides proved challenging (Chapter 5), by coupling 
AA sequences HPLC separation will be most likely easier to achieved due to larger 
differences in the structure, not only limited to the alkyl chain. We postulate that chiral 
coupling reagents could fulfill this gap in carbon-11 peptide chemistry.  
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Part 3: H.O.P.E. (Hold On Pain Ends) with Substance P1-7 Derived 11C-
Peptidomimetics 
 
Substance P1-7 derived 
11C-peptidomimetics, illustrated in Figure 9 in Chapter 1, have 
sparked our interest for several reasons. Besides their favorable properties, published by 
Sandström group in Uppsala, our main reasoning was to design a small library of these 
attractive carbon-11 labeled SP1-7 peptidomimetics and evaluate them as a research tool 
to investigate the SP1-7 binding site in order to provide an insight in the imaging of 
neuropathic pain. Besides that, we were attracted by the versatile carbon-11 reactions, in 
particular 11C-alkylation that could be achieved by our [11C]benzyl iodide, depicted in 
Figure 3. For these two obvious reasons, a detailed plan for each compound of interest 
has been prepared. 
 
Figure 3: Proposed radiosyntheses of Substance P1-7 derived small 
11C-peptidomimetics. 
Dipeptide H-Phe-Phe-NH2 (a), a lead compound for other peptidomimetics, could be 
prepared using 11C-benyzlation in presence of chiral phase-transfer catalysts (Chapter 5, 
Figure 2), following novel methodology described in this thesis (Chapter 3 – 6). All the 
reference compounds and precursors to support the radiochemistry have been 
synthesized by liquid-phase peptide synthesis in high purity and moderate yields (using 
general methodology described in the Experimental Section of Chapter 6). After 
identifying optimal conditions providing high incorporation of [11C]benzyl iodide towards 
intermediate Ph2C=N-[
11C]Phe-Phe-NH2(Table 2), catalyst screening showed 
enantioinduction, reported as diastereomeric excess (de), cannot be properly achieved. As 
can be deducted from Table 2, de values are fluctuating, which might be explained by the 
proposed tetrahedron selectivity model and no enolate formation between the 
ammonium cation of the PTC and amidated precursor (Chapter 4, Experimental Section, 
Figure 7). Despite smooth automation, further isolation of amidated H-[11C]Phe-Phe-NH2 
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revealed radiolabeled product decomposes in aqueous media[21,22], eliminating this 
dipeptide from further research.  
Aiming to synthesize compound b (Figure 3) we engaged in solid-phase synthesis (Figure 
4A) as well as solution-phase (Figure 4B) from commercially available racemic proline 
derivative to obtain L- and D-reference of compound b, and glycine precursor. Both 
approaches proved to be unsuccessful, despite optimization, which is most likely linked 
with amide moiety on proline and impurities during the synthesis (e.g. diketopiperazine 
formation[23]). Furthermore, starting racemic proline derivative could not be purified as a 
optically pure L,L-proline derivative by column chromatography, semi-prep HPLC (reverse-, 
normal-phase or chiral column), TLC or crystallization.[24]   
Table 2: Screening of the PTC, reaction time and temperature.  
 
Entry PTC PTC [% ,mol] a RCC [%]b 
de [%] (towards  
L,L-peptide)c 
1 / / 67.9 -16.9 
2 Cat 1 33.5 71.8 48.9 
3 Cat 5 58.3 95.9 58.2 
4 Cat 1 38.6 61.1 58.9 
5 Cat 1 33.4 27.9 21.5 
6 Cat 1 67.4 77.9 30.5 
7 Cat 9 54.3 81.9 -25.4 
8 Cat 9 73.7 23.6 11.4 
9 Cat 4 103.4 76.7 49.7 
10 Cat 4 94.8 94.4 55.9 
11 Cat 4 47.0 25.7 61.2 
12 Cat 5 53.0 87.11 55.9 
13 Cat 5 70.6 75.5 48.7 
14 Cat 5 70.6 34.7 -25.4 
All reactions were conducted with 1-4 mg of precursor, 80-400mg CsOH·H2O as base and 
200µL [11C]benzyl iodide in toluene, as a solvent, at 0 °C for 6 min. aMol % of Cat is compared 
to precursor. b,cRCC: Radiochemical conversions; de: diastereomeric ratio; determined by 
analytical HPLC. 
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Figure 4: Solid (A) and solution-phase (B) peptide synthesis forwards precursor for 
radiolabeling. Grey part present unsuccessful reaction steps. 
After discouraging results for compounds a and b, we shifted focus to compounds d and e, 
which proved their success discussed in Chapter 7.  
Since the synthesis of compound c has never been started, we would propose following 
two approaches for the synthesis for precursor and reference compound (Scheme 2A and 
2B). 11C-Benzylation for introduction of carbon-11 should be according to Chapter 2 
straightforward and high yielding in desired time frame. After successful synthesis, 
automation and formulation step, we would propose ex vivo metabolite analysis and 
biodistribution studies in healthy male rats identifying pharmacokinetics profile and BBB 
penetration. These studies could be followed by PET scanning.  
Moving back to promising radiotracers candidates d and e and their future potential, in 
vitro evaluation of inhibition constant (Ki) and binding affinity (Kd) of D-tracer should be 
performed on rat spinal cord membrane and rat ventral tegmental area, for comparison 
with its L-counterpart. The next logical step would be determination of lipophilicity, as we 
suspect that our low molecular weight (M: 298.1 g·mol-1) peptidomimetics are not PgP-
transporters. Determined  Log D7.4 values in n-octanol/water should range from 2.0 to 3.5 
for passive brain entry.[25] We would also propose an ex vivo autoradiography imaging 
using a coronal rat brain slices for both PET-tracer candidates to determine brain 
localization (e.g. ventral tegmental area).  
Special attention should be also dedicated to neuropathic pain induced animal model[26], 
PET imaging blocking studies and identification of effective blocker to show high affinity 
and selectivity for the target and low non-specific binding.  SP1-7-NH2 could be used for 
pre-treatment, however should be injected immediately before the radiotracer candidate 
(SP1-7-NH2: t1/2 = 6.4 min), another option would be DAMGO or endomorhpin-2, which 
both showed some affinity for these binding sites[27], or even a non-selective opioid 
receptor antagonist naloxone.[28]  
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Scheme 2: A: Proposed synthesis of the reference compound and precursor for the 
compound c. B: Alternative synthesis of the precursor to avoid possible problems with low 
molar activity. [29] 
 
As known for this SP1-7 target, its identification presents a formidable problem. Therefore, 
cell-based screening with designed chemical library of compounds, effecting through the 
covalent modifications, could serve for in situ proteome reactivity profiling.[30] A frequent 
tool used in drug discovery would be also photo affinity labeling where a molecule of 
interest, for instance SP1-7 carbamate, would be tagged with photo reactivity moiety (e.g. 
trifluoromethylphenyl diazirine) and an identification tag (e.g. biotin). After irradiation 
with a specific wavelight of light, the photogroup forms a reactive intermediate that reacts 
and covalently cross-link with proximate target, which can be monitored for example by 
SDS-PAGE.[31] 
Overall, inspiring results showed in Chapter 7 with the future recommendations in this 
chapter, Part 3, suggest that careful selection of a blocker compound and a neuropathic 
pain induced animal model[26], next to well-planned assay is imperial for future research 
for such a unique target like SP1-7.   
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and selectivity for the target and low non-specific binding.  SP1-7-NH2 could be used for 
pre-treatment, however should be injected immediately before the radiotracer candidate 
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 Reflections and Future Perspectives   
219 
 
 
Scheme 2: A: Proposed synthesis of the reference compound and precursor for the 
compound c. B: Alternative synthesis of the precursor to avoid possible problems with low 
molar activity. [29] 
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trifluoromethylphenyl diazirine) and an identification tag (e.g. biotin). After irradiation 
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and covalently cross-link with proximate target, which can be monitored for example by 
SDS-PAGE.[31] 
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chapter, Part 3, suggest that careful selection of a blocker compound and a neuropathic 
pain induced animal model[26], next to well-planned assay is imperial for future research 
for such a unique target like SP1-7.   
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Part 4: The Future is Bright! 
 
Over the last two decades, peptides have grown in prominence in pharmaceutical 
research and development due to their wide-range of applications in numerous diseases. 
Their main disease indications, driving the demand for peptide therapeutics, are cancer, 
metabolic disorders (e.g. obesity) and neurology. In 2016, peptide cancer research 
involved over 300 companies developing 292 peptide based drugs in 780 oncology 
projects, showing one of the fastest growth of peptide therapeutics in the pharmaceutical 
industry.[32] 
As generally known, cancer occurance is expanding due to aging and growth of the world 
population, increasing adoption of cancer-causing behaviors (e.g. smoking), rising the 
mortality and broader focus on other alternatives to chemotherapy.[32,33] Peptide-based 
drugs are nowadays used for treatment of breast, ovarium and pancreatic cancer, not 
mentioning the variety of peptides tested at preclinical stages for their efficacy in cancer 
treatment. Despite the plethora of opportunities to use peptides in therapy, numerous 
challenges are impending their widespread adoptions. Next to the oral administration, 
conformational flexibility and short biological half-life, limited options for structural 
optimization drastically increase their commercialization costs. Especially at this stage, 
application of PET could facilitate the rapid and smooth translation of various peptide-
based candidates for translational research and consequently minimize the costs. For this 
reason, isotopologue radiolabeling with carbon-11 resulting in unmodified, moreover 
enantiomerically pure radiopharmaceutical, would enhance the research and 
development of peptide therapeutics. Therefore, approaches for high stereoselective 
synthesis could serve as a particularly versatile tool to access chiral peptides, next to 
amino acids, without relying on resolution of racemates.  
An attractive feature of the proposed two novel methodologies in Chapter 8 would be 
site-specific labeling in carboxylic position, compared to β-position by 11C-alkylation. By 
using PET, this would allow the detection of different metabolism of the investigated 
molecule (e.g. peptide). Thus, unique monitoring of the distribution and kinetics by PET 
combined with our technique where biologically active peptides retain their properties 
after radiolabeling, could also result in reduced cost in pharmaceutical development and 
accelerated clinical trials, excluding the drugs with unfavorable biodistribution and/or 
pharmacokinetics.  
Beside the potential in pharmaceutical development, PET has nowadays found a broad 
clinical application in personalized imaging, where PET-tracer specific for that individual’s 
tumor is used, predefined by gene and protein profiling. These can enhance an early 
evaluation of treatment response, adaptions of treatment protocols and effective patient 
selection. With the enormous costs for cancer treatment, personalized prescribed drugs 
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could drastically decrease the cost of ineffective and over treatment.[34] PET provides 
greater sensitivity in all aspects, radiolabeled peptides targeting cancer-associated 
pathways would certainly warrant their use. More specifically, carbon-11 labeled peptides 
would be exciting PET-tracers for personalized imaging. By avoiding the use of long-lived 
isotopes and enabling multiple PET scans in a single day, hospitals visits and radiation 
burden of the patient’s relatives would decrease consequently. 
Furthermore, native carbon-11 peptide labeling would be ideal strategy to radiolabel cell 
penetrating peptides and peptides targeting the CNS, like BBB shuttles.[35] Nonetheless, 
brain delivery remains one of the major challenges in drug development as BBB prevents 
most drugs reaching their targeting. For this reason, highly sensitive and efficient 
validation of BBB penetration in the preclinical stage is imperative.  
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The short-lived positron-emitting radionuclide carbon-11 possesses unique potential for 
labeling a variety of interesting molecules for positron emission tomography (PET) imaging 
without interfering the molecular lead structure. Construction of carbon-11 labeled amino 
acids and peptides in a rapid, multi-step, and stereocontrolled manner has been a key 
challenge up to now. In this thesis, we have proven that comprehensive step-by-step 
investigation results in so far unprecedented highly stereoselective catalysis of prochiral 
substrates allowing the preparation of a broad variety of carbon-11 labeled amino acids 
and short peptides with excellent regioselectivity and enantiomeric or diastereomeric 
excess.  
Chapter 1 provides a concise introduction on the topic investigated in this thesis. Chapter 
clearly shows that asymmetric synthesis in carbon-11 chemistry has been until now strictly 
limited to carbon-11 labeled amino acids and introduces general principles of peptides 
radiolabeling for PET imaging with an examples of prominent somatostatin analogues as 
diagnostic and therapeutic agents in cancer. 
The synthesis of carbon-11 labeled amino acids, their analogues and peptides has been 
thoroughly discussed in Chapter 2, providing an overview of possible enzymatic and 
synthetic strategies towards these carbon-11 radiolabeled probes since 1975 up to now. 
Their use in imaging studies, with some very successful examples in clinic (e.g. L-
[11C]Methionine and  L-[11C]DOPA), is summarized as well. As of now, carbon-11 labeled 
peptides have been exceedingly scarce. We believe that recent proliferation of new 
approaches for carbon-11 peptide labeling is a positive development, confirming our 
vision of 11C-peptides potential when start developing this idea.  
The research within the thesis has begun with the very first and simplest steps, with the 
synthesis of a carbon-11 alkyl halide, namely [11C]benzyl iodide, from [11C]CO2. As 
discussed in Chapter 3, automated 3-step procedure in 11 min resulted in high 
radiochemical yield (52 ± 3%; decay-corrected), molar activity (123 ± 17 GBq·µmol-1) and 
radiochemical purity (95 ± 3% in dichloromethane). Latest has been achieved with 
introduction of uncommon solid-phase purification. This labeling reagent proved highly 
reactive and well-suitable for application in radiopharmaceutical production, exemplified 
by [11C]clebopride, a dopamine D2 antagonist drug with antiemetic and prokinetic 
properties.  
Chapter 4 investigated asymmetric phase-transfer catalyzed reactions for enantiopure 
carbon-11 labeled D- and L-phenylalanine, as a proof-of-principle amino acid, using 
previously optimized [11C]benzyl iodide. The carbon-11 radiolabel and chirality is 
introduced by an enantiopure catalyst meaning that phase-transfer catalyst activates the 
glycine substrate under basic conditions following an interfacial mechanism in a reversible 
manner to afford the optically active monoalkylated product. This reliable 5-step 
radiolabeling method yielded D- and L-[11C]phenylalanine with an excellent enantiomeric 
excess up to 90% and high molar activity ranging 85 - 135 GBq·µmol-1.  
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Chapter 5 describes successive and high yielding N-terminal 11C-benzylations 
(incorporation of >85%) towards variety of H-[11C]Phe-XXX-OH dipeptides in moderate to 
high diastereoselectivity (diastereomeric ratios up to 90:10) using this novel asymmetric 
phase-transfer catalyzed radiolabeling. Chapter also includes reaction with an additional 
alkylating agent, [11C]methyl iodide, which is especially challenging due to relatively low 
steric volume of the small alkylating agent.  
Finally, Chapter 6 introduces first native and stereochemically pure carbon-11 labeled 
small peptides, in particular tetrapeptides. This challenging project involved multistep 
solution-phase peptide synthesis, to furnish Schiff base precursors and all L- and D-
references, and 5-step N-terminal 11C-benzylation reactions to label the tetrapeptide Phe-
Trp-Lys-Thr, the binding motif of somatostatin, in excellent diastereomeric excess of 94%. 
Considerable influence of peptidic backbone on stereoinduction was observed, therefore 
we thougourly explored the control of adjacent tryptophan and catalyst induction, 
identifying matched/mismatched catalyst situation of Cinchona-based catalysts. 
Moreover, automation of this methodology revealed that procedure is reproducible and 
realiable to access novel stereochemically pure carbon-11 native small peptides ready for 
in vivo evaluation.  
Chapter 7 of this thesis also describes peptide analogues such as the first Substance P1-7 
derived L- and D-11C-peptidomimetics, achieved via [11C]CO2-fixation. These two potent 
peptidomimetics for SP1-7 binding site were successfully radiolabeled in excellent yield (up 
to 42%; decay-corrected), molar activity (58 - 115 GBq·μmol-1) and radiochemical purity 
(>99%), and investigated in healthy male rats. Both radiotracers showed promising ex vivo 
metabolic and biodistribution profile and further PET scanning confirmed both 
peptidomimetics enter the rodent brain, where further validation of these two 
radiotracers is needed to select the most appropriate radioligand candidate. 
 
Taken together, the research described provides fundamental advances in carbon-11 
chemistry and presents the tremendous potential of carbon-11 peptides, as well as 
peptidomimetics, in cancer and brain imaging. Thus, the research in medicine, supported 
by fundamental science, should always strive for top-class health care, where already the 
ancient Latins had perceived a good diagnosis as highly important.  
 
“Bona diagnosis, bona curatio.” (Good diagnosis, good cure.) 
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“Bona diagnosis, bona curatio.” (Good diagnosis, good cure.) 
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Samenvatting 
Het kortlevende positron-uitscheidende radionuclide koolstof-11 bezit de unieke 
eigenschap om verschillende interessante moleculen door middel van positron emissie 
tomografie (PET) in beeld te brengen zonder de moleculaire “lead” structuur veranderd 
wordt. De constructie van koolstof-11 gelabelde aminozuren en peptides in een snelle, 
meer staps, en stereo gecontroleerde manier is nog steeds een enorme chemische 
uitdaging. In dit proefschrift, hebben we bewezen dat een uitgebreid stap-voor-stap 
onderzoek resulteert in een tot nu toe non niet gekende hoge stereoselectieve 
katalystische alkylering van prochirale substraten, waardoor we een chiraal zuiver 
radiochemisch product hebben verkregen. Hierdoor kunnen een groot aantal koolstof-11 
gelabelde aminozuren en peptidens met een hoge regioselectiviteit en enantiomerische of 
diastereomerische zuiverheid worden gesynthetiseerd.  
Hoofdstuk 1 geeft een korte introductie over het onderwerp dat wordt onderzocht in dit 
proefschrift. Het hoofdstuk laat duidelijk zien dat de asymmetrische synthese in koolstof-
11 chemie tot nu toe alleen nog maar heeft plaatsgevonden bij koolstof-11 gelabelde 
aminozuren. Dit hoofdstuk introduceert ook de algemene principes van amino zuur en 
peptide radiolabeling voor PET-beeldvorming met een voorbeeld van een vooraanstaand 
somatostatine analoog als diagnostische en therapeutisch middel in kanker. 
De synthese van koolstof-11 gelabelde aminozuren, de analogen en de peptides worden 
uitgebreid behandeld in hoofdstuk 2. Hierin wordt een uitgebreid overzicht gegeven van 
mogelijke enzymatische en synthetische strategieën naar die koolstof-11 gelabelde probes 
vanaf 1975 tot nu. Het gebruik in beeldvorming studies, met een aantal succesvolle 
voorbeelden (zoals L-[11C]Methionine en L-[11C]DOPA), wordt ook samengevat. Tot nu toe 
is de synthese koolstof-11 gelabelde peptides nog nauwelijks beschreven. Wij geloven dat 
recent ontwikkelde nieuwe synthetische strategien voor koolstof-11 peptide labelingen 
een goede ontwikkeling is. Dit bevestigd onze visie toen we dit idee gingen ontwikkelen 
dat 11C-peptides een goede potentie hebben.  
Het onderzoek in dit proefschrift is begonnen met de makkelijkste, maar ook heel 
essentiele reactie en dit is de productie van het koolstof-11 alkyl halide, genaamd 
[11C]benzyl iodide, vanaf [11C]CO2. Zoals beschreven in hoofdstuk 3. In een 
geautomatiseerde 3 staps procedure werd [11C]benzyl iodide in 11 minuten in een hoge 
radiochemische opbrengst van 52 ± 3% (gecorrigeerd voor verval), een molaire activiteit 
van 123 ± 17 GBq·µmol-1 en een radiochemische zuiverheid van 95 ± 3% in 
dichloromethane verkregen. De radiochemische zuiverheid is bereikt door middel van een 
nog niet eerder gepubliceerde vaste-fase zuivering. De reactiviteit van [11C]benzyl iodide  
is aangetoond door dit labelings reagens toe te passen in radiochemische enkele 
producties, geillustreerd door de synthese van [11C]clebopride, een dopamine D2 
antagonist met antiemetic and prokinetische eigenschappen.  
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Hoofdstuk 4 beschrijft de asymmetrische “phase-transfer catalyzed” reacties voor 
enantiozuivere koolstof-11 gelabeld D- en L-phenylalanine, als eerste enantioselectief 
verkregen aminozuur. Er is gebruik gemaakt van eerder beschreven [11C]benzyl iodide 
voor de alkylering. De koolstof-11 en de chiraliteit wordt geïntroduceerd door een 
alkylering in de aanwezigheid van een enantio zuivere katalysator, wat inhoud dat de 
“phase-transfer catalyst” de glycine substraat onder basische condities activeert gevolgd 
door een grensvlak mechanisme in een onomkeerbare manier zodat het optisch actieve 
mono gealkyleerde product wordt gevormd. Deze betrouwbare 5-staps radio labelings 
methode gaf een zeer hoge opbrengst van D- en L-[11C]phenylalanine met een zeer goede 
enantiomerische overmaat tot 90% en een hoge molaire activiteit tussen de 85 en 135 
GBq·µmol-1. 
Hoofdstuk 5 beschrijft de succesvolle N-terminal 11C-benzylation (incorporatie van >85%) 
naar verschillende H-[11C]Phe-XXX-OH dipeptides met gemiddelde tot hoge 
diastereoselectiviteit (diastereomeric ratio’s tot 90:10) door gebruik te maken van nieuwe 
asymetrische “phase-transfered catalyzed” radiochemie. Dit hoofdstuk bevat ook reacties 
met een andere alkylerings reagentia genaamd [11C]methyl iodide. Dit is vooral lastig door 
het relatieve lage sterische volumen van het kleine alkylerings reagentia. 
Tenslotte, introduceert hoofdstuk 6 de eerste stereochemisch zuivere koolstof-11 
gelabelde peptide, in het bijzonder tetrapeptides. Dit uitdagende project maakt gebruik 
van de “solution-phase peptide” synthese technieken, om alle Schiff base startmaterialen 
en alle L- en D-referentie verbindingen te synthetiseren. De 11C-benzylerings reactie om de 
tetrapetide Phe-Trp-Lys-Thr te synthetiseren verliep in zeer hoge diastereomerische 
overmaat van 94%. Een aanzienlijke invloed van de naburige aminozuren van het peptide 
op de stereoinductie werd waargenomenn. Daarom is de invloed van een aangrenzend 
tryptophan en de katalysator grondig onderzocht op de identificatie van op elkaar 
afgestemd en niet afgestemde katalysatorische situaties van cinchona-gebaseerde 
katalysatoren. Bovendien, liet automatisering van deze methode zien dat de procedure 
reproduceerbaar is en betrouwbaar om nieuwe stereochemisch zuivere koolstof-11 
gelabelde peptides te maken die in vivo kunnen worden geëvalueerd. 
 
Schema 1: Asymmetrische “phase-transfer catalyzed” reacties voor aminozuur 
phenylalanine en tetrapeptides. 
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Hoofdstuk 7 in dit proefschift worden ook peptide analogen beschreven zoals de eerste 
stof P1-7 verkregen L- en D-
11C-peptidomimetics, gekregen via [11C]CO2 fixatie. Deze twee 
veelbelovende peptidomimetics die binden aan SP1-7 werden succesvol gelabeld met hoge 
opbrengsten (tot 42%; gecorrigeerd voor verval), een molaire activiteit van 58 - 115 
GBq·μmol-1 en een radiochemische zuiverheid van >99%. De tracers werden geëvalueerd 
in gezonde ratten. Allebei de tracers lieten een veelbelovende ex vivo metabolisch en 
biodistributie profiel zien en verdere PET beeldvorming liet zien dat de peptidomimetics 
de hersenen van het knaagdier bereikte, alhoewel verdere validatie van de tracers moet 
uitwijzen welk van de twee de beste kandidaat is. 
Samenvattend, het onderzoek wat hier is beschreven geeft een fundamentele vooruitgang 
in koolstof-11 chemie weer en laat het enorme potentieel van koolstof-11 peptides zien, 
net zoals peptidomimetics, in kanker en hersenen beeldvorming. Dus, onderzoek in 
medicijnen, ondersteunend bij fundamenteel onderzoek, moet zich altijd inspannen voor 
de beste gezondheidszorg, waar ook de oude romeinen zich ervan bewust waren dat een 
goede diagnose zeer belangrijk is.   
 
“Bona diagnosis, bona curatio.” (Good diagnosis, good cure.) 
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Krajši uvod in povzetek v slovenskem jeziku 
 
Pozitronska emisijska tomografija 
Pozitronska emisijska tomografija (PET) je izredno natančna ne-invazivna metoda 
nuklearno-medicinskega slikanja, ki z uporabo radiofarmakov prikazuje funkcionalno 
stanje tkiv in organov v telesu. Uporablja se za diagnosticiranje v onkologiji, nevrologiji 
(npr. Alzheimerjeva in Parkinsonova bolezen) in kardiologiji (npr. ugotavljanje viabilnosti 
miokarda) ter tudi pri (pred)kliničnih študijah tekom razvoja novih zdravil. Tehnika PET je 
ponavadi združena z računalnisko tomografijo (CT) ali magnetno resonanco (MRI), ki 
omogočata natančno lokacijo s PET vidnih procesov v telesu in posledično njihovo 
interpretacijo. Princip uporabe tehnike PET, prikazan na Sliki 1, temelji na injiciranju 
radiofarmaka v telo pacienta, ki leži pod kamero PET, katere osnova je obroč sestavljen iz 
mnogo dobrih detektorjev za detekcijo gama žarkov. Po radioaktivnem razpadu 
pozitronskega radionuklida oz. sevalca se z mesta razpada izsevata dva žarka gama z 
energijo 511 keV, ki odletita v nasprotnih straneh, in sicer pod kotom 180 ⁰. Ker ta dva 
žarka hkrati zaznajo fotopomnoževalke v kameri PET kameri, lahko sklepamo, da je razpad 
v pacientu potekal nekje na ravni črti, ki povezuje oba dela obroča detektorja. Po zaznavi 
več stotisoč takšnih dogodkov računalnik iz šopa omenjenih ravnih črt izračuna 
tridimenzionalno sliko preiskovanega dela telesa. 
Slika 1: Shematski prikaz principa delovanja PET slikanja.  
Radiofarmaki so radiofarmacevtski izdelki, ki jih ponavadi vnašamo v organizem 
intravensko z namenom radiodiagnostike in/ali radioterapije, odvisno od uporabljenega 
radionuklida. Sestavljeni so iz dveh delov – biološko aktivne substance, ki je lahko sladkor, 
amino kislina ali peptid, in radioaktivnega izotopa. Med pozitronski sevalci, ki se 
uporabljajo za diagnostiko s PET, so najpogosteje prisotni 15O (razpolovni čas - t1/2 = 2 
min), 13N (t1/2 = 10 min), 
11C (t1/2 = 20 min), 
68Ga (t1/2 = 68 min), 
18F (t1/2 = 110 min) in 
89Zr (t1/2 = 3.3 dni). Najpogostje uporabljen radiofarmak v diagnostiki PET na področju 
onkologije je z radioaktivnim izotopom 18F označen analog glukoze, 2-[18F]fluoro-2-deoksi-
D-glukoza ali krajše [18F]FDG, ki omogoča prikaz rakavih obolenj še preden nastopijo 
zaznavne morfološke spremembe.  
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onkologije je z radioaktivnim izotopom 18F označen analog glukoze, 2-[18F]fluoro-2-deoksi-
D-glukoza ali krajše [18F]FDG, ki omogoča prikaz rakavih obolenj še preden nastopijo 
zaznavne morfološke spremembe.  
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Radioaktivne izotope ponavadi pridobivamo v krožnih pospeševalnikih, tako imenovanih 
ciklotronih. Naprava s pomočjo električnega in magnetnega polja v vakumu, ki je v obliki 
kroga, pospešuje nabite delce na visoke hitrosti. Delci se spiralno gibljejo dokler ne 
dosežejo roba elektrod, kjer so usmerjeni v tarčo za pridobitev željenega izotopa, kjer 
poteka jedrska reakcija.  
Izbira radioaktivnega izotopa za izdelavo radiofarmaka je odvisna od uporabe 
radiofarmaka. Tako za diagnostiko in dozimetrijo uporabljamo gama in pozitronske sevalce 
(npr. 99mTc, 68Ga, 18F in 111In), alfa in beta sevalce (npr. 90Y, 177Lu in 131I) pa za radioterapijo. 
Poleg fizikalnih in kemijskih lastnosti izotopa moramo upoštevati še njegovo dostopnost, 
čas in lokacijo študije, čas in mesto označevanja, zahtevnost priprave končnega izdelka in 
možne spremembe, ki jih doprinese radioznačevanje. Le-te lahko drastično spremenijo 
biološko aktivno spojino in posledično njeno afiniteto do vezavnega mesta (npr. 
receptorja), v pozitivnem ali negativnem smislu.  
Označevanje z ogljikom-11   
Ogljik (ogljik-12 in ogljik-13) se pojavlja v vseh biološko aktivnih organiskih spojinah. 
Prav zaradi tega je označevanje z ogljikom-11 tako zanimivo za področje PET, saj 
substitucija ogljika-12 z radionuklidom ogljik-11 ne spremeni tarčne molekule in 
posledično njenih bioloških, farmakoloških in fizioloških značilnosti. V teoriji lahko z 
ogljikom-11 označimo vse molekule, vendar je slednje ponavadi omejeno s kratkim 
razpolovnim časom ogljika-11, ki znaša 20 min. Poleg hitrega razpada, so 
radiokemiki omejeni na dve začetni spojini, [
11]CO2 in [
11C]CH4, ki se pridobita s 
pomočjo ciklotrona, in zahtevno avtomatizacijo samega procesa v svinčenih “vročih 
celicah”, ki preprečijo izpostavljenost radiokemika pred radioaktivnim sevanjem.  
Delo z radioaktivnimi izotopi, v primerjavi z organsko kemijo, prinaša najrazličnejše 
izzive, tako tehnične, časovne in tudi kemijske. V radiokemiji uporabljamo zgolj 
nano do pikomolarno količino radionuklida v primerjavi z presežkom, nekaj 
miligrami prekurzorja oz. spojine, ki jo želimo radioakivno označiti. Slednje 
drastično poruši stehiometrično razmerje, zato reakcije v radiokemiji potekajo zelo 
hitro, v nekaj sekundah oz. minutah. Pri delu s kratkoživim ogljikom-11 je to seveda 
dobrodošlo, saj omogoča več sinteznih stopenj v zelo kratkem času. To je še 
posebej pomembno pri sami pripravi radiofarmaka za pacienta, saj velja pravilo, da 
mora biti končni označevalec pripravljen v trikratnem času razpolovnega časa 
samega izotopa, torej 60 min za ogljik-11. V tem časovnem intervalu mora biti 
radiofarmak sintetiziran, prečiščen, filtriran in tudi analiziran, preden je lahko 
injiciran v pacienta.        
Označevanje radiofarmakov z ogljikom-11 pričnemo z začetnega z 11C označenega 
reaktanta, [11]CO2 ali [
11C]CH4, ki ga pretvorimo v bolj reaktivno obliko, najpogosteje 
metil jodid [11C]CH3I. Tako se pri označevanju največkrat poslužujemo 
11C-metilacije, 
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ki nam omogoča različne O-, N-, S-metilirane spojine in  11C-C cross-coupling reakcije, z 
visoko stopnjo stereoselektivnosti končnega radiofarmaka. Slednja ni posledica reakcije 
11C-oznacevanja, temvec kiralnosti samega prekurzorja. Kljub temu, da so organske spojine 
velikokrat kiralne, samo stereoselektivno označevanje spojin v radiokemiji ni enostavno 
dosegljivo. 
Z ogljikom-11  označene amino kisline  
Radioaktivno označene amino kisline so pogosto uporabljene kot radiofarmaki v onkologiji 
in nevrologiji. Najbolj znan primer aminokislinskega označevalca je 11C-označen metionin, 
ki se uporablja za slikanje sinteze proteinov v tumorjih. Zaradi svoje edinstvene strukture 
skoraj vse amino kisline izkazujejo optično izomerijo (levo- in desnosučnost) in se lahko 
nahajajo v dveh izomernih oblikah (L in D). V naravni nasploh najdemo L-amino kisline, 
vendar so tudi D-aminokisline zanimive za uporabo zaradi njihove povečane stabilnosti 
proti razgradnji z encimi.  
 
Označevanje amino kislin z ogljikom-11 je mogoče doseči na dveh mestih, na karboksilni 
skupini ali na beta ogljiku. V preteklosti so bile 11C-amino kisline pripravljene s pomočjo 
encimov, kar je omejilo njihovo sintezo na zgolj L-enantiomer. Začetki sinteznih method 
označevanja, kot naprimer 11C-karboksilacija ali označevanje z 11C-cianidom, so izkazali 
omejeno stereoselektivnost, hkrati pa so bili nezanesljivi/neponovljivi, z nizkim 
izkoristkom in dolgim sinteznim časom. Poleg tega so velikokrat zahtevali dodatno 
encimsko ali kiralno čiščenje. Dandanes lahko s sinteznimi postopki dosežemo 
enantioselektivnost amino kislin do 95% enantiomernega presežka (ee), vednar smo 
omejeni na L-amino kisline in komercialno dostopnost ustreznih prekurzorjev in 
reagentov.   
 
Radioaktivno označeni peptidi  
Radioaktivno označeni biološko aktivni peptidi so pomembno orodje za diagnosticiranje 
različnih bolezenskih stanj s pomočjo PET. Krajši peptidi oziroma oligopeptidi, sestavljeni iz 
manj kot 20 amino kislin, imajo ugodne lastnosti za diagnosticiranje, kot naprimer kratek 
očistek iz preiskovanega telesa in sposobnost selektivnega prepoznavanja tarčnega mesta. 
Slednja so velikokrat receptorji, katerih ekspresija je povečana v določenih tumorjih. Tako 
imajo nevroendokrini tumorji na svoji površini močno izražene somatostatinske 
receptorje, zato se radioaktivno označeni analogi somatostatina, peptida z visoko afiniteto 
do teh receptorjev, kopičijo v tumorski celici in nam ob preiskavi s kamero PET podajo 
natančno lokacijo tumorja v telesu.  
Najrazličnejši krajši peptidi so že bili označeni s pomočjo dobro poznanih metod 
označevanja v radiokemiji. Tako lahko danes peptide označimo preko 4 različnih metod, 
kot je prikazano na Sliki 2. Najpogosteje se uporabljajo tako imenovani šibki kelatorski 
reagenti oz. koordinacijski ligandi, ki so pritrjeni na želeno spojino, ki je seletivno sposobna 
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prepoznati tarčno mesto, in vežejo radionuklid. Kljub pogosti uporabi in enostavnosti 
omenjene tehnike, lahko s takšnimi dodatnimi spremembami na molekuli vplivamo na 
farnakološke lastnosti biološko aktivnega peptida. Takšnim spremembam se lahko 
izognemu ob uporabi direktnega označevanja, pri katerem radionuklid vgradimo v samo 
strukturo peptida in tako zmanjšamo možnost vpliva na biološko aktivnost peptida. Pri 
načrtovanju je zelo pomembno upoštevati, da biološko aktiven peptid, skupaj s 
kelatorjem, prostetično skupino ali zgolj radionuklidom ne spremeni afinitete do 
receptorja, hkrati pa se mora razpolovni čas izotopa ujemati z biološko razpolovno dobo 
molekule.  
 
Slika 2: Prikaz obstoječih načinov označevanja peptidov. 
Velika večina trenutnih metod označevanja lahko vpliva na prenos peptidnih 
radiofarmakov iz začetnih in vitro do bolj naprednih in vivo študij, ki so kritične za nadaljnji 
razvoj in končne klinične študije. Prav zato je dodaten razvoj v smeri direktnega oziroma 
označevanja, ki ne spremeni same biološko aktivne molekule, toliko bolj potreben. 
Omenjeno bi lahko dosegli z radionuklidom PET ogljik-11, saj bi minimalne spremembe v 
sami strukturi peptida poenostavile translacijo študij iz predklinične do klinične faze in  
zmanjšale obsežna farmakološka in toksikološka testiranja. Zaradi kratkega razpolovnega 
časa ogljika-11 pa bi zmanjšali izpostavljenost pacienta radioaktivnemu sevanju in 
omogočili več preiskav PET v enem dnevu (npr. najprej študija PET z radiofarmakom 
označenim z ogljikom-11, ki ima kratek razpolovni čas, in nato študija PET z 
radiofarmakom z daljšim razpolovnim časom).  
Peptidomimetiki 
Biološko aktivni peptidi izkazujejo pomembno vlogo v fizioloških procesih človeškega 
telesa in so posledično zanimiva tarča za zdravljenje raznovrstnih bolezni ali kot 
diagnostično orodje za uporabo v nuklearni medicini. Kljub potenicalu, ki ga izkazujejo, pa 
so peptidi redko prva izbira pri terapiji. Zaradi njihove kompleksne strukture, omejene 
stabilnosti in relativno hitrega očistka iz telesa, so sinteza, aplikacija in shranjevanje 
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peptidov pogosto prekompleksni, in posledično tudi predragi za splošno uporabo pri 
zdravljenju. Takšnim neugodnim lastnostim pa se lahko izognemo z načrtovanjem 
peptidomimetikov, molekul, ki nosijo enako sporočilo kot peptid, po katerem so 
zasnovani. Skrbno načrtovanje peptidomimetikov ohrani tridimenzionalno interakcijo z 
vezavnim mestom, hkrati pa enostavnejša struktura, manj dovzetna za metabolizem, in 
nižja molekulska masa, drastično izboljšata farmakokinetične lastnosti in njihovo uporabo 
v zdravljenju.    
Radioaktivno označena Substanca P 
Substanca P (SP) je nevromodulator in nevrotransmitor v centralnem in perifernem 
živčnem sistemu, ki je neposredno vpletena v prenos bolečine v človeškem telesu. Poleg 
omenjene funkcije SP preko receptorja nevrokinin-1 (NK-1R) vpliva tudi na aktivacijo 
imunskega sistema, vazodilatacijo, prebavne procese in duševne motnje. Selektivne 
antagoniste SP so označili z izotopom 
11C in 18F z namenom vizualizacije NK-1 receptorja. 
Močna izraženost NK-1R na nevronskih in tumorskih celicah je bila izhodišče za uporabe α-
radionuklidov kot ligandov za ciljno terapijo pri selektivnem obsevanju malignih gliomov, z 
namenom zmanjšanega obsevanja sosednjih tkiv. Tako so analoge SP radioaktivno označili 
z dolgoživimi izotopi (npr. 177Lu, 213Bi, 111In ali 90It) in uporabili v kliničnih študijah.   
Eden izmed glavnih metabolitov SP je substanca P1-7 (SP1-7), ki ima nedefinirano tarčno 
mesto v možganih in hrbtenjači ter v svojem delovanju pogosto kaže nasprotne učinke kot 
njen starševski peptid SP. Takšno delovanje lahko pomeni, da ima SP1-7 potencial v 
protibolečinski terapiji, in sicer pri zdravljenju nevropatske bolečine. Kljub slabemu 
razumevanju mehanizma delovanja SP1-7 na molekulski ravni, so nedavne raziskave v 
eksperimentalnih modelih bolečine pokazale, da aplikacija krajših peptidomimetikov SP1-7 
razbremeni nevropatsko bolečino. Tako lahko ti radioaktivno označeni peptidomimetiki z 
ogljikom-11 služijo kot zanimive spojine za razumevanje delovanje SP1-7. 
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Povzetek doktorske teze  
Kratkoživi radionuklid ogljik-11 ima edinstven potencial za označevanje različnih zanimivih 
molekul za njihovo uporabo v pozitronsko emisijski tomografiji (PET) brez vpliva na njihovo 
strukturo. Kljub omenjenemu dejstvu je bilo hitro, večstopenjsko in stereokontrolirano 
označevanje z ogljikom-11 označenih aminokislin in peptidov do sedaj velik izziv. V tej 
doktorski nalogi smo dokazali, da lahko s celovitim pristopom dosežemo, doslej 
nemogočo, stereoselektivno pripravo široke palete z ogljikom-11 označenih amino kislin in 
krajših peptidov, z odlično regioselektivnostjo in enantiomernimi ali diastereomernimi 
presežki. 
Predstavitev ozadja tematike raziskovanja te doktorske teze je prikazana v Poglavju 1. V 
tem poglavju smo pojasnili osnove asimetrične sinteze z ogljikom-11, ki je bila do sedaj 
omejena na amino kisline, in predstavili splošna načela označevanja radioaktivnih 
peptidov za uporabo v PET, s primeri znanih analogov somatostatina kot diagnostičnih in 
terapevtskih sredstev pri zdravljenju raku. 
Sinteza z ogljikom-11 označenih aminokislin, njihovih analogov in peptidov je podrobno 
predstavljena v Poglavju 2. Poglavje poda bralcu pregled nad sinteznimi in encimskimi 
postopki za označevanje amino kislin in peptidov, vse od leta 1975 do danes. Zadnji del 
poglavja prikazuje njihovo uspešno uporabo v predkliničnih in kliničnih študijah (npr. L-
[11C]metionina in L-[11C]DOPA). Kot je lahko razbrati, je bila sinteza in uporaba z ogljikom-
11 označenih peptidov precej redka, zato verjamemo, da nedavni postopki označevanja 
peptidov prinašajo pozitiven razvoj, ki potrjuje našo vizijo in potencial 11C-peptidov.  
V nadeljevanju Poglavje 3 povzame sintezo z ogljikov-11 označenega alkil halida, in sicer 
[11C]benzil jodida. Avtomatiziran tristopenjski postopek priprave [11C]benzil jodida smo 
dosegli v pičlih 11 minutah, in sicer z visokim radiokemijskim izkoristekom, molarno 
aktivnostjo in radiokemijsko čistoto. Omenjeni reagent smo dalje uporabili za označevanje 
[11C]kleboprida, antagonista dopamina D2 z antiemetičnimi in prokinetskimi lastnostmi, in 
tako potrdili uporabo [11C]benzil jodida v radiofarmacevtski kemiji.  
V Poglavju 4 smo raziskovali asimetrično katalizirano reakcijo faznega prenosa za 
označevanje optično čistega D- in L-fenilalanina s pomočjo alkilnega reagenta [11C]benzil 
jodida. Razvili smo zanesljivo stereoselektivno 5-stopenjsko metodo označevanja D- in L-
[11C]fenilalanin z odličnim enantiomernim presežkom do 90% in visoko molsko aktivnostjo.  
V Poglavju 5 smo se osredotočili na različne dipeptide, z namenom prenosa nove 
stereoseletkivne metode označevanja na krajše peptide. Z ogljikom-11 označene dipeptide 
smo sintetizirali z zmerno do visoko diastereoselektivnostjo. 
V Poglavju 6 pa smo dokazali, da lahko označimo prvi naravni peptid, in sicer tetrapeptid 
Phe-Trp-Lys-Thr, vezavni motiv somatostatina, z diastereomernim presežkom do 94%. Ta 
zahtevni projekt je najprej vključeval večstopenjsko sintezo peptidov in pripravo 
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prekurzorjev ter referenčnih spojin, katere smo dalje uporabili v 5-stopenski reakciji 11C-
benziliranja. Avtomatizacija celotnega procesa je pokazala, da je postopek ponovljiv in 
dostopen za sintezo novih stereokemično čistih peptidov.  
 
Shema 1: Shematski prikaz večstopenjske sinteze fenilalanine in tetrapeptida. 
Poglavje 7 te teze opisuje tudi peptidna analoga, in sicer L- in D- 11C-peptidomimetika, 
zasnovana na osnovi SP1-7. Prva z oglikom-11 označena peptidomimetika smo pridobili s 
pomočjo metode fiksiranja [11C]CO2 z odličnim izkoristkom, molarno aktivnostjo in 
radiokemijsko čistostjo. Nadalje smo radiofarmaka raziskali na zdravih podganjih samcih in 
s pomočjo PET potrdili, da oba tako L- kot tudi D- peptidomimetik prestopata krvno-
možgansko pregrado.  
Za zaključek lahko povzamemo, da opisana raziskava v tej doktorski tezi zagotavlja temeljit 
napredek v radiofarmacevtski kemiji ogljika-11 in predstavlja potencial z ogljikom-11 
označenih peptidov ter peptidomimetikov pri slikanju raka in/ali možganov. S takšnimi 
temeljnimi študijami lahko znatno vplivamo k raziskavam v medicini in vrhunski zdravsteni 
oskrbi. Pri tem pa ne pozabimo, da so že stari Rimljani prepoznali dobro diagnozo kot zelo 
pomemben faktor. 
 
“Bona diagnosis, bona curatio.” (Good diagnosis, good cure.) 
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List of Abbreviations 
(CD3)2SO Deuterated Dimethyl Sulfoxide 
AA  Amino Acid 
AM  Molar Activity 
AUC  Area Under the Curve 
BEMP  2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2- 
  diazaphosphorine 
Boc  tert-butyloxycarbonyl 
Boc2O  di-tert-butyl dicarbonate 
BOP  (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium   
  hexafluorophosphate 
Cat 1  O-Allyl-N-(9-anthracenylmethyl)cinchonidinium bromide 
Cat 2  (11bS)-(–)-4,4-Dibutyl-4,5-dihydro-2,6-bis(3,4,5-trifluorophenyl)-3H- 
  dinaphth[2,1-c:1′,2′-e]azepinium bromide 
Cat 3  (11bR)-(–)-4,4-Dibutyl-4,5-dihydro-2,6-bis(3,4,5-trifluorophenyl)-3H- 
  dinaphth[2,1-c:1′,2′-e]azepinium bromide 
Cat 4  (R,R)-3,4,5-fluorophenyl-NAS Bromide 
Cat 5  O,O′-Diallyl-N,N′-(2,7-naphthalenediyldimethyl)bis(hydrocinchonidinium) 
  dibromide 
Cat 6  O-Allyl-N-(9-anthracenylmethyl)cinchonium bromide 
Cat 7  (S,S)-3,5-Bistrifluoromethylphenyl-NAS Bromide 
Cat 8  6,10-Dibenzyl-N,N'-dimethyl-N,N,N',N'-tetrakis(4-methylbenzyl)-1,4- 
  dioxaspiro[4.5]decane-(2S,3S)-diylbis(methylammonium)   
  tetrafluoroborate 
Cat 9  6,10-Dibenzyl-N,N'-dimethyl-N,N,N',N'-tetrakis(4-methylbenzyl)-1,4- 
  dioxaspiro[4.5]decane-(2R,3R)-diylbis(methylammonium)   
  tetrafluoroborate 
Cat 10  N-(9-anthracenylmethyl)cinchonium chloride 
Cat 11  (4R,5R)-2,2-Dimethyl-α,α,α′,α′-tetraphenyldioxolane-4,5-dimethanol 
Cbz  Carboxybenzyl 
DAMGO  (2S)-2-[[2-[[(2R)-2-[[(2S)-2-Amino-3-(4-hydroxyphenyl)propanoyl]amino] 
  propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3- 
  phenylpropanamide 
CD3OD  Deuterated Methanol 
CDCl3  Deuterated Chloroform 
CH3CN/MeCN Acetonitrile 
CsOH∙H2O Cesium Hydroxide Monohydrate 
CT  Computer Tomography 
CuTC  Copper(I)-thiophene-2-carboxylate 
DCM/CH2Cl2 Dichloromethane 
de  Diastereomeric Excess 
DIPEA  N,N-Diisopropylethylamine 
DMF  Dimethylformamide 
DMPU  1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO  Dimethylsulfoxide 
EDT  1,2-Ethanedithiol 
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ee   Enantiomeric Excess 
EOB  End of Bombardment 
ESI-HRMS Electrospray Ionization-High Resolution Mass Spectroscopy 
EtOAc  Ethylacetate 
EtOH  Ethanol 
FDA  U.S. Food and Drug Administration 
Fmoc  9-Fluorenylmethyloxycarbonyl 
GMP  Good Manufacturing Practice 
HATU  1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium  
  3-oxid hexafluorophosphate 
HCl  Hydrochlorid Acid 
He  Helium 
HPLC  High Pressure Liquid Chromatography 
HRMS  High Resolution Mass Spectroscopy 
J  Coupling Constant 
LPPS  Liquid-Phase Peptide Synthesis 
MeOH  Methanol 
MP  Mobile Phase 
NaOH  Sodium Hydroxide 
n-BuLi  N-butyl Lithium  
NMP  N-Methylpyrrolidone 
NMR  Nuclear Magnetic Resonance 
p.i.  Post Injection 
PET  Positron Emission Tomography 
Ppm  Parts per Million 
PTC  Phase-Transfer Catalyst 
RCC  Radiochemical Conversion; Stands for a radiochemical yield, determined 
  by analytical HPLC of the crude reaction mixture. In some of the older 
  papers cited Chapter 2 there was not a clear statement between isolated 
  and non-isolated radiochemical yield.    
RCP  Radiochemical Purity 
RCY  Radiochemical Yield 
RP  Reverse Phase 
Rt  Retention Time 
SD  Standard Deviation 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SPPS  Solid-Phase Peptide Synthesis 
SUV  Standardized Uptake Value 
TAC  Time Activity Curve 
TAEA  Tris(2-aminoethyl)amine 
TBAB  Tetra-n-butylammonium Bromide 
TBAF  Tetra-n-butylammonium Fluoride 
TBAHS  Tetra-n-butylammonium Hydrogen Sulfate 
TBAT  Tetra-n-butylammonium Triphenyldifluorosilicate 
t-BuOH  tert-Butanol 
TFA   Trifluoroacetic Acid 
THF  Tetrahydrofuran 
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TLC  Thin Layer Chromatography 
TMEDA  N,N,N′,N′-Tetramethylethylenediamine 
TOI  Time of Injection; referring to the injection of the PET-tracer 
UV Ultra Violet 
δ Chemical Shift  
 
Amino Acids: 
Ala Alanine 
Cys Cysteine 
Glu Glutamic Acid 
Gln Glutamine 
Gly Glycine 
Leu Leucine 
Lys Lysine 
Met Methionine 
Phe Phenylalanine 
Pro Proline 
Ser Serine 
Thr Threonine 
Trp Tryptophan 
Tyr Tyrosine 
Val Valine 
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slikc. Če povzamem, zelo sem vesela, da smo se spoznali in srčno upam, da se v prihodnje 
čim več vidimo! 
Seveda pa ne smem pozabiti na našo prelepo Slovenijo in Stašo, Tejo (Darko tebe pa 
nisem že videla 100 let!), še eno super Tejo, Anjo in Uroša, Andraža, Matica in vse boljše 
polovice! Hvala za razumevajoče usklajevanje kavic tekom mojih »dopustovanj«!  
Mijn lieve paarden vriendin Priscilla. After all the years, I finally learnt that cross is the 
most difficult part of the whole course - haha! Heel veel success met alle paarden, ik ga je 
missen! Robi, hvala za konje doma. Omarico na klubu z najboljšim razgledom bom pa še 
kar malo obdržala!     
Navsezadnje gre največja zahvala moji mami Romani, ki me je vedno podpirala, poslušala 
moje prijetne in kdaj malo manj zabavne zgodbice, in mi stala ob strani z nasveti. Hvala za 
obiske v A'damu, Bostonu in New York-u. Se že veselim najinih skupnih raziskovanj Švice! 
Mama, hvala za skrb, pa tudi vse čokoladice in sladkarijo, ki ponavadi žal ni prišla do 
Nizozemske (le zakaj). Lepo je iti nakoli, ampak doma doma je še vedno najlepše!!  
In seveda, moj Žiga! Glavna stavba VU me še vedno spomni na najina prva kosila v kantini 
(toliko o fancy zmenkih). Hvala, ker mi stojiš ob strani, skrivaš čokoladice in me prenašaš 
tudi, ko znam biti tečna. Močno upam, da bova uspešno uskladila najini karieri in našla 
skupno mesto bivanja. Še na veliko SKUPNIH avanturističnih potovanj, športnih podvigov  
in preostalih vragolij. Rada te imam!   
In short… Besides getting my PhD, I developed admirable cycling skills. Most importantly, I 
met fantastic people that made my stay in the Netherlands very pleasant! 
 
Aleksandra 
 
 
 
Ko hodiš, pojdi zmeraj do konca. 
Spomladi do rožne cvetice, 
poleti do zrele pšenice, 
jeseni do polne polic, 
pozimi do snežne kraljice, 
v knjigi do zadnje vrstice, 
v življenju do prave resnice. 
 
A če ne prideš ne prvič ne drugič 
do krova in pravega krova, 
poskusi vnovič in zopet in znova. 
(Tone Pavček; Popotnik)  
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Nizozemske (le zakaj). Lepo je iti nakoli, ampak doma doma je še vedno najlepše!!  
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in preostalih vragolij. Rada te imam!   
In short… Besides getting my PhD, I developed admirable cycling skills. Most importantly, I 
met fantastic people that made my stay in the Netherlands very pleasant! 
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Ko hodiš, pojdi zmeraj do konca. 
Spomladi do rožne cvetice, 
poleti do zrele pšenice, 
jeseni do polne polic, 
pozimi do snežne kraljice, 
v knjigi do zadnje vrstice, 
v življenju do prave resnice. 
 
A če ne prideš ne prvič ne drugič 
do krova in pravega krova, 
poskusi vnovič in zopet in znova. 
(Tone Pavček; Popotnik)  
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most difficult part of the whole course - haha! Heel veel succes met alle paarden, ik ga je 
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kar malo obdržala!☺     
Navsezadnje gre največja zahvala moji mami Romani, ki me je vedno podpirala, poslušala 
moje prijetne in kdaj malo manj zabavne zgodbice, in mi stala ob strani z nasveti. Hvala za 
obiske v A'damu, Bostonu in New York-u. Se že veselim najinih skupnih raziskovanj Švice! 
Mama, hvala za skrb, pa tudi vse čokoladice in sladkarijo, ki ponavadi žal ni prišla do 
Nizozemske (le zakaj☺). Lepo je iti nakoli, ampak doma doma je še vedno najlepše!!  
In seveda, moj Žiga! Glavna stavba VU me še vedno spomni na najina prva kosila v kantini 
(toliko o fancy zmenkih☺). Hvala, ker mi stojiš ob strani, skrivaš čokoladice in me prenašaš 
tudi, ko znam biti tečna. Močno upam, da bova uspešno uskladila najini karieri in našla 
skupno mesto bivanja. Še na veliko SKUPNIH avanturističnih potovanj, športnih podvigov  
in preostalih vragolij. Rada te imam!   
In short… Besides getting my PhD, I developed admirable cycling skills. Most importantly, I 
met fantastic people that made my stay in the Netherlands very pleasant! 
 
Aleksandra 
 
 
 
Ko hodiš, pojdi zmeraj do konca. 
Spomladi do rožne cvetice, 
poleti do zrele pšeni
jeseni d  l  police, 
pozimi do snežne kraljice, 
v knjigi do zadnje vrstice, 
v življenju do prave resnice, 
a v sebi - do rdečice 
čez eno in drugo lice. 
A če ne prideš ne prvič ne drugič 
do krova in pravega kova, 
poskusi vnovič in zopet in znova. 
 (Tone Pavček; Popot i
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